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Abstract 
Colorectal cancer is a common, age-associated disease with significant co-
morbidity and mortality. Biomarkers of ageing may have prognostic or predictive 
value in colorectal cancer. Fetuin A, members of the sirtuin family of proteins 
and telomeres have shown promise as potential biomarkers of ageing. 
AIM: To evaluate these potential biomarkers in the context of colorectal cancer. 
METHODS: Two cohorts of patients were used. Telomere length was measured in 
peripheral blood leukocytes (PBL), and for a subset of patients, in normal 
colorectal and colorectal tumour tissue. Serum fetuin A was measured for these 
patients and data on clinico-pathological factors of accepted significance in 
colorectal cancer was collected prospectively. Telomere length in the matched 
samples of leukocytes, normal colorectal and colorectal tumour tissue was 
compared. Associations between telomere length in the different tissues, serum 
fetuin A and clinico-pathological factors of accepted significance in colorectal 
cancer were evaluated. A systematic review of the literature was performed to 
examine the evidence for correlation between telomere length in different 
tissues in humans. 
Tissue from colorectal tumours from the second cohort of patients was mounted 
in a tissue microarray (TMA) and stained for sirtuin proteins (SIRT2-SIRT7). This 
TMA also contained tissue from a subset of matched samples of adjacent normal 
colorectal mucosa. Staining of normal colorectal and colorectal tumour tissue 
was evaluated by the weighted Histoscore method and compared. The effect of 
staining in tumour tissue on cancer-specific survival was examined. Associations 
between Histoscores and clinico-pathological factors of accepted significance in 
colorectal cancer were assessed. 
RESULTS: Systematic review of the literature did not show robust evidence of 
correlation between telomere length in different tissues in humans. Telomere 
length in peripheral blood leukocytes did not show correlation with telomere 
length in normal colorectal mucosa, or in colorectal tumour tissue. 
iii 
PBL telomere length was potentially related to the presence of distant 
metastases. Fetuin A was inversely associated with markers of systemic 
inflammation and with T stage. 
Novel nuclear localisation was described for SIRT4 and SIRT5. Protein expression 
of the sirtuins was reduced in tumour tissue in comparison to normal colorectal 
mucosa, apart from SIRT3 cytoplasmic and nuclear and SIRT6 nuclear stainng. 
Lowest and highest quartile SIRT2 expression was associated with worse survival. 
Sirtuin protein expression levels and localisation correlate with increased 
systemic inflammation and pathological markers of poor prognosis in tumour 
tissue. 
Intercorrelations between sirtuin expression levels in normal tissue are not seen 
in tumour tissue, possibly indicating a breakdown of signalling and control. 
DISCUSSION: These results indicate that PBL telomere length cannot be used as a 
surrogate measure for telomere length in the colorectal mucosa, nor by 
extrapolation, provide a measure of the biological age of this compartment. 
However, individualised measures of PBL telomere length may be useful in 
assessing frailty. Colorectal tissue telomere length may be useful for screening 
or surveillance of this compartment, but requires further evaluation. Fetuin A 
may be a useful marker of local invasion, but it is not clear whether this offers 
information independent of inflammatory status. 
Expression of SIRT2 in the nucleus requires further assessment as a poor 
prognostic marker in colorectal cancer. The information available on the 
function of sirtuins in colorectal tissue is limited. Novel subcellular localisations, 
particularly for SIRT3, SIRT4 and SIRT5 in the nucleus and for SIRT6 in the 
cytoplasm described here will need to be verified in normal tissue. There are 
significant alterations in sirtuin protein expression in tumour tissue with respect 
to normal tissue. These, with the correlations with markers of systemic 
inflammatory status and pathological indicators of poor prognosis reinforce the 
important place of the sirtuins in colorectal cancer biology. A precise 
understanding of the pathways involved could open up new avenues of research 
iv 
and therapeutic potential using the diverse functions of this important family of 
proteins to the patient’s advantage once again. 
Network analysis of interactions within the human proteasome is a growing area 
of research and is likely to be of particular use in the further evaluation of each 
of the multifunctional markers of cellular resilience investigated in this thesis. 
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 1 INTRODUCTION 
1.1 Ageing and longevity 
1.1.1 Ageing: Increased chance of death as time passes. 
Ageing is familiar to everyone and easy to describe in an individual but 
surprisingly difficult to define in the generality, and particularly to define in 
terms of its underlying causes and mechanisms, even by experts in the 
field(Hayflick 2007). With increasing numbers of older people in the population 
worldwide, ageing is an area of growing interest for policy makers at 
international and all other levels of organisation(United Nations Department of 
Economic and Social Affairs 2008; WHO 2011). It is a constant consideration for 
clinicians treating a patient population whose average age is increasing as the 
lifespan, and the healthspan, or healthy lifespan, of the general population 
increases(House of Lords Select Committee 2013). Ageing is a fascinating 
conundrum with ramifications in many scientific disciplines, and notably and 
more commonly, across boundaries between disciplines. Ageing encompasses a 
cumulative deterioration in function and resilience in many systems as well as 
effects, which are obvious, but of no clear functional significance such as skin 
wrinkling and loss of hair or hair colour. Despite significant investment over the 
past 25 years, no reliable single or composite measure has conclusively replaced 
chronological age in assessing functional or biological age of the organism. 
Ageing is a cumulative, stochastic, deleterious sequence of random events. 
Living organisms differ from inanimate objects in the capture of energy and 
conversion of this energy to a form that is used in a purposeful manner to 
maintain the integrity of the organism and for growth. However, the organism is 
constantly exposed to the effects of the non-self environment, which tends to 
break down its integrity either to use it as a source of energy (predation, 
infection) or in a random fashion (injury, ‘wear and tear’ e.g. contact with 
moving particles, or incident electromagnetic radiation). There is a degree of 
uncertainty always inherent in the processes of molecular level interaction, even 
though the organism may have evolved to develop a degree of control at this 
same level. The build-up of the deleterious effects of external forces constitutes 
ageing. The consequences of ageing are ubiquitous, incident on all systems, 
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including and pertinently, those responsible for repair and maintenance of 
cellular machinery.  
Longevity, on the other hand, is determined by the robustness to withstand 
these events. This is in large part a feature of the mechanisms that repair 
damage to cellular machinery on a molecular level, but there are other elements 
involved. Longevity is subject to evolutionary selection like any trait of a living 
organism. Selection pressures integral to the evolutionary process are already 
well known and centre around the efficacious immortalisation of the organism’s 
genetic code, in its ability to reproduce successfully. Relevant attributes of the 
organism include its ability to use available energy sources efficiently, to 
balance the availability of energy with energy-expensive periods in its lifecycle, 
to minimise damage to its component parts through avoidance of exposure or 
internally by good control of reactive chemicals, among other traits. 
Over the past century, several theories have attempted to explain the 
phenomenon of ageing and variable lifespan between species and within 
members of the same species. In the literature, these are generally referred to 
as Theories of Ageing, although it may be more logical to think of them, as 
Hayflick suggests, as theories of longevity (Hayflick 2007). 
Recent reviews of the prevalent evolutionary theories of ageing have pointed out 
that although they are not accepted by all gerontologists and do not provide a 
complete explanation for the phenomenon of ageing, they do go some way 
towards this and provide an acceptable platform for research(Le Bourg 2001; 
Ljubuncic and Reznick 2009). The main Theories of Ageing are discussed below. 
1.1.2 Theories of ageing 
1.1.2.1 Accumulation of mutations. Stochastic: conservation of energy is 
never 100% efficient. 
As time goes on mutations accumulate despite the organism’s best efforts at 
repair. Ageing as described in this way is thus an inevitable process. Following 
from this is the inference that ageing is a process outwith genetic control, and 
not a characteristic that can be selected for(Medawar 1952). Likewise there is 
no evolutionary means to select out organisms which exhibit traits that cause 
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declining function in old age as they will have passed on these traits by the time 
they become apparent and evolutionarily relevant (i.e. by the time they have an 
adverse effect on mortality). Thus traits which allow/promote ageing (decline in 
function over time) will accumulate in organisms of a species over time, unless 
these traits also have other effects which expose the organism to other 
evolutionary selection pressures. 
1.1.2.2 Pleiotropic antagonism 
The recognition that genes may have more than one effect on survival gave rise 
to the theory of antagonistic pleiotropy (Williams 1957). This describes the 
evolutionary selection for traits, which, while they confer a survival advantage 
at younger ages, have deleterious effects with the passage of time. These may 
involve, for example, an evolutionarily beneficial acceptance of damage in one 
system, which increases the chances of the whole individual reaching sexual 
maturity. The difference between this theory and that of mutation accumulation 
is that these traits are selected for because of their beneficial effects in earlier 
life. 
1.1.2.3 Disposable soma 
Given finite energy resources, the more investment is made in maintenance of 
the soma, the less remains for reproduction. Obviously a certain amount of 
maintenance of both components is necessary for the organism to reproduce 
successfully, but the balance may be subject to modification in different 
individuals and this balance may be subject to evolutionary selection(Kirkwood 
and Rose 1991). Thus individuals that strike the optimum balance will be 
evolutionarily more successful, with more progeny and a lifespan tailored to the 
duration of reproductive (and childrearing) capability. 
1.1.2.4 Rate of living, free radical theory 
It has been noted for a century that animals with higher metabolic rates often 
have shorter life spans. The “rate of living” hypothesis proposed that organisms 
with higher basal metabolic rates had a shorter lifespan. The mechanistic 
explanation for this observation was initially unclear. It was speculated that free 
radicals produced in the cell by metabolic reactions caused damage and this 
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accumulated over time(Harman 1956). This initiated a fruitful line of research. 
The discovery of superoxide dismutase as the first enzyme evolved to dispose of 
free radicals gave support to this theory. Further research has shown that 
because of their intrinsic reactivity, free radicals are very useful intracellular 
signalling molecules. However, also because of their reactivity and the danger 
they pose to cell components, there is a certain amount of damage caused by 
their use. 
As the rate of reactions within a cell increases, the damage produced by 
molecular activity will also increase. This may not happen proportionately, as 
cells may develop mechanisms to limit the risk of using reactive oxygen species 
(ROS), but it seems logical that if the rate of reactions increases to an extreme, 
eventually the rate of damage will begin to increase also. Reactive chemical 
species will have the greatest effect, but increase in the rate of any reactions 
will increase ‘wear and tear’ on that system. Reactive nitrogen species are 
garnering interest as they appear to pose similar risks to ROS(Afanas'ev 2010). 
This theory may partly explain the protective effect of caloric restriction, and 
the toxic sequelae of nutrient excess. Nutrients not needed for immediate use 
must be converted to storage forms, with concomitant wear and tear on 
molecular machinery. Storage forms of nutrients are less reactive; there may be 
unwanted effects of the (more reactive) nutrient substances awaiting 
conversion. This will be discussed later in the context of “inflamm-ageing”, the 
concept of caloric restriction and the inflammatory effect of obesity. 
1.2 Cancer  
1.2.1 Ageing and cancer 
The incidence of cancer varies with age but it is much commoner in older 
people. Ageing increases the susceptibility to cancer. Cancer is thus an age-
associated disease; this may not be the same as a ‘disease of ageing’.  
Childhood cancers are a very heterogeneous group and they are much rarer than 
cancer in adults. They also tend to originate from different groups of tissues, 
which are often postmitotic (neural, bony) or of foetal origin. Childhood cancers 
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may be caused by single gene defects, and gave support to the ‘two-hit’ 
hypothesis, whereby an inherited predisposition to cancer may be explained by 
inheritance of a mutated form of a ‘tumour suppressor gene’. Tumour suppressor 
genes are of vital importance in cell cycle regulation and cell death, and in 
many cases have helped elucidate cell cycle processes. Mutation of the 
remaining normal allele can occur at a young age and results in the development 
of cancer.  
The classic example is the retinoblastoma gene, named for the cancer which 
most commonly results from its mutation(Murphree and Benedict 1984). 
Inherited retinoblastoma accounts for one third of cases and most cases of 
bilateral disease. The retina is the most commonly affected tissue as it is 
subject to high levels of incident UV irradiation. Retinoblastoma survivors are 
prone to higher levels of other forms of cancer in adulthood as well. The 
retinoblastoma gene is located on chromosome 13. It binds transcription factors 
of the E2F family, holding the cell in G1 phase. It prevents progression to S 
phase by inhibition of E2F-related transcription but also because the complex 
with E2F attracts histone deacetylases to chromatin, further reducing gene 
transcription. The retinoblastoma protein is thus involved in the DNA repair 
response and in apoptosis. 
In adult cancers, the commonest tissues of origin are epithelial or 
haematopoietic, tissues characterised by high rates of cell turnover. Cancer in 
the old is unlike most other age-associated diseases. It is characterized by 
certain gains of function at cellular level, rather than the deterioration of 
function central to other conditions. However, in cancer this is a paradoxical 
gain of function, caused by more hidden deterioration at the higher levels of 
strategic regulation of cellular function and proliferation. 
Cancer occurs when necessary criteria are met. Ageing makes it more likely 
these criteria will be met, with associated attenuation of the integration and 
effectiveness of control systems and homeostatic mechanisms. 
1.2.2 Hallmarks of cancer 
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The development of cancer involves accumulation of damage, dysregulation and 
some gain of function. The necessary criteria for malignant transformation of a 
cell were initially described as the Hallmarks of Cancer and more recently 
updated with increased understanding of changes at the molecular 
level(Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). 
1.2.2.1 Sustaining proliferative signalling 
Normal cells exist in an environment replete with chemical signals, a proportion 
of which support growth and are essential for the normal development of each 
cell. Anoikis is the process of cell death instigated in the absence of 
extracellular membrane attachment, an essential process in the maintenance of 
cellular proportions for tissue homeostasis. Cells in culture fail to propagate in 
the absence of suitable signals, and of a suitable growth stratum. Cancer cells 
are notoriously resistant to anoikis. Cancer cells also exhibit striking loss of the 
normal dependence on external growth signals. In some cases, they synthesise 
the growth factors they require, in other cases, mutated transmembrane 
receptors for such factors are constitutively ‘on’ and in some cases, the 
intracellular signalling cascades that translate the signals into molecular activity 
are altered. The SOS-RAS-RAF-MAP kinase pathway has been the focus of much 
research in colorectal cancer, as a high proportion of cancer cells exhibit 
mutations of the Ras protein. Cancer cells may also affect the paracrine 
signalling of stromal cells in such a manner as, for instance, to supply necessary 
growth signals. 
1.2.2.2 Evading growth suppressors 
Growth inhibition is the converse balancing control to cell proliferation which 
adds accuracy and flexibility. Diffusible molecules, transmembrane receptors 
and signalling cascades are also involved and can be subverted to allow 
independence of a different kind from these external signals. Specifically 
however, cells usually respond to growth inhibitory signals by entry into G0 
(quiescent phase) from which they can return to G1 under the correct 
circumstances, or by entry into a post-mitotic state where they relinquish future 
proliferative capacity. Almost all response to antiproliferative signalling involves 
the retinoblastoma (Rb) protein pathway, hence its central importance in cell 
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cycle control and the widespread effects of its mutation and inactivity. TGFβ 
reduces phosphorylation of Rb protein, increasing the proportion of the 
underphosphorylated form which is instrumental in maintaining cells in G1 
growth arrest(Laiho, DeCaprio et al. 1990) and its importance in colorectal 
cancer will be discussed in later sections of this chapter. c-Myc promotes entry 
into a terminally differentiated postmitotic state and is also of significant 
interest in chemotherapeutic strategies for many cancers. 
1.2.2.3 Resisting cell death 
Apoptosis is the classic method of programmed cell death, of central importance 
in embryologic development but retained throughout adult life as a means of 
disposing of damaged or unnecessary cells without initiation of an inflammatory 
response. A specific sequence of events breaks down cell membrane, 
chromosomes, nuclear membrane and nuclear and cytosolic skeletons over 30-
120 minutes and the cell components are phagocytosed over the following 24 
hours by neighbouring cells. Apoptosis requires sensors, to detect appropriate 
triggers, and effectors, to initiate and control the dismantling of the cell. 
Sensors (ligand/receptor pairs) promoting survival include the insulin-like growth 
factor types 1 and 2 (IGF-1/2) and their receptor, and those promoting cell 
death include FAS and TNFα and their receptors. Effectors include caspases and 
p53. p53 is very commonly mutated in cancers, with loss of its proapopototic 
effect leaving cells more vulnerable to unregulated proliferation. 
1.2.2.4 Enabling replicative immortality 
Normal cells demonstrate limited replicative potential and after a relatively 
conserved number of population doublings, cells in culture enter a non-
proliferative state termed replicative senescence(Hayflick 1965). Inactivation of 
p53 and Rb allow further cycles of cell division but cells soon enter a period of 
‘crisis’ characterised by massive cell death and end-to-end chromosomal fusions. 
A tiny proportion of cells emerge from this process with the ability to continue 
to proliferate and are said to be ‘immortalised’. Cancer cells reset the ‘mitotic 
clock’ that measures population doublings but it is not clear how they 
circumvent the onset of senescence in becoming immortalised. The state of 
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senescence is has been induced in certain groups of cells in conditions of stress 
or by overexpression of certain genes, as well as by repeated cell division. 
1.2.2.5 Inducing angiogenesis 
Cells depend for the delivery of oxygen and nutrients on the capillary 
vasculature and proliferation therefore requires a concomitant expansion in the 
vascular supply. Angiogenesis appears in many tumours at an early-to-middle 
stage, before an explosive growth period and is activated by means of an 
‘angiogenic switch’ which alters the balance of pro- and antiangiogenic factors 
in the microenvironment to promote and sustain growth of new capillaries. 
Different tumours achieve this in different ways but all with the fundamental 
aim of supporting the metabolic demands of neoplastic tissue. 
1.2.2.6 Activating invasion and metastasis 
Tissue invasion and subsequent metastasis is the pathological hallmark of 
distinction between a benign and malignant lesion. It is dependent on the earlier 
hallmarks. It indicates an altered relationship with neighbouring cells and with 
the remainder of the organism (which may by this time be considered a separate 
‘host’). At a microscopic level, physical coupling with the extracellular matrix 
and the adjacent cells is altered, and expression of extracellular proteases is 
required. Interactions with adjacent cells and with the extracellular matrix have 
regulatory effects that must be ignored by cancer cells. Protease secretion is 
usually tightly controlled to maintain integrity of the microenvironment and this 
is one of the most significant changes in cancer cells.  
1.2.2.7 Emerging hallmarks of cancer 
Inflammation was proposed as the seventh hallmark of cancer (Colotta, Allavena 
et al. 2009). It is not strictly speaking a characteristic of cancer cells but was 
accepted by as an important ‘enabling characteristic’(Hanahan and Weinberg 
2011). Inflammation causes the release of proangiogenic signals and 
extracellular-matrix-modifying enzymes which promote angiogenesis and 
invasion. Inflammation alters the balance of prevailing growth factors (growth 
inhibition signals are reduced and growth promotion factors emphasised) so the 
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microenvironment becomes more supportive of neoplastic cells. Release of ROS 
with mutagenic effect can also accelerate development of cancer cells. 
Genetic instability and metabolic reprogramming are two important emerging 
characteristics of cancer cells which, with inflammation, are further discussed in 
later sections. 
1.2.3 Colorectal Cancer 
Colorectal cancer is common. With an incidence of 40,700 in the UK in 2010 it is 
the third commonest cancer in both males and females. It is commoner in older 
people; 80% of cases occur in people aged over 60 years. Although survival has 
improved over the past 5 years, five year survival varies from 93% if the cancer is 
Dukes’ Stage A at diagnosis and 6% if Dukes’ Stage D. According to latest figures 
available (2010) 9% of cases are diagnosed at Dukes’ A and 9% at Dukes’ D. 34% 
of cases have unknown stage at diagnosis. As colorectal cancer screening 
programs have been introduced, an increasing proportion of cases are diagnosed 
at earlier stages. 
1.2.3.1 Familial colorectal cancer 
5% of colorectal cancer cases are associated with recognized genetic defects, 
where the ‘first hit’ is already present in the form of a germline or acquired 
mutation in one allele of the relevant gene. 1% of cases are due to familial 
adenomatous polyposis (FAP). A mutation in the APC (adenomatous polyposis 
coli) gene which codes for the APC protein, controller of β-catenin, is present in 
FAP and attenuated FAP. In attenuated FAP, the less severe form, the APC 
protein has impaired function so the effects are less florid. In autosomal 
recessive FAP, the mutation is in a separate protein, MYH glycosylase, which is 
involved in base excision repair.  
Hereditary non-polyposis colorectal cancer (HNPCC) was reported by Lynch in 
1966 and is caused by an autosomal dominant defect in DNA mismatch repair 
genes. There is also a higher risk of other cancers (uterus, small intestine, ureter 
and renal pelvis). Currently the Amsterdam II criteria are used to define non-FAP 
familial colorectal cancer. 35% of families fulfilling the Amsterdam criteria do 
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not have a demonstrable DNA mismatch deficiency and are sometimes diagnosed 
with ‘familial colorectal cancer Type X’. 
Patients can be stratified according to family history and those identified as 
high- or –moderate-risk may be offered regular colonoscopy investigation 
according to protocols determined by the British Society of Gastroenterology 
(BSG) and the Association of Coloproctology for Great Britain and Ireland 
(ACPGBI) (Cairns, Scholefield et al. 2010). 
1.2.3.2 Non-familial colorectal cancer 
Most cases of colorectal cancer are non-familial and are termed sporadic. No 
specific genetic cause for these cases is identified. They are multifactorial and 
often occur against a background of increasing tissue dysfunction. Considered 
from a histological rather than a genetic viewpoint, the development of pre-
malignant and then malignant change in colorectal epithelium is well-described 
in the colorectal adenoma-carcinoma sequence (Leslie, Carey et al. 2002). 
Research continues to identify important pathways involved and to clarify the 
physiological functions of these pathways and their components, and the 
pathophysiological effects of dysfunction. 
However, the high turnover of intestinal mucosal cells means that the lifetime of 
differentiated colonic epithelial cells is 4-5 days. They do not live long enough to 
develop the mutations necessary for malignant transformation. 
1.2.3.3 Colonic stem cells 
Colonic stem cells are more properly termed multipotent adult stem cells and 
are the source cells that continuously regenerate the colonic epithelium. They 
are found at the base of crypts of Lieberkuhn, where their ‘stemness’ is 
maintained by the niche in which they are located(Zeki, Graham et al. 2011). 
The spatial and chemical characteristics of the niche are controlled by 
pericryptal myofibroblasts located below the basal lamina(Powell, Mifflin et al. 
1999). This important epithelial-mesenchymal interaction foreshadows the 
fundamental relationship of colonic epithelial cells with their environment, 
which becomes dysfunctional in the development of colorectal cancer.  
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Colonic stem cells are capable of symmetric and asymmetric cell division. 
Dividing asymmetrically they form one daughter stem cell and one daughter cell 
destined for terminal differentiation. They can also divide symmetrically to form 
two daughter cells destined for differentiation, although this must happen 
relatively rarely as it would reduce the stem cell population. Symmetrical 
division to produce two daughter stem cells is also possible and is likely to be 
important in the repair and resolution of cytocidal damage of any sort affecting 
the colonic epithelium. 
A small population of colonic stem cells exists at the base of each crypt. As 
these divide, their descendants move up the crypt, differentiating into one of 
the four cell types within the colonic epithelial population. Cell division does not 
occur at an equivalent rate among all stem cells, and in fact, varies among them 
so that at any one time, the crypt is populated by clonal expansion of the 
progeny of only one stem cell. Differentiation of cells progressing up the crypt is 
tightly controlled and important regulators are the Wnt/β-catenin family 
(Kosinski, Li et al. 2007; van der Flier and Clevers 2009). The importance of the 
APC gene in the development of colorectal cancer is therefore obvious. Members 
of the bone morphogenetic protein family are thought to exert a growth-
inhibitory effect and are expressed at higher levels towards the top of 
crypts(Kosinski, Li et al. 2007; Hardwick, Kodach et al. 2008). 
Obviously, if the one stem cell dividing to replenish the differentiated cell 
population develops a significant degree of damage, there is propagation of a 
clone of cells carrying important mutations with a clear risk of development of 
cancer. Stem cells already show some of the necessary hallmarks of transformed 
cells. Functions necessary for epithelial repair mean that several more of the 
hallmarks are within their repertoire or the repertoire of the cells which support 
the stem cell niche. 
If the resident population of stem cells is reduced significantly, replacements 
will be recruited from the haematopoietic stem cell compartment. TGFβ is 
central to this process(Sipos, Valcz et al. 2012). 
1.2.3.4 Cancer stem cells 
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This term can be used in different ways. It can be used to indicate stem cells 
which have become transformed. Alternatively, the concept of a stem cell as 
one which maintains a cohort of cells can be applied to the cancer as well as to 
the colonic epithelium. In this sense cancer stem cells are a subdivision within 
the tumour cell population which are able to survive many forms of treatment 
and divide to produce new populations of tumour cells, not all of which may 
have the full complement of functional capabilities of the stem cell parent. 
Treatments may in effect select for these cells and by killing less virulent cells, 
provide them with a selective advantage. 
1.2.3.5 Ageing in colonic mucosa 
Although the effect of age on colonic mucosa is not completely understood, 
several aspects have been described(Sipos, Leiszter et al. 2011). Colonic stem 
cells may be reduced in number over time and their response to injury was less 
effective in a mouse model(Kirkwood 2004). Altered methylation patterns of 
several genes with age indicate that there is an epigenetic effect of ageing. 
Oestrogen receptor 1 (ER1) shows age-dependent methylation in colonic mucosa; 
it may predispose to tumour formation by dysregulation of colonic epithelial cell 
growth and differentiation. Methylation of ER1 is more common in ulcerative 
colitis patients with colonic carcinoma than those without(Tominaga, Fujii et al. 
2005). 
Response to growth factors is also altered in older colonic epithelium. Age-
related increase in epidermal growth factor receptor is associated with 
increased colonic cell proliferation in rats(Malecka-Panas, Relan et al. 1996). 
Hepatocyte-derived growth factor is produced by mesenchymal cells and acts on 
epithelial cells expressing the appropriate receptor. It is important in gut 
epithelial cell homeostasis and gastrointestinal wound healing(Sipos, Galamb et 
al. 2008). In vitro expression by fibroblasts increases after 70% of lifespan in 
culture. 
Telomere length has been shown to be shorter in chronologically aged 
colonocytes. Telomerase is normally expressed in stem cells in the base of 
colonic crypts but in some cases telomerase activity is reduced in conjunction 
with ulcerative colitis(Usselmann, Newbold et al. 2001; Kleideiter, Friedrich et 
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al. 2003). Telomere length as a marker of biological age in colonic epithelium 
and other tissues will be discussed in more detail in later chapters. 
1.3 Cancer and Inflammation 
Cancer risk in several tissues is noted to be increased in the context of chronic 
inflammation. The link between inflammatory bowel disease of extensive 
anatomic involvement and prolonged chronologic duration is well 
documented(Lashner, Silverstein et al. 1989; Eaden, Abrams et al. 2001). 
Barrett’s oesophagus is a condition of lower oesophageal metaplasia thought to 
develop in response to chronic acid-induced oesophagitis which is strongly 
associated with oesophageal adenocarcinoma. Chronic inflammation resulting 
from smoking probably contributes to the development of lung adenocarcinoma, 
as well as the effects of carcinogens in smoke. In histological assessment of 
urothelial lesions, it is recognised that it may be impossible to conclusively 
differentiate reactive from dysplastic lesions and a separate category of 
Urothelial Atypia of Unknown Significance  allows for such cases to be identified 
for closer followup(Reuter, Epstein et al. 1999).  
Repeated episodes, or chronic continuous inflammation results in repeated 
tissue damage. There is an ongoing requirement for repair and cell division to 
replace damaged tissue and the cellular microenvironment is permissive for 
repeated cell division. Increased rates of cell division will increase the chance of 
cancer cells escaping the stringent controls on propagation of damaged cells.  
The body has numerous mechanisms to identify and manage cells under stress, 
or which have sustained damage. Most of these operate in the context of 
inflammation, which is the most ancient defence system in the evolutionary 
armamentarium. 
1.3.1 Inflammation: A brief overview 
Inflammation is the most basic form of defence seen in multicellular organisms. 
It has been developing for 800 million years and is both a complex and well-
integrated process. The inflammatory response works closely with the innate 
immune system in the defence of the organism. 
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The initial insult triggers a local inflammatory response, which may be dealt 
with by tissue-resident cells. If this is not possible, other cells will be recruited 
and the response may become systemic. 
Generically, the inflammatory process involves induction, effect and resolution. 
The aim is to nullify the external threat, and return to baseline homeostasis. 
The initial trigger for the inflammatory response can be categorised as infective, 
or resulting from tissue death, or from tissue stress and dysfunction. The 
sequelae of this last trigger are referred to as para-inflammation, indicating the 
intermediate nature of the damage. 
The inflammatory response involves several interlinked pathways with many 
component parts; it has cellular and humoral arms. As such, it can be useful to 
classify inducers, sensors, mediators and effectors of inflammation(Medzhitov 
2008). Different triggers of inflammation invoke a variable subset of downstream 
responses, tailored (to a certain degree) to the initial insult. The resolution 
phase also requires a similar set of response elements. 
Inducers of the inflammatory response can be exogenous or endogenous. 
Exogenous inducers are pathogen-associated molecular patterns (PAMPs) or 
virulence factors. Virulence factors are not recognised by chemical interaction, 
but by their effects, such as the potassium-efflux resulting from pore-forming 
exotoxins of Gram-positive bacteria. PAMPs are organic particles of pathogen 
origin which are recognised by evolutionarily conserved pattern recognition 
molecules (PRMs). 
Endogenous inducers of the inflammatory response are less well-defined but 
desequestration has a potent effect. Desequestration refers to contact between 
substances normally kept separate in the functioning cell, such as ATP, K+ ions 
and members of the calcium-binding protein families. Epithelial and 
mesenchymal cells are normally separated from each other by a basement 
membrane and ‘unscheduled contact’ can also be a powerful trigger for an 
inflammatory response. Epithelial and mesenchymal cell interaction is also 
central in determining colonic stem cell differentiation as discussed earlier. 
Chapter 1: Introduction    45 
Inflammation has a positive protective effect overall, but the actions of effector 
cells and molecules are not specific and there is an inherent degree of damage 
to surrounding cells on evocation of the inflammatory response. Repeated or 
sustained inflammation may overcome the ability of the organism to completely 
repair the damage due to the triggering insults or to the inflammatory response 
itself. This is one important source of ageing and of increasingly damaged repair 
systems. 
The inflammatory response is linked to epithelial cell function on a constitutive 
level as well. Tissue-resident macrophages make up approximately 10-15% of the 
cell population and are intrinsically involved in maintaining the tissue 
microenvironment. They constantly monitor cell state and can detect variation 
in cell stress by expression of specific peptides on the cell membrane.  
Cell state is generally categorised into 4 levels of increasing stress; transit 
between these levels is by specific genetic ‘switches’. The stages are basal 
(normal and unstressed), stressed, apoptotic and necrotic. Although necrosis was 
thought to be an unregulated event, recent evidence appears to suggest that 
there may be some underlying regulated ‘emergency plan’. Switching between 
these states as a distinct action ensures that the cell does not give out mixed 
messages and also that it exhausts all possibilities of remediation before 
switching to the next, less desirable state. 
The significance of macrophage monitoring of cell state is twofold. Macrophages 
have a certain capacity to support cells by release of growth factors and 
modulation of the microenvironment and may be able to prevent deterioration 
and change of state by doing so. Equally, if a cell is reverting to apoptosis or 
necrosis, macrophages are central in coordinating the appropriate response, 
with or without the induction of an inflammatory response. Macrophages, with 
their regulatory effect on epithelial cell growth and maintenance, and also on 
angiogenesis and extracellular matrix breakdown can also be co-opted in tumour 
development and metastasis. The important role that macrophages play in this 
situation has been reviewed (Condeelis and Pollard 2006) and is the subject of 
more recent study. Effects on survival in cancer are varied, and probably reflect 
the variable functions of macrophages in the tumour microenvironment 
(Mohammed, Going et al. 2012; Richards, Flegg et al. 2012). 
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1.3.1.1 Local inflammatory response 
The initial inflammatory response will be local. Ideally the external threat is 
nullified at this stage and localised damage is repaired by the organism. 
Recovery requires cell division to replace cells lost or damaged. If the threat 
overcomes local resources, humoral signals stimulate an escalated response 
which may become systemic.  
1.3.1.2 Systemic inflammatory response 
A truly systemic inflammatory response induces measureable changes in a wide 
range of serum markers. Hepatic synthesis of positive ‘acute phase proteins’ 
(APPs) increases and there is a reduction in serum levels of negative APPs due to 
increased catabolism and decreased synthesis. The systemic inflammatory 
response induced by infection is more completely understood than the chronic 
systemic inflammatory response to other pathological processes. The systemic 
response to cancer may reflect a modulation of a chronic inflammatory response 
already present and instigated by an inflammatory pathology predisposing to the 
cancer or it may be almost solely due to the cancer itself. 
NFκB appears to have a central role in the systemic response, whatever the 
causal insult. 
1.3.1.3 Inflamm-ageing: inherent systemic inflammatory response? 
Inflamm-ageing refers to the age-associated changes in the innate immune 
system, which can be summarised as a progressive loss of regulatory control of 
the adaptive immune system and general upregulation of the innate immune 
system with time(Cevenini, Caruso et al. 2010). As many systems show 
progressive low-level dysfunction there are correspondingly more endogenous 
sources of inflammation in the aged organism. There is also a less appropriate 
inflammatory response from the similarly affected (innate) immune system. 
1.4 Fates of aged - damaged - cells 
1.4.1 Apoptosis 
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Programmed cell death is a planned and carefully orchestrated process resulting 
in the removal of a cell. It is seen in embryological life as body parts take on 
their final form. For instance, it occurs in the digital web spaces to create the 
digits and is thought to explain the recanalisation of the gut. There is a minimum 
of inflammatory reaction and there are characteristic changes in the nuclei and 
cytoplasm preceding the breakdown of the cell and nuclear membrane allowing 
phagocytosis of cell components for recycling. If control of apoptosis is lost, 
cells may proliferate or survive despite having sustained significant damage. 
1.4.2 Anoikis 
Anoikis is programmed cell death in response to loss of contact with the 
extracellular matrix. Organisms have evolved with the threat of cancer over the 
course of generations and anoikis is a fundamental defence against cancer. It 
means that not only must the malignant cell escape from external controlling 
signals, but simple lack of those signals itself invokes cell death, and this process 
too must be overcome. 
1.4.3 Necrosis 
Pathological cell death results in cell lysis and release of contents stimulating an 
inflammatory reaction. It is associated with the characteristic macroscopic 
features of erythema, swelling, pain and heat. At a cellular level there is 
vasodilation, increased capillary permeability and oedema. Inflammatory cells 
are recruited and debris cleared by phagocytosis as part of the reaction. 
1.4.4 Transformation 
A very few aged and damaged cells achieve transformation to become 
immortalised cancer cells. Characteristics of these cells were described earlier. 
The path of their development is an important focus of cancer research:  
identification of essential and decisive changes at a cellular level will guide the 
development of novel effective and precise therapeutic strategies with minimal 
damage to surrounding cells. This is likely to be increasingly important to 
preserve remaining function in more aged patients. 
1.4.5 Senescence 
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1.4.5.1 The Hayflick Limit 
Leonard Hayflick (Hayflick and Moorhead 1961) described a finite and similar 
number of cell divisions undergone by repeatedly examined cultures of human 
cells. This phenomenon became known as the Hayflick Limit. It was predicted by 
Olovnikov as a result of the end replication problem due to the mechanism of 
DNA replication(Olovnikov 1973). The Hayflick Limit was explained by the 
discovery of telomeres (Blackburn and Gall 1978); it was suggested that they 
acted as a replicometer or ‘mitotic clock’, which induced cell cycle arrest after 
a prescribed number of cell divisions. However telomeres are much more than a 
length of expendable DNA, as will be discussed in later sections. 
1.4.5.2 Organ senescence 
Increasing numbers of senescent cells affect organ function by mass effect 
through reduction in the number of normally functioning cells. ‘Senescence’ as 
applied to organs describes progressively reduced function over time. 
1.4.5.3 Cellular senescence 
Senescent cells enter a state of irreversible growth arrest. There are many 
triggers for this process but critically short telomeres are one of the most 
powerful. DNA damage is also a potent inducer of senescence(von Zglinicki, 
Saretzki et al. 2005). Shortened telomeres are associated with significant 
genetic anomalies such as chromosomal translocation or fusion. The 
phenomenon of senescence-induced growth arrest is thought to constitute a 
defence against cancer; thus cells with significant DNA damage, or critically 
shortened telomeres are prevented from passing on their damaged DNA to 
daughter cells. 
1.4.5.4 Senescence-associated secretory phenotype 
As research into the phenomenon of senescence accumulates, it has become 
clear that senescent cells, while no longer dividing, are not merely passive. The 
damage that has accrued can cause them to continue to function within their 
niche but this function may be aberrant, with the potential accumulation of 
abnormal proteins or other molecules. A characteristic senescence-associated 
secretory phenotype is recognisable and this appears to have a pro-inflammatory 
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paracrine effect(Campisi 2013). Thus, senescent cells within a tissue may alter 
the microenvironment. The effects of their paracrine secretions (while not yet 
clear) could support or promote malignant change in neighbouring cells.  
1.5 Markers and Mediators of Inflammation 
1.5.1 CRP 
CRP is a short pentraxin, member of one of the fluid-phase families of pattern 
recognition molecules which recognise PAMPs. CRP is the major acute-phase 
reactant in humans(Mantovani, Valentino et al. 2013). Neutrophils store CRP for 
release as an immediate response to injury. It is also synthesised by 
macrophages in response to gene-activation, and by hepatocytes in a slightly 
delayed systemic response, on stimulation by IL-6. Levels are usually <3mg/ml in 
normal human serum but can increase a hundredfold within 6 hours in response 
to insult. 
1.5.2 Albumin 
Albumin is synthesised by the liver and is the most abundant plasma protein. It 
has important roles in acid-base balance, in binding and transport of drugs, 
hormones, ions (including calcium, iron and copper), and metabolites including 
amino acids and fatty acids. Albumin is an important part of extracellular 
defences against ROS-induced stress, due to its volume and a biochemical 
structure which allows it to bind copper, iron and hydrogen ions and free 
radicals, undergoing oxidation of a thiol group in the process(Sitar, Aydin et al. 
2013). Albumin also has an inhibitory effect on platelet aggregation. 
It is a negative acute phase protein, with synthesis reduced as part of the 
‘hepatic reprioritisation’ response to proinflammatory cytokines, and deficiency 
of specific amino acids. Albumin levels do not respond to nutritional 
supplementation immediately but rather to the resolution of the cause of 
inflammation(Hulshoff, Schricker et al. 2013). Albumin replacement is used in 
critically ill patients but it may be that improved outcomes are due to other 
actions apart from its ability to maintain colloid osmotic pressure, and it is not 
clear that all patients experience benefit from its use over crystalloid for fluid 
resuscitation(Cochrane 1998). 
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Despite its poor reflection of nutritional status, and because this is due to the 
numerous other competing effects on serum level, particularly relating to the 
systemic inflammatory response, hypoalbuminaemia has for some time been 
recognised as a risk factor and predictor of general debilitation and poor 
prognosis in patients with sepsis and cancer as well as after surgery (Herrmann, 
Safran et al. 1992; Daley, Khuri et al. 1997; Don and Kaysen 2004). 
1.6 Colorectal Cancer and inflammation 
1.6.1 Inflammation as a defence in the gut 
The gastrointestinal epithelium provides a single-cell barrier between the 
controlled internal milieu of the organism and the external environment, and 
harbours a rich commensal microbiological flora as well as a multitude of 
pathogenic organisms(Elinav, Henao-Mejia et al. 2013). The large surface area of 
this barrier provides for essential physiological functions but also offers a 
significant risk of breach with potential life-threatening systemic infection. 
Inflammation is a fundamental second-line of defence, and constant low-level 
activation is probably necessary to maintain a healthy micro-environment within 
the epithelium and submucosa. Likewise, inflammatory responses may have 
some success in recognising and eliminating dysplastic cells in the earliest stages 
of their development(Rizzo, Pallone et al. 2011). 
1.6.2 Increased cancer incidence in chronic inflammation: IBD 
and cancer 
An increased risk of colorectal cancer in association with inflammatory bowel 
disease has been noted for some years(Lashner, Silverstein et al. 1989; Lennard-
Jones, Melville et al. 1990; Eaden, Abrams et al. 2001). Mechanisms which may 
underlie this include inflammation induced by commensal species as well as 
pathogens, inflammatory oxidative stress, p53 mutation, telomere shortening 
and genetic instability, with alteration in the relationship between mucosal and 
submucosal cell populations(Okayasu 2012). In ulcerative colitis, there is a 
higher risk of CRC in pancolonic inflammation after 15 years, which justifies 
increased colonoscopic screening and subtotal colectomy in some 
patients(Connelly and Koltun 2013). Cancer has been observed in chronically 
inflamed tissue associated with Crohn’s disease as well (Zagoni, Peter et al. 
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2006), although the discontiguous nature of the disease process has made it 
more difficult to quantify the extent of inflammation and draw reliable 
associations between the extent of inflammation and neoplastic change. 
1.6.3 Dysregulation of inflammation in the gut 
Ageing is the most potent risk factor for colorectal cancer as it ‘represents the 
general framework within which the tumour environment evolves’(Garagnani, 
Pirazzini et al. 2013). Inflamm-ageing may increase the likelihood of a 
dysregulated response to the recurrent threats posed to gastrointestinal 
epithelial integrity. Chronicity of inflammation may in itself be a risk factor for 
dysregulation as there are more opportunities over time for control to be 
impaired.  
A direct link between inflammation and colorectal epithelial cell proliferation 
has been observed in a mouse model deficient in components of the 
inflammatory response, with colitis-associated colorectal cancer. The NLRC4 
protein activates an inflammatory response to Gram-negative bacteria common 
in the gut. Unexpectedly increased tumorigenesis in NLRC4-deficient mice was 
not due to alteration of inflammatory pathways but to enhanced proliferation 
and attenuated apoptosis(Hu, Elinav et al. 2011). It is not clear what the 
underlying mechanism for this interaction is, but further analysis of the process 
will likely be informative. 
1.6.3.1 Anti-inflammatories and CRC 
Given the evidence on the involvement of inflammation in CRC, the role of non-
steroidal anti-inflammatory agents (NSAIDs), has also received extensive 
scrutiny. A National Institute for Health Research Health Technology Assessment 
review of aspirin use for primary prevention of CRC confirmed a small effect in 
reducing incidence, evident after 5 years of use(Sutcliffe, Connock et al. 2013). 
Initial studies were generally performed in patients on treatment with aspirin for 
cardiovascular disease and aspirin use for primary prevention has been limited 
by incidence of gastrointestinal bleeding. 
Aspirin is a non-selective cyclo-oxygenase (COX) inhibitor, which at low doses 
inhibits platelet function by irreversible inactivation of COX-1. It also has 
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inhibitory effects on NFκB and Wnt/β-catenin signalling. Its effectiveness against 
colorectal cancer at doses which affect platelet function suggests that colorectal 
cancer and atherothrombotic disease may share pathophysiological processes 
related to platelet activation(Dovizio, Bruno et al. 2013). This is an interesting 
concept, particularly in view of relationships between the metabolic syndrome 
and ageing, and between fetuin A (one of the subjects of this thesis) and 
cardiovascular disease. These interactions are discussed in more detail later. 
Cyclo-oxygenase 2 (COX-2) is an early response gene inducible by a range of 
inflammatory stimuli, encoding an enzyme which catalyses a rate-limiting step in 
prostaglandin synthesis. Levels of COX-2 are elevated in a large proportion of 
colorectal tumours. Selective COX-2 inhibitors have also been shown to reduce 
incidence of CRC and resolution of adenomas, particularly in FAP patients. 
Cardiovascular events have limited treatment to an extent, but studies indicate 
that the mechanism of action, although unclear, involves global reduction in 
prostaglandin synthesis, particularly PGE2 (Wang and Dubois 2010). 
1.6.4 Inflammatory response to colorectal cancer 
Inflammatory processes also have a role to play in the host response to 
colorectal cancer. At a local level, as indicated earlier, these probably involve 
recognition and destruction of neoplastic cells detected as abnormal, and may 
often be successful, in that only the failures continue to develop into clinically 
evident tumours. 
In established tumours, pathologists have for some time recognised that there is 
often an inflammatory cell infiltrate within the tumour and that the density of 
infiltration corresponds to a better outcome. The precise nature of the 
infiltrate, the cells recruited and type of immune response initiated have a 
bearing on tumour invasion, and response to treatment(Roxburgh and McMillan 
2012). 
1.6.5 Worse prognosis with systemic inflammatory response in 
colorectal cancer 
A large body of work has shown the detrimental effect of systemic inflammation 
as a separate marker of poor prognosis in a range of cancers. There seems to be 
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an inverse relationship between the strength of the local and systemic 
inflammatory responses, with weak local and heightened systemic responses 
constituting poor prognostic factors. Tumour necrosis may be one factor 
triggering a systemic inflammatory response(Richards, Roxburgh et al. 2012). 
The balance between these two in the response to colorectal cancer probably 
reflects the pre-existing inflammatory landscape in which the tumour develops. 
1.6.6 Modified Glasgow Prognostic Score (mGPS) 
Initial studies of several markers of inflammation identified the combination of 
CRP and albumin as being of particular predictive efficacy, and defined the 
threshold level for each which is associated with worse outcome. The original 
Glasgow Prognostic Score gave equal weighting to albumin and CRP, but was 
modified as CRP appeared to carry greater predictive value(Leitch, Chakrabarti 
et al. 2007). The modified score awards 1 point for CRP over 10, and a further 
point if albumin levels are 35 or below. 
The modified Glasgow Prognostic Score has been validated in colorectal cancer 
in several populations, and in many other cancers (Al Murri, Bartlett et al. 2006; 
Crumley, McMillan et al. 2006; Glen, Jamieson et al. 2006; McMillan, Crozier et 
al. 2007; Ishizuka, Nagata et al. 2012; McMillan 2013). The poor prognosis of 
patients with elevated mGPS appears to result from a less effective host 
inflammatory response to the cancer, in combination with the effect of 
malnutrition. The malnutrition observed in cancer, particularly in advanced 
stages of the disease, may reflect the subversion of normal homeostatic 
mechanisms to the metabolic demands of malignant cells not responsive to 
signals indicating a need to curb demand for the survival of the organism as a 
whole. 
1.6.7 Obesity, inflammation and CRC 
Obesity is recognised as a chronic inflammatory condition and feedback loops set 
up by visceral adipose-derived molecules such as leptin, resistin and adiponectin 
can increase the background proinflammatory state of the gut(Vazzana, Riondino 
et al. 2012). Macrophages resident in obese adipose tissue contribute by 
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secretion of proinflammatory cytokines, as distinct from the secretory patterns 
of macrophages in lean adipose tissue(Yehuda-Shnaidman and Schwartz 2012). 
Obesity is only one of several metabolic factors in the aetiology and 
pathophysiology of cancer. 
1.7 Metabolism in colorectal tissue 
1.7.1 Normal cellular respiration 
Glucose is the carbon source for 80% of phosphorylated compounds in cells so it 
is difficult to overstate its importance in control of metabolism and secondarily 
in control of cell proliferation. Other energy sources are used but in the normal 
cell, these are tightly controlled. Most cells maintain a small amount of glycogen 
as a glucose store; glucose itself has a significant effect on several enzymatic 
reactions and is not freely available within the cell for this reason. Glucose 
conversion to glycogen is controlled by glycogen synthase, which is inhibited by 
phosphorylation by glycogen synthase kinase (GSK). The isoform GSK3 is 
inhibited by PI3K/AKT pathway, which is activated by insulin and the insulin–like 
growth factor (IGF) family. Recent research on GSK3 has shown its activity in the 
fields of inflammatory response, apoptosis, cell migration and control of cell 
adhesion. 
Glycolysis (fermentation) and aerobic respiration are the two main energy-
releasing pathways used by the normally functioning cell. Glycolysis converts 
glucose to pyruvate which is reduced to lactate and excreted in the 
bloodstream, with the generation of 2 molecules of ATP per molecule of glucose 
used. It takes place in the cytosol. Aerobic respiration is a much more complex 
process which begins with glycolysis in the cytosol and continues by means of the 
Krebs (or tricarboxylic acid) cycle and oxidative phosphorylation in the 
mitochondria. Glucose and other substrates are completely oxidised to CO2 and 
water, with the generation of 15 times more ATP. There is more likelihood of 
ROS production but as with all processes that generate ROS, they are generally 
tightly controlled. 
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As a rule, fermentation is reserved for short-term energy generation in hypoxic 
conditions, and with the return of normal oxygenation, aerobic respiration 
resumes with the oxidation of any lactate that has not been removed by the 
vascular system. Under these conditions cells, even cardiac myocytes which are 
specialised to function in intermittent hypoxia, tend to restrict non-essential 
synthesis and proliferation. 
The pentose phosphate pathway (PPP) is the major route for conversion of 
glucose to 5 carbon sugars which are used in nucleic acid synthesis. Glucose-6-
phosphate is converted to ribose-5-phosphate and NADPH, which is essential for 
fatty acid synthesis, and is a scavenger of ROS. 
1.7.2 Metabolism under different conditions of substrate 
availability 
Cells have evolved to cope with a wide variation in the ambient availability of 
nutrients. Within the parameters of survivable variation in nutrient availability, 
the redox status of the normal cell will vary in response to external ambient 
conditions. In multicellular organisms, integrating the function of individual cells 
with overarching strategies for the survival of the organism is key, but 
maintaining homeostasis of the extracellular environment to optimise cellular 
performance is fundamental to achieving this. It is important to consider this 
difference between single cell model systems and whole organisms in 
considering metabolic adaptations. 
1.7.2.1 Acute fasting 
In the acute response to lack of food or nutrients, glucose production is 
prioritised. There is no mitochondrial biogenesis. Glycogen stores in cells are 
used and active gluconeogenesis commences in response to glucagon secretion in 
humans. 
1.7.2.2 Prolonged fasting 
Prolonged lack of food or nutrients activates additional responses. As hepatic 
glycogen stores are used up, other energy sources are required to replace them 
for essential tissues such as brain and skeletal and cardiac muscle. Specific 
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pathways are activated to suppress hepatic gluconeogenesis. Fatty acid 
oxidation is activated to obtain the additional required energy substrates 
initially; amino acid catabolism will also be induced if necessary. There is no 
stimulus for mitochondrial biogenesis. 
1.7.2.3 Caloric restriction 
Caloric restriction is defined as a reduction in caloric intake by 30-40% with 
respect to organisms fed ad libitum, with optimal levels of vitamins and minerals 
to maintain nutrition. It is thus significantly different from the fasting states 
described above. It has been noted to produce increase in lifespan in organisms 
from yeast, nematodes and Drosophila to mice. Caloric restriction can increase 
the lifespan of laboratory rodents by up to 50%(Sohal and Weindruch 1996). 
Caloric restriction is not documented in humans; the degree of restriction is 
difficult to maintain. 
Mild and severe caloric restriction have different effects on gene expression 
profiles. In yeast, caloric restriction triggers a switch from fermentation to the 
tricarboxylic acid cycle for energy generation. A consideration in extrapolating 
observations on caloric restriction from unicellular to multicellular organisms is 
that in a multicellular organism, some cell types will be initially screened from 
the effects of reduced availability of resources. Essential tissues such as brain, 
heart, and skeletal muscle will be preferentially supplied with necessary 
substrates. Thus, there may be tissues which experience severe caloric 
restriction, at least initially, and tissues which experience milder caloric 
restriction(Qiu, Brown et al. 2010). Variables of note will include tissue, 
duration of caloric restriction, state of function of the vascular supply and of 
overall systemic control systems such as hormonal messengers. In mammals, 
there is an observed switch from glucose to fatty acid metabolism in caloric 
restriction. 
The mechanism underlying the benefits of CR is still debated. Slowing of 
development has been discarded as the causal factor as CR can be started at 
anytime during the lifespan and still confer benefit. It has been postulated that 
CR works by slowing down metabolic activity and thus reducing free radical 
damage. Stochastic oxidative damage is increased with increased number of 
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metabolic processes ongoing in a cell. Active cellular metabolism for any reason 
therefore incurs more damage and if resources – of energy and raw materials – 
are insufficient to repair these, then longer-term damage may result.  
Caloric restriction reduces the oxidative burden on cells as measured by a 
reduction in by-products of oxidative damage to fats (lipofuscin) proteins and 
DNA(Qiu, Brown et al. 2010). However, the metabolic rate does not slow. It may 
be that there is a gross reduction in metabolic activity, rather than rate. A 
simplified repertoire of metabolic processes may be required to maintain the 
steady state in an austere environment with a reduction in free radical damage 
overall. 
Conversely, excess food intake could render glucose or fatty acids, in molecular 
terms, as much a pollutant as other more familiar toxins. Increased cellular 
metabolic activity puts more pressure on disposal systems or systems to control 
reactive oxygen species used as messengers, cofactors, intermediates.  
Caloric restriction in SIR2-deleted yeast strains does not produce the increase in 
lifespan observed in wild-type yeast. SIR2 (Silent Information Regulator Type 2) 
is a yeast protein evolutionarily conserved across most classes of higher 
organisms; these orthologues are known as sirtuins. It has been hypothesised 
that sirtuins extend lifespan in the organisms in which caloric restriction has 
been observed, by control of metabolic pathways. The involvement of specific 
sirtuins in metabolic control will be discussed in more detail subsequently 
(Section 1.15). 
Caloric restriction may produce a shift in metabolism in cells allowing them to 
increase efficiency in energy usage or to delay energy-hungry metabolic 
processes, such as cell division (Lamming, Wood et al. 2004). 
The central effects of caloric restriction focus on the mitochondria: increased 
mitochondrial biogenesis, and activation of mitochondria to increase respiration 
rate, increase ATP production and maximise the extraction of energy from 
chronically depleted resources. This is achieved by use of other fuels such as 
fatty acids, ketones and amino acids, oxidation of which produces many more 
molecules of ATP per unit fuel than glycolysis alone and also avoids the 
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production of acidic products. This activation involves other members of the 
sirtuin family; in humans the so-called ‘mitochondrial sirtuins’ are SIRT3, SIRT4 
and SIRT5 and are also discussed later. 
1.7.3 Control of metabolism: tailoring to prevailing conditions 
Strategic control of metabolism is a multilayered hierarchical process, with 
integration of feedback loops within and between levels. In a comprehensive 
review (Lindsley and Rutter 2004), 5 pathways are described. These are the 
AMPK pathway, mTOR, PAS kinase, hexosamine biosynthesis pathway and the 
networks involving the sirtuins. There is crosstalk between some, if not all, of 
them. SIRT1 is thought to activate the AMPK pathway indirectly as increasing 
energy usage depletes stores of ATP and ADP, and it is the change in these 
molecules that stimulates AMPK activity (Qiu, Brown et al. 2010; Ruderman, Xu 
et al. 2010). Indeed these molecules are thought to regulate each other. AMPK 
downregulates processes not imminently required for survival, which consume 
ATP, while stimulating those that replenish ATP stores, which are generally 
catabolic in nature.  
Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) 
controls genes involved in fatty acid metabolism. It is inhibited by high levels of 
Acetyl-CoA after eating and activated (indirectly) by NAD (via SIRT1) on fasting. 
These two small molecules also modulate chromatin packaging and thus gene 
expression in opposite directions(Naimi, Arous et al. 2010). 
With this degree of complexity, a systems biology approach has been used with 
success to identify constraining parameters and common scaling laws in cellular 
metabolism among species(Kriete, Sokhansanj et al. 2006). 
1.8 Metabolism and Ageing: Regulation of metabolism 
and longevity 
1.8.1 Dysregulation of metabolism with age 
The links between metabolic process and longevity are intuitive since efficient 
metabolism will enable growth when advantageous, and will maintain essential 
systems in a good state of repair. Organisms in the prime of life will likewise 
Chapter 1: Introduction    59 
exhibit well-regulated metabolic processes capable of timely and smooth 
adjustment to optimise response to prevailing environmental conditions. Aged 
and imperfect disposal systems are more likely to allow build-up of toxic 
metabolites. 
The mechanistic descriptions of both metabolic pathways, and control and 
integration of these pathways are still incompletely understood. Improved 
understanding of metabolism and control of metabolism with increased agedness 
is an important health concern in the Western world and is also an increasing 
problem in countries where populations are becoming more affluent. Excess 
normal metabolic substrates can also be toxic. 
1.8.2 Metabolic syndrome 
The ‘metabolic syndrome’ was first described in 1988, in the Bantling lecture to 
the American Diabetic Association(Reaven 1988). Reaven described a 
constellation of co-morbidities and proposed increasing insulin resistance as the 
unifying underlying factor. The existence and defining criteria of metabolic 
syndrome are a matter for debate still(Meigs 2000) but include obesity, glucose 
intolerance, hypertension, high triglycerides and LDL cholesterol, low HDL 
cholesterol and a proinflammatory and prothrombotic state(Arai, Kojima et al. 
2009). Metabolic syndrome and insulin resistance are more common with 
age(Kobayashi, Nishimura et al. 2007) but centenarians appear to have 
demonstrable differences in adipokines which modulate insulin 
sensitivity(Kanaya, Wassel Fyr et al. 2006). Given links between visceral 
adiposity, insulin resistance and other potential markers of biological ageing 
(like peripheral blood leukocyte (PBL) telomere length), one theory suggests that 
the metabolic syndrome may amplify or accelerate the ageing process(Barzilay 
and Stein 2011). 
Of note, there is also evidence to support early programming of metabolic 
control in response to adverse nutritional states with subsequent increased risk 
of development of the metabolic syndrome(Gluckman and Hanson 2004; McMillen 
and Robinson 2005). Certainly, appreciation of a ‘big picture’ integrating 
function of brain, liver, gut, pancreas, and adipose tissue will be necessary to 
understand whole-body energy homeostasis and its effects on longevity. One 
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such theory integrates hormonal modulation (by oestrogen, androgens and 
insulin), inflammation and lipid mediators of redox stress and notes 
epidemiologic evidence in support of the combined effect of these factors on 
colorectal cancer risk(Slattery and Fitzpatrick 2009). 
1.8.3 Mitochondrial dysfunction with age 
Oxidative stress has been implicated in the pathophysiology of several 
components of the metabolic syndrome. Excess production of free radicals or 
failure to neutralise them efficiently allows damage to accrue. Mitochondria, as 
the site of much cellular production of free radicals, are in the front line. 
Damaged mitochondria will also function less efficiently in the handling of free 
radicals and so a vicious cycle has been described(Frisard and Ravussin 2006). It 
is logical that different individual susceptibilities and genetic predispositions to 
mitochondrial disease should underlie the identity of the initiating lesion, but in 
due course a common positive feedback loop may lead to ongoing damage. 
1.9 Metabolism in cancer 
Cancer cells and inflammatory cells share challenges incumbent on cells with a 
high (or unregulated) metabolic rate. However, several specific aspects of 
cancer cell metabolism have been noted for over 50 years, and renewed interest 
in these phenomena may produce more complete explanation with the 
integration of more recent discoveries. 
1.9.1 Glycolysis: the Warburg effect. 
In 1924 Otto Warburg observed that cancer cells exhibit increased uptake of 
glucose and extrusion of lactate into the surrounding tissues, with consequent 
effect on the pH in the vicinity, compared to normal cells(Warburg 1956). This 
pattern of metabolism is not altered by the presence of oxygen, another 
difference in comparison to normal cells. His data formed the basis for a lively 
debate, and for a lifetime of distinguished research on the part of its discoverer 
and several other scientists. Warburg’s research uncovered several facets of 
cancer cell metabolism, which remain relevant, and indeed are the focus of 
renewed interest in recent years. 
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The initial experiments used slices of tumour tissue, whose thickness was 
thought to have introduced a degree of hypoxia; further experiments also used 
ascites cancer cells, which live virtually free in the peritoneal cavity and 
confirmed the observed results in the absence of hypoxia. 
More recent studies have also shown that glycolysis is used as the primary mode 
of energy generation in cancer cells even in presence of other energy sources. 
Genetic studies have confirmed that enzymes of the glycolytic pathway are 
upregulated in 76% of colorectal cancer specimens(Yeh, Wang et al. 2008). 
Administration of glucose increased proliferation in colorectal cancer cell lines 
and this was also associated with an increase in transcription of eight genes 
involved in glucose uptake (GLUT-1) and glycolysis. 
GLUT-1 encodes glucose-transporter-1; it is consistently upregulated in 
colorectal cancer cells with K-RAS mutations, which are able to survive in low-
glucose conditions(Yun, Rago et al. 2009). These authors found that cells with 
wild-type KRAS which survived a low-glucose environment tended to express high 
levels of GLUT-1 and 4% acquired KRAS mutations not present in parent cells. 
Why cancer cells should preferentially use a less efficient mode of energy 
generation is not clear. The data above suggest there might be an advantage in 
being able to survive in a low-glucose environment such as might arise within a 
tumour mass without regulated vascular supply to provide adequate nutrients. 
Further information comes from a study of HCT116-derived colorectal carcinoma 
cell lines. These were engineered to express varying levels of a mitochondrial 
ATP-synthase subunit and showed widespread changes in transcription, protein 
expression, mitochondrial function and in vivo tumour-forming 
capability(Sanchez-Arago, Chamorro et al. 2010). Following treatment with 
oligomycin (an inhibitor of ATP-synthase) cells showed a more aggressive 
tumour-forming phenotype (termed G cell phenotype). These cells, surprisingly, 
also showed reduced expression of genes associated with mitochondrial 
biogenesis and function. Tumourigenicity appeared to be selected for in 
conjunction with glycolytic tendency and these cells also had a cell-death 
resistant phenotype. G cells showed increased resistance to 5-FU treatment 
which was reduced by treatment with an activator of mitochondrial 
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decarboxylation of pyruvate, whose effect was to reduce aerobic glycolysis to 
baseline levels. 
1.9.2 Specific enzyme involvement in glycolysis in cancer 
A recent review of the Warburg effect highlighted several important 
enzymes(Bayley and Devilee 2012).  The role of the M2 isoform of pyruvate 
kinase (PK) is debated, since it seems not to be a tumour-specific 
isoform(Bluemlein, Gruning et al. 2011) but is still of importance(Zhou, Li et al. 
2012). The interaction between PK and HIF-1α is one example of interplay 
between metabolic pathways and those controlling cell growth (Luo, Hu et al. 
2011). 
Lactate dehydrogenase is key to a lactate-based signalling interaction between 
cancer and endothelial cells, which directly modifies endothelial cell function 
(Vegran, Boidot et al. 2011). Interestingly, these authors also demonstrated that 
lactate stimulated an NFκB/IL-8 pathway which resulted in cell migration and 
tube formation. This process was repressed by action of ROS inhibitors, 
suggesting their use by tumour cells as signalling molecules. Subsequent work by 
this group has indicated that p53-deficiency may permit increased expression of 
monocarboxylate transporter MCT1 (which transports lactate across the cell 
membrane) in hypoxic conditions(Boidot, Vegran et al. 2012). Loss of p53 
alleviates inhibition of glycolysis with upregulation of glucose uptake 
transporters GLUT1 and GLUT4(Bensaad, Tsuruta et al. 2006). 
p53 has also been implicated in the control of glutamine metabolism, whereby 
increased glutaminase activity reduces ROS levels and protects against ROS-
mediated apoptosis(Suzuki, Tanaka et al. 2010). Loss of p53 as seen in most 
cancers will have complex effects, but as previously alluded to, increased levels 
of ROS may promote certain pathways, and create a pro-inflammatory state 
which facilitates tumour development. 
1.9.3 Emphasis on biosynthesis 
Cancer cells have high biosynthetic requirements to sustain their rate of 
proliferation(Icard and Lincet 2012). Lipid synthesis and the pentose phosphate 
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pathway, which provides the substrates for nucleic acid synthesis, are primarily 
supported. The glutamine pathway is important but it may be as a source of 
substrate for glycolysis rather than for protein synthesis. Amino acid usage far 
exceeds the rate of protein synthesis(Eagle, Oyama et al. 1956) and glutamine 
can be converted into lactate and α-ketoglutarate. Lactate, rather than being 
the end-product of the inefficient glycolytic pathway, may be of use to the 
tumour cell. Active acidification of the microenvironment may facilitate tissue 
invasion (Gatenby and Gawlinski 2003). 
1.9.4 Redox status in cancer cells 
Intrinsic and extrinsic redox buffer systems exist in all cells, and have diverse 
functions in signalling and modulation of cell fate, due to interaction with other 
apoptotic regulators such as NFκB (McEligot, Yang et al. 2005). Active 
acidification of their environment suggests that tumour cells are not subject to 
the normal mechanisms maintaining homeostasis in the cell and its surroundings, 
but tumour cells do require a plentiful capacity for oxidation in multiple 
synthetic reactions, most importantly in the form of NAD+. Conversion of 
pyruvate to lactate in the final step of glycolysis provides one source of this co-
factor. Cancer cells are particularly prone to DNA breaks and cells seem to be 
particularly vulnerable to NAD+ usage by PARP in the response to such 
damage(Mazurek and Eigenbrodt 2003). NAD will be further discussed in the 
context of regulation of sirtuin function, and the functions of these potential 
biomarkers of ageing in colorectal cancer. 
1.9.5 Inflammation and proliferation 
NFκB, a mediator of inflammation, which has been mentioned above in 
conjunction with angiogenesis and lactate production, also coordinates cellular 
metabolism during proliferation by altering the balance between glycolysis and 
oxidative phosphorylation, promoting increased mitochondrial activity(Mauro, 
Leow et al. 2011). Inhibition of NFκB causes reversion to glycolysis under basal 
conditions, with necrosis of cells in case of glucose starvation. Cells lacking a 
subunit of NFκB showed characteristics of transformation such as anchorage-
independent growth, even in the presence of wild-type p53. Although NFκB has 
been shown in some conditions to promote tumorigenesis through the facilitating 
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effect of its proinflammatory actions, it appears, like many other genes of 
central importance, to have dichotomous effects depending on context, tissue 
and contemporaneous state of activity of associated genes. 
1.10 Biomarkers of Ageing 
It will be clear from the preceding discussion that ageing, while it bears some 
relationship to chronological time since birth of an organism, is a complex 
process and cannot be accurately measured in terms of the period since birth. 
Instead, other markers have been sought for several years. Characteristics of 
these ‘biomarkers of ageing” were defined as follows(Baker and Sprott 1988): 
“A biomarker of aging is a biological parameter of an organism that either alone 
or in some multivariate composite will, in the absence of disease, better predict 
functional capability at some late age than will chronological age.” 
As yet no single biomarker, or composite panel, has been described that will 
definitively fulfil the criteria. It is recognised that the original definition invokes 
prerequisites that are difficult to fulfil such as separation of characteristics of 
the ageing process from disease processes. These may be of secondary 
importance in practical and clinical usage, when prognosis of functional capacity 
may be as useful as prognosis related specifically to disease progression. As such 
the concept of ‘biomarkers of ageing and disease’ has gained ground, 
particularly among some of the authors of the original definition(Sprott 2010). 
1.10.1 Biomarkers of Ageing – level of measurement 
Like senescence, useful measurement of ageing can be undertaken on several 
levels and candidate biomarkers may reflect this. Ageing of the whole organism 
may best be assessed with serum markers which integrate ageing from several 
systems.  
More specific reflection of ageing in individual systems may be obtained from 
analysis of function within those tissues. Potential biomarkers of ageing may 
originate within the domain of metabolic control given the fundamental 
importance of the control of energy usage for the whole organism and on the 
level of tissue and cellular function. 
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The MTR hypothesis proposes that optimal control of cellular metabolism is 
achieved by the integration of function of the trinity of Mitochondria, Telomeres 
and Ribosomes(Shiels and Davies 2004). This is particularly important in response 
to any insult causing damage to the cell. Telomeres have an important role in 
limiting cell division if DNA damage is severe to prevent promulgation of 
dangerous mutations. Mitochondria assess and provide the necessary energy from 
respiration to fuel repairs. Ribosomal synthesis of the enzymes needed to 
perform the repairs progresses if this is a viable option. Failure of any one 
component of the trinity to respond adequately could be fed back to the others 
and instigate a switch to a safe default outcome of programmed cell death. 
The sirtuins as a group provide an intuitive physical representation of this 
hypothesis, both because of their dependence on the redox state of the cell to 
function and because of their subcellular locations, which encompass all three of 
the key intracellular structures involved (nucleus, mitochondria and ribosomes). 
Fetuin A is a negative acute phase protein with several biochemical functions 
including inhibition of TGFβ, calcium-binding capacity, and interactions with the 
insulin receptor, annexins and matrix metalloproteinases. As a serum protein, it 
may be a candidate biomarker of ageing at a whole-organism level. 
These three subjects of study in this thesis have gained prominence in the fields 
of ageing research and also in the study of other human diseases. This suggests 
that as biomarkers of ageing or biomarkers of pathology and disease, they may 
be of importance in some of the fundamental pathways of regulation within 
human cells.  
1.11 Fetuin A 
There is a large body of work indicating the importance of fetuin A in a range of 
pathways (cell-cell interaction, inflammation, calcium physiology and metabolic 
regulation as well as cancer) but it is relatively dispersed among specialty areas. 
A comprehensive analysis of the literature was undertaken to achieve a fuller 
understanding of the breadth of its activity and interactions and to contextualise 
the experimental observations made on its associations with clinicopathological 
factors in colorectal cancer. A synopsis of relevant papers is included. 
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1.11.1 Discovery and naming 
Fetuin was discovered in 1944 (Pedersen 1944), as a glycoprotein isolated from 
fetal calf serum. Subsequently α-2-Heremans-Schmid glycoprotein, purified in 
1960 by Heremans(Heremans 1960) and Schmid(Schmid and Burgi 1961), was 
proved by similarity of structure to be identical to the human homologue of 
fetuin, referred to as fetuin A (Christie, Dziegielewska et al. 1987; 
Dziegielewska, Mollgard et al. 1987). Literature review is complicated by regular 
usage of both names, and there is a variety of spellings and punctuation of the 
composite name. There is additionally a human fetuin B protein, a separate 
member of the family about which even less is known(Olivier, Soury et al. 2000; 
Denecke, Graber et al. 2003). 
1.11.2 Genetic location of fetuin A 
Fetuin A is a single copy gene localised to chromosome 3q27(Magnuson, McCombs 
et al. 1988). This area is known to be susceptible to chromosomal translocations 
in non-Hodgkin’s lymphoma (Bastard, Tilly et al. 1992) and the fetuin A gene is 
positioned in the same linkage group as transferrin, transferrin-receptor, and 
caeruloplasmin, and close to other members of the cystatin superfamily, of 
which it is a member. 
The common fetuin A alleles are associated with serum levels of the protein, in 
a dose-dependent manner, such that levels are lower in allele 2 homozygotes, 
highest in allele 1 homozygotes and intermediate in heterozygotes(Osawa, Tian 
et al. 2005) 
1.11.3 Protein structure of fetuin A 
The mature form of the protein consists of two peptide chains, ‘heavy’ and 
‘light’. Twelve cysteine residues form 6 covalent disulphide bonds contributing 
to the protein’s tertiary structure. The heavy chain contains two homologous 
cystatin domains (Elzanowski, Barker et al. 1988), indicating this protein’s 
membership of the cystatin superfamily, although they do not have cysteine 
protease inhibitor capacity. The cystatin domains contain a calcium-binding 
motif(Heiss, DuChesne et al. 2003), and a TGFβ binding motif, with homology to 
the TGFβII receptor.  
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The third domain of fetuin, located on the ‘light’ chain, has a relatively 
hydrophobic character and contains stretches that resemble a transmembrane 
sequence. A degree of sequence homology with steroid receptor and growth 
factor receptors led to speculation that fetuin A may have a role of this sort 
(Dziegielewska and Brown 1995) (pp 82-84). Fetuin A is reported to exist in 
serum with 20% phosphorylation at steady state (0.2mol PO4/mol fetuin A) 
(Haglund, Ek et al. 2001). Phosphorylated fetuin A alters function of the insulin 
receptor in humans and rats (Srinivas, Wagner et al. 1993; Mathews, Chellam et 
al. 2000). There are 5 sugar moieties attached to the human fetuin protein, 2 N-
linked chains and 3 O-linked chains (Gejyo, Chang et al. 1983; Yoshioka, Gejyo 
et al. 1986; Hayase, Rice et al. 1992; Watzlawick, Walsh et al. 1992). 
1.11.4 Genetic modulation of Fetuin A 
1.11.4.1 Regulation of Fetuin A 
The 5’ transcription control region of the human and rat fetuin A gene contains 
binding sites for the promoters CCAAT enhancer binding protein (C/EBP) and NF-
1 in the order 5’-N2-C2-N1-C1-3’ and these are necessary for basal activation 
(Gangneux, Daveau et al. 2003).  
IL1β and IL6 downregulate fetuin A in humans(Daveau, Christian et al. 1988). In 
a hepatoma cell line model, maximal decrease in fetuin A synthesis and 
secretion was observed after 4 days, despite incubation for 10 days with 
monocyte-conditioned medium (Hiron, Daveau et al. 1992). Macrophages 
produce TNFα, IL1 and IL6, although this paper did not specify an interaction 
with these cytokines. 
Although IL6 acts primarily through the STAT pathway, one of its effects is to 
upregulate C/EBP synthesis in the liver. IL1β also transduces its effects through 
the C/EBP gene family. This may be why maximal downregulation of fetuin A 
requires both IL1β and IL6 input(Daveau, Christian et al. 1988). The initial report 
on the fetuin A promoter region suggested that there were potential binding 
sites for several other nuclear factors including STAT3(Banine, Gangneux et al. 
1998). Overexpression of c-Jun and c-Fos also inhibits fetuin A gene 
transcription(Inoue, Takata et al. 2008). 
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Decrease in fetuin A mRNA transcription occurs in response to glutamine 
enrichment of the extracellular space and the resultant hypotonic stress 
(Claeyssens, Banine et al. 1998).  
There is limited information on the upregulation of fetuin A but dexamethasone 
does have this effect. This interaction is mediated through C/EBP binding and 
hepatocyte nuclear factor-3 (HNF-3, which is a promoter predicted in earlier 
reports) (Woltje, Tschoke et al. 2006). Dexamethasone is a glucocorticoid, 
produced in response to the acute phase response and forms a negative 
feedback loop, inhibiting expression of proinflammatory mediators and resolving 
the episode of inflammation. 
Regulation of fetuin A expression thus appears to be closely integrated with the 
control of the inflammatory response, and it is not surprising that fetuin A was 
initially studied as a negative acute phase protein. 
1.11.5 Tissue localisation 
1.11.5.1 Synthesis 
There is limited information available about expression of fetuin A in human 
foetal tissues, but it is seen in osteoid material and lung tissues(Dziegielewska, 
Mollgard et al. 1987). Fetuin A is produced in adult humans by the liver and 
secreted into the bloodstream. Fetuin A mRNA has been reported in human 
kidney in the epithelial cells of distal and proximal renal tubule cells(Umekawa, 
Iguchi et al. 1999), and in the tongue and placenta(Denecke, Graber et al. 2003). 
1.11.5.2 Plasma protein: variation in levels in foetus and adult 
Fetuin A is secreted from the liver and is present at higher levels in the human 
foetus where it forms approximately 5.8% of plasma protein. This decreases to 
0.6% of plasma protein in adults(Dziegielewska, Mollgard et al. 1987). There is 
evidence of significant variation among individuals, but serum levels of fetuin A 
of approximately 100mg/100ml are standard in newborn humans, and fall to 
around 60mg/100ml in adulthood. Lower levels observed in disease are of the 
order of 30-40mg/100ml(Dziegielewska, Guminska et al. 1993). 
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Interestingly, fetuin A is one of a handful of proteins tested which show higher 
serum levels in women than men, decrease after menopause and are restored to 
premenopausal levels by administration of exogenous oestrogen(Hashimoto, 
Miwa et al. 1991). This may be of relevance to fetuin A as a biomarker of ageing 
in that it parallels the change in telomere length in PBLs. PBL telomere lengths 
are generally longer in women, but this advantage is lost after menopause.  
1.11.5.3 Target tissues for the secreted protein in the adult  
Immunohistochemistry of human colorectal tissue and tumour samples has shown 
extracellular staining consistent with fetuin A binding to the cell membrane 
(Swallow, Partridge et al. 2004), with lower staining in tumour tissue. Potential 
associations with bone mineral density and osteoporosis, another age-related 
disease, are discussed later in the context of fetuin A and calcium metabolism, 
implying bone as another target tissue. 
 
1.11.6 Fetuin A in Inflammation and the Acute Phase 
Response 
1.11.6.1 Fetuin A – a negative acute phase protein 
Initial studies identified fetuin A as a negative acute phase protein (whose levels 
decrease in response to inflammation) in illnesses of varying aetiology including 
trauma(van Oss, Bronson et al. 1975), bacterial infection(Lebreton, Joisel et al. 
1979), Crohn’s disease(Kalabay, Cseh et al. 1992) and systemic lupus 
erythematosus(Kalabay, Jakab et al. 1990) and in cancer(Baskies, Chretien et al. 
1980). All of these are now recognised to have a significant inflammatory 
component. 
In cattle and mice fetuin is a positive acute phase protein, and a negative acute 
phase protein in rat. This distinction underlines the care that must be taken in 
translating results between species even in evolutionarily conserved proteins: 
the molecular pathways may have significantly diverged. 
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Modulation of fetuin A in the short term acute phase response to conditions like 
bacterial infection shows some differences from that observed in the longer 
term response to multiple myeloma(Biro, Domjan et al. 1998). Myeloma patients 
showed correlation between fetuin A and TNFα but not with IL6, whereas CRP 
correlated with IL6 in both conditions. 
1.11.6.2 Fetuin A and the innate immune system. Opsonin, increases 
uptake of inhibitors of cytokine synthesis 
Much initial information from human studies concentrated on the interaction of 
fetuin A with the several classes of blood cells involved in the innate immune 
response. Fetuin A enhanced phagocytosis of E coli and S aureus by 
neutrophils(van Oss, Gillman et al. 1974). Fetuin A improved the rate of uptake 
of DNA and latex beads by macrophages and monocytes from mouse and human 
blood(Lewis and Andre 1981). It appeared not to function as a classic opsonin as 
it was necessary for the phagocyte, fetuin A and the target to be present at the 
same time for the enhanced phagocytosis to be demonstrated. Fetuin A has also 
been shown to be chemotactic for monocytes but not neutrophils or 
lymphocytes(Malone and Richards 1987; Kew and Webster 1988). 
Binding of fetuin A to macrophages was partially calcium dependant and resulted 
in some internalization of the protein(Lewis and Andre 1981). Internalization is 
achieved through membrane-ruffling and macropinocytosis (Jersmann, Dransfield 
et al. 2003). One model to integrate these reports is that fetuin A binds opsonic 
targets and then binds to a cell-membrane receptor which stimulates uptake. 
Given the repertoire of receptor binding exhibited by fetuin A, there are several 
possible candidates. Cell-surface receptors are discussed in more detail in the 
following sections. 
The role played by fetuin A as a non-classical opsonin has been implicated in the 
resolution of the inflammatory response. Macrophages are activated by 
proinflammatory cytokines, NO and LPS, among other substances. Balancing this 
are anti-inflammatory cytokines such as TGFβ, IL10 and glucocorticoid 
hormones. Spermine is a ubiquitous polyamine that accumulates at sites of 
injury, and is deacetylated by sirtuins (see section 1.15) (Grozinger 2002). 
Spermine uptake reduces macrophage production of TNFα, IL1 and IL6 (Zhang, 
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Caragine et al. 1997). Fetuin A binds spermine and the complex inhibits 
macrophage secretion of TNFα. 
Macrophages use fetuin A to take up CNI-1493, a pharmacological cationic 
inhibitor of cytokine synthesis from the extracellular environment. They respond 
by a downregulation of TNFα synthesis (Wang, Zhang et al. 1998). It was not 
clear how the intracellular transport was mediated. Given that the C-terminal 
part of fetuin A has a negative charge, addition of a positively charged molecule 
of endogenous (spermine) or synthetic (CNI-1493) origin may render it more 
lipophilic and facilitate transport across the cell membrane. The process of 
membrane-ruffling and pinocytosis described above may be involved. 
TNFα has a major role to play in the immune response underlying rejection of 
transplanted (foreign) tissue. During pregnancy, rejection of ‘foreign’ foetal 
tissue must be prevented. Levels of spermine and fetuin A are particularly high 
in the amnion. Thus, fetuin A may help maintain the privileged immune status of 
the foetus (Wang, Zhang et al. 1997). 
Thus, fetuin A has a role in deactivating macrophages by increasing spermine 
uptake but also inhibits TGFβ, an anti-inflammatory cytokine. Its actions in this 
area (as in many others) are not amenable to simple dichotomous description. 
1.11.7 Fetuin A and inhibition of TGFβ  signalling 
One of the fetuin A cystatin domains includes a motif with homology to the 
TGFβ2 receptor which allows fetuin to bind several of the TGFβ family with 
reducing affinity as follows: BMP2 > BMP4 > BMP6 > TGFβ1 > TGFβ2 (Demetriou, 
Binkert et al. 1996).  
1.11.7.1 TGFβ signalling and cancer 
As has been previously mentioned TGFβ has several important roles relevant to 
cancer pathophysiology. It inhibits phosphorylation of Rb which supports cell-
cycle arrest in G1 phase (Laiho, DeCaprio et al. 1990). It has been identified as a 
trigger for induction of senescence in cultured cell lines (Katakura 2006). Cells 
senesced in this manner showed reduced tumorigenic potential. It is also 
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instrumental in the process by which haematopoietic stem cells are recruited to 
supply the stem cell niche in the gut(Sipos, Valcz et al. 2012). 
TGFβ is also a strong driver for epithelial-to-mesenchymal transition (EMT), 
which alters cellular interaction with the microenvironment (Cufi, Vazquez-
Martin et al. 2010). TGFβ-induced EMT increases cellular motility and increases 
‘stemness’: replicative potential and de-differentiation. TGFβ can thus be seen 
to have cytostatic (tumour suppressive) and oncogenic effects (Elliott and Blobe 
2005). Ultimately the effect it has at any one time is likely to be determined by 
the genetic context, other mutations and the cellular microenvironment: a 
recurring theme in cancer biology (Schiemann 2007).  
TGFβ has anti-inflammatory cytokine properties and reduced activity may be a 
factor in the development of IBD and in the increased risk of cancer these 
patients show (Skeen, Paterson et al. 2012). With regard to risk of developing 
sporadic colorectal cancer, polymorphisms in the TGFβ gene and in the TGFβ 
receptor are associated with increased risk, and interaction with NFκB signalling 
and lifestyle factors such as obesity, aspirin use and smoking were also 
demonstrated(Slattery, Lundgreen et al. 2012). Further analysis of high-risk 
genotypes has shown a hazard ratio for survival after diagnosis with colorectal 
cancer of 5.1 for the group with the highest number of ‘at risk’ 
genotypes(Slattery, Lundgreen et al. 2011). This group has also shown high-risk 
genetic variation in BMP proteins, which may also be relevant to fetuin A 
interactions in colorectal cancer(Slattery, Lundgreen et al. 2012). 
1.11.7.2 Fetuin A, TGFβ signalling and cancer 
Inhibition of TGFβ signalling by serum fetuin A in cell lines has been 
demonstrated(Swallow, Partridge et al. 2004). Fetuin A blocked TGFβ binding to 
its receptor on MvLu1 cells, preventing intracellular signal transduction and EMT 
effects. This team also showed by immunohistochemical analysis that fetuin A 
binding to human colorectal tumour tissue was reduced to one third of the 
binding to normal colorectal mucosa. The overall effect of fetuin A on the 
pathogenesis of colorectal cancer may therefore be as variable as that of TGFβ 
since it opposes some of the oncogenic potential of TGFβ but appears to bind 
less to tumour than to normal tissue.  
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Further information on the dynamics of fetuin A interaction with TGFβ in serum 
matched with an assessment of fetuin and TGFβ binding to colorectal normal and 
tumour tissue may add useful information. Given that fetuin A also binds to 
other cell surface receptors (e.g. annexins in breast cancer(Sakwe, Koumangoye 
et al. 2010)) it would be interesting to know which receptors fetuin A is 
interacting with on the colorectal cell surface. Since fetuin A has also been 
shown to inhibit TGFβ signalling in a mouse model of mammary tumourigenesis, 
it is possible that both pathways are active in colorectal cancer too (Guillory, 
Sakwe et al. 2010). 
1.11.8 Fetuin A in calcium and phosphate metabolism 
The inhibition of TGFβ family members, particularly modulation of BMP 
cytokines, indicated a role for fetuin A in embryological skeletal modelling and 
potentially in bone remodelling by osteoblasts. Fetuin A was described in early 
reports as an inhibitor of ectopic calcification and was unusual in that it was the 
first circulating molecule with such action described. 
Fetuin A is one of a small number of non-collagen plasma proteins identified in 
bone, and is present there at much higher concentrations than in plasma. 
Comparison of levels at different ages and in different pathologies suggested 
likely involvement in bone turnover and resorption(Quelch, Cole et al. 1984). 
Fetuin A was also identified in ascites fluid in patients with cancer, when it was 
demonstrated that it was one tenth as effective as parathyroid hormone at 
releasing calcium from bone (Lamkin, Colclasure et al. 1987). This effect on 
calcium was seen at lower concentrations. In fact, in vitro, fetuin A has a 
variable effect. Calcium mobilisation is higher at lower concentrations, peaking 
at serum fetuin A level of 40 micrograms/ml and returning to baseline at 
(Colclasure, Lloyd et al. 1988). Of note, this threshold is equivalent to 
0.04mg/ml, well below the ranges reported in normal or diseased states but may 
be relevant in terms of local fetuin A concentrations in bone (Dziegielewska, 
Guminska et al. 1993). 
1.11.8.1 Fetuin A and osteoporosis in postmenopausal women 
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As fetuin A is a constituent of calcified bone and intimately involved in calcium 
metabolism, studies of bone mineral density in postmenopausal women were 
performed to investigate an association with osteoporosis, another age-related 
disease. There is a significant dose-dependent association between fetuin A 
polymorphisms and oestradiol levels(Eichner, Friedrich et al. 1990). 
Homozygotes for allele 1 showed lowest levels of oestradiol, homozygotes for 
allele 2 showed highest levels and heterozygotes showed intermediate levels.  
1.11.8.2 Action of fetuin A in prevention of ectopic mineralisation and 
inflammation 
Serum is supersaturated with calcium ions and the natural tendency is for 
ectopic mineralisation to occur, unless the calcium ions are sequestered and 
stabilized in some form. Initial studies found that fetuin A bound basic calcium 
phosphate crystals, and reduced the hydroxyapatite crystal-induced release of 
superoxide from neutrophils(Terkeltaub, Santoro et al. 1988). 
“Calciprotein particles” are colloidal spheres, similar to the apolipoprotein 
conglomerations which allow the transport of insoluble lipids through the 
bloodstream (Heiss, DuChesne et al. 2003). The calciprotein particles are 
transiently soluble and prevent formation of basic calcium phosphate (precursor 
to apatite) for 6 hours.  
Formation of these particles could reduce the local inflammatory effect of 
crystals, and thus allow a coordinated degradation, without triggering the non-
specific immune response. This may include targeted recruitment of phagocytes 
which can digest the calciprotein particles. High molecular weight complexes of 
calcium, phosphate, fetuin A and matrix GLA protein were described recently 
(Jahnen-Dechent, Heiss et al. 2011). They protect against the otherwise 
chemically favourable tendency to mineral deposition in most tissues where it is 
undesirable and results in inflammation.  
1.11.9 Fetuin A and role in Vascular Calcification 
Vascular disease is recognised as having a significant inflammatory component. 
Deposition of calcium in atheromatous plaques is a large part of the 
pathogenesis of this disease and it is not surprising that fetuin A has attracted 
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interest in this field. Initial studies confirmed presence of fetuin A in aortic 
atheromatous plaques(Keeley and Sitarz 1985; Stastny, Fosslien et al. 1986) 
Fetuin A is inversely correlated with calcification in patients with peripheral 
vascular disease but without renal disease, and this relationship persists on 
adjusting for traditional risk factors such as diabetes(Szeberin, Fehervari et al. 
2011). 
Fetuin A inhibits vascular smooth muscle cell (VSMC) calcification through 
inhibition of apoptosis and caspase cleavage (Reynolds, Skepper et al. 2005). 
Fetuin A is taken up by VSMCs and concentrated in intracellular vesicles. These 
are subsequently released. Vesicles have previously been shown to take up basic 
calcium phosphate and were a focal point for mineralisation. Presence of fetuin 
A prevents their nucleation of the mineral ions and increases vesicle reuptake. 
1.11.10 Fetuin A and renal disease 
Calcium handling in renal disease is altered because the damaged kidney cannot 
play its role in normal calcium homeostasis. Patients with chronic renal failure 
have an increased risk of death from cardiovascular causes. Fetuin A is one 
nexus for the processes of inflammation, altered calcium handling and vascular 
disease which underlie the pathological manifestations of chronic renal failure 
(Tsirpanlis 2007). IL6 as an inflammatory cytokine could connect inflammation 
and cellular senescence in this context, in a pathway which is likely to involve 
fetuin A (Tsirpanlis 2009). Low level IL6 as seen in patients with end stage renal 
disease but no signs of systemic inflammation does downregulate hepatic 
synthesis of fetuin A(Memoli, Salerno et al. 2010). 
Low fetuin A has been linked to all cause mortality (Carrero, Stenvinkel et al. 
2008) and cardiovascular mortality in renal patients irrespective of CT-assessed 
coronary vascular calcification(Jung, Baek et al. 2011). 
1.11.11 Fetuin A as an inhibitor of the insulin receptor tyrosine 
kinase 
Fetuin A inhibits the tyrosine kinase activity of the insulin receptor(Srinivas, 
Wagner et al. 1993). In rat and cow, the phosphorylated form of fetuin is a 
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single chain protein, and it is the phosphorylated form which exhibits activity 
against the insulin receptor(Haasemann, Nawratil et al. 1991). There is no direct 
experimental demonstration that the same is true in humans, but the 
phosphorylated form of human fetuin A is separately metabolically active. After 
a bout of exercise, phosphorylated fetuin A, but not total fetuin A, levels were 
reduced in lean individuals(Mathews, Grandjean et al. 2010). The recombinant 
single chain form of human fetuin A has markedly greater activity on the insulin 
receptor tyrosine kinase than does the form isolated from human 
plasma(Srinivas, Deutsch et al. 1996). 
Binding of insulin to the insulin receptor induces a conformational change which 
enhances fetuin A binding; one of the results is to inhibit insulin-stimulated 
autophosphorylation of the insulin receptor(Mathews, Chellam et al. 2000). This 
interaction does not alter insulin binding to the receptor but does markedly 
reduce insulin-stimulated GLUT4 translocation and AKT activation in mouse 
myoblasts(Goustin, Derar et al. 2013). 
Fetuin A abrogates the mitogenic effects of insulin in H-35 hepatoma cells 
(Srinivas, Wagner et al. 1993). Through this mechanism, fetuin A inhibits insulin-
induced activation of Ras signalling in Chinese hamster ovary cells 
overexpressing the human insulin-receptor(Srinivas, Deutsch et al. 1996). In this 
system, RAF phosphorylation was also reduced with resultant abolition of MEK 
phosphorylation; phosphorylation of SHC was abolished as well. RAF is part of 
the RAS/RAF/MEK/ERK signalling pathway and SHC is part of the stress-induced 
ERK activation response. 
A polymorphism of the fetuin A gene in humans associated with lower serum 
levels is associated with leanness in a study of 504 Swedish men(Lavebratt, 
Wahlqvist et al. 2005). Fetuin A is thus characterised as a ‘thrifty gene’, which 
blunts the response to insulin, tending to tip the balance of metabolism towards 
storage rather than cell division (Goustin and Abou-Samra 2011). 
1.11.12 Fetuin A: role in metabolic regulation and diabetes 
Given the alteration in sensitivity to insulin, associations with Type 2 diabetes 
have been a focus for research. Fetuin A was associated with insulin sensitivity 
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in normoglycaemic but not diabetic subjects (Mori, Emoto et al. 2006). In non-
diabetic Caucasians, fetuin A levels were higher in those with reduced insulin 
sensitivity and impaired glucose tolerance and were correlated with liver 
fat(Stefan, Hennige et al. 2006).  Fetuin A was higher in the vitreous humour of 
patients with diabetic eye disease than those with macular 
degeneration(Nakanishi, Koyama et al. 2002). Fetuin A polymorphisms have been 
associated with diabetes in Danish and French populations (Siddiq, Lepretre et 
al. 2005; Andersen, Burgdorf et al. 2008). 
Fetuin A is associated with liver steatosis and general BMI but not with regional 
fat distribution in humans(Mussig, Staiger et al. 2009). Allelic variation in the 
fetuin A gene alters the effect of exercise on change in basal metabolic rate 
(Suchanek, Kralova-Lesna et al. 2011). Some variants were associated with 
increase in lean muscle mass and decrease in total body fat, but there was no 
significant association with BMI. 
Diabetes is one of the traditional risk factors for cardiovascular disease. Fetuin A 
levels were compared in diabetic patients with and without peripheral vascular 
disease (PVD) and in patients with normal glucose metabolism and PVD: fetuin A 
levels were higher in patient with PVD irrespective of their glucose 
metabolism(Lorant, Grujicic et al. 2011). It is possible that vascular disease 
precedes diabetes, occurring through the same dysfunctional response to insulin 
and dysregulation of glucose metabolism, particularly in the presence of 
longterm excess caloric intake. 
1.11.13 Fetuin A and Cancer 
1.11.13.1 Relevance of previously discussed molecular interactions 
The molecular interactions of fetuin A described earlier are relevant to cancer 
biology in several ways. 
As an opsonin, fetuin A may modulate the innate immune response to the 
tumour. By its effect on TNFα levels, this may affect the rejection of abnormal 
cells. 
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Calcium regulation is important for signalling within cells, so management of 
external cell calcium homeostasis may be relevant. Prevention of abnormal 
calcification in damaged tissue and coordination of clearing of calcium-
containing crystals would reduce the local inflammatory response in the tumour 
environment. 
As an inhibitor of TGFβ, fetuin A may modify transcription of a wide variety of 
genes important in cell death, differentiation and the response to injury which 
has been shown to contribute to the malignant phenotype. It also provides 
another modulatory role for fetuin A in calcium regulation, as this is another 
area in which TGFβ is effective. Fetuin A is a negative APP which inhibits TGFβ 
which in turn has anti-inflammatory properties: fetuin A is intimately linked to 
the process of inflammation, but may be more affected than an effector of the 
process. IL6 regulation of fetuin A implies it may be a target in ameliorating the 
poor prognostic impact of high IL6 levels and active systemic inflammation in 
cancer. 
Matrix metalloproteinases (MMP2 and MMP9) are targets for fetuin A, and these 
are important in cell interaction with the extracellular matrix. The gelatinase 
activity of MMP9, protected by fetuin A, may increase cell motility(Ochieng and 
Green 1996). 
Inhibition of tyrosine kinase activity of the insulin-receptor means that fetuin A 
plays a role in metabolic regulation, which has recently become a focus for 
attention as it is profoundly altered in cancer cells. 
The interaction with Annexin 6 will be discussed in detail later but is included in 
this summary of molecular interactions (Sakwe, Koumangoye et al. 2011)for 
completeness. Fetuin A binds to Annexin 6 with effects on cell-to-cell adhesion 
and mobility, relevant in the metastatic behaviour of breast cancer cells and 
conceivably the cells of other cancers. 
All of these are viable reasons why fetuin A should be a relevant target in 
treating cancer, and they are strengthened by the following reports of alteration 
in fetuin A levels in cancer and a relationship with survival in one type of cancer 
shown so far. 
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1.11.13.2 Altered serum levels in cancer 
There is a wide-ranging literature attesting to altered fetuin A levels in cancer.  
Most reports show decreased serum levels of fetuin A, in line with its recognised 
role as a negative acute phase protein, altered within the acute phase response 
which occurs specifically to cancer. Control of fetuin A levels appears to be 
similar in cancer and in shorter infective illnesses, in contrast to CRP (Biro, 
Domjan et al. 1998). It is not certain therefore that the poor prognostic value of 
high CRP will be associated with alteration in fetuin A levels as well.  
The change in fetuin A levels in cancer may be part of the body’s inflammatory 
response to cancer. Equally however, the tumour cell handling of fetuin A which 
binds to it may subvert this response. 
Reduced levels of fetuin A (relative to normal) have been demonstrated in serum 
in haematological malignancies including acute myeloblastic 
leukaemia(Wiedermann, Wiedermann et al. 1980; Kalabay, Cseh et al. 1991; 
Kwak, Ma et al. 2004), germ-line ovarian carcinoma(Chen, Lim et al. 2008), 
cervical cancer(Onizuka, Migita et al. 1994) and in squamous cell carcinoma of 
the lung (Dowling, O'Driscoll et al. 2007). Barbieri et al reported that fetuin A 
levels discriminated between patients with and without bony metastases 
(Barbieri, Pazzaglia et al. 1987). 
Reduced levels of fetuin A (relative to normal) have also been demonstrated in 
nipple aspirate in breast cancer(Pawlik, Hawke et al. 2006). 
1.11.13.3 Serum fetuin A and cancer survival 
Patients with normal levels of fetuin A in serum with glioblastoma had longer 
survival than those with low levels (Petrik, Saadoun et al. 2008). However, levels 
of two isoforms of fetuin A in CSF were higher in patients with low-grade gliomas 
than in CSF from non-neoplastic or normal cases(Ribom, Westman-Brinkmalm et 
al. 2003). Brain is one of few other suggested sites of fetuin expression, although 
it has not been confirmed in the adult (Dziegielewska and Brown 1995). CSF 
fetuin A levels may thus reflect cancer cell synthesis beyond the blood-brain 
barrier rather than serum levels and the host response to the cancer. 
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Fetuin A levels in multiple myeloma correlated inversely with serum calcium, 
and showed significant decrease from relatively stable levels as calcium rose in 
the end stages of disease(Crawford 1984). 
1.11.13.4 Fetuin A in liver disease and liver cancer 
Serum fetuin A levels were raised in hepatocellular carcinoma (HCC) (Wang et 
al. Cancer Letters (2009) 281:144–150). Fetuin A is synthesised by hepatocytes, 
so increased expression in carcinoma of hepatocellular origin may reflect tumour 
cell phenotype. Levels of fetuin A decreased after radiofrequency ablation of 
HCC lesions(Kawakami, Hoshida et al. 2005). 
1.11.13.5 Fetuin A and lung cancer 
Glycoproteomic analysis of human lung adenocarcinoma tissue showed 30 
differentially expressed proteins, of which only fetuin A showed concordant 
decrease in mRNA and protein levels. The glycan structure of fetuin A in lung 
tissue also showed alterations in tumour tissue, with high mannose component 
not seen in fetuin A from normal tissue(Rho, Roehrl et al. 2009). 
1.11.13.6 Fetuin A and breast cancer 
There is a significant body of work by Ochieng and colleagues investigating 
fetuin A in breast cancer. They have shown that breast cancer cells interact with 
serum-derived fetuin A by binding to cell-surface Annexin-6 in a calcium 
dependent manner(Ochieng, Pratap et al. 2009; Sakwe, Koumangoye et al. 
2010). This interaction stimulates PI3K and AKT; it also activates MAPK 
independently of calcium. Annexin-6 is involved in cell-cell interaction and 
mouse mammary tumour lines with Annexin-6 knockout show increased 
anchorage independent growth, which may indicate the tendency to 
metastasize(Guillory, Sakwe et al. 2010). 
Fetuin A and antibodies to it were identified as potential tumour biomarkers in 
breast cancer; the sensitivity of fetuin A antibodies was 79%, which may not be 
sufficiently high(Yi, Chang et al. 2009). It may be useful as part of a panel of 
biomarkers and several investigators have proposed this(Schaub, Jones et al. 
2009). In HCC, a panel of fetuin A, KRT23 and ferritin light chain antibodies had 
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sensitivity of 98.2% in detection of HCC over chronic hepatitis and normal 
sera(Wang, Xu et al. 2009). 
1.11.13.7 Fetuin A and colorectal cancer 
Blockage of TGFβ signalling by fetuin A has been shown to prevent 
phosphorylation of Smad 2/3 in a mouse cell line and blocks epithelial-
mesenchymal transition of colorectal cancer cells (Swallow, Partridge et al. 
2004). Immunohistochemical analysis demonstrated specific reduction of fetuin 
A in colorectal tumour tissue as compared with adjacent normal mucosa. 
Recent evidence indicates that there is interplay between IL6, STAT3 and fetuin 
A in chronic renal disease(Memoli, Salerno et al. 2010). The IL6-JAK-STAT3 
pathway is important in colonic tumorigenesis by bone-marrow-derived 
myofibroblasts (Zhu, Cheng et al. 2014) and this network also involves TGFβ. 
Fetuin A is likely to have a role in this process also. 
Familial adenomatous polyposis (FAP) is associated with almost 100% risk of 
colorectal cancer by the 4th decade of life. Proteomic analysis of sera from 
patients with (FAP) identified fetuin A and apolipoprotein D as significantly 
downregulated in carpeting FAP with respect to the diffuse form, and to normal 
serum(Quaresima, Crugliano et al. 2008). 
Fetuin A is a TGFβ antagonist, with effects on BMP (members of the same 
family). BMPs exert growth inhibitory effect towards the top of crypts which 
renew the colonic epithelium(Zeki, Graham et al. 2011). Fetuin A inhibition of 
BMP may increase the chance of aberrant proliferation of colonic cells. However, 
the available evidence shows decreased binding of fetuin A to colonic epithelium 
in colonic cancer. Further information on the existence and location of 
interaction between fetuin A and BMP, and on the outcomes of such interaction 
are necessary to interpret the available information. 
1.11.14 Biomarker of ageing 
Fetuin A is associated with several diseases of ageing including diabetes, 
vascular disease in its many forms, Alzheimer’s disease, osteoporosis and cancer. 
Unlikely as it may have seemed previously, an underlying inflammatory process 
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seems to be a common feature of all of these. Fetuin A may offer characteristics 
of a candidate integrative biomarker of ageing, but it is more likely that a 
composite measure of several factors will be necessary to adequately represent 
the dysfunction of such a complex process. 
1.12 The Sirtuin family 
The silent information regulator type 2 (SIR2) gene came to prominence in yeast, 
when it was noted that overexpression was associated with increased lifespan, 
and underexpression with shortened lifespan(Kaeberlein, McVey et al. 1999). 
Homologues for this gene family known as sirtuins have been identified in many 
other classes of organism including mammals, with similar effects on lifespan in 
mice. There are seven sirtuins (SIRT1-SIRT7) in humans. SIRT3 is associated with 
increased lifespan as will be discussed in more detail in the following sections on 
the individual sirtuins. In general terms, sirtuins seem to be particularly 
important in protecting internal systems from external environmental variation 
and stresses, maintaining systemic homeostasis and modulating more drastic 
responses to injury(Satoh, Stein et al. 2011). 
1.12.1 General control of sirtuin activity: NAD 
Sirtuins use nicotinamide adenine dinucleotide (NAD) as a co-factor in 
deacetylation reactions. Control of sirtuin activity is thus linked to cell 
metabolism and to the redox status of the cell. Control is both sirtuin-specific, 
and tissue specific, with activation and inhibition of different sirtuins in the 
same tissue. Part of the control is via NAD levels and thus the NAD cycle is of 
considerable importance. Different sirtuins have different dissociation constants 
for NAD (Schmidt, Smith et al. 2004), and this is particularly relevant for sirtuins 
operating in the same subcellular compartments, e.g. SIRT3, SIRT4 and SIRT5.  
1.12.1.1 NAD cycle 
There are two separate NAD pools within human cells: nuclear/cytoplasmic and 
mitochondrial, as NAD cannot pass across the mitochondrial membrane. 
NAD levels are affected by the redox state of the relevant cell compartment but 
also by the activity of NAMPT, the rate-limiting enzyme in the NAD cycle. NAD is 
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used as a co-factor in enzymatic reactions by sirtuins (among many other 
enzymes) and nicotinamide is formed. This is converted to nicotinamide 
mononucleotide (NMN) by nicotinamide phosphoribosyltransferase (NAMPT). 
Regeneration of NAD is completed by nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase (NMNAT) which catalyses the addition of 
ATP to NMN (Imai and Yoshino 2013). NAMPT may regulate sirtuin activity by its 
effect on levels of NAD(Hufton, Moerkerk et al. 1999) 
 
Figure 1.1 The NAD cycle (simplified). NAD is used as a co-factor in enzymatic reactions by 
sirtuins (among many other enzymes) and nicotinamide is formed. This is converted to 
nicotinamide mononucleotide (NMN) by nicotinamide phosphoribosyltransferase (NAMPT) 
the rate-limiting enzyme. Regeneration of NAD is completed by nicotinamide/nicotinic acid 
mononucleotide adenylyltransferase (NMNAT) which catalyses the addition of ATP to NMN. 
1.12.1.2 NAMPT/PBEF 
As well as being the rate-limiting enzyme in NAD synthesis, there is a growing 
body of evidence that NAMPT has diverse functions outside the cell as well (Luk, 
Malam et al. 2008; Imai 2009). One of the other names it was given on discovery 
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in microarray studies was pre-B cell colony-enhancing factor (PBEF)(Samal, Sun 
et al. 1994), and its cytokine functions include induction of TNFα, Il-1β and IL-
6(Moschen, Kaser et al. 2007). It is also an adipokine with effects that both 
mimic and oppose those of insulin (Fukuhara, Matsuda et al. 2005). NAMPT has 
also been implicated in the genesis of colorectal carcinoma(Hufton, Moerkerk et 
al. 1999). Elucidation of its place in the complex regulatory strategy (on levels 
above the sirtuins) is likely to provide further fascinating insights into the 
precision of integration of organism-wide homeostatic systems.  
Aspects of function specific to the individual sirtuins are discussed in the 
following sections, with a focus on the sirtuins investigated in this thesis. This is 
followed by consideration of how the sirtuins contributes to control of 
metabolism, inflammation, cell cycle and cancer development. Over half of the 
published literature on human sirtuins is focused on SIRT1 as it was the original 
sirtuin identified, and has the greatest homology to the yeast SIR2 gene. 
However, no new data on SIRT1 is presented in this thesis and so only a brief 
review of its important functions and interactions will be undertaken here. 
1.13 SIRT1 
The table below summarises major SIRT1 substrates and these interactions are 
considered in more detail in following paragraphs.  
1.13.1 SIRT1 involvement in the DNA damage response 
As the table at the beginning of this section indicates, SIRT1 numbers among its 
direct substrates four of the key players in the nucleotide excision repair 
pathway for dealing with single-strand DNA breaks. SIRT1 deacetylates and 
activates APE (Yamamori, DeRicco et al. 2010), NBS1 (Yuan and Seto 2007), XPA 
(Fan and Luo 2010) and XPC (Ming, Shea et al. 2010). The latter three are 
involved in sensing DNA damage and recruiting other repair proteins.  
One of the original and consistently important interactions is between p53 and 
SIRT1. Deacetylation of p53 by SIRT1 inhibits p53-induced apoptosis. This is 
thought to protect cells from apoptosis in times of stress, as it allows a period 
for normal physiology to resume if possible. 
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Cell cycle control Transcription Signalling Metabolism DNA damage response Other 
p53 FOXO1, FOXO3a, 
and FOXO4, 
forkhead 
transcription factors 
β-catenin, 
component of 
Wnt signaling 
pathway 
Acetyl CoA 
synthetase 1, 
AceCS1  
Ku70, initiates non-
homologous end-joining 
(NHEJ) 
BMAL1 and Per2, 
circadian rhythm/ 
clock proteins 
PTEN, tumor 
suppressor 
regulating PI3K/ 
AKT pathway 
PCAF, 
transcriptional 
coactivator 
associated with p53 
RelA/p65 (NFκB 
component), 
immune function 
and signalling 
PGC-1alphas, nuclear 
coactivator involved 
in control of 
gluconeogenic genes 
Apurinic/ apyrimidinic 
endonuclease-1 (APE1), 
base-excision repair 
pathway 
Cortactin, 
promotes cell 
migration 
Notch1 intracellular 
domain (NICD), 
signalling pathway 
regulating cell fate 
Myocyte enhancer 
factor, (MEF2), 
transcription factor 
Oestrogen 
receptor-α 
PPAR-gamma, 
nuclear receptor 
regulating fatty acid 
oxidation and glucose 
metabolism 
p300 histone 
acetyltransferase, 
inflammation and DNA 
damage response 
IRS-2, important 
for neuroprotection 
p73, putative tumor 
suppressor involved 
in cell cycle, 
apoptosis 
Hypoxia-inducible 
factors HIF-1alpha, 
HIF-2alpha 
Androgen 
receptor 
Uncoupling protein 2 
(UCP2), inhibits 
glucose-stimulated 
insulin secretion 
Nijmegen breakage 
syndrome protein (NBS1) 
part of MRE11-RAD50-
NBS1 (MRN) complex 
Tau, implicated in 
neurodegeneration 
and Alzheimer's 
disease 
E2F1, transcription 
factor with role in 
cell cycle control 
SREBP-1C, 
transcription factor 
modulating hepatic 
lipogenesis 
Liver V receptor 
(LXR), nuclear 
hormone 
receptor 
 Xeroderma pigmentosum 
protein (XPA), DNA 
damage sensing and 
nucleotide excision repair 
 
 TAF(I)68, Pol I 
transcription 
TSC2, part of the 
mTOR complex 
 Xeroderma pigmentosum 
protein C(XPC), as XPA 
 
 SUV39H1, histone 
methyltransferase 
Rictor, part of 
the mTOR 
complex 
 TIP60, histone 
acetyltransferase, dsDNA 
break repair 
 
 TNF-alpha promoter SMAD7, TGFβ-
pathway 
   
 IL-1beta promoter     
 STAT3, 
transcription factor 
    
Table 1.1 Summary of important SIRT1 substrates. 
 1.14 SIRT2 
1.14.1 Gene location and subcellular localisation: nuclear-
cytoplasmic shuttling  
The SIRT2 gene is localised to chromosome 19q13.1, and the 5’ flanking region of 
DNA has binding sites for NFκB and GATA transcription factor(Voelter-
Mahlknecht, Ho et al. 2005). A total of 16 exons are encoded. This group 
identified two isoforms of the protein translated: isoform 2 lacked the first 3 
exons. 
SIRT2 is found in the nucleus and in the cytoplasm in human cells. The SIRT2 
gene encodes an N-terminus nuclear export signal but at least one human 
isoform does not contain this sequence of amino acids. Subcellular localisation 
and specific trafficking of SIRT2 protein are likely regulatory mechanisms. As yet 
no nuclear localisation sequence has been identified, so that it is unclear how 
the protein enters the nucleus. 
It appears that nuclear export is the dominant process in non-dividing cells(North 
and Verdin 2007). SIRT2 is actively exported from the nucleus during interphase 
via a nuclear export signal which is leptomycin-B sensitive and interacts with 
Crm1(Inoue, Hiratsuka et al. 2007; North and Verdin 2007). There may also be a 
second nuclear export signal functioning independently of leptomycin-B, as a 
fraction of SIRT2 persists in the cytoplasm, possibly bound to structures there. 
There is little information on which isoforms of SIRT2 are concerned in the 
interactions with other substrates and proteins described in the following 
paragraphs. 
1.14.2 Interaction with tubulin  
SIRT2 deacetylates lysine 40 of α-tubulin, mainly in the cytoplasm. It colocalises 
with HDAC6, another tubulin deacetylase(North, Marshall et al. 2003). α-tubulin 
binds only to the SIRT2/HDAC6 complex (Nahhas, Dryden et al. 2007). These 
investigators also showed that SIRT2 is enzymatically active in phosphorylated 
and unphosphorylated forms, and that cells which overexpress the shorter 
isoform2 of SIRT2 have reduced cell survival. Tubulin, which exists in at least 4 
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forms (α-δ) in humans(Smrzka, Delgehyr et al. 2000) is an integral part of 
microtubules, involved in cell mobility and in cytokinesis, when the single cell 
splits apart as the two daughter cells are formed in mitosis. In the formation of 
microtubules in the cytoskeleton to enable cell motility, tubulin is generally 
cytoplasmic in location, but as the nuclear membrane breaks down in mitosis, it 
is associated with chromosomes and other nuclear components. 
SIRT2 induction reduces adhesion of cultured cells to substratum, in association 
with reduced levels of acetylation of α-tubulin(Pandithage, Lilischkis et al. 
2008). 
1.14.3 SIRT2 in mitosis 
In dividing cells, the interaction between SIRT2 and α-tubulin is a key factor, 
and it was reported on the basis of experiments with microtubule poisons that 
SIRT2 functions in early metaphase to prevent chromosomal instability(Inoue, 
Hiratsuka et al. 2007). SIRT2 blocks entry into chromosome condensation in 
response to mitotic stress, implying that it acts as a mitotic checkpoint sensor, 
preventing progression of cell division before appropriate chromosomal 
alignment. 
SIRT2 levels increase during mitosis and the protein is multiply phosphorylated 
during G2/M transition in the cell cycle. Wildtype overexpression mutants show 
prolonged mitotic phase. This may relate to an effect on histone H4. Histone 
deacetylation facilitates the formation of condensed chromatin which occurs 
after DNA duplication and prior to the M stage of cell cycle. SIRT2 deacetylates 
lysine 16 of histone H4 (H4Lys16) (Buck, Gallo et al. 2004). Levels of acetylated 
H4Lys16 decrease during the G2/M cell cycle transition coinciding with SIRT2 
localisation to chromatin(Vaquero, Scher et al. 2006).  
At different time points during mitosis, SIRT2 is associated with the centrosome, 
the mitotic spindle and the midbody. SIRT2 regulates the APC/C complex which 
triggers the transition from metaphase to anaphase(Kim, Vassilopoulos et al. 
2011) and this group found SIRT2 null cells showed more mitotic abnormalities 
than normal cells. Overexpression of wildtype, or catalytically inactive SIRT2 
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increases multinucleation, possibly due to a failure to complete the mitotic 
separation(North and Verdin 2007). 
1.14.4 Transcription regulator 
SIRT2 deacetylates eukaryotic translation initiation factor 5A (eIF5A), in 
association with HDAC6 causing acetylated eIF5A to accumulate in the nucleus 
(Ishfaq, Maeta et al. 2012). Histone 3 is acetylated on lysine 56 as a necessary 
part of chromatin formation, localises to sites of repair after DNA damage and 
H3K56Ac levels are increased in many types of cancer. H3K56Ac (histone 3 
acetylated on lysine 56) is deacetylated by SIRT1 and SIRT2(Das, Lucia et al. 
2009) SIRT3 (Vempati, Jayani et al. 2010) and SIRT6(Michishita, McCord et al. 
2009). 
Autoacetylation of p300 occurs readily in the presence of Acetyl CoA but it is 
largely deacetylated in human cells. SIRT2 − uniquely among the human sirtuins 
− deacetylates p300 and allows it to bind with VP16 and GAL4 in an essential 
step in formation of the preinitiation complex for mammalian genetic 
transcription(Black, Mosley et al. 2008). Conversely, p300 interacts with SIRT2, 
which is acetylated and thus downregulated, completing a negative feedback 
loop (Han, Jin et al. 2008). 
SIRT2 deacetylates and downregulates p53 (Jin, Kim et al. 2008).  
1.15 SIRT3 
1.15.1 Gene location, subcellular localisation and tissue 
expression 
The SIRT3 gene is located on chromosome 11p15.5, close to the telomeric 
DNA(Frye 1999; Onyango, Celic et al. 2002). It consists of 7 exons which encode 
a protein of 399 amino acids.  
SIRT3 mRNA is widely expressed in human adult and foetal tissues; expression is 
specifically reported in colon tissue samples in the adult(Frye 1999). It is 
localised to the mitochondrial subfraction and has definite NAD-dependent 
deacetylase activity (Onyango, Celic et al. 2002). Mitochondrial import of SIRT3 
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requires the presence of an N-terminal sequence, and the 43.6kDa SIRT3 is 
cleaved within the mitochondrial matrix to form a protein of 28kDa weight, and 
thereby activated(Schwer, North et al. 2002). In a range of 12 adult tissues, 
SIRT3 expression showed remarkably little variation, in contrast to other 
sirtuins. 
Initial reports commented that endogenous expression levels were very low in 
U2OS and HeLa cells and confined to the mitochondria(Cooper and Spelbrink 
2008). However, using highly specific antibodies to the N-terminus and C-
terminus, Scher et al placed SIRT3 in the nucleus, with translocation of a 
processed form to the mitochondria; export increased on exposure to UV 
irradiation or DNA damaging agent(Scher, Vaquero et al. 2007). The short form 
was only detected in mitochondria but both were evident in the nucleus, 
suggesting processing occurs in the nucleus to direct mitochondrial transfer.  
SIRT3 translocates to the nucleus on over expression with SIRT5 in COS7 (monkey 
fibroblast-derived) cells(Nakamura, Ogura et al. 2008). This may be the 
mechanism by which it achieves access to genes for transcription. A putative 
nuclear targeting signal was identified; mutations within this sequence prevent 
nuclear localisation of both SIRT3 and a proportion of the SIRT5 signal. 
Currently it is generally accepted that the majority of SIRT3 is mitochondrial, 
but nuclear and cytoplasmic functions are discussed below. 
Mitochondrial (short form) SIRT3 is protected, whereas the long form has a short 
half-life of 30 minutes. Further truncation of SIRT3, likely occurring within the 
mitochondrial matrix, increases its activity against certain substrates and may 
be relevant in a wider context in determining substrate specificity ranges, and 
rate of catalysis(Schlicker, Gertz et al. 2008). Both N- and C-terminal processing 
thus have demonstrable effects. 
1.15.2 Association with lifespan 
SIRT3 is the only one of the human sirtuins shown to have an effect on human 
longevity(Rose, Dato et al. 2003). A single nucleotide polymorphism increases 
longevity in males only. This team also identified a VNTR (variable nucleotide 
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tandem repeat) sequence in intron 5 of the SIRT3 gene which is commoner in the 
oldest (over 80 years) section of a cohort of Italian males(Bellizzi, Rose et al. 
2005). Again, there was no difference in allele distribution by age in females. 
1.15.3 Association with transcription 
SIRT3 represses transcription by deacetylation of H4K16 and H3K9(Scher, 
Vaquero et al. 2007). Targets include PTK2, a cell adhesion molecule which 
reduces mobility, GAL3ST1, a sulphotransferase involved in metabolism of many 
drugs and OTOG, a glycoprotein expressed in the inner ear which may have 
functions in cell adherence. 
Further actions of SIRT3 are described in later sections but in summary, it is 
linked to cancer progression as it regulates production of ROS which may be 
tumorigenic, and it is a key regulator of oxidative phosphorylation and the 
balance between this and the less-efficient energy production of glycolysis. 
However, SIRT3 null mice do not display an obvious phenotype when young and 
have normal ATP levels in liver, heart and kidney. Since several other sirtuins 
are also implicated in pathways that confer resistance to oxidative stress, energy 
metabolism and cell fate and longevity, it raises the question how the sirtuins 
interact in the context of different or several stressors. At present we have 
evidence of many interesting relationships, and the full picture of interactions of 
any sirtuin will be very complicated but it may be the interplay between them 
that is essential to an understanding of how they integrate pathways such as 
metabolism and cell division. 
1.16 SIRT4 
1.16.1 Gene location, subcellular localisation and tissue 
expression 
The SIRT4 gene is located on chromosome 12q(Frye 1999) and resembles 
prokaryotic sirtuin sequences. It has ADP-ribosylation activity on histones(Haigis, 
Mostoslavsky et al. 2006). Deacetylation activity has not been demonstrated so 
far. 
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SIRT4 is widely expressed in human adult and foetal tissues but colonic 
expression levels are comparatively low(Frye 1999). SIRT4 localises to the 
mitochondria on immunofluorescence and Western blot of subcellular fractions 
and in human and mouse cells (Michishita, Park et al. 2005; Haigis, Mostoslavsky 
et al. 2006). An N-terminal signal sequence is cleaved during mitochondrial 
import(Ahuja, Schwer et al. 2007) and SIRT4 is localised as a soluble protein 
within the mitochondrial matrix.  
1.17 SIRT5 
1.17.1 Gene location, subcellular localisation and tissue 
expression 
SIRT5 is located as a single gene on chromosome 6 and is transcribed in two 
isoforms(Mahlknecht, Ho et al. 2006). The longer full-length form encodes a 310 
amino acid protein and the shorter version includes a variation in the last exon, 
a 299 protein(Matsushita, Yonashiro et al. 2011). SIRT5 sequence is more similar 
to prokaryotic sirtuins than to yeast Sir2 protein(Frye 1999).  
SIRT5 is widely expressed in adult and foetal human tissues, particularly in 
testis, skeletal muscle, kidney and heart; colonic mRNA expression is at 
comparatively high levels(Frye 1999). SIRT5 was first reported to be localised to 
mitochondria in human fibroblasts and HeLa cells(Michishita, Park et al. 2005). 
COS7 cells are fibroblast-like cells of simian origin. Using these cells, SIRT5 was 
more precisely located in the mitochondrial intermembrane space(Nakamura, 
Ogura et al. 2008). Interestingly, when coexpressed at supraendogenous levels 
with SIRT3, SIRT5 signal remained in the mitochondria whereas SIRT3 signal was 
seen in the nucleus. When a putative nuclear targeting signal of SIRT3 was 
mutated (SIRT3nu), SIRT3nu and a proportion of SIRT5 signal were distributed 
within the cytoplasm.  
These results may indicate that SIRT5 interferes with SIRT3nu localisation to 
mitochondria, or it could be that SIRT3 and SIRT5 bind together for nuclear 
targeting. Transport of SIRT5 into the mitochondrial matrix has been confirmed 
in mouse hepatocytes and also showed the existence of a typical N-terminal 
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sequence cleaved on import into the mitochondrial matrix(Nakagawa, Lomb et 
al. 2009). 
Mouse cerebellar neurons were reported to show localisation of SIRT5 to nucleus 
and cytoplasm as well as mitochondria, although in a subpopulation of these 
cells only mitochondrial localisation was found. Cells in this subpopulation were 
more susceptible to apoptosis(Pfister, Ma et al. 2008). 
The two different isoforms of SIRT5 identified in human cells were investigated 
further and it was found that isoform 2 has a shorter C-terminal 
sequence(Matsushita, Yonashiro et al. 2011). When overexpressed in HEK293, 
COS7 and HeLa cells, isoform 1 localised to the nucleus and cytoplasm, while 
isoform 2 localised to the mitochondria. Unlike the mouse cerebellar neurons 
reported previously, none of these cell lines showed exclusive mitochondrial 
localisation. These investigators concluded that the longer C-terminal sequence 
was necessary for nuclear and cytoplasmic localisation. SIRT5 isoform 2 appears 
to be quickly degraded in cytoplasm by the proteasome; the stability of the 
longer form seems important, but there may also be yet unidentified targeting 
interactions for which the C-terminus is required. 
1.17.2 Enzyme activity and susceptibility to NAD 
SIRT5 acetylation activity has been shown, but is less efficient than that of 
SIRT1-3(Du, Zhou et al. 2011). By contrast, Du et al showed that its active site 
can also accommodate malonyl and succinyl groups, and removal of these groups 
occurs with much greater (29-100 times) efficiency than the deacetylation 
reaction. Carbamoyl phosphate synthetase 1 (CPS1), which is known to undergo 
deacetylation by SIRT5, also undergoes desuccinylation, and succinylation levels 
of specific lysine residues are much higher in Sirt5 knockout mice.  
Malonyl-CoA and succinyl-CoA are present in HeLa cells, and function in fashions 
similar to acetyl-CoA as donors in protein modification(Peng, Lu et al. 2011). 
SIRT5 is the only HDAC to demonstrate significant lysine demalonylation or 
desuccinylation, and that knockdown of SIRT5 changes global lysine 
demalonylation and desuccinylation, but has little effect on global 
deacetylation. 
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SIRT5 desuccinylation activity is sensitive to NAD, due to the presence of a 
specific arginine amino acid near the active site, which may also underlie the 
desuccinylase activity of SIRT5.(Fischer, Gertz et al. 2012).  
Thus although SIRT5 can and does deacetylate in the classic sirtuin fashion, it 
appears that this may not be its most important mode of action. SIRT5 seems to 
be one that expands the sirtuin sphere of influence into other protein 
modification pathways. 
1.18 SIRT6 
1.18.1 Gene location and subcellular localisation 
SIRT6 is localised to chromosome 19p13.3(Frye 2000; Mahlknecht, Ho et al. 
2006). In the first report of its subcellular localisation, in human fibroblasts, 
SIRT6 was found in the nucleus, associated with heterochromatin but excluded 
from the nucleolus (Michishita, Park et al. 2005). Similar nuclear expression of 
SIRT6 protein was reported in fibrosarcoma cells, but light cytoplasmic staining 
was described in embryonic stem cells(Mostoslavsky, Chua et al. 2006).  
A more recent investigation into the subcellular localisation of SIRT6 in HeLa 
cells reported exclusive nuclear location of the protein, but also showed that it 
was enriched in the nucleolus with variability in the degree among different 
cells(Ardestani and Liang 2012). S phase cells show little nucleolar staining while 
there is a significant increase in G1 phase. SIRT6 levels increase in mitosis but it 
is spread throughout the cytoplasm and associates in part with α-tubulin and 
mitotic spindles. 
Cytoplasmic staining in breast cancer cells (Khongkow, Olmos et al. 2013) is 
explored further below. 
1.18.2 Enzymatic activity 
In initial experiments, only lysine deacetylase activity against histone H3 in 2 
locations was noted (Kawahara, Michishita et al. 2009; Michishita, McCord et al. 
2009). SIRT6 has ADP-ribosylation activity, and was reported to act on 
itself(Liszt, Ford et al. 2005). Other targets include PARP1, further discussed in 
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connection with the role of SIRT6 in DNA repair (Mao, Hine et al. 2011). Unlike 
other sirtuins, SIRT6 can bind NAD in the absence of an acetylated 
substrate(Pan, Feldman et al. 2011). ADP-ribose and NAD appear to induce 
different conformational changes and SIRT6 does not accommodate NADH in its 
binding site, in contrast to other sirtuins. Thus its regulation may be also be 
different. 
1.18.3 Role in regulation of base excision repair (BER) 
Investigating the effect of SIRT6 deficiency, it was noted that SIRT6-null mouse 
embryonic fibroblasts (MEFs) and embryonic stem cells (ESCs) showed increased 
sensitivity to IR but normal UV sensitivity(Mostoslavsky, Chua et al. 2006). There 
were higher numbers of metaphase chromosomes with abnormalities such as 
fragmentation, detached centromeres, gaps and translocations. BER rather than 
cell cycle checks or double strand break (DSB) repair mechanisms was confirmed 
as the underlying defective process. 
Consistent with these findings, SIRT6 null cells showed increased sensitivity to 
alkylating agents and damage due to ROS, which tend to cause single strand 
breaks repaired by BER. 
However, surprisingly, SIRT6 did not localise with the base excision repair 
machinery, although over expression of components of the BER restored 
wildtype function after treatment with alkylating agents. The specific action of 
SIRT6 was not clearly demonstrable. 
1.18.4 Role in double strand DNA break repair 
SIRT6 mobilises the DNA-protein kinase subunit of the DSB repair complex and 
stabilises it at chromatin adjacent to DSB (McCord, Michishita et al. 2009). SIRT6 
also interacts with CtIP, a protein crucial for the DNA resection step in DSB 
repair(Kaidi, Weinert et al. 2010) 
SIRT6 ADP-ribosylates PARP1, which autoactivates and, by ADP-ribosylation, 
recruits repair proteins to DSB (Mao, Hine et al. 2011) in human fibroblasts. 
SIRT6 significantly increases the rate of NHEJ in experimental conditions of 
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oxidative stress. PARP1 is involved in BER and in DSB repair by the DNA-
dependent and alternative (DNA-independent) pathways. 
Homologous recombination, the more precise mechanism for repair of DSB, 
decreases with onset of replicative senescence in human fibroblasts, in 
association with decreasing levels of SIRT6, and other proteins(Mao, Tian et al. 
2012). This phenotype can be rescued by increasing SIRT6 expression and it is 
due to SIRT6 mono-ADP-ribosylation of PARP1, rather than interaction with CtIP. 
1.18.5 Role in telomere maintenance 
Given the reduced lifespan in Sirt6 null mice, Michishita et al investigated the 
effects of SIRT6 depletion in cells(Michishita, McCord et al. 2008). SIRT6 
knockdown human fibroblasts (S6KD cells) showed more end-to-end chromosomal 
fusions, and more telomere dysfunction-induced foci, although mean telomere 
length was not shorter. hTERT expression reversed signs of premature replicative 
senescence seen in S6KD cells. SIRT6 localised to telomeric chromatin in S-
phase, and S-phase was longer in S6KD cells.  
This team also indentified lysine 9 of histone 3 (H3K9) as the first confirmed 
deacetylation target for SIRT6, and showed that its activity is responsible for 
maintaining low levels of H3K9Ac at telomeres in S-phase. WRN is. The telomere 
fusion sites in S6KD cells had weak telomeric signals, implying shortening of 
telomeres prior to fusion, rather than lack of telomeric capping proteins. The 
conclusion drawn was that SIRT6 and WRN (a DNA helicase, responsible for the 
Werner syndrome, a profound progeria) interact to stabilise telomeres and 
prevent premature replicative senescence. Absence of this interaction leaves 
telomeres vulnerable to and underlies the premature ageing phenotype seen in 
Sirt6 null mice. 
SIRT6 has also been shown to deacetylate H3K56Ac, which localises to telomeric 
chromatin and increases dramatically at G2/M phase(McCord, Michishita et al. 
2009). 
The telomere position effect refers to the epigenetic silencing of genes close to 
telomeres. Maintenance of this state requires SIRT6, likely through its action on 
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H3K9Ac, which promotes the closed chromatin structure which inhibits 
transcription(Tennen, Bua et al. 2011). 
1.19 SIRT7 
1.19.1 Gene location, subcellular localisation and tissue 
expression 
SIRT7 is a single copy gene, localised to chromosome 17q25.3, and translated as 
a single isoform of 400 amino acids (Voelter-Mahlknecht, Letzel et al. 2006). 
Like SIRT4 and SIRT6, it lacks conserved amino acids thought necessary for 
deacetylation(Tanny and Moazed 2001), but deacetylation of p53 by murine Sirt7 
has been reported (Vakhrusheva, Smolka et al. 2008). 
SIRT7 was predicted to localise mainly to the nucleus, but cytoplasmic and 
mitochondrial targeting signals were also noted(Dryden, Nahhas et al. 2003). In 
the original immunohistochemistry report using normal human fibroblast cells 
overexpressing SIRT7, expression in the nucleus and most prominently in the 
nucleolus was observed(Michishita, Park et al. 2005).  
The first finding of cytoplasmic SIRT7 staining was reported in human fibroblasts 
and colonic epithelium, as well as the expected nucleolar staining (Kiran, 
Chatterjee et al. 2013). Heavy cytoplasmic staining, but no nuclear staining was 
observed in normal human colon epithelial cells on immunohistochemistry. Two 
isoforms of SIRT7 were identified, with molecular weights of 45 and 47.5 kDa 
respectively. The former localises to the nucleus in fibroblasts and epithelial 
cells, and the latter to the cytoplasm, in fibroblasts only. The same paper 
reported that fibroblasts which developed replicative senescence lost the 
nucleolar staining gradually with increasing passage; this change was not seen in 
cells with prematurely induced senescence. There was an inverse and reciprocal 
relationship between levels of the 45kDa and 47.5kDa isoforms in young and 
senescent fibroblasts (less 45kDa SIRT7 was identified in older cells).  
Following from this, epithelial cells in G2/M arrest, or held at end of mitosis had 
an increased proportion of 47.5kDa SIRT7 and a decreased proportion of 45kDa 
SIRT7. The opposite effect was obtained by serum starvation, which maintained 
cells in G1/S phase. Treatment of the cells with phosphatase did not change the 
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proportion of 47.5kDa SIRT7 detected, implying that differences between 
isoforms is due to posttranslational processing other than phosphorylation alone. 
1.19.2 Interaction with RNAPol1 
SIRT7 in mouse tissue was associated with coding and promoter sequences of 
rDNA(Ford, Voit et al. 2006). 25% of SIRT7 complexes co-precipitated with 
RNAPol1. rRNA synthesis decreased in cells transfected with siRNA to SIRT7 and 
mutations affecting enzymatic activity did not interfere with nucleolar 
localisation but did reduce rRNA synthesis and association of Pol1 with rDNA. 
Selective inhibition of rRNA synthesis released SIRT7 from the nucleolus. The 
specific substrate of SIRT7 in its association with Pol1 and rDNA was not 
identified, and its enzymatic action was likewise not discerned. Neither 
deacetylation nor ADP-ribosylation of the histone substrates tested was 
observed.  
Grob et al found that activation of SIRT7 is required for the resumption of rDNA 
transcription in late stages of mitosis(Grob, Roussel et al. 2009). Proteomic 
analysis of SIRT7 interactions has shown significant interactions with RNAPolII as 
well as Pol1, and with B-WICH, a chromatin remodelling complex(Tsai, Greco et 
al. 2012). SIRT7 deacetylates H3K18Ac (acetylated lysine18 on histone H3), and 
reduces transcription of a specific set of genes, primarily involved with RNA 
transcription and processing, and with transcription of ribosomal 
proteins(Barber, Michishita-Kioi et al. 2012). This implies that SIRT7 may have a 
wider impact on rDNA transcription as well as the specific associations 
demonstrated so far, and further results are awaited. 
The following paragraphs describe common areas of influence of the sirtuins of 
particular relevance to this thesis, with description of areas of sirtuin 
interrelationships. 
1.20 Sirtuins and control of metabolism 
1.20.1 SIRT2: maintenance of substrate availability 
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In adipocytes, by overexpression and in low insulin and low glucose states, SIRT2 
inhibits differentiation (Jing, Gesta et al. 2007) and promotes binding of FOXO1 
to PPARγ, reducing transcription of its targets(Wang and Tong 2009).  
Through another pathway inhibited by HIF1α, SIRT2 deacetylates PGC1α 
(Krishnan, Danzer et al. 2012). This in turn increases transcription of PPARγ and 
expression of beta-oxidation and mitochondrial gene targets, hindering the 
development of a state of obesity. SIRT2 deacetylates phosphoenolpyruvate 
carboxykinase (PEPCK1), the rate-limiting enzyme in gluconeogenesis, stabilising 
it(Jiang, Wang et al. 2011). SIRT2 therefore seems to maintain availability of 
substrate in conditions of scarcity, but its actions on PPARγ appear to depend on 
which upstream pathway is activated. 
1.20.2 SIRT4: Switch to fatty acid catabolism from glucose 
and protein substrates  
SIRT4 levels in the liver were reduced when the animals were fed a high fatty 
acid diet, and elevated in response to a high fructose diet(Chen, Fang et al. 
2010). 
SIRT4 knockdown increases expression of mitochondrial and fatty acid oxidation 
genes in mouse hepatocytes, and increases rates of fatty acid oxidation(Nasrin, 
Wu et al. 2010). This was associated with increased SIRT1 protein and mRNA 
levels. In vivo SIRT4 knockdown in mice resulted in upregulation of SIRT3 in 
hepatocytes and slight decrease in blood glucose. Investigations on mouse 
myotubes confirmed SIRT4 has a role in negative regulation of mitochondrial 
oxidative metabolism in these cells. These results suggest that SIRT4 may be 
instrumental in regulating SIRT1 and to a lesser extent SIRT3 expression. Nuclear 
localisation has not so far been reported for SIRT4 and it will be interesting to 
find out how it achieves these effects. 
Investigation of peripheral blood cells in diabetic and normal human subjects 
showed decreased levels of SIRT4 (and SIRT1) in the diabetic cases(Song, Xu et 
al. 2011). This team also noted negative correlation between fasting glucose and 
markers of high-risk lipids (triglycerides and lipoprotein A), and SIRT4. 
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1.20.2.1 Effect on insulin signalling 
SIRT4 ADP-ribosylates and inhibits GDH in mouse and human cell lines at 
endogenous levels. Leucine stimulates GDH so that amino acids are used as fuel 
for the tricarboxylic acid cycle (TCA) and directly and via this alternative 
production of energy, stimulates insulin secretion. (This process of amino acid-
stimulated insulin secretion is abbreviated to AASIS). SIRT4 null mice have higher 
insulin secretion in response to glucose and show more AASIS. SIRT4 may 
coordinate pancreatic and hepatic metabolism, decreasing AASIS in the pancreas 
and reducing the use of amino acids for gluconeogenesis in the liver. 
Experiments on human cell lines identified further targets for SIRT4 ADP-
ribosylation involved in insulin signalling. Insulin-degrading enzyme is a 
metalloproteinase which regulates amyloid-β and insulin levels. ADP/ATP 
translocases 2 and 3 exchange ATP generated by respiration in the mitochondrial 
matrix for cytosolic ADP(Ahuja, Schwer et al. 2007). 
1.20.3 SIRT1: sensitivity to insulin 
SIRT1 influence on metabolic processes varies according to the tissue under 
investigation, and is tailored to integrate tissue-specific functions into a whole-
body homeostatic network(Imai and Yoshino 2013). Most of the available data 
comes from mouse models. Liver-specific knockout mice are more prone to 
hepatic steatosis on a high fat diet, with impaired PPARγ function, reduced fatty 
acid β-oxidation and more endoplasmic reticulum stress(Purushotham, Schug et 
al. 2009). SIRT1 deficiency in another model interfered with mTOR/AKT 
signalling, resulting in chronic hyperglycaemia, oxidative stress and insulin 
resistance, on a normal diet(Wang, Kim et al. 2011).  
Similarly, SIRT1 seems to improve white adipose tissue sensitivity to insulin, 
through action on PPARγ (Qiang, Wang et al. 2012). In skeletal muscle of mice 
under caloric restriction, SIRT1 deactivates STAT3, altering availability of 
subunits of PI3K and effecting a more efficient insulin-stimulated response in 
PI3K(Schenk, McCurdy et al. 2011). 
1.20.4 SIRT1 and SIRT3: substrate availability in starvation 
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Acetyl CoA synthase (AceCS) 1 and 2 convert free acetate into a usable 
metabolite in mammals; endogenous sources are important for use of acetate as 
a substrate in starvation. AceCS1 is located in the cytoplasm, AceCS2 in the 
mitochondrial matrix(Fujino, Kondo et al. 2001). Acetate metabolism is impaired 
as humans age(Skutches, Holroyde et al. 1979). SIRT1 deacetylates and activates 
AceCS1, improving use of acetate in lipid synthesis. SIRT3 has very similar 
activity but lack of function in whole cell analyses probably results from the 
subcellular confinement of SIRT3 to the mitochondrial matrix. Deacetylation by 
SIRT3 reactivates AceCS2 with 5 times greater effect than SIRT1(Hallows, Lee et 
al. 2006; Schwer, Bunkenborg et al. 2006). Increased AceCS2 activity increases 
CO2 output whereas increased AceCS1 activity has no such effect. This suggests 
that different pools of AcetylCoA exist with different sirtuin regulatory 
mechanisms and possibly different functions in increasing energy storage by lipid 
synthesis, versus increasing energy output by increased respiration. 
1.20.5 SIRT3: shift in balance from glycolysis to enhanced 
oxidative phosphorylation 
SIRT3 germline knockout mice showed increased susceptibility to oxidative stress 
and significant metabolic dysfunction. Surprisingly, mice with SIRT3 knockdown 
in a tissue-specific manner do not show any particular phenotypic variation 
although mitochondrial protein acetylation is increased(Fernandez-Marcos, 
Jeninga et al. 2012). 
AceCS2 expression increases in ketogenesis. It is proposed that in fasting 
conditions fatty acids are released by adipose tissue, oxidised to acetate and 
ketone bodies in the liver and available for muscle after conversion to acetyl-
CoA by AceCS2. Gene expression was studied in the context of hypoenergetic 
dieting in obese women (Capel, Viguerie et al. 2008). Subjects on a moderate 
fat/low carbohydrate hypoenergetic diet showed increased expression of SIRT3, 
consistent with a regulatory effect increasing fatty acid oxidation.  
Within mitochondria, SIRT3 is localised to the mitochondrial matrix(Schwer, 
North et al. 2002). Its deacetylation activity is deemed to be important but 
given that the levels of NAD are generally high in this compartment it is not 
clear whether this is a rate-controlling factor or may serve merely to keep SIRT3 
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activity rate high. It is also possible that it is the NAD:NADH ratio which is more 
important for enzyme function than the absolute level of NAD. 
Experiments with Sirt3 null mice show that SIRT3 promotes amino acid 
catabolism in low intake situations by activating ornithine transcarbamoylase 
and increased urea cycle throughput, along with alterations in β-oxidation of 
fatty acids(Hallows, Yu et al. 2011). 
SIRT3 also regulates ATP levels by deacetylation of subunits of the electron 
transport chain Complex 1 in mice(Ahn, Kim et al. 2008). In human HeLa cells, 
both the long and short isoforms of SIRT3 interacted with Complex 1. 
SIRT3 interacts with subunits of electron transport chain complexes 2 and 5, 
succinate dehydrogenase A (SDHA), and ATP synthase subunit O-mitochondrial 
(ATP5O) respectively. SIRT3 deacetylates SDHA, and its activity is reduced in 
Sirt3 null mice(Finley, Haas et al. 2011). 
Palmitate (a free fatty acid) stimulates ROS accumulation and production of 
cytokine MCP1 in tubular cells of a mouse model of proteinuric kidney 
disease(Koyama, Kume et al. 2011). SIRT3 is decreased in these cells and MCP1 
inversely correlated; SIRT3 overexpression reduced ROS levels and increased 
antioxidant gene expression, linking it to lipotoxic ROS-mediated inflammation. 
This may be of relevance in human metabolic syndrome and associated disease. 
ATP levels are thought to be important in initiation of cell death by apoptosis or 
necrosis. Thus there are at least 2 pathways by which SIRT3 could influence cell 
fate. SIRT3 deacetylates and activates glutamate dehydrogenase (GDH) which is 
deactivated by ADP-ribosylation by SIRT4(Schlicker, Gertz et al. 2008), and also 
deacetylates and activates isocitrate dehydrogenase, a key regulator of the 
citric acid cycle, both of which increase ATP production. 
SIRT3 is central to a shift in balance from glycolysis to enhanced oxidative 
phosphorylation in one cell line through deacetylation of cyclophilin D. (Shulga, 
Wilson-Smith et al. 2010) Cyclophilin D is necessary to maintain hexokinase II 
binding to voltage-dependent anion channels which preserve mitochondrial 
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integrity. This may be of relevance in transformed cells, but will depend on 
SIRT3 levels. As shown below, SIRT3 levels in cancer cells are variable. 
SIRT3 interacts with hypoxia-inducible factor 1α (HIF1α). Finley et al (Finley, 
Carracedo et al. 2011) showed that increased reactive oxygen species, such as 
may result from SIRT3 knockdown, decrease the activation of prolyl hydroxylases 
which by adding hydroxyl groups to HIF1α enable binding of von Hippel-Lindau 
protein and targeting of HIF1α to degradation by the proteasome. Thus 
decreased SIRT3 results in increased levels of HIF1α, with increased expression 
of genes controlling glycolysis. This may offer one mechanistic explanation for 
the Warburg effect, a tendency of cancer cells to use glycolysis to generate 
energy even in the presence of adequate oxygenation. They also linked this 
knockdown with increased glycolysis in breast cancer cells and with increased 
cancer cell proliferation in these lines. SIRT3 is shown to be reduced in several 
breast cancers and in other epithelial cancers. 
1.20.6 SIRT5: Regulation of throughput in protein catabolism 
In vitro and physiological investigation showed that Sirt5 deacetylates carbamoyl 
phosphate synthetase 1 (CPS1) in murine hepatocytes(Nakagawa, Lomb et al. 
2009). CPS1 catalyses the combining of ammonia and bicarbonate to form 
carbamoyl phosphate, the first step in the urea cycle. Sirt5 knockout mice show 
lower levels of CPS1 activity and build-up of ammonia when subjected to caloric 
restriction, as they are unable to adequately handle the ammonia produced 
when amino acids are used for gluconeogenesis. Since neither Sirt5 nor CPS1 
protein levels increases in CR, it appears that increased NAD levels activate 
SIRT5 which in turn activates CPS1. Experimental results show that 
intramitochondrial NAD levels and CPS1 activity both increase in caloric 
restriction in wildtype but not Sirt5 KO mice. 
Proteomic analysis of mouse cells showed over 700 proteins with 2,500 lysine 
succinylation sites(Park, Chen et al. 2013). Global levels of lysine succinylation 
increase in response to fasting, and show a higher baseline in Sirt5-deficient 
mice. A subset of specific proteins showing higher levels of lysine succinylation 
in Sirt5-deficient mice included histones and ribosomal proteins, and over half of 
proteins involved in fatty acid metabolism and the TCA. A significant proportion 
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of these function outside of mitochondria, and immunofluorescence confirmed 
localisation of SIRT5 in the cytosol. Proof of principle experiments showed that 
two of the proteins identified (pyruvate dehydrogenase complex and succinate 
dehydrogenase (in electro transport chain Complex II) showed more lysine 
succinylation and increased activity in SIRT5 knockdown in HeLa cells, and SIrt5 
null mouse cells respectively. 
SIRT5 appears to have an important part to play in regulation of gluconeogenesis 
using amino acid sources. 
1.20.7 SIRT1 and SIRT6: Balancing lipid metabolism 
Both rat and human cell lines showed increased SIRT6 protein expression when 
grown in nutrient-deprived serum(Kanfi, Shalman et al. 2008). Similar effects 
were seen in rat and mouse tissues after caloric restriction regimes. This 
increase was achieved by stabilisation of SIRT6 protein which is usually degraded 
by the proteasome pathway.  
SIRT6 in mouse cells is positively regulated by SIRT1 in complex with FOXO3a and 
NRF1 through their combined effect on the SIRT6 gene promoter, in conditions 
of glucose starvation(Kim, Xiao et al. 2010). SIRT6 deficiency causes reduced 
expression of genes involved in glycolysis and synthetic lipid metabolism, by 
deacetylation of H3K9 at their promoters and hepatic knockdown of SIRT6 causes 
development of fatty liver in mice.  
HIF1α regulates a metabolic switch to glycolysis under nutrient-deprived 
conditions. HIF1α levels are higher in SIRT6 deficient cells as a result of both 
increased protein synthesis and stability. All of the genes upregulated in SIRT6 
deficient cells are targets of HIF1α, and SIRT6 binding to the promoters is 
contingent on interaction between SIRT6 and HIF1α. This may relate to H3K9 
deacetylation of SIRT6 in the region of glycolytic gene promoters or it may be a 
separate regulatory mechanism. 
Sterol-regulatory element-binding proteins (SREBPs) regulate lipid metabolism. 
MicroRNAs within their introns have a negative effect on expression of targets 
including fatty acid β-oxidation genes as well as SIRT6, and a subunit of PKA and 
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IRS2 (Horton, Goldstein et al. 2002; Horton, Goldstein et al. 2002). SIRT6, AMPK 
and IRS2 tend to counteract the lipogenic effects of SREBP, placing SIRT6 within 
a complex regulatory framework for lipid metabolism. 
SIRT1 decreases acetylation of PGC-1α, to activate it and thus increase 
expression of target genes to promote gluconeogenesis(Rodgers and Puigserver 
2007). SIRT6 indirectly inhibits PGC-1α in U2OS and HEK293A cells, (Dominy, Lee 
et al. 2012) through the action of SIRT6 on GCN5, which acetylates PGC1α. 
Overexpression of Sirt6 in mouse primary hepatocytes did reduce expression of 
gluconeogenic genes as expected. Indeed, knockdown of SIrt6 in whole animal 
studies increased hepatic gluconeogenesis and glucose output and expression of 
key gluconeogenic genes. 
An important link between inflammation and metabolism has recently been 
reported, identifying a change from the acute stage of inflammation, dependent 
on glycolysis to a later adaptive phase where fatty acid oxidation is 
essential(Liu, Vachharajani et al. 2012). The adaptive response phase requires 
NAMPT synthesis of NAD. TLR4-stimulation increases expression of SIRT1 and 
SIRT6, and SIRT1 activation also stimulates SIRT6 expression. SIRT1 and SIRT6 
knockdown experiments show that SIRT6 inhibits glycolysis and SIRT1 activates 
the fatty oxidation pathways. Clinical relevance of these results comes from 
assessment of leukocytes from human patients with sepsis, in late stage as 
assessed by TNFα expression. The human leukocytes exhibited the expected 
increase in fatty acid metabolism with reduction in rates of glycolysis. 
1.21 Sirtuins and control of inflammation 
Several of the sirtuins act through effects on transcription of subunits of NFκB. 
This process is influenced by TNFα with evidence of a feedback loop involving 
SIRT6. 
1.21.1 SIRT1 and inflammatory responses 
SIRT1 deacetylates the RelA/p65 subunit of NFκB, inhibiting its transcriptional 
activity(Yeung, Hoberg et al. 2004). This leaves cells more vulnerable to TNFα 
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mediated apoptosis (in contrast to the anti-apoptotic effects of SIRT1 
deacetylation of p53).  
1.21.2 SIRT2 and inflammatory responses 
SIRT2 deacetylates p65, which is a component of NFκB(Rothgiesser, Erener et al. 
2010). Hyperacetylation of p65 in SIRT2 null cells after TNFα stimulation results 
in expression of a subset of NFκB target genes. 
1.21.3 SIRT6: Associations with inflammation 
SIRT6 inhibits transcription of NFκB target genes, by deacetylation of H3K9Ac in 
the region of NFκB promoters (Kawahara, Michishita et al. 2009). It is recruited 
to these promoters by interaction with the RelA subunit of NFκB. This 
interaction is inducible by TNFα, which also promotes nuclear transfer of NFκB 
for transcription of target genes, but interestingly, decreases the transcription 
of NFκB target genes by destabilising the interaction between RelA and the 
promoter. Both SIRT6 and RelA homozygous deficiency are lethal in mice, but 
SIRT6-null, RelA heterozygotes survive much longer, suggesting that some of the 
lethal effect of the SIRT6 deficiency is mediated by excess NFκB action. 
TNFα protein synthesis in inflammatory leukocytes is regulated by SIRT6 by 
posttranslational modification(Van Gool, Galli et al. 2009) 
SIRT6 and TGFβ expression was investigated in idiopathic pulmonary fibrosis 
(IPF) (Minagawa, Araya et al. 2011), where TGFβ1 induced senescence in IPF 
cells, via p21 activity, independently of p53. SIRT6 overexpression reduces p21 
activity by labelling p21 mRNA for degradation and can prevent senescence. 
SIRT6 overexpression also reduces IL1β expression; since IL1β also functions as a 
paracrine signal, inducing myoepithelial differentiation in neighbouring cells, it 
is conceivable that SIRT6 and IL1β affect surrounding epithelial cells in lung and 
other tissues. This may be relevant to SIRT6 interactions in cancer as well as 
other inflammatory pathologies. 
Specific examination of the role of SIRT6 in inflammation was performed using 
HUVECs exposed to LPS(Lappas 2012). SIRT6 knockdown was associated with 
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increased levels of IL1β, IL6, IL8, MMP2, MMP9, PAI1, ICAM1 and VEFG and FGF2. 
It would be useful to know if these observations persist in colonic epithelial 
cells. 
1.22 Sirtuins and control of cell fate 
Inflammatory responses instigated by TNFα are interlinked with the effect of 
sirtuins on cell fate.  
1.22.1 SIRT2 and cell death 
TNFα instigates cell death by necrosis, acting through SIRT2 and the RIP3-RIP1 
complex which initiates the cell death process. Hearts of SIRT2 null mice show 
some protection from ischaemia reperfusion injury and TNFα is ineffective in the 
face of SIRT2 inhibition(Narayan, Lee et al. 2012) which suggests therapeutic 
potential for modulation of SIRT2 function. 
SIRT2 is upregulated by a GSK3 inhibitor and induced apoptosis via a caspase-
independent pathway(Pizarro, Folch et al. 2009). Decreased activity of SIRT2 can 
result in necrosis and apoptosis by caspase-3-dependent pathways(He, Nie et al. 
2012). p53 deficient chicken cells were treated to prevent transcription of 
functional SIRT1 and SIRT2(Matsushita, Takami et al. 2005). SIRT2 deficient cells 
were more sensitive to pro-apoptotic stimuli, implying regulation of cell death 
pathways in p53-independent manner. 
SIRT2 binds to FOXO3a, increasing its DNA binding, and elevating transcription of 
MnSOD and Bim. Bim is a propapoptotic factor, thus SIRT2 is part of the pathway 
which promotes cell death in cells under severe stress. Increased levels of 
MnSOD tend to reduce levels of ROS, normalising the oxidative stress. 
SIRT2 depletion enhances anoxia-reoxygenation tolerance(Lynn, McLeod et al. 
2008) and this effect is achieved through interaction with another 14-3-3 
isoform, 14-3-3ζ, which interacts with Bad, a member of the Bcl-2 gene family 
which is involved in initiating apoptosis. 
1.22.2 SIRT3: Association with cell cycle and cell death 
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After Bcl-2 knockdown in human colorectal carcinoma HCT116 cells, apoptosis 
increases. Silencing of SIRT3 has no effect on cell fate, but knockdown of both 
Bcl-2 and SIRT3 reduces the rate of apoptosis to that of wildtype cells(Allison 
and Milner 2007). In human epithelial non-carcinoma cell line ARPE19, Bcl-2 
knockdown induced cell cycle arrest at G1 phase, rather than apoptosis. SIRT3 
silencing alone had no effect on cell growth but dual silencing prevented the cell 
cycle arrest seen with knockdown of Bcl-2 alone. 
JNK2 also inhibits apoptosis, in a p53-independent manner, in a pathway which 
requires JNK1 activity(Allison and Milner 2007). Again, after JNK2 knockdown, 
apoptosis increases. Silencing of SIRT3 has no effect on cell fate, but knockdown 
of both JNK2 and SIRT3 rescues cells from apoptosis. SIRT3 expression is 
increased by JNK1. 
NAMPT catalyses the rate-limiting step in NAD recycling. Knockdown experiments 
showed that SIRT3 and SIRT4 are necessary for the protective effect of NAMPT, 
on treatment with methylmethane sulphonate, which causes cell death by 
hyperactivation of PARP(Yang, Yang et al. 2007).  
1.22.3 SIRT4: Association with cell death 
Opening of the mitochondrial permeability transition pore (PTP) in a sustained 
manner is a decisive event in irreversible cell injury. Verma et al showed that 
SIRT4 suppression prevents PTP opening in response to calcium and to calcium-
independent mechanisms(Verma, Shulga et al. 2013). SIRT4 decreases 
mitochondrial capacity to store calcium, through its inhibition of GDH but the 
downstream mechanics of GDH action are not entirely clear. SIRT4 
downregulation inhibited TNF-induced cell death, which is mediated via PTP, 
and this process also depended on GDH function. 
The ability of the mitochondria to absorb calcium may be protective when 
calcium homeostasis is perturbed. SIRT4 expression may therefore be controlled 
as part of the cell’s defence in cases of cell damage and loss of control of 
calcium containment. 
1.23 Sirtuins and cancer 
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There is a wide-ranging literature on sirtuin mRNA expression in a variety of 
cancers, and a smaller body of work describing sirtuin protein levels as assessed 
by immunohistochemistry. Both expression levels and associations with disease 
progression or survival are very variable. Data on associations with colorectal 
cancer are highlighted. 
1.23.1 SIRT1 and cancer 
Context appears to be important in assessing SIRT1 function in cancer. Two 
studies commented on changes in staining intensity in colorectal cancer tissue 
alone; in one, loss of SIRT1 staining associated with progression along the 
adenoma-carcinoma sequence (Jang, Min et al. 2012). In another, 30% of 
tumours showed lower SIRT1 expression, 25% of Stage 1-3 tumours showed 
overexpression and SIRT1 expression tended to be lower in more advanced 
tumours(Kabra, Li et al. 2009). 
Studies have reported SIRT1 overexpression in pancreatic(Zhao, Cui et al. 2011), 
prostate(Wang, Hasan et al. 2011), liver (Chen, Zhang et al. 2011), ovarian 
(Jang, Kim et al. 2009) and gastric cancers (Cha, Noh et al. 2009), and 
melanoma(Nihal, Ndiaye et al. 2011). Wang et al reported reduced SIRT1 
expression in 44 breast cancer samples in comparison to 25 unmatched normal 
control samples(Wang, Sengupta et al. 2008).  
It appears that SIRT1 cannot be simply characterised as a tumour suppressor or 
as an oncogene. It may contribute to defence against malignant transformation, 
but once this has taken place, its functions in protecting the cell from apoptosis 
may be subverted in the interest of cancer cell immortality. 
1.23.2 SIRT2 and cancer 
No description of SIRT2 expression at the mRNA or protein level in colorectal 
cancer was indentified. SIRT2 is part of a three-gene biomarker panel that 
indicates worse outcome in oesophageal adenocarcinoma(Ong, Shapiro et al. 
2013). 
SIRT2 protein expression is associated with high PSA level, old age, high Gleason 
score and clinical progression and reduced survival time in a cohort of 110 cases 
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of prostate cancer(Hou, Chen et al. 2012). This analysis did not distinguish 
between nuclear and cytoplasmic staining for SIRT2. 
Samples from a cohort of glioblastoma and diffuse astrocytoma cases showed 
that SIRT2 cytoplasmic staining was generally reduced in malignant versus 
normal specimens(Imaoka, Hiratsuka et al. 2012). The opposite was true of 
nuclear staining, which was higher in tumour specimens. Percentage of 
positively stained nuclei was calculated for each sample but cytoplasmic staining 
was categorised only absent or present. Lower percentage (<60%) of positively 
stained nuclei correlated with longer survival. 
SIRT2-null mice developed increased numbers of tumours and these were 
gender-specific (mammary gland in females and various liver and GI cancers in 
males)(Kim, Vassilopoulos et al. 2011). This same group also found reduced 
protein expression in 36 human breast cancer specimens, and 18 metastatic 
breast cancer specimens compared with adjacent normal tissue. Of 264 
hepatocellular carcinoma samples, protein levels were increased in 10, 
unchanged in 125 samples relative to normal unmatched liver tissue, and were 
reduced in 129 cases.  
SIRT2 and HDAC6 are associated with increased cellular migratory and invasive 
potential in bladder cancer models(Zuo, Wu et al. 2012). This effect is likely to 
be achieved through action on tubulin and the cytoskeleton. 
1.23.3 SIRT3 and cancer 
No studies analysing at the mRNA or protein level in colorectal cancer were 
located but SIRT3 is implicated in apoptosis in colorectal cancer cell lines as an 
effector in both the Bcl-2 and JNK2 mediated pathways (Allison and Milner 
2007). In this context its effects are contingent on the background nutritional 
and stress status of the cell. 
In a human tumour microarray, immunohistochemical staining for SIRT3 was 
reduced in breast tissue with respect to normal tissue. It also correlated with 
pathological grade of tumour. It was reduced in a variety of other human 
tumours (head and neck squamous cell cancer, glioblastoma multiforme, 
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hepatocellular and clear cell renal cancer, testicular and prostate cancers). By 
contrast, SIRT3 overexpression is reported in oral squamous cell 
cancer(Alhazzazi, Kamarajan et al. 2011) and lymph node-positive breast cancer 
(Ashraf, Zino et al. 2006). 
Following on from data linking SIRT3 to metabolic control were investigations 
linking SIRT3 and its regulation of mitochondrial ROS levels to cancer. SIRT3 null 
mice embryonic fibroblasts (MEFs) were shown to have increased levels of ROS 
and specifically mitochondrial ROS (Kim, Patel et al. 2010). This was associated 
with chromosomal instability with increased numbers of chromosomes after a 
modest dose of radiation. SIRT3 knockout mouse liver tissue and MEFs showed 
decreased mitochondrial DNA integrity over time. The MEFs did not tend to form 
tumours of themselves but when exposed to Myc or Ras overexpression became 
immortalised. In contrast, wild-type cells required expression of both Myc and 
Ras for immortalisation.  
SIRT3 knockout MEFs showed more aneuploidy with overexpression of either or 
both of these genes. These cells also showed anchorage independence growth 
capacity, by their ability to grow in soft agar, and tumorigenic potential when 
transplanted into nude mice. Oxidative phosphorylation was also affected by 
removal of SIRT3 activity, with effects as previously predicted on Complex I and 
also on Complex III of the electron transport chain. These characteristics were 
not shown by wild-type SIRT3 cells with overexpression of either of Myc or Ras. 
These characteristics were also reduced by overexpression of MnSOD, suggesting 
that loss of SIRT3 activation of MnSOD underlies the permissive aspect of the 
SIRT3 knockout tumorigenic phenotype. There was an-age-associated variation in 
this response, suggesting that loss of SIRT3 is associated with loss of MnSOD 
primarily in older mice. 
SIRT3 knockout mice tend to develop tumours more often than wild-type mice. 
These tumours tended to be of a well-differentiated type, expressing both 
oestrogen and progesterone receptors. This parallels the type of tumours found 
in older women. Murine SIRT3-null tumours also showed evidence of increased 
nitrosative and oxidative damage, postulated to occur as a function of age. 
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SIRT3 in human bladder cancer cell line associates with p53 in the mitochondria 
to prevent p53-induced growth arrest(Li, Banck et al. 2010).  
1.23.4 SIRT6: Associations with cancer 
SIRT6 gene expression is downregulated in a proportion of human colorectal and 
pancreatic cancers(Sebastian, Zwaans et al. 2012). SIRT6 nuclear protein 
expression is reduced in colorectal and pancreatic cancers and low SIRT6 is 
associated with node positive colorectal cancers and systemic inflammation, a 
poor prognostic factor for colorectal cancer. There was no specific mention of 
SIRT6 cytoplasmic staining. APC mutant mice which tend to develop multiple 
colonic polyps show more high grade and invasive neoplasms when the SIRT6 
mutation is added. 
SIRT6 expression using immunohistochemistry in breast cancer reported 
cytoplasmic staining as well as nuclear staining for the first time (Khongkow, 
Olmos et al. 2013). In 118 cases, high nuclear SIRT6 staining was associated with 
worse overall survival, and the converse was true for cytoplasmic staining. There 
was a trend towards worse disease-specific survival with higher nuclear SIRT6 
staining. 
In mice, deletion of c-Jun increases DEN-induced liver tumorigenesis with 
evidence of increased apoptosis (Min, Ji et al. 2012). In early cancers there was 
increased SIRT6 binding to the survivin promoter, and reduced acetylation of 
H3K9 at the same promoter. Dysregulation of several NFκB genes, and decreased 
binding of p65/NFκB to the survivin promoter was also found, in keeping with 
previously reported effects of SIRT6 on NFκB genes(Kawahara, Michishita et al. 
2009). c-Fos increases SIRT6 transcription and is itself inhibited by c-Jun. c-Fos 
levels are higher after DEN treatment in c-Jun deficient liver cells. 
c-Fos and SIRT6 levels were high in 11 healthy human liver samples, with low c-
Jun and survivin; the pattern was reversed in 12 of 73 dysplastic liver nodules 
which are recognised as precursor lesions to hepatocellular carcinoma (HCC).  
SIRT6 activity in relation to cancer was investigated in more general terms in 
mice: SIRT6 deficiency promoted tumour development and conferred a growth 
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advantage on transformed and non-transformed MEFs, which also exhibited 
increased glycolysis(Sebastian, Zwaans et al. 2012). Transformed SIRT6-deficient 
cells did not activate any of the downstream effectors of oncogenic activation 
but still maintained increased glycolysis. Notably, inhibition of the rate-limiting 
enzyme in glycolysis, PDK, inhibited anchorage-independent growth, reversed 
glucose-addiction (apoptosis induced by absence of glucose in growth medium) 
and reduced tumour formation in whole animals. 
1.23.5 SIRT7: Associations with cancer 
There was no data located on SIRT7 expression in colorectal cancer, but SIRT7 
gene expression was much higher in thyroid cancer (papillary, follicular and 
anaplastic) cell lines and tissue samples than in cell lines derived from normal 
thyroid tissue, samples of normal thyroid tissue or samples from benign 
adenomas(de Nigris, Cerutti et al. 2002). SIRT7 expression is higher in breast 
cancer tissue than in normal tissue, and is higher in node-positive breast 
cancers(Ashraf, Zino et al. 2006). 
SIRT7 expression was increased in a cohort of human hepatocellular carcinoma 
samples(Kim, Noh et al. 2013). Further investigation by this group suggested the 
existence of a regulatory pathway involving p53, which promoted microRNA 
inhibition of SIRT7. SIRT7 inhibits p21 expression and cell-cycle arrest in G1/S 
phase. Several cancer cells with higher levels of SIRT7 carried mutations in p53. 
In 39 cases of head and neck squamous cell carcinoma, SIRT7 gene expression 
was reduced in tumour tissue relative to normal tissue(Lai, Lin et al. 2013). 
Protein immunohistochemistry showed staining in nuclei and was lower in 
tumour tissue, but not quantitatively analysed. Expression was progressively 
reduced with advancing cancer stage, but there was no relationship with 
survival. 
There are widespread associations between the sirtuins and metabolic 
regulation, cell cycle control, and cancer, but there is a lack of information on 
protein expression in colorectal epithelium and in colorectal tumour tissue. 
Analysis of protein expression and associations with markers of 
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clinicopathological prognosis in colorectal cancer was therefore felt to be of 
interest. 
1.24 Telomeres 
Discovered (Blackburn and Gall 1978) soon after the seminal publication 
describing the Hayflick limit, telomeres were postulated to be the replicometer 
which counted cell divisions and prevented cell division past the predetermined 
limit. A neat corollary from this was the idea that critically short telomeres were 
the signal for sidetracking a cell into quiescence(Harley 1991). 
1.24.1 Structure of telomeres 
Telomeres are nucleoprotein complexes at the end of chromosomes. The DNA 
component in humans consists of the repeated hexamer TTAGGG; similar 
sequences in other species attest to evolutionary conservation of this motif. 
Telomeric DNA forms a buffer beyond coding sequences, necessary because the 
mode of action of the DNA polymerase requires an RNA template to begin 
elongation of the copied strand. This template is subsequently degraded and so a 
variable length of terminal DNA is lost with each cell division – the ‘end-
replication problem’ which produces telomere shortening identified by 
Olovnikov(Olovnikov 1973).  
The two ends of the DNA strands are bent back and hidden within an ordered 
loop structure(Griffith, Comeau et al. 1999). This protects the ends of DNA 
strands from damage and prevents exposure and recognition of the chromosome 
ends as double stranded DNA breaks. This conformation is achieved through the 
action of some of the shelterin proteins (de Lange 2005).  
1.24.1.1 Shelterin complex 
Six proteins form the shelterin complex which together with the looped DNA 
configuration hide and protect the ends of the DNA strands at the end of 
chromosomes. Several other proteins, notably those involved in DNA damage 
response like the MRN complex, and PARP2, associate with shelterin. They are 
not felt to be integral components of the complex, as the shelterin proteins are 
defined as those which are localised at telomeres only and remain there 
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throughout the cell cycle, and whose known functions are confined to telomeres. 
TRF1, TRF2 and POT1 bind the telomeric hexamer directly, and were discovered 
first from their predicted affinity for this sequence(Zhong, Shiue et al. 1992; 
Broccoli, Smogorzewska et al. 1997; Baumann and Cech 2001). 
 
Figure 1.2 Schematic diagram of components of the shelterin complex. 
TPP1 binds to POT1. TIN2 is of central important to the complex as it binds the 
heterodimer of TPP1/POT1 to both TRF1 and TRF2 and binds TRF1 and TRF2 
together as well. RAP1 binds to TRF2. 
The schematic above gives a basic representation of these interactions between 
the shelterin proteins but in vivo, multiple shelterin complexes bind at stretches 
of telomeric DNA and can adopt different conformations, varying also if other 
DNA-associated proteins are involved. This dynamic system responds to 
prevailing intracellular conditions. Alteration of the shelterin configuration, 
particularly with recruitment of DNA repair proteins to other sites of DNA 
damage can expose telomeric DNA to damage. This may be one of the means by 
which accelerated telomere shortening occurs. 
1.24.2 Telomerase 
Shelterin prevents degradation and shortening of telomeres by physically 
sequestering them, but it also controls the length of telomeres to a certain 
degree by regulating telomerase activity(Loayza and De Lange 2003). 
Telomerase can synthesise telomeric DNA and thus elongate telomeres. It is 
composed of a reverse transcriptase, encoded by the TERT (TElomerase Reverse 
Transcriptase) gene, and a template: TERC (TEmplate RNA Component).  
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Telomerase activity and TERT expression reduce soon after birth, but are 
maintained in cells which need to maintain telomere length. Telomerase is 
generally inactive in differentiated cells, but remains active at a low level in 
stem cells to support the necessary number of cell divisions required in the 
lifespan of an organism(Gunes and Rudolph 2013). Stem cell exhaustion with 
telomere shortening despite these mechanisms is one means by which ageing in 
a particular organ or compartment may be explained(Hiyama and Hiyama 2007). 
Mutations in the TERC or TERT genes have been shown to underlie dyskeratosis 
congenita and aplastic anaemia; the pathology in both diseases is explained by a 
failure of the haematopoietic stem cell compartment(Vulliamy, Marrone et al. 
2002; Westin, Chavez et al. 2007). 
1.24.3 Associations with telomere shortening 
In keeping with the effect of repeated cell division, it is estimated that 6-11% of 
PBL telomere shortening is attributable to age(Weischer, Nordestgaard et al. 
2013). Several other factors have been associated with an increased rate of 
telomere shortening, which may eventually overtake the physiological rate of 
replacement, if telomerase is activated, or attenuate telomere length to a 
problematic degree. 
1.24.3.1 Sex  
Telomere length in leukocytes, and umbilical artery endothelium is equivalent in 
male and female neonates(Okuda, Bardeguez et al. 2002). Reports of longer 
leukocyte telomere length in adult females have been suggested to offer some 
explanation for the longevity gender gap(Nawrot, Staessen et al. 2004). Males 
had a higher rate of telomere attrition in a cohort aged 0-100 years of 
age(Mayer, Bruderlein et al. 2006). Oestrogen activates telomerase in MCF-7 
cells and if this effect was widespread in vivo could attenuate stem cell 
telomere shortening(Kyo, Takakura et al. 1999). 
The most recent meta-analysis of this interaction has concluded that robust data 
on the gender-attributable variability of telomere length decrease with age is 
not available(Muezzinler, Zaineddin et al. 2013). 
1.24.3.2 Oxidative stress  
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Oestrogen reduces oxidative stress(Aviv 2002) and this may be the explanation 
for longer leukocyte telomere length in females. Oxidative stress (the 
production of ROS in excess to what can be safely managed by the cell) is 
particularly damaging to telomeres because of their guanine-rich 
sequences(Oikawa and Kawanishi 1999) and repair of single-stranded DNA lesions 
is less efficient in telomeric regions(Petersen, Saretzki et al. 1998). A large 
study in a Scottish population identified 5 oxidative stress genes with robust 
associations with markers of functional bio-age, and linked 2 of these with 
effects on telomere length(Starr, Shiels et al. 2008). Oxidative stress has been 
mechanistically linked to accelerated telomere erosion by association with 
polymorphisms in uncoupling protein 2 (UCP2) in patients with diabetes(Salpea, 
Talmud et al. 2010). UCP2 is involved in mitochondrial production of ROS. 
1.24.3.3 Smoking 
Particulate matter air pollution is associated with increasing oxidative stress, 
telomere erosion and cardiovascular disease(Grahame and Schlesinger 2012). 
Smoking is a classic paradigm of such pollution and has also been linked with 
telomere shortening(Babizhayev, Savel'yeva et al. 2011). Smoking also has 
potent links with cancer, and the interaction between telomere length and 
cancer will be discussed further in subsequent sections. 
1.24.3.4 Inflammation 
One of the effects of cigarette smoking is to induce a chronic inflammatory 
state. Inflammation also increases oxidative stress. Short telomeres in 
leukocytes have been correlated with IL-6 levels in patients with COPD, 
independent of smoking history(Savale, Chaouat et al. 2009). Uncontrolled 
viraemia was associated with shorter leukocyte telomere length in HIV-infected 
children(Cote, Soudeyns et al. 2012). Of course, leukocytes are part of the 
inflammatory response so that short telomeres in these cells may reflect immune 
activation and increased numbers of cell divisions, as much as any ageing effect 
of an inflammatory response.  
In patients with rheumatoid arthritis, muscle cell telomere length was shorter 
than in a control group with osteoarthritis(Duijnisveld, Bigot et al. 2011). 
Colorectal mucosal cell telomeres are shorter in patients with longstanding UC 
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with respect to non-colitics (O'Sullivan, Bronner et al. 2002). Short telomeres 
associated with ulcerative colitis in colorectal mucosa are thought to be a part 
of the tumorigenic process in IBD-related colorectal cancer(Risques, Lai et al. 
2011). 
1.24.4 Effects of critically short telomeres: senescence 
There are thus a variety of pluripotential factors potentially causative for 
telomere attrition. The effects of telomere shortening are comparably 
important. 
1.24.4.1 Senescence 
After a relatively constant number of population doublings, cell in culture enter 
a state of replicative senescence, characterised by a cessation of division and s 
senescence-associated secretory phenotype. This state is associated with 
significant telomere shortening relative to the starting length (Harley, Futcher 
et al. 1990). Cells with shorter telomeres undergo less population doublings than 
cells which begin with longer telomeres before entering replicative senescence 
(Allsopp, Vaziri et al. 1992) so there seems to be a threshold telomere length to 
trigger the change(Hayflick 2000). 
1.24.4.2 Aneuploidy 
Senescent cells are initially cleared by the innate immune system(Hornsby 2010), 
but with time, their numbers accumulate. In this scenario, ongoing telomere 
shortening is possible, particularly in situations where cell-cycle checkpoints are 
malfunctioning, to cellular ‘crisis’. Once telomere shortening has proceeded to 
such a degree, the secondary loop structure of the telomere can no longer be 
maintained. The shelterin complex may not be able to bind and the telomere 
ends are exposed and stimulate the same reaction as any double stranded DNA 
break(von Zglinicki, Saretzki et al. 2005). These ‘breaks’ are ‘repaired’ by non-
homologous end-joining, creating dicentric chromosomes, which break at a 
different point during the next cell division(Murnane 2012). This cycle can 
repeat, with consequent recurrent translocation of large swathes of DNA, 
causing measurable genomic instability and aneuploidy. 
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1.24.5 Telomere length and cancer 
The sequence described in the preceding paragraph is very reminiscent of one at 
least of the Hallmarks of Cancer delineated in an earlier section. There is an 
extensive literature on telomere length in cancer because of the associations 
with aberrant cell division and also because telomere length is an attractive 
candidate Biomarker of Ageing. It is worth noting that much of this literature 
deals with leukocyte telomere length and therefore associations between cancer 
and ageing on a whole-organism level, but there is also an extensive examination 
of telomere length in specific ageing tissues, and association with cancer in that 
particular compartment. 
The telomere hypothesis of carcinogenesis at a cellular level involves shortened 
telomeres, crisis and genomic instability. Activation of telomerase is also a 
necessity in the transformed phenotype to maintain replicative potential(Kim, 
Piatyszek et al. 1994). In colorectal epithelium, there is an established 
adenoma-carcinoma sequence(Plentz, Wiemann et al. 2003) which has leant 
itself to investigation of the telomere hypothesis of carcinogenesis, and several 
reports have demonstrated shorter telomere lengths in tumour than in adjacent 
non-malignant mucosa, evidence of ageing at a tissue level(Valls Bautista, Pinol 
Felis et al. 2009; Maxwell, McGlynn et al. 2011; Valls, Pinol et al. 2011). 
The process of reactivation of telomerase and its place in malignant 
transformation was assessed initially by correlation in normal mucosa, adenomas 
and carcinomas in colorectal and gastric mucosa, with some studies showing 
detectable telomerase at the adenoma stage (Maruyama, Hanai et al. 1997)The 
variation in telomere length through the sequence from crisis to immortalisation 
was analysed in detail in spontaneously immortalising Nijmegen breakage 
syndrome T-cells (Degerman, Siwicki et al. 2010). These cells showed attrition of 
telomeres to the point of crisis, when telomere lengths were very short. Cells 
escaped from crisis by aberrant DNA damage response and repression of 
senescence controlling genes, but telomere length remained very short. 
Subsequently, TERT expression increased in association with c-Myc expression, 
telomerase activity and elongation of telomeres to a certain degree. This implies 
that telomerase expression may be quite a late event in the process of 
immortalisation. 
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Reactivation of telomerase is seen in 90% of cancers(Shay and Bacchetti 1997). A 
further small proportion use a process called Alternative Lengthening of 
Telomeres (ALT) for elongation(Henson, Neumann et al. 2002) which happens by 
a process of homologous recombination between sister chromatids(Bechter, Zou 
et al. 2004) Since most data indicates that tumour tissue telomere length is 
shorter than telomere length in adjacent normal tissue, it seems that telomere 
length is maintained above the level of crisis, but not particularly higher, 
assuming that the cells analysed are at a range of points along the spectrum 
described by Degerman et al. However, there are also sporadic but recurrent 
reports of tumour tissue with extremely long telomeres. Ten-fold variability in 
telomere length in not uncommon in cells employing ALT and there is some 
evidence to suggest that it carries a poorer prognosis(Valls, Pinol et al. 2011). 
1.24.6 Telomere Length as a Biomarker of Ageing (and 
Disease) 
Telomere length presents as an attractive candidate Biomarker of Ageing. The 
‘miles on the clock’ hypothesis proposes that telomere length functions as a 
measure of the biological age of an individual because telomere length 
integrates attrition due to the increasing chronological age through the end-
replication problem, and accelerated attrition from ambient stressors. This is 
analogous to a car which will deteriorate gradually as time passes even if it 
merely sits idle, but will wear out faster if it accrues more miles on the clock. 
Telomere length may integrate several influences which separately, additively or 
synergistically produce telomere shortening. It is thought by many that 
leukocyte telomere length provides an accessible surrogate measure of ageing in 
different tissues, with integration of ageing influences from many tissues to give 
an overall summary of the ‘agedness of the organism’. 
In a recent review of telomere length and susceptibility to disease, 47 case-
control studies were reviewed and all but 2 showed an association between short 
telomeres and the disease in question, or an adverse change of variable or 
lifestyle characteristic(Bojesen 2013). 26 studies tabulated in this same paper 
assessed the association between short telomere length and mortality in a wide 
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range of diseases. 10 of the studies investigated populations over 70 years of 
age; 9 of these were included in the 11 studies which showed no association.  
Two of the studies showing no association were in cancer patients with age 
ranges 30-90 years (breast and renal cancer)(Svenson, Nordfjall et al. 2008; 
Svenson, Ljungberg et al. 2009). In the breast cancer patients, there was a 
significant association between short telomere length and survival in patients 
under 50 years, but this was not the case for patients aged over 50. The study in 
older people which did show an association between short telomeres and 
mortality was performed in twins aged 73-94(Kimura, Hjelmborg et al. 2008). It 
showed that shorter length of the shortest 25% of telomeres predicted the 
mortality of that twin better than mean telomere length. 
These results attest to a relationship between short leukocyte telomeres and 
adverse outcomes. It also appears that in an unselected population, shorter 
telomere lengths in leukocytes are associated with increased mortality. It may 
show evidence of ‘premature ageing’ but reliable measurements which take 
account of inter-individual variation have limited its usefulness so far. In older 
people (age above 70 may be a reasonable definition of ‘older’, on the basis of 
the studies reviewed) the relationship between leukocyte telomere length and 
age appears not to be maintained (Martin-Ruiz, Gussekloo et al. 2005; Martin-
Ruiz, Jagger et al. 2011). 
The 26 studies reviewed above used leukocyte telomere length in all but 1 case.  
The generalisability of the association between leukocyte telomere length and 
mortality to specific other tissues is unproven(von Zglinicki and Martin-Ruiz 
2005). The assumption of telomere length correlation among all tissues within 
the body is repeatedly made, but there is a large degree of inter-individual 
variation in telomere length.  The volume of data available may not be large 
enough to adjust for the variation noted. This inaccuracy may not affect the 
usefulness of leukocyte telomere length as a marker of whole-organism bioage.  
It may introduce confusion in interpretation of the totality of literature on 
telomere length and ageing as applied to specific diseases. The literature on 
telomere length in different tissues is reviewed in a subsequent chapter. 
1.24.7 Measurement of telomere length 
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The method of telomere length measurement is important. Interpretation of 
telomere length results in the literature has been complicated by variability in 
terminology and methods of measurement of telomere length(Shiels 2010). 
Methods of measurement of telomere length vary in applicability to different 
tissues, scaleability and the level of specificity of measurement. Measurement of 
telomere length by any means in specific tissues is limited to some extent by the 
ability to purify cells of that tissue. 
1.24.8 Terminal Restriction Fragment Length 
The classical method of measurement of telomere length uses restriction 
endonucleases which cleave DNA in the subtelomeric region. Frequent cutting 
restriction enzymes digest non-telomeric DNA and the remaining fragments are 
run on an agarose gel. Depending on the endonuclease used, a variable amount 
of subtelomeric DNA is included. Southern blot is performed with radio-labelled 
probes specific to the telomere sequence. Densitometric analysis of the 
autoradiograph produced allows measurement of the average length of these 
telomere terminal restriction fragments.  
This method allows quantitative measurement of telomere length in kilobase 
pairs. It is a relatively cumbersome process which takes time and a substantial 
amount of tissue is required for the extraction of sufficient DNA.  
The average telomere length measured is calculated from all nucleated cells in 
the sample, so it provides data at a cell population level. It is hypothesised that 
the location of the restriction enzyme cleavage site in the subtelomeric regions 
may vary between individuals and depending on the endonuclease used. All of 
these are factors in the variability in the data obtained. 
1.24.1 FISH/Q-FISH and Flow Cytometry 
Quantitative fluorescence in-situ hybridization (Q-FISH)) is used to measure 
telomere length in metaphase spreads. Probes emit fluorescent signal when 
bound to the DNA under investigation. The signal is proportional to the number 
of hybridized probes and thus to the telomere length. Results correlate well with 
the Southern blot technique but this technique is even more specialised. It also 
requires the use of dividing cells from which to make metaphase spreads. Cell 
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division is less likely in senescent tissues, so that they may be underrepresented 
in telomere measurement. 
Unlike TRFL measurement, since telomere lengths are measured in individual 
cells and even on individual chromosomes, a specific analysis of telomere length 
for defined populations of cells is possible. 
In situ hybridization was combined with flow cytometry to increase the 
throughput possibilities and generalisability of the technique. Cells can be fixed, 
and permeabilised to allow nuclear insertion of telomere specific fluorescent 
probes. The process also requires heating to DNA denaturation temperatures 
(>80ºC) to allow binding of the probe. While allowing for tissue fixation, the 
need for these high temperatures may limit the applicability of 
immunohistochemical identification of cells as specific epitopes may also be 
denatured. 
1.24.1 Measurement of Relative Telomere Length 
Relative telomere length analysis of DNA using real-time polymerase chain 
reaction as described by Cawthon is in routine use within our laboratory 
(Cawthon 2002). This process uses DNA polymerase in a polymerase chain 
reaction to amplify specific sequences of DNA present in small quantities in a 
sample to more easily measurable amounts, from which the initial 
concentration, or relative concentration, of the sequence under investigation 
can be estimated.  
Repeated cycles of DNA denaturation, annealing of specific primers and 
synthesis of the complementary strand gradually increase the number of copies 
of the sequence of interest. The primers limit the length of the DNA sequence 
repeatedly synthesized. The DNA polymerase used is from a thermophilic 
bacterium, which is stable at high temperatures. It is not destroyed by the high 
temperatures necessary to denature the DNA strands between cycles of 
amplification. Sufficient amounts of the 4 bases must be added so they do not 
limit the reaction rate. 
1.24.1.1 Real-time PCR 
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Real-time PCR is a modification of the PCR process to give a quantitative 
assessment of how many copies have been formed as cycles progress. SYBR 
Green fluoresces only when bound to double-stranded DNA (dsDNA), and the 
fluorescence level is therefore proportional to the amount of dsDNA which has 
been formed during the synthesis part of each cycle.  
Maximum fluorescence is measured during each cycle and plotted against cycle 
number. The cycle number at which fluorescence rises above the background 
level is known as the crossing point (Cp). Given that, in theory the amount of 
DNA present doubles with each cycle, it is possible to estimate the relative 
concentration of the original DNA sample by backwards extrapolation using the 
number of cycles needed to achieve the crossing point. In fact, the efficiency of 
the reaction (the actual increase in DNA copy numbers) is rarely as high as 2 but 
is an important marker of the reliability of the experiment. (See below in 
reference to the single copy reference gene.) 
Measurement of telomere length in terms of the number of telomeric repeats is 
made difficult by the repetitive DNA sequence of which they are composed. This 
favours the formation of primer dimers, when the primers bind to each other 
instead of to the DNA. Cawthon developed two primers whose structures are 
sufficiently different to each other to prevent the formation of primer dimers 
but can bind to the telomeric DNA(Cawthon 2002). 
1.24.1.2 Single copy reference gene 
Telomere length varies between cell types, and between experimental subjects 
and it is this that we are trying to measure. Since it is formed of a hexameric 
repeat sequence, primers can bind at many points on its length and various 
lengths of product will be synthesized but the total amount of DNA copied will 
be proportional to the length of telomeric repeats present. A reference point is 
therefore needed. The reference used is a single copy gene which is present in 
all cells; 36B4, the gene coding for ribosomal protein, large P0 (also known as 
RPLP0) is the reference used in this method. 
The measurement obtained is actually a ratio of telomere repeat copy number 
to single copy gene copy number for the experimental sample, relative to the 
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same ratio for an arbitrarily determined control. All experimental samples are 
normalized to this control, and so can be compared with each other in the 
normalized form. This normalized ratio is the T/S ratio. The efficiency of 
reaction for the telomere plate and the single copy gene plate must be 
comparable in order for the two to be compared. 
This is the method of telomere measurement used in the experiments described 
in this thesis. Reproducibility of results and comparison between different 
investigators have been limited by variability in protocols used and reliability of 
the process. The protocol used in this laboratory is highly standardised and 
processes to assess and ensure reliability of results are described in the chapter 
on Experimental Methods. 
Like the TRFL method, this measurement of relative telomere length by real-
time PCR analyses telomere length in all nucleated cells within a sample. As 
such, the data obtained represents a mean telomere length for all cell types 
within the sample.  
1.24.2 Limitations of telomere length measurement methods 
This subject is explored in more detail on the chapter on telomere lengths in 
different tissues. Briefly, unless specific steps are taken to purify cell types 
within tissue samples, the telomere length measurement obtained will be an 
average from all nucleated cells in the sample. In colonic tissue for example, 
this may include stromal cells, or cells from neighbouring muscle layers. Within 
any one cell type, there may be a range of telomere lengths resulting from 
variable expression of telomerase in stem cells. Comparison of telomere length 
in individual cell types using the common denominator of TRFL might allow an 
assessment of the magnitude of this effect, but this data is so far not available. 
It is important that protocols specify tissue preparation steps to allow adequate 
understanding of the cell types that are likely to be included. This would aid 
assessment of the comparability of results within the field. 
1.25 Clinicopathological factors investigated: rationale 
for selection 
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There are many clinical and pathological factors associated with outcome in 
colorectal cancer. The selection of certain specific factors for comparison with 
the experimental variables of telomere length, serum fetuin A and colorectal 
tumour sirtuin expression in this thesis is explained as follows. 
1.25.1 Demographic factors 
Assessment of relationship with chronological age is important as a baseline in 
the context of assessment of biological ageing. Sex has been associated with 
potential measures of biological ageing such as telomere length(Aviv, Shay et al. 
2005). There is increasing evidence to implicate obesity in the pathogenesis of 
colorectal cancer(Giovannucci, Ascherio et al. 1995; Larsson, Rutegard et al. 
2006; Pischon, Lahmann et al. 2006; Sinicrope, Foster et al. 2010). BMI was used 
as a surrogate marker of obesity. 
1.25.2 Inflammatory markers 
Serum C-reactive protein (CRP) is a non-specific marker of inflammation. 
Inflammation has been recently accepted as the newest hallmark of 
cancer(Colotta, Allavena et al. 2009). CRP, as a measure of the systemic 
inflammatory response, has been associated with a poorer prognosis for many 
types of cancer, including colorectal cancer (McMillan, Elahi et al. 2001). 
Albumin is a negative acute-phase protein and hypoalbuminaemia is associated 
with poorer outcome from cancer(McMillan, Watson et al. 2001). As such, it has 
been incorporated into the modified Glasgow Prognostic Score, which has been 
validated as a prognostic tool in many types of cancer, including colorectal 
cancer(Forrest, McMillan et al. 2003; Elahi, McMillan et al. 2004; Hilmy, Bartlett 
et al. 2005; Al Murri, Bartlett et al. 2006; Crumley, McMillan et al. 2006; Glen, 
Jamieson et al. 2006; Al Murri, Wilson et al. 2007; McMillan, Crozier et al. 2007; 
Ramsey, Lamb et al. 2007). 
1.25.3 Atypical inflammatory markers 
Anaemia and high platelet count reflect inflammation which is often sub-clinical 
and chronic. Anaemia or rectal bleeding is often a presenting symptom of 
colorectal cancer. Low haemoglobin has recently been reported as an 
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independent risk factor for mortality from non-cardiac surgery(Leichtle, 
Mouawad et al. 2011; Musallam, Tamim et al. 2011). This may reflect an 
increasing biological age in anaemic patients, particularly since anaemia is also 
associated with chronic disease.  
Thrombocytosis has been associated with poor prognostic features in colorectal 
cancer and with worse survival from the disease(Cravioto-Villanueva, Luna-Perez 
et al. 2012; Ishizuka, Nagata et al. 2012; Ishizuka, Nagata et al. 2012; Kawai, 
Kitayama et al. 2013).  
Smoking induces a systemic inflammatory response, and has been associated 
with increased colorectal cancer risk(Paskett, Reeves et al. 2007; Liang, Chen et 
al. 2009; Kato, Boleij et al. 2013; Parajuli, Bjerkaas et al. 2013). 
1.25.4 Comorbid conditions and antioxidant levels 
Presence of other comorbid conditions may indicate increased biological age. 
Serum antioxidant levels may mitigate the effect of reactive oxygen species on 
telomere shortening. Data on total number of comorbid conditions and on serum 
antioxidant levels were available for the telomere analysis cohort. The Charlson 
comorbidity index has prognostic value in longitudinal studies. Data was 
available for the sirtuin immunohistochemistry cohort. 
1.25.5 Factors of prognostic significance in colorectal cancer 
In colorectal cancer, there are 2 widely recognised systems of staging. Dukes’ 
staging system was described in the early 20th century(Dukes 1949) but has 
remained in use because of its simplicity and clinical relevance for prognosis. 
The criteria for the 4 stages in Dukes’ classification are outlined below. 
Dukes' 
Stage 
Description 
A Tumour confined to the mucosa 
B Tumour spread beyond the mucosa but not metastasized 
to lymph nodes 
C Tumour spread to lymph nodes but not beyond the gut. 
This was later divided into C1 (affecting local lymph 
nodes) and C2 (affecting the apical lymph node). 
D Metastases in different organs 
Table 1.2 Dukes’ stages of colorectal cancer and defining criteria 
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The other widely used staging system is the TNM system which defines criteria 
relevant to tumour (T), nodal spread (N) and presence of distant metastases (M). 
Each component is relevant individually in certain circumstances and can be 
analysed separately. They can also be combined into an overall numerical 
American Joint Committee on Cancer (AJCC) staging. A comparison of staging 
systems in common use is presented in the table below. 
AJCC stage T N M Dukes' 
O Tis N0 M0 - 
I T1 N0 M0 A 
 T2 N0 M0 A 
IIA T3 N0 M0 B 
IIB T4a N0 M0 B 
IIC T4b N0 M0 B 
IIIA T1-T2 N1/N1c M0 C 
 T1 N2a M0 C 
IIIB T3-
T4a 
N1/N1c M0 C 
 T2-T3 N2a M0 C 
 T1-T2 N2b M0 C 
IIIC T4a N2a M0 C 
 T3-
T4a 
N2b M0 C 
 T4b N1-N2 M0 C 
IVA Any T Any N M1a D 
IVB Any T Any N M1b D 
Table 1.3 Comparison of AJCC staging with T, N, M components and Dukes’ staging for 
colorectal cancer. 
These systems largely define extent of spread of the cancer. Specific histological 
features of the resected colorectal tumour specimen are also relevant. Grade of 
tumour, assessed as degree of differentiation is a recognised prognostic factor, 
with poorly differentiated tumours generally being accepted as more aggressive 
with a worse prognosis. Several histological features of prognostic significance 
identified on examination of the resected specimen have been combined to form 
the Petersen Index(Petersen, Baxter et al. 2002). These are venous invasion, 
margin involvement, peritoneal involvement and tumour perforation. Tumour 
perforation carries a score of 2 in this model, while the other factors carry a 
score of 1. Low risk Petersen Index (score 0 or 1) is associated with significantly 
better survival in Dukes’ B cancer.  
Peritumoural inflammation is becoming recognised as a factor in better 
prognosis (Roxburgh, Salmond et al. 2009). Data on peritumoural inflammation 
was only available for the sirtuin immunohistochemistry cohort. 
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1.26 Statement of Research Aims 
1.26.1 Statement of Aims: Prospectively collected matched 
tissue and blood cohort 
To measure telomere length in PBLs, normal colorectal tissue and colorectal 
tumour tissue in patients with colorectal cancer. 
To measure fetuin A levels and markers of inflammation in serum from the same 
patients. 
To evaluate any correlation between telomere lengths in matched samples from 
PBLs, normal colorectal tissue and colorectal tumour tissue. 
To correlate levels of fetuin A and other serum inflammatory markers with 
telomere length in PBLs, normal colorectal tissue and colorectal tumour tissue, 
in patients with colorectal cancer. 
To correlate telomere length in PBLs, normal colorectal tissue and colorectal 
tumour tissue of patients with colorectal cancer with clinicopathological markers 
of prognostic value in colorectal cancer. 
To correlate levels of fetuin A with other markers of inflammation in serum, and 
with accepted clinicopathological markers of prognostic value in colorectal 
cancer. 
1.26.2 Statement of Aims: TMA cohort 
To stain a colorectal tissue microarray (TMA) containing normal and tumour 
tissue with antibodies to human sirtuins 2-7 and measure staining using the 
weighted Histoscore method.  
To compare staining patterns in normal and colorectal tumour tissue. 
To correlate staining for sirtuins 2-7 with cancer-related mortality and with 
clinicopathological markers of prognostic value, and serum markers of 
inflammation. 
Chapter 1: Introduction   129 
To compare protein expression levels to mRNA levels of the human sirtuins in 
normal and colorectal tumour tissue, and to compare protein levels in normal 
and tumour tissue. 
To assess any interrelationships between protein expression levels of the human 
sirtuins 2-7 in normal colorectal tissue and in colorectal tumour tissue.
 2 Materials and Methods 
2.1 Patient Cohorts 
Tissue used in the experiments described in this thesis came from two separate 
cohorts of patients. One cohort of patients contributed blood and colorectal 
normal and tumour tissue for the measurement of telomere length in matched 
tissues and for the measurement of serum fetuin A levels. Tissue from a second 
cohort of patients was used to construct the tissue microarray (TMA) for sirtuin 
immunohistochemistry (IHC). Patient inclusion in each cohort is further 
described below. 
2.2 Ethical Approval 
Ethical approval was obtained from Glasgow Royal Infirmary Research and Ethics 
Committee (REC ref number 08/S0704/22) for the measurement of telomere 
lengths and of serum fetuin A. A substantial amendment was completed to allow 
collection of blood samples from other hospitals in the same NHS Board, and 
expand the analysis of blood samples to measure RNA levels of sirtuins. This is 
not a focus of this thesis but is a logical extension of this project. Colorectal 
normal and tumour tissue specimens were obtained on application to the 
Glasgow Royal Infirmary Biobank. 
2.3 Patient recruitment 
2.3.1 Telomere length cohort 
All patients diagnosed with colorectal cancer at Glasgow Royal Infirmary, 
Gartnavel General Hospital and the Western Infirmary, Glasgow from 10 July 
2010 to 10 June 2011 were invited to participate in this study. 97 chose to do so 
and gave informed consent for the use of blood samples. Information on relevant 
clinicopathological parameters was gathered from the medical notes. 
2.3.2 Sirtuin immunohistochemistry cohort 
277 patients were diagnosed with operable colorectal cancer in the Greater 
Glasgow area between 1997 and 2007 and were considered for inclusion in this 
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cohort. These patients received standard (neo)adjuvant chemoradiotherapy 
according to local protocols at the time of diagnosis. Patients were excluded if 
tissue blocks were not available or contained insufficient tumour tissue for 
research purposes, as determined by the assessing consultant pathologist. The 
final cohort numbered 272 patients. Information on relevant clinicopathological 
parameters was obtained from a database prospectively maintained by MR James 
Park. 
Clinical and pathological characteristics of the patient cohorts are summarised in 
the relevant chapters of this thesis with results of data analysis. 
2.4 Collection and preparation of tissue samples for 
telomere length and fetuin A measurement. 
2.4.1 Blood Sample Collection 
Informed consent was gained from patients by EM prior to surgery and blood 
samples were taken in EDTA to allow DNA and RNA extraction, and in sodium 
heparin to allow analysis of antioxidants and vitamin levels. Within 1 hour, 1ml 
of blood in EDTA was mixed with 3ml of TRIzol to stabilize RNA and allow later 
analysis of RNA levels. All samples were transported back to the laboratory on 
ice. The details of further treatment protocols necessary to allow storage and 
later analysis of blood samples are described in the following sections. 
2.4.2 Initial Preparation of Blood Samples 
2.4.2.1 Preparation for RNA Analysis 
The blood in TRIzol was vortexed thoroughly, divided in 4 aliquots and stored at 
-80°C. 
2.4.2.2 Extraction of DNA from peripheral blood leukocytes 
The first 30 samples were divided. Half of the sample was centrifuged at 1400g 
for 15mins, and the precipitant portion retained, with the aim of improving 
capture of leukocytes and thus better DNA yield. The remainder of the sample 
was processed as whole blood without centrifugation. DNA yield was not 
significantly improved by centrifugation and whole blood was used for DNA 
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extraction for the remaining 67 samples. DNA extraction was performed using 
the Maxwell® 16 Instrument (Promega) and Blood DNA Purification Kit 
cartridges, according to the manufacturer’s instructions. DNA was stored in 
elution buffer at -20°C until analysed. 
2.4.2.3 Processing of serum for Fetuin A ELISA 
Samples were centrifuged at 1400g for 15mins to separate serum from red cells 
and buffy coat. Serum from the samples in EDTA was aliquoted off and stored at 
-20°C for ELISA. 
2.4.2.4 Processing of serum for antioxidant and vitamin analysis 
200ul of serum in sodium heparin was thoroughly mixed with an equal volume of 
6% metaphosphoric acid and vortexed thoroughly to denature enzymes and 
stabilize Vitamin C content. The remaining serum was divided into 2 aliquots, 
ensuring no contamination with packed red cells. The interface serum and buffy 
coat was discarded. Packed red cells were divided into 2 aliquots and all 5 
aliquots stored at -80°C until transfer to a partner laboratory at the Department 
of Biochemistry, Glasgow Royal Infirmary for analysis. 
2.4.3 Colorectal Tissue Samples 
Informed consent for tissue donation to the Glasgow Royal Infirmary Biobank was 
sought routinely by clinical staff at the time of preassessment, or at the time of 
consent for surgery for resection of colorectal cancer. Where this consent was 
available, the resected specimen was assessed by a consultant pathologist and, 
once sufficient tissue had been examined and retained as necessary for 
diagnostic purposes, surplus tissue was stored at -80°C in the Biobank. On 
successful application to the Biobank by EM, tissue was transferred to our 
laboratory on dry ice and stored at -80°C until analysed. 
2.4.4 Extraction of DNA from Colorectal Normal and Tumour 
Tissue 
DNA extraction was performed using the Maxwell® 16 Instrument (Promega) and 
Tissue DNA Purification Kit cartridges, according to the manufacturer’s 
instructions. DNA was stored in elution buffer at -20°C until analysed. 
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2.5 Measurement of Telomere Length 
Relative telomere length analysis of DNA using quantitative polymerase chain 
reaction as described by Cawthon (Cawthon 2002) was used in the following 
experiments, and it is further described below. 
2.5.1 Plate Preparation for QPCR reaction 
2.5.1.1 Plate Layout 
96-well plates were used with layout as indicated in the table below. Two plates 
were run together, one with telomere-specific primers and the other with 36B4 
primers. This minimized the variation between the paired plates as aliquots of 
the same samples were used for each plate. Primer sequences are detailed in 
Appendix 1. Each well was loaded with the relevant primers, DNA sample and 
constituents for the PCR reaction. 
 Columns 
Rows 1 2 3 4 5 6 7 8 9 10 11 12 
A SD1 SD1 SD1 1 1 1 9 9 9 17 17 17 
B SD2 SD2 SD2 2 2 2 10 10 10 18 18 18 
C SD3 SD3 SD3 3 3 3 11 11 11 19 19 19 
D SD4 SD4 SD4 4 4 4 12 12 12 20 20 20 
E SD5 SD5 SD5 5 5 5 13 13 13 21 21 21 
F SD6 SD6 SD6 6 6 6 14 14 14 22 22 22 
G SC SC SC 7 7 7 15 15 15 23 23 23 
H NTC NTC NTC 8 8 8 16 16 16 24 24 24 
Table 2.1 Layout of 96 well plate for RT-PCR measurement of telomere length. SD = standard 
dilution, SC = standard calibrator, ntc = no-template control. Numbers in wells indicate 
sample number; all standards and samples were analysed in triplicate. 
2.5.1.2 Standard Curve and Control Samples 
A standard curve was constructed for each plate. The control DNA sample was 
heated to 65°C for 10 minutes to resuspend the DNA, vortexed and the 
concentration was measured on a Nanodrop spectrophotometer. A starting 
solution with concentration 20ng/µl was made from the control DNA sample. 
This is standard dilution sample SD1. A serial dilution of the SD1 1:1 with 
nuclease-free water produced standard dilution samples SD2 to SD6 with 
decreasing concentrations from SD1 at 20ng/µl to SD6 at 0.625ng/µl. The 
standard dilutions were made in bulk and divided into aliquots of 70µl. These 
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were stored at 4°C. Before use, they were heated again to resuspend the DNA 
and vortexed before use, to ensure homogeneous aliquots were analysed. 
Negative and positive controls were also used on each plate. The negative 
control contained only nuclease-free water (a no-template control – ntc). The 
positive control contained control DNA at a concentration midway along the 
standard curve. This was the standard calibrator (SC) and acted as the reference 
sample to which all experimental samples were normalized.  
In initial experiments, a standard calibrator containing 10ng DNA/µl (50ng DNA 
total per well) was used, as was standard practice in this laboratory, but it was 
difficult to achieve a reliable standard curve. A standard calibrator containing 
5ng DNA/µl (25ng DNA total per well) improved the reliability of the standard 
curve. The starting concentration of the control DNA was lower than in previous 
experiments, and therefore there was little dilution required to form the 
standard dilution solutions for this analysis. It may be that components of the 
elution buffer for DNA extraction were present in high enough concentrations to 
interfere with the PCR reaction in the more concentrated standard calibrator. 
2.5.1.3 Experimental Sample Preparation 
24 samples were run in triplicate on each 96-well plate. 35ng DNA is required as 
a solution of 7ng/µl per well, a volume of 5µl. Both telomere and 36B4 plates 
were prepared together. Thus 6 aliquots of each sample were needed to load 2 
plates in triplicate. Samples were prepared to a total volume of 70µl (14 
aliquots) to allow for a second run if the first was unsuccessful.  
To make the 7ng/µl “telomere dilutions”, DNA samples were heated to 65°C for 
10 minutes to resuspend the DNA and vortexed; their concentration was 
measured on a Nanodrop spectrophotometer. The relevant volumes of DNA 
sample and nuclease-free water were calculated to produce the total volume of 
70µl, with concentration 7ng/µl. These “telomere dilution” samples were stored 
at 4°C until used. If storage exceeded 24 hours, they were heated again to 
resuspend the DNA and vortexed before use, to ensure homogeneous aliquots 
were analysed. 
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2.5.1.4 Plate Preparation 
SYBR Green Master Mix (Roche) and telomere and 36B4 primers (Invitrogen) were 
combined using PCR grade water to the manufacturer’s instructions. Plates were 
loaded with 5µl standard or sample DNA per well, and then with 15µl Master Mix 
containing the appropriate primer per well, sealed, centrifuged and analysed on 
the Roche LightCycler LC480. 
Telomere and 36B4 plate running conditions are described in Appendix 2. 
The LightCycler plots the fluorescence output from bound primers against PCR 
cycles for each of the 96 wells in a plate. This produces an amplification curve 
for each well: an example is shown in Figure 1.1. 
 
Figure 2.1 Sample amplification curve 
In the preliminary phase, fluorescence from the products of the PCR reaction is 
insufficient to register above the baseline level (determined by the fluorescence 
of the ‘no template’ control). In the terminal plateau phase, replication rate is 
limited by lack of substrate. In the exponential phase, the reaction conditions 
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are optimal; during this phase the replication rate is fastest. The straight portion 
of the curve (which has the highest gradient) represents the exponential phase. 
Extrapolation back to the threshold fluorescence level marks the ‘crossing 
point’. The crossing point (Cp) is the number of cycles necessary to replicate 
enough DNA to reach threshold fluorescence (as compared to the ‘no template’ 
control). Calculation was performed by Light Cycler LC480 software using the 
‘2nd derivative maximum’ method to find the maximum rate of reaction from the 
fluorescence curve and extrapolate back to the Cp. 
2.5.2 Analysis of PCR Plates 
2.5.2.1 Assessment of the efficiency of the PCR reaction 
Before proceeding to determine T/S for the experimental samples, it is 
necessary to verify that the telomere and 36B4 plates had similar efficiency. The 
Roche LightCycler 480 software constructs a standard curve using the Cp for the 
standard dilution samples. The slope of this curve, which would correspond to 
the maximum possible efficiency of reaction of 2, is -3.4. Standard curve slopes 
of between -2.8 and -3.8 are acceptable. Both the telomere and 36B4 plates 
should have standard curve slopes within this range to be comparable. The 
concentration of the standard calibrator according to the standard curve should 
be close to the expected concentration of 5ng DNA/µl. 
These conditions were met for each plate analysed in order to include results 
from that plate. Some plates were repeated to achieve this standard. 
2.5.2.2 Assessment of plate-to-plate comparability 
Each plate allows the analysis of 24 samples in one experiment. Plate-to-plate 
comparability determines whether results obtained from individual experiments 
can be combined in assessing the full cohort of samples. There are two methods 
to assess plate-to-plate comparability. The more stringent looks at the 
coefficient of variation (CV) of T/S ratios for each plate under investigation. This 
usually produces a higher but more accurate CV. 
For the data reported in this thesis: 
Chapter 2: Materials and Methods   137 
CV = Standard deviation/Mean 
%CV = Standard deviation/Mean x 100 
In this case T/S ratios for 5 plates under investigation were examined. 
%CV = Standard deviation/Mean x 100 = 1.016725/0.052509 x 100 
%CV = 5.164527 
The second method calculates the average of the standard deviations and the 
average of the means for the concentrations of each standard triplicate and 
positive control from each plate under investigation. The CV is calculated as 
above using the average standard deviation divided by the average mean. 
For the data reported in this thesis: 
“Average” standard deviation = 0.645841408 
“Average” mean concentration = 20.20016116 
%CV = Standard deviation/Mean x 100 = 0.645841408/20.20016116 
%CV = 3.197209183 
These values for plate-to-plate comparability are acceptable.  
2.5.2.3 Measurement of relative telomere length (T/S) 
Absolute quantification compares an experimental sample relative to standards 
of known concentration to provide a quantitative measure of telomere length. 
Relative quantification measures the Cp for one sample relative to the reference 
gene (in this case 36B4). Absolute quantification of experimental samples 
relative to the standard curve was performed for telomere and 36B4 DNA. 
Relative quantification of the telomere DNA relative to 36B4 DNA. These values 
were normalised relative to the standard calibrator to give relative telomere 
length (T/S) measurements which were used in further statistical evaluation. 
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This standard comparison means that the results could be translated into 
kilobasepairs (kbp) of DNA. This translation is not necessary for comparison of 
T/S values, but may be useful to compare these results with other studies using 
direct measurement of telomere length by the terminal restriction fragment 
length method in future analysis. 
2.6 Fetuin A ELISA 
Fetuin A levels in serum samples from colorectal cancer patients were analysed 
using the Human Fetuin-A ELISA kit (BioVendor) according to the manufacturer’s 
instructions. Enzyme-linked immunosorbent assays (ELISA) used microplate wells 
coated with antibodies to fetuin A. Standard dilutions, quality controls and 
experimental samples were added to the wells, incubated and washed. 
Horseradish peroxidase (HRP)-linked antibody to fetuin A was added and bound 
the captured fetuin A. A further washing step ensured that only bound HRP 
remained to react with added substrate solution. This reaction was stopped by 
addition of an acidic solution after a defined time, and the amount of coloured 
product formed (proportional to the absorbance of the well contents) was 
measured by a microplate reader. The standard dilutions were used to construct 
a standard curve from which absorbance of experimental samples was converted 
into concentrations of the fetuin A. 
Samples were analysed in triplicate and the coefficient of variance for each 
triplicate was routinely less than 6%. 
2.7 Analysis of Antioxidant and Vitamin levels 
After initial preparation and stabilisation as described earlier, these samples 
were transferred to the Department of Biochemistry at Glasgow Royal Infirmary, 
where further analysis was performed according to previously validated 
methods(Talwar, Ha et al. 1998). 
2.8 Sirtuin Immunohistochemistry 
2.8.1 Tissue microarray construction 
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Use of a tissue microarray (TMA) enabled staining of the whole patient cohort in 
one experiment and ensured uniformity of experimental conditions. TMAs were 
constructed by Mr Jonathan Platt (JP) and Ms Clare Orange, with advice from Dr 
Karin Oien, consultant pathologist. JP selected the tissue to be used by 
examination of haematoxylin and eosin (H+E) stained sections of tissue from 
previously diagnosed colorectal cancer patients. CO constructed the TMAs by 
extracting cores from tissue blocks corresponding to the areas identified on the 
H+E sections and mounting these in wax blocks. Four cores of 0.6mm diameter 
were taken from each specimen. Cores of normal tissue of various histological 
subtypes were included for reference and to help orient the slides.  
Five TMAs were constructed to accommodate the full cohort and a small group 
of normal samples. Sections of thickness 2.5µm were cut and mounted on 3-
aminopropylethoxysilane coated slides which were incubated at 56°C before 
being stored at 4°C till needed. 
The layout of the TMAs is represented in Appendix 3. 
2.9 Preparation of Slides for IHC 
2.9.1 Dewaxing and Rehydration 
Tissue was embedded in paraffin blocks to allow thin sections to be cut and 
mounted on slides. In order to perform IHC, the paraffin was dissolved away and 
the tissue rehydrated. Slides were incubated in xylene for 2x2 minutes, and then 
in reducing concentrations of alcohol (2x2mins in 100%, 2mins in 90%, 2mins in 
70%) and finally rinsed in running tap water. 
2.9.2 Antigen Retrieval 
Formalin fixation of tissue involves the formation of methylene bridges within 
tissue proteins, which can hide antigenic epitopes. In order to retrieve (or 
unmask) these epitopes, i.e. break the methylene bonds, the slides were heated 
under pressure in a buffer solution appropriate to the antibody in use. Other 
methods were used in trying to optimise antibodies to SIRT1 (trypsin digestion 
and heating in a waterbath) but without success. 
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2.9.3 Blocking of Endogenous Peroxidase 
As peroxidase is used to catalyse the colour change in the final step of IHC, 
endogenous peroxidase was blocked by incubation with 3% H2O2 for 10 minutes 
on a stirrer. Slides were then washed in running water. 
2.9.4 Blocking of Non-Specific Protein Binding 
High-volume, low-affinity binding between other proteins in the tissue under 
investigation and the primary antibody may interfere with the staining pattern 
of the specific protein under investigation. To mitigate this effect, the tissue 
was incubated with a solution of optimum concentration of horse serum in TBS 
for 60 min at 25°C. The proteins in the horse serum blocked these low-affinity 
binding sites but did not compete with the specific binding of the primary 
antibody. 
2.9.5 Antibody Staining 
The slides were incubated with the primary antibody under optimum conditions, 
deduced from the preliminary optimisation experiments. These were specific to 
the antibody in question, and are detailed later. 
2.9.6 Secondary Antibody Staining 
The slides were stained with the appropriate secondary antibody system 
(Envision™ or LSAB) and with chromogen (diaminobenzidine, DAB), according to 
the manufacturer’s instructions.  
2.9.7 Counterstain 
In order to visualise the cell components in the background, a haematoxylin 
counterstain was applied by incubation for 3 minutes in Harris haematoxylin, 
followed after rinsing by incubation in Scott’s Tap Water Substitute for 2 
minutes.  
2.9.8 Dehydration and mounting 
Chapter 2: Materials and Methods   141 
The slides were dehydrated by incubation in the series of increasing 
concentrations of alcohol (1 min in 70%, 1 min in 90%, 2x1 min in 100%) xylene 
(2x1min). They were mounted in di-n-butyl-phthalate in xylene (DPX) and a 
coverslip applied. 
2.10 Sirtuin Antibodies 
The antibodies used are detailed in the table below. 
Sirtuin Antibody 
SIRT1 Abcam ab32441 and ab32424. 
Unsuccessful. 
SIRT2 Lifespan Biosciences B-1565 
SIRT3 Cell Signal C73E3 
SIRT4 Abcam ab49173 
SIRT5 Abcam ab10140 
SIRT6 Lifespan Biosciences B-900 
SIRT7 Abcam ab78977 
Table 2.2 Antibodies used for sirtuin immunohistochemistry. 
No reliable staining could be achieved for SIRT1 due to manufacturing problems, 
despite repeated attempts to optimize staining ‘in house’. The antibodies used 
were validated by Western blot in-house. 
2.10.1.1 Antibody Optimisation 
Optimal specific conditions for IHC for each antibody were determined by 
experimental modification of pre-existing protocols used in this laboratory to 
stain other tissues with some of these antibodies. For new antibodies, 
experimental assessment and modification of the manufacturer’s advised 
conditions for IHC was performed. In all cases a practice TMA using colorectal 
cancer tissue cores was used initially. 
The specific conditions used for each antibody are summarized in the following 
table.
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Sirtuin Antibody 
reference and 
manufacturer 
Buffer Antibody 
type 
Block Blocking 
conditions 
Optimum 
titre 
Antibody 
incubation 
conditions 
Secondary 
system 
Secondary 
system 
conditions 
SIRT2 LS-B1565, 
Lifespan 
Biosciences 
TE Polyclonal 
Rabbit 
1.5% 
Normal 
horse serum 
60 mins 
25deg 
1:1500 37deg, 1hr Envision 37deg, 30mins 
SIRT3 C73E3, Cell Signal Citrate Monoclonal 
Rabbit 
1.5% 
Normal 
horse serum 
60mins 
25deg 
1:50 4deg, 
overnight 
Envision 25deg 30mins 
SIRT4 ab10140, AbCam Citrate Polyclonal 
Goat 
10% Normal 
horse serum 
60mins 
25deg 
1:200 4deg, 
overnight 
LSAB+ Biotin 
secondary 
antibody 
30mins 25deg, 
Streptavidin 60 
mins 25 deg 
SIRT5 ab49173, AbCam TE Polyclonal 
Rabbit  
1.5% 
Normal 
horse serum 
20 mins 
37deg 
1:700 4deg, 
overnight 
Envision 37deg, 30mins 
SIRT6 LS-B900, Lifespan 
Biosciences 
TE Polyclonal 
Rabbit  
1.5% 
Normal 
horse serum 
20 mins 
37deg 
1:400 37deg, 
2hrs 
Envision 37deg, 30mins 
SIRT7 ab78977, AbCam TE Polyclonal 
Rabbit 
1.5% 
Normal 
horse serum 
60mins 
25deg 
1:300 4deg, 
overnight 
Envision 25deg 30mins 
Table 2.3 Optimised staining conditions for each sirtuin antibody used. 
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2.11 Weighted Histoscore Analysis of Sirtuin-stained 
TMAs 
Each TMA was scored by EM, according to the weighted Histoscore method 
described, validated and extensively used in this laboratory (Edwards, Mukherjee 
et al. 2004). Scoring was carried out separately for nuclei and cytoplasm. 
Staining was categorized as none (0), weak (1), moderate (2) or strong (3). The 
percentage of total tumour nuclear or cytoplasmic component falling within 
each category was multiplied by the weighting factor (in brackets), to give a 
maximum possible score of 300. 
0 x percentage tumour tissue with no staining 
+ 1 x percentage tumour tissue with weak staining 
+ 2 x percentage tumour tissue with moderate staining 
+ 3 x percentage tumour tissue with strong staining 
 Total Histoscore (max possible score 300) 
 
All of the cores stained for SIRT6 were double scored by Jacqueline Martin 
(medical student) and 10% of the cores stained for SIRT2 were rescored by EM. 
Inter-rater and intra-rater correlation coefficients were calculated according to 
standard methods in use in this laboratory (Kirkegaard, Edwards et al. 2006). 
Satisfactory inter-rater and intra-rater correlations were confirmed by 
independent assessors. 
Scatterplots and Bland-Altman charts for inter-rater and intra-rater comparisons 
are included in Appendix 6. Inter-rater intra-class correlation coefficient (ICCC) 
for nuclear Histoscores was 0.851 and for cytoplasmic Histoscores was 0.913. 
Intra-rater intra-class correlation coefficient (ICCC) for nuclear Histoscores was 
0.789 and for cytoplasmic Histoscores was 0.716. 
Mean Histoscores for nuclear and cytoplasmic staining were calculated for each 
sample using EM’s scores. 
2.12 Statistical Analysis 
Chapter 2: Materials and Methods   144 
All statistical analyses were carried out using a statistical software package (IBM 
SPSS Statistics 21.0). 
2.12.1 Telomere Length Cohort 
2.12.2 Availability of Matched Samples 
Of the 97 patients who gave informed consent for the use of blood samples, one 
was found to have a well-differentiated neuroendocrine carcinoma involving the 
terminal ileum rather than the colon and was excluded from further analysis. 29 
of the remaining patients had given consent for tissue deposition in the Glasgow 
Biobank and had sufficient surplus tissue (as judged by a consultant pathologist) 
to provide samples for research. In one of these cases the tumour tissue 
telomere length was 7.5 standard deviations greater than the mean of the rest 
of the samples (shown in the scatterplot below); DNA extraction from the 
corresponding normal colorectal tissue for this case was unsuccessful. This case 
was excluded from further analysis.  
 
Figure 2.2 Scatterplot showing distribution of age and tumour tissue telomere length, with 
outlier. There is no significant correlation. 
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In 1 further case, DNA extraction from the normal colorectal tissue was 
unsuccessful and 1 other case had insufficient tumour tissue but normal 
colorectal tissue was provided for telomere length analysis. Thus there were 95 
patients with blood available for telomere length analysis and 28 patients in the 
matched tissue cohort; 26 of these had tissue for both normal and colorectal 
tumour tissue. 27 patients had samples of normal colorectal tissue and PBLs. 27 
patients had samples of colorectal tumour tissue and PBLs. 
Of the 95 patients with PBLs and serum available for analysis, 4 cases did not 
have samples for serum fetuin A measurement. 1 of these 4 cases had both 
normal and colorectal tumour tissue available for telomere length analysis. 
2.12.3 Statistical analysis of data from telomere length cohort 
Statistical analysis for comparison of telomere lengths in matched tissue samples 
is detailed in the chapter discussing these results. 
2.12.4 Associations with clinicopathological variables 
Associations between experimental variables and clinicopathological variables 
were assessed. Non-parametric tests were used throughout. Correlation of 
continuous variables was assessed using Spearman’s rho, Mann-Whitney U test 
was used for binary variables and Kruskal-Wallis for those with more than 2 
categories. As there were multiple correlations (30) a higher p-value (p<0.01) 
was determined as the level of statistically important significance. 
2.13 Statistical Analysis of Immunohistochemistry 
Studies 
2.13.1 Availability of matched samples from normal and 
colorectal tumour tissue 
Normal tissue was included on the TMA for 22 of the total 272 cases, although 
processing of the TMA resulted in included tissue for 20 -21 of these cases on 
some slides. 
2.13.1.1 Comparison of staining in normal and tumour tissue, and 
survival analysis 
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Basic descriptive statistics were used to investigate the distribution of staining 
for each protein and subcellular localisation in normal and tumour tissue and to 
compare normal and tumour tissue. Assuming equal distribution of deaths in 
each group as the null hypothesis, the cohort was divided into quartiles by 
protein Histoscore for each combination of protein (SIRT2-7) and subcellular 
location (nuclear or cytoplasmic) Kaplan-Meier survival curves were produced for 
each combination. Equality of survival distribution was compared using the log 
rank (Mantel-Cox) test. Univariate and multivariate analysis using Cox 
(proportional hazard) regression was performed to investigate significant 
influences on survival. 
2.13.2 Associations with clinicopathological variables 
Associations between protein expression and clinicopathological variables were 
assessed. Correlation of Histoscores with clinicopathological factors known to be 
of relevance in colorectal cancer was assessed using nonparametric tests 
throughout (Mann-Whitney U test for binary variables and Kruskal-Wallis for 
those with more than 2 categories). Correlation of continuous variables was 
assessed using Spearman’s rho. As there were multiple correlations (22) a higher 
p-value (p<0.01) was determined as the level of statistically important 
significance. 
2.14 Sirtuin Interrelationships: Statistical Considerations 
Previous data on intercorrelation of normal sirtuin RNA levels and 
intercorrelation of tumour sirtuin RNA levels comes from a different population 
of colorectal cancer patients published in the MD thesis ‘The influence of 
biological ageing in the pathogenesis of colorectal cancer’ by F Maxwell (Maxwell 
2013). The Pearson correlation coefficient was quoted, implying normal 
distribution of the data.  
2.14.1 Appropriate level of significance for correlations 
The correlations between levels of expression of sirtuin RNAs were compared 
with the correlations between levels of expression of sirtuin proteins. This was 
complicated by the measurement of Histoscores for two subcellular locations 
(nuclear and cytoplasmic) for the proteins. In keeping with the statistical 
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approach in the rest of this thesis, (using nonparametric tests throughout) only 
Spearman correlations were used. For correlations between sirtuin Histoscores in 
the two subcellular locations, the total number of correlation tests performed is 
66 for tumour tissue and 55 for normal tissue. (There was no positive staining for 
SIRT5 in the nucleus in normal tissue, so there are no correlation tests with 
SIRT5N for normal tissue). A p-value less than 0.01 was accepted as the level of 
statistically important significance for correlations. This is a higher level than 
was accepted in the previous data on correlations between levels of expression 
of sirtuin RNAs, although the correlation used was the Pearson correlation. The 
comparisons examine the networks of correlations at RNA and protein level 
rather than the individual correlations, for which the different analyses are 
used. In order to compare like with like, RNA correlations with p-value <0.01 
were included in this comparative analysis. 
2.14.2 Correlation coefficient and p-value 
In assessing correlations, the correlation coefficient must also be taken into 
account, as correlation coefficients <0.35 in magnitude are generally deemed 
weak, and correlation coefficients >0.65 in magnitude, strong. It is possible to 
have a strong correlation that is not statistically significant. Likewise, 
statistically significant correlations may not be very strong. The interpretation of 
these two parameters must be made in context of information on interactions 
between the correlated variables. In the case of sirtuin interactions, such 
information is sparse at present. It is described further in the relevant results 
chapter.  
2.14.3 Correlations between RNA expression of different 
sirtuins in normal colorectal tissue 
Correlations in RNA expression in normal colorectal tissue with p<0.01 are 
indicated in the table below with green squares. This table is adapted with 
permission from ‘The influence of biological ageing in the pathogenesis of 
colorectal cancer’, MD Thesis, University of Glasgow (Maxwell 2013). 
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SIRT2 SIRT3 SIRT4 SIRT5 SIRT6 SIRT7
SIRT1
SIRT2
SIRT3
SIRT4
SIRT5
SIRT6
SIRT7  
Table 2.4 Correlations in RNA expression in normal colorectal tissue with p<0.01 are 
indicated with green squares. This table is adapted with permission from ‘The influence of 
biological ageing in the pathogenesis of colorectal cancer’, MD Thesis, University of 
Glasgow (Maxwell 2013). 
2.14.4 Correlations between RNA expression of different 
sirtuins in colorectal tumour tissue 
Correlations in RNA expression in colorectal tumour tissue with p<0.01 are 
indicated in the table below with red squares. This table is adapted with 
permission from ‘The influence of biological ageing in the pathogenesis of 
colorectal cancer’, MD Thesis, University of Glasgow (Maxwell 2013). 
 
SIRT2 SIRT3 SIRT4 SIRT5 SIRT6 SIRT7
SIRT1
SIRT2
SIRT3
SIRT4
SIRT5
SIRT6
SIRT7  
Table 2.5 Correlations in RNA expression in colorectal tumour tissue with p<0.01 are 
indicated with red squares. This table is adapted with permission from ‘The influence of 
biological ageing in the pathogenesis of colorectal cancer’, MD Thesis, University of 
Glasgow (Maxwell 2013). 
2.14.5 Correlations between protein expression of different 
sirtuins in normal colorectal tissue 
Correlations between sirtuin/localisation combinations in normal colorectal 
tissue samples were examined. A p-value of 0.01 was accepted as statistically 
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significant. These correlations are indicated in the table below with red 
background. 
Normal SIRT 
2  Mean 
Histoscore 
(Nuclei)
Normal SIRT 
2 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
3 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
3 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
4 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
4 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
5 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
5 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
6 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
6 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
7 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
7 Mean 
Histoscore 
(Cytoplasm)
Correlation 
Coefficient 1.000 .258 -.515
* .229 .473* .204 -.344 -.160 -.319 .494* .683**
Sig. (2-
tailed) 0.25905171 0.01684037 0.31719032 0.03018218 0.37438564 0.13734272 0.49951340 0.17072109 0.02284917 0.00065208
N 21 21 21 21 21 21 20 20 20 20 21 21
Correlation 
Coefficient 1.000 -.315 -.210 .079 .026 .168 -.326 .003 .271 -.161
Sig. (2-
tailed) 0.16478125 0.36002887 0.73240624 0.91114317 0.47861634 0.16068484 0.99114458 0.23475101 0.48556225
N 21 21 21 21 21 20 20 20 20 21 21
Correlation 
Coefficient 1.000 .130 -.186 .218 .563
** .436 .050 -.138 -.058
Sig. (2-
tailed) 0.56425762 0.40618851 0.32896873 0.00974608 0.05487084 0.83531378 0.53932690 0.79895652
N 22 22 22 22 20 20 20 20 22 22
Correlation 
Coefficient 1.000 .245 .442
* .313 .246 -.150 .124 .581**
Sig. (2-
tailed) 0.27181124 0.03952189 0.17855114 0.29524638 0.52846796 0.58114663 0.00461773
N 22 22 22 20 20 20 20 22 22
Correlation 
Coefficient 1.000 .576
** .207 .086 -.500* .256 .157
Sig. (2-
tailed) 0.00501604 0.38219090 0.71733897 0.02470505 0.24966014 0.48577449
N 22 22 20 20 20 20 22 22
Correlation 
Coefficient 1.000 .371 .279 -.297 .236 .195
Sig. (2-
tailed) 0.10750844 0.23350537 0.20322531 0.29134365 0.38354247
N 22 20 20 20 20 22 22
Correlation 
Coefficient
Sig. (2-
tailed)
N 20 20 20 20 20 20
Correlation 
Coefficient 1.000 .195 -.024 -.156 -.291
Sig. (2-
tailed) 0.40913607 0.91961890 0.51252191 0.21256507
N 20 20 20 20 20
Correlation 
Coefficient 1.000 .367 .058 .038
Sig. (2-
tailed) 0.11096973 0.80771043 0.87318218
N 20 20 20 20
Correlation 
Coefficient 1.000 -.176 -.233
Sig. (2-
tailed) 0.45665962 0.32270038
N 20 20 20
Correlation 
Coefficient 1.000 .450
*
Sig. (2-
tailed) 0.03576067
N 22 22
Correlation 
Coefficient 1.000
Sig. (2-
tailed)
N 22
Normal SIRT 
7 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
2  Mean 
Histoscore 
(Nuclei)
Normal SIRT 
2 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
3 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
3 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
4 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
4 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
5 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
5 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
6 Mean 
Histoscore 
(Nuclei)
Normal SIRT 
6 Mean 
Histoscore 
(Cytoplasm)
Normal SIRT 
7 Mean 
Histoscore 
(Nuclei)
 
Table 2.6 Correlations between Histoscores for each combination of sirtuin and subcellular 
localisation in normal colorectal tissue. Red cells indicate combinations with p<0.01. 
2.14.6 Correlations level of significance for correlations 
between protein expression of different sirtuins in colorectal 
tumour tissue 
Correlations between sirtuin/localization combinations in colorectal tumour 
tissue were examined. A p-value of 0.01 was accepted as statistically significant. 
Correlations with p<0.01 and correlation co-efficient >0.35 are indicated in the 
table below with red background. There were several correlations with p<0.01 
and weak correlation coefficients. Correlations with p<0.01 and correlation co-
efficient <0.35 are indicated in the table below with orange background. 
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Tumour 
SIRT2 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT2 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT3 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT3 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT4 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT4 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT5 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT5 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT6 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT6 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT7 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT7 Mean 
Histoscore 
(Cytoplasm)
Correlation 
Coefficient 1.000 .253
** .066 -.003 .241** -.020 .000 -.141* .128* -.125* .234** -.058
Sig. (2-
tailed) 0.00002813 0.28675450 0.96744814 0.00007120 0.74673546 0.99466348 0.02207710 0.03916414 0.04240744 0.00012232 0.34337191
N 267 267 266 266 266 266 265 265 262 262 265 265
Correlation 
Coefficient 1.000 -.206
** .339** .085 .470** -.038 .181** -.157* .351** -.077 .205**
Sig. (2-
tailed) 0.00072281 0.00000001 0.16865287 0.00000000 0.54036548 0.00317293 0.01090360 0.00000001 0.21404104 0.00079613
N 267 266 266 266 266 265 265 262 262 265 265
Correlation 
Coefficient 1.000 -.235
** .256** -.248** .210** .011 .466** -.301** .265** .011
Sig. (2-
tailed) 0.00010933 0.00002332 0.00004163 0.00058052 0.86061763 0.00000000 0.00000069 0.00001231 0.85919518
N 267 267 267 267 265 265 262 262 265 265
Correlation 
Coefficient 1.000 -.016 .563
** .004 .156* -.148* .460** -.040 .321**
Sig. (2-
tailed) 0.79888735 0.00000000 0.94790442 0.01091280 0.01638800 0.00000000 0.51560479 0.00000009
N 267 267 267 265 265 262 262 265 265
Correlation 
Coefficient 1.000 .110 .152
* .087 .279** -.025 .121* -.043
Sig. (2-
tailed) 0.07114308 0.01275253 0.15567146 0.00000439 0.68796835 0.04883032 0.48778645
N 270 270 267 267 262 262 265 265
Correlation 
Coefficient 1.000 -.009 .274
** -.123* .438** -.160** .284**
Sig. (2-
tailed) 0.88315279 0.00000535 0.04686922 0.00000000 0.00886534 0.00000258
N 270 267 267 262 262 265 265
Correlation 
Coefficient 1.000 -.140
* .231** -.014 .061 .071
Sig. (2-
tailed) 0.02224058 0.00015750 0.81559412 0.32504268 0.25249582
N 268 268 263 263 263 263
Correlation 
Coefficient 1.000 -.024 .189
** -.063 .218**
Sig. (2-
tailed) 0.70106867 0.00204316 0.30741700 0.00036046
N 268 263 263 263 263
Correlation 
Coefficient 1.000 -.274
** .305** -.094
Sig. (2-
tailed) 0.00000657 0.00000054 0.13017869
N 263 263 260 260
Correlation 
Coefficient 1.000 -.220
** .335**
Sig. (2-
tailed) 0.00034230 0.00000003
N 263 260 260
Correlation 
Coefficient 1.000 .197
**
Sig. (2-
tailed) 0.00125036
N 266 266
Correlation 
Coefficient 1.000
Sig. (2-
tailed)
N 266
Tumour 
SIRT7 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT2 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT2 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT3 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT3 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT4 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT4 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT5 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT5 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT6 Mean 
Histoscore 
(Nuclei)
Tumour 
SIRT6 Mean 
Histoscore 
(Cytoplasm)
Tumour 
SIRT7 Mean 
Histoscore 
(Nuclei)
 
Table 2.7 Correlations between sirtuin/localization combinations in colorectal tumour tissue 
were examined. A p-value of 0.01 was accepted as statistically significant. Correlations with 
p<0.01 and correlation co-efficient >0.35 are indicated in the table below with red 
background. Correlations with p<0.01 and correlation co-efficient <0.35 are indicated in the 
table below with orange background. 
Only 6 of the 36 correlations between sirtuin protein levels identified as 
statistically significant in tumour tissue have correlation coefficients greater 
than 0.35. 
Only correlations which were both strong and statistically significant were used 
to build networks representing associations between sirtuins at mRNA and 
protein levels. These correlations could be a proxy measure of sirtuin protein 
interaction, although the interaction may be indirect. 
 3 Fetuin A, Inflammation and Prognostic Markers 
in Colorectal Cancer 
3.1 Introduction  
Fetuin A is a negative acute phase serum protein produced in the liver. It is 
pertinent to telomere biology in chronic kidney disease as mortality associated 
with short telomeres in PBLs is dependent on fetuin A levels (Carrero, Stenvinkel 
et al. 2008). This relationship is independent of inflammatory status. More 
recent work has highlighted that in colorectal cancer, a very different age-
associated disease, short telomeres were associated with lower fetuin A levels 
(Monaghan, Maxwell et al. 2010; Maxwell, McGlynn et al. 2011). This may reflect 
loss of systemic capacity for redox homeostasis. 
Associations between serum fetuin A and accepted markers of prognostic 
significance in colorectal cancer were evaluated in a cohort of colorectal cancer 
patients. 
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Clinical and Pathological Characteristics of the Patient 
Cohort 
Clinical and pathological characteristics of this patient cohort are summarised in 
the table below. The total cohort numbers 95, with fetuin A measurements for 
91. 
Sex M 42 Dukes' code NTF 5 
F 53 A 18 
Age  <40 2 B 36 
40-49 4 C 25 
50-59 16 D 7 
60-69 33 Not recorded 4 
70-79 25 Total 95 
>80 15 T stage NTF 5 
Total 95 1 11 
BMI  <20 3 2 11 
20-25 30 3 48 
25.1-30 29 4 14 
30.1-35 11 Not recorded 6 
>35 12 Total 95 
Not recorded 10 N stage 0 60 
Total 95 1 19 
Albumin   <35 26 2 10 
>35 68 Not recorded 6 
Not recorded 1 Total 95 
Total 95 AJCC stage NTF 5 
CRP  >10 74 1 18 
<10 20 2 35 
Not recorded 1 3 26 
Total 95 4 6 
mGPS 0 74 Not recorded 5 
1 8 Total 95 
2 12 Peritoneum 
involved 
Y 9 
Not recorded 1 N 78 
Total 95 Total 87 
Smoking 
history 
N 49 Margin involved Y 6 
Y 14 N 81 
Ex 32 Total 87 
Total 95 Venous invasion Y 46 
Tumour 
location 
Colon 59 N 40 
Rectum 36 Total 86 
Total 95 Tumour perforation Y 3 
Differentiation Poor 4 N 84 
Well/Mod 79 Total 87 
NTF 4 High risk Petersen 
Index 
Y 52 
Not recorded 8 N 48 
Total 95 Total 90 
Table 3.1 Clinicopathological characteristics of the patient cohort for measurement of 
telomere lengths and serum fetuin A. 
Chapter 3: Fetuin A and Clinicopathological Factors   153 
3.2 Overview of serum fetuin A and clinicopathological 
factors 
Associations between fetuin A and 22 clinicopathological factors are summarised 
in the following tables. p<0.01 was accepted as the level of statistical 
significance; associations with p-value >0.01 are lowlighted in grey text. 
Significant associations are subsequently discussed in more detail. 
Serum fetuin A
Age
Weak inverse relationship, Spearman rank 
correlation coefficient -0.211, p=0.045. Pearson 
Chi square, p=0.197
Sex Pearson Chi square, p=0.333
Weight
Fetuin A below the median is associated with 
lower weight, Pearson Chi square, p=0.024
BMI
Fetuin A below the median is associated with 
lower BMI. Pearson Chi square, p=0.044, Linear-
by-Linear Association, p=0.370
WCC
Inverse relationship, Spearman rank correlation 
coefficient -0.348, p=0.00084.
CRP
Inverse relationship, Spearman rank correlation 
coefficient -0.368, p=0.00043.
Albumin
Direct relationship, Spearman rank correlation 
coefficient 0.369, p=0.00035
mGPS
High fetuin A is associated with lower mGPS, 
Kruskal-Wallis Test, p=0.001
Hb
Direct relationship, Spearman rank correlation 
coefficient 0.385, p=0.00019.
Plt
Weak inverse relationship, Spearman rank 
correlation coefficient -0.282, p=0.007. Lower 
fetuin A is associated with platelet count above 
the median. Mann-Whitney U test, p=0.016
Smoking status
Fetuin A levels are higher in never smokers, 
Mann-Whitney U test, p=0.034
Lutein Pearson Chi square, p=0.697
Lycopene Pearson Chi square, p=0.897
alpha-carotene Pearson Chi square, p=0.129
beta-carotene Pearson Chi square, p=0.591
VitA Pearson Chi square, p=0.897
VitE Pearson Chi square, p=0.172
Fetuin A below the median is associated with 
more comorbidities. Pearson Chi square, 
p=0.195, Linear-by-Linear Association, 
p=0.036
Pearson Chi square, p=0.573
Leukocytes Pearson Chi square, p=0.173
Normal colorectal 
tissue Pearson Chi square, p=1.000
Colorectal tumour 
tissue
Highest quartile telomere length is associated 
with highest quartile fetuin A, Pearson Chi 
square, p=0.029 
Inflammatory 
markers
Total comorbidities
Tumour location
Serum 
antioxidant 
levels
Demographic 
variables
Atypical 
markers of 
inflammation
Telomere 
length
 
Table 3.2 Associations between serum fetuin A and demographic variables and markers of 
inflammatory status. p<0.01 was accepted as the level of statistical significance. 
Associations with higher p-value are lowlighted. 
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Serum fetuin A
Dukes' stage
Fetuin A above median is asssociated with 
lower Dukes'stage. Pearson Chi square, 
p=0.195, Linear-by-Linear Association, 
p=0.036
AJCC overall stage
Fetuin A above median is asssociated with 
lower AJCC stage. Pearson Chi square, 
p=0.034, Linear-by-Linear Association, 
p=0.030
T stage
Fetuin A above median is asssociated with 
higher T stage. Pearson Chi square, p=0.028, 
Linear-by-Linear Association, p=0.008
N stage Pearson Chi square, p=0.634
M stage Pearson Chi square, p=0.457
Differentiation
Fetuin A above the median is associated with 
poor differentiation, Pearson Chi square, 
p=0.033
Margin involvement Pearson Chi square, p=0.747
Peritoneal 
involvement Pearson Chi square, p=0.871
Tumour perforation Pearson Chi square, p=0.061
Venous invasion Pearson Chi square, p=0.261
High risk Petersen 
index Pearson Chi square, p=0.244
Pathological 
prognostic 
markers
Measures of 
cancer staging
 
Table 3.3 Associations between serum fetuin A and markers of histopathological prognostic 
significance. p<0.01 was accepted as the level of statistical significance. Associations with 
higher p-value are lowlighted. 
3.2.1 Inflammatory status 
3.2.1.1 Markers of classical systemic inflammatory response 
Serum fetuin A levels correlated with white cell count, serum CRP and albumin, 
as expected since it is an acute phase protein. Correlation coefficients were of 
moderate strength, although statistically significant to a high degree. 
! Spearman!rank!
correlation!
coefficient!
p!value!
WCC! 40.348! 0.00084!
CRP! 40.368! 0.00043!
Albumin! 0.369! 0.00035!
Table 3.4 Spearman rank correlation coefficients and associated p-values, summarising 
correlations between serum fetuin A and markers of inflammation. 
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Figure 3.1 Scatterplot of serum fetuin A level with white cell count, including line of best fit, 
showing the moderate inverse correlation between the two (Spearman rank correlation 
coefficient -0.348, p=0.00084). 
 
Figure 3.2 Scatterplot of serum fetuin A level with preoperative CRP, including line of best 
fit, showing the moderate inverse correlation between the two (Spearman rank correlation 
coefficient -0.368, p=0.00043). 
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Figure 3.3 Scatterplot of serum fetuin A level with serum albumin, including line of best fit, 
showing the moderate positive correlation between the two (Spearman rank correlation 
coefficient 0.369, p=0.00035). 
High serum fetuin A is associated with mGPS (Kruskal-Wallis Test, p=0.001). 
 
Figure 3.4 Boxplot showing serum fetuin A data grouped by mGPS score. Higher fetuin A 
was significantly associated with lower mGPS (Kruskal-Wallis Test, p=0.001). 
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3.2.1.2 Association with haemoglobin and platelet count 
Serum fetuin A showed significant correlation with the atypical inflammatory 
markers haemoglobin and platelet count. The correlation with haemoglobin was 
much stronger. 
! Spearman!rank!
correlation!
coefficient!
p!value!
Haemoglobin! 0.385! 0.00019!
Platelet!count! 40.282! 0.0074!
Table 3.5 Spearman rank correlation coefficients and associated p-values, summarising 
correlations between serum fetuin A and atypical inflammatory markers. 
 
Figure 3.5 Scatterplot of serum fetuin A level with haemoglobin, including line of best fit, 
showing the moderate correlation between the two (Pearson correlation coefficient= 0.322, 
p=0.0021). 
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Figure 3.6 Scatterplot of serum fetuin A level with haemoglobin, including line of best fit, 
showing the relatively weak correlation between the two (Spearman’s rho= -0.282, 
p=0.0074). 
3.2.2 Pathological prognostic factors 
3.2.2.1 Association with tumour stage 
T stage measures local invasion of tumour. Lower fetuin A was associated with 
higher T stage (Pearson Chi square, p=0.028, linear-by-linear association, 
p=0.008). 
   Fetuin A 
Total 
Below median Above 
median 
T stage No tumour 0 5 5 
Confined to 
submucosa 
4 7 11 
Muscularis 
propria 
2 9 11 
Pericolorectal 
tissues 
27 20 47 
Through serosa 
and/or beyond 
6 5 11 
Total 39 46 85 
Table 3.6 Chi square analysis of fetuin A categorised about the median with respect to T 
stage. Lower fetuin A levels were more likely to be associated with higher T stage (Pearson 
Chi square, p=0.028, linear-by-linear association, p=0.008). 
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3.3 Discussion 
3.3.1 Fetuin A and age 
The inverse correlation with age shown before in humans (Maxwell 2013) is not 
statistically significant here although a similar trend is seen. The age range of 
patients in this study was 32-94, a wider range than Maxwell reported. Fetuin A 
levels are typically very high in neonatal life and decrease after birth. One study 
investigated levels in a cohort of the very old (Bellia, Tomaiuolo et al. 2012). 
These authors found that in 256 subjects aged 81-100 years, fetuin A levels were 
positively correlated with age. There are no definitive accounts of fetuin A 
variation throughout adult life, nor any correlation with lifespan in younger 
adults. Different trajectories of fetuin A variation with time may differentiate 
those with a longer lifespan and a larger analysis over the range of adult life 
would be informative. 
3.3.2 Fetuin A and inflammation 
Fetuin A has a central, although not straightforward, role in the promulgation of 
the inflammatory response and this is evident in the range of associations with 
specific markers of inflammation, and with smoking. The associations with other 
atypical markers of inflammation suggests that fetuin A might also provide a 
reflection of the resilience of the organism, in terms of the ability to cope with 
the demands of the systemic inflammatory response over the longer term and to 
effect significant repair. 
Survival data for this cohort is not yet available, but it will be interesting to 
observe whether the poor prognosis associated with systemic inflammation is 
specifically related to fetuin A levels as well. 
3.3.3 Fetuin A and telomere length 
One of the aims of this project was to investigate a possible relationship 
between telomere length in PBLs and colorectal tissue and serum fetuin A. 
Unfortunately, this experiment had very low power, due to the small number of 
incident cases of colorectal cancer within the time period for sample collection. 
This meant that it was not possible to comment definitively on any relationship 
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between fetuin A and telomere lengths in PBLs, or gut tissue. Previous 
associations reported from this laboratory cannot be corroborated, nor is there 
strong evidence to refute them. 
Telomere lengths in PBLs tend to be shorter in patients with inflammatory 
conditions, including renal failure. It would be expected that an appropriately 
powered study would demonstrate an association between low fetuin A levels 
and short telomeres.  
Likewise, the relationship between telomere length in gut tissue and fetuin A 
may well shed interesting light on the relationship between these two 
parameters. At present, one study has shown that colorectal epithelium binds 
fetuin A and colorectal tumour binds less fetuin A than normal mucosa (Swallow, 
Partridge et al. 2004). Information on the binding substrate, and intracellular 
effects is limited. Telomere length is known to be vulnerable to damage by ROS 
and so the reduced activity of fetuin A in inflammation may exacerbate this 
situation, but further comment is not possible on the basis of available data. 
3.3.4 Fetuin A and cancer 
Decreasing fetuin A levels are associated with higher T stage in this dataset. This 
is the first demonstration of an association between serum fetuin A and cancer 
stage in colorectal cancer. No separate association with nodal status was 
evident. 
In contrast to the situation in most other cancers studied, there is no clear 
evidence of reduced levels of serum fetuin A in colorectal cancer. One study 
shows decreased fetuin A on serum proteomic analysis, in carpeting FAP patients  
(n=3) compared to diffuse FAP patients (n=5) or normal cases (n=8) (Quaresima, 
Crugliano et al. 2008). Diffuse FAP shows less severe polyposis. Although FAP 
increases the risk of development of colorectal cancer (and other forms of 
cancer) significantly, all of these patients had already undergone prophylactic 
colectomy; none had a diagnosis of colorectal cancer.  
This study also analysed serum from 3 sporadic cases of colorectal cancer and 2 
with HNPCC, and these did not show the variations in fetuin A seen in the FAP 
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cases. Fetuin A inhibits TGFβ, which in turn modulates the Wnt pathway, by 
targeting its components including APC, which is the gene mutated in FAP. This 
may explain the particular interaction between fetuin A and FAP. APC mutations 
are common in colorectal cancers generally however, so that it should not 
exclude a general effect of fetuin A on sporadic colorectal cancers. Admittedly 
the numbers of cases in each category in this report were low. 
Another paper showed no significant difference between serum fetuin A levels in 
31 cases with cancer and 30 controls, (Dowling, Clarke et al. 2011). In this 
report, cases with cancer had tumours of AJCC stages 3b-4 so they were of 
higher stage generally than the cases in this cohort. The number of cases was 
much smaller and the variation in fetuin A levels within the cancer group was 
higher than either normal males or normal females. Still the mean and median 
serum fetuin A of the cancer groups tended to be lower than in normal samples, 
although this difference did not reach statistical significance. 
As mentioned above, fetuin A binds to colorectal epithelium, and binding was 
reduced in colorectal cancer(Swallow, Partridge et al. 2004). With the data 
provided here, correlation of fetuin A immunohistochemical staining in 
colorectal tissue, serum fetuin A and colorectal cancer stage would be ideal to 
investigate the relationship further. 
3.3.5 Fetuin A as a biomarker of ageing 
Low serum fetuin A is associated with several age-associated diseases. There was 
no significant association with previous history of cancer or with total 
comorbidities in this cohort, likely because of the relatively small numbers of 
cases. The trend in association with numbers of comorbidities could suggest an 
integration of information about previous illness, and insults to the structural 
integrity of the organism – cumulative ageing. 
An integrated summary of the effects of multiple disease processes within one 
organism, a valid marker of resilience, would be ideal characteristics of a 
possible surrogate marker for biological age. However, in order to investigate 
this possibility, the essential starting point would be a good understanding of the 
variation in fetuin A levels with chronological age. 
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The possibility alluded to above that fetuin A differentiates those with long 
lifespan would be of great interest to the study of fetuin A as a biomarker of 
ageing. Given the variation (both up and down) of fetuin A levels with acute 
influences (e.g. acute inflammation) is it possible that it may exhibit a more 
general drift in response to more gradual processes such as biological ageing? 
Does a Biomarker of ageing necessarily follow a unidirectional course? Could a 
Biomarker of Ageing identify a person as becoming biologically younger as well 
as older, or as ageing at a variable rate?  
Certainly the original Baker and Sprott definition referred to ‘physiological 
(functional) age’ – and does not exclude regaining of function with the passage 
of time. If repair processes were sufficiently time-consuming, and complete, as 
to allow us to measure function during the repair process as well as after it, 
there is no reason why such a re-gain of function should not be observed. This 
may be a question of scale of measurement of biomarker as well as scale of 
repair, and at present large scale repair of a severely damaged organ is not 
within our power, or normal physiological process. Measurement of the rate of 
ageing or deterioration may be a more realistic aim.  
McClearn acknowledges ‘continuities and discontinuities in the subprocesses of 
ageing’ which could describe the utility of fetuin A as a biomarker of ageing. 
Measurements taken in the context of acute self-limiting inflammatory episodes 
would give an inaccurate estimate but observation of longer-term trends may be 
useful for assessment of individuals if we have a framework of reference. 
McClearn also allows for the possibility that biomarkers may change through the 
course of an organism’s life. It is possible that the relationship between fetuin A 
and renal function described in the study referred to above(Bellia, Tomaiuolo et 
al. 2012) offers such an example. Renal function declines with age and this 
continues in the very old. Fetuin A on the other hand, which seems to decline 
with age in an unselected population over most of the adult age range, increases 
with age in those who attain significant age. Self-selection into this group 
implies a different physiological handling of fetuin A. Understanding how and 
why this occurs could be quite illuminating. 
 4 Sirtuin Protein Expression in Normal Colorectal 
Tissue and in Colorectal Tumour Tissue and 
Relationship with Survival in Colorectal Cancer 
4.1 Introduction 
The yeast Sir2 proteins came to attention because of their effect on longevity of 
yeast cells (Imai, Armstrong et al. 2000). Sirtuins are human homologues of yeast 
Sir2 proteins; there are 7 sirtuins, SIRT1-7, and they have diverse effects on 
processes from metabolic regulation and cell-cycle control to DNA repair(Dali-
Youcef, Lagouge et al. 2007). Polymorphisms in SIRT3 have been shown to 
associate with human longevity (Rose, Dato et al. 2003). 
Altered RNA expression of sirtuins in human breast (Ashraf, Zino et al. 2006) and 
colorectal cancer (F Maxwell, unpublished data) was demonstrated in this 
laboratory. A Pubmed search was conducted on 4 Nov 2012, using the MeSH 
terms Sirtuins and Immunohistochemistry indicated that there were no published 
immunohistochemical studies defining the subcellular localisation of the 7 
human sirtuins in the large intestine and linking protein expression with disease 
outcomes.  
Protein levels of sirtuins 2-7 were individually assessed on a human colorectal 
TMA. Data from these investigations are presented below. Descriptive statistics, 
graphical representation and photographic examples of staining patterns for 
each sirtuin, in nuclei and cytoplasm, in normal and tumour tissue are detailed. 
Sirtuin protein expression in normal and tumour tissue was compared. 
Associations between survival and Histoscores for each combination of individual 
sirtuin and subcellular location in tumour samples were examined and data on 
univariate and multivariate analysis is presented. There were insufficient 
numbers of normal samples for meaningful analysis of relationship with survival. 
4.2 SIRT2 Immunohistochemistry 
Representative pictures of sections stained for SIRT2 are shown. 
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Figure 4.1 Normal colorectal tissue. Negative control stained for SIRT2. 
 
Figure 4.2 Normal colorectal tissue stained for SIRT2. Arrows show normal colorectal 
epithelium and stromal tissue. 
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Figure 4.3 Colorectal tumour tissue stained for SIRT2. Arrows show weak and moderate 
nuclear staining, and generalised weak cytoplasmic staining, some of which is highlighted 
by the circle. 
 
Figure 4.4 Variable SIRT2 cytoplasmic staining, with areas of moderate staining indicated by 
arrows. These were representative of the strongest staining areas of cytoplasm. 
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Figure 4.5 Variable SIRT2 nuclear staining with arrows indicating weak, moderate and 
strong staining. 
Basic descriptive statistics for SIRT2 staining are given below. 
SIRT2 
Nuclear 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
165.00 90.00 97.50 290.00 135.00 225.00
Tumour 
tissue 105.00 48.75 0.00 218.33 76.25 125.00
SIRT2 
Cytoplasmic 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
130.00 33.75 60.00 190.00 120.00 150.00
Tumour 
tissue 111.25 35.00 48.75 196.25 97.50 132.50
 
Table 4.1 Descriptive statistics for SIRT2 Histoscores in nuclei and cytoplasm, in normal 
colorectal epithelium and tumour tissue. 
4.2.1 SIRT2 protein expression levels in the nucleus in normal 
and tumour tissue. 
Distribution of SIRT2 Histoscores in nuclei is represented graphically below for 
both normal and tumour tissue.  
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Figure 4.6 Two histograms showing the frequency distribution of SIRT2 Histoscores in 
nuclei, in normal and tumour tissue samples. 
Staining intensity was generally less in tumour than normal tissue and this was 
confirmed on related samples Wilcoxon Signed Rank test (p=0.00008). Thus 
matched levels of SIRT2 protein in the nucleus were significantly lower in 
colorectal tumour cells than in normal colorectal cells. 
 
Figure 4.7 Scatterplot shows SIRT2 nuclear Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the line of 
equivalence. Most points showed higher Histoscore in normal than in tumour tissue. The 
boxplots of SIRT2 nuclear Histoscores from matched samples of colorectal tumour and 
normal tissue showed lower Histoscores in tumour tissue (Wilcoxon Signed Rank test, 
p=0.00008). 
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4.2.2 SIRT2 protein expression levels in the cytoplasm in normal 
and tumour tissue. 
Distribution of SIRT2 Histoscores in cytoplasm is represented graphically below 
for both normal and tumour tissue. 
 
Figure 4.8 Two histograms showing the frequency distribution of SIRT2 Histoscores in 
cytoplasm, in normal and tumour tissue samples. 
Staining intensity was generally less in tumour than normal tissue and this was 
confirmed on related samples Wilcoxon Signed Rank test (p=0.0082). Thus 
matched levels of SIRT2 protein in the cytoplasm were significantly lower in 
colorectal tumour cells than in normal colorectal cells. 
 
Figure 4.9 Scatterplot shows SIRT2 cytoplasmic Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the line of 
equivalence. Most points showed higher Histoscore in normal than in tumour tissue. The 
boxplots of SIRT2 cytoplasmic Histoscores from matched samples of colorectal tumour and 
normal tissue showed lower Histoscores in tumour tissue (Wilcoxon Signed Rank test, 
p=0.0082). 
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4.3 SIRT3 Immunohistochemistry 
Representative pictures of sections stained for SIRT3 are shown. Staining appears 
granular when it is stronger. 
 
Figure 4.10 Normal colorectal tissue, negative control. Arrows indicate colorectal epithelium 
and stroma. 
 
Figure 4.11 Normal colorectal tissue stained for SIRT3. Colorectal epithelium and stroma are 
labelled. 
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Figure 4.12 Colorectal tumour tissue stained for SIRT3. Arrows indicate weak nuclear and 
cytoplasmic staining. 
 
Figure 4.13 Cytoplasmic staining in colorectal tumour tissue stained for SIRT3. Arrows 
indicate weak, moderate and strong staining. 
Basic descriptive statistics for SIRT3 staining are given below. 
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SIRT3 
Nuclear 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
0.00 1.00 0.00 3.00 0.00 1.00
Tumour 
tissue 0.50 1.50 0.00 12.00 0.00 1.50
SIRT3 
Cytoplasmic 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
2.00 4.38 0.00 40.00 1.00 5.00
Tumour 
tissue 17.50 34.25 0.00 181.25 5.00 39.25
 
Table 4.2 Descriptive statistics for SIRT3 Histoscores in nuclei and cytoplasm, in normal 
colorectal epithelium and tumour tissue. 
Staining intensity was overall very low, particularly in the nucleus; however, it 
appeared that SIRT3 protein is located in both the nucleus and the cytoplasm in 
colorectal tissue. As the antibody used here does not distinguish between the 
short and long isoforms of SIRT3, it is not possible to determine if the isoforms 
are differentially localised. SIRT3 protein expression levels in the nucleus in 
normal and tumour tissue. 
4.3.1 SIRT3 protein expression levels in nuclei in normal and 
tumour tissue. 
Distribution of SIRT3 Histoscores in nuclei is represented graphically below for 
both normal and tumour tissue. 
 
Figure 4.14 Two histograms show the frequency distribution of SIRT3 Histoscores in nuclei, 
in normal and tumour tissue samples. 
Chapter 4: Sirtuin Protein Expression in Normal and Colorectal Cancer and Survival   172 
Related samples Wilcoxon Signed Rank test comparing the distribution of 
Histoscores in both tissues confirmed there was no significant difference in 
staining (p=0.3915). 
 
Figure 4.15 SIRT3 nuclear Histoscores for matched samples from colorectal tumour tissue 
and adjacent normal colorectal tissue are plotted. The solid line is the line of equivalence. 
There was no significant difference in staining in matched normal and tumour tissue 
(Wilcoxon Signed Ranks test, p=0.3915). Boxplot of SIRT3 nuclear Histoscores from the full 
cohort of normal and colorectal tumour tissue samples, Median Histoscore is higher in 
tumour than in normal tissue (Mann-Whitney U test, p=0.029). 
Analysis of the full cohort as unmatched samples confirmed that staining in 
tumour tissue is higher than in normal tissue (Mann-Whitney U test, p=0.029). 
Thus levels of SIRT3 protein in nuclei were significantly higher in colorectal 
tumour cells than in normal colorectal cells. 
4.3.2 SIRT3 protein expression levels in the cytoplasm in normal 
and tumour tissue. 
Distribution of SIRT3 Histoscores in cytoplasm is represented graphically below 
for both normal and tumour tissue. 
Chapter 4: Sirtuin Protein Expression in Normal and Colorectal Cancer and Survival   173 
 
Figure 4.16 Two histograms show the frequency distribution of SIRT3 Histoscores in 
cytoplasm, in normal and tumour tissue samples. 
Wilcoxon Signed Rank test comparing the distribution of Histoscores in both 
tissues confirmed staining was significantly stronger in tumour tissue (p=0.0015). 
Thus matched levels of SIRT3 protein in the cytoplasm were significantly lower 
in colorectal tumour cells than in normal colorectal cells. 
 
Figure 4.17 The scatterplot shows SIRT3 cytoplasmic Histoscores for matched samples 
from colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the 
line of equivalence. Most points showed higher Histoscore in tumour than in normal tissue. 
The boxplots show SIRT3 cytoplasmic Histoscores from matched samples of normal and 
colorectal tumour tissue, with higher Histoscores in tumour samples. This difference is 
statistically significant (Wilcoxon Signed Ranks test, p=0.0015). 
Thus SIRT3 protein levels in the cytoplasm were higher in tumour tissue. 
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4.4 SIRT4 Immunohistochemistry 
Representative pictures of sections stained for SIRT4 are shown. 
 
Figure 4.18 Normal colorectal tissue, negative control. Colorectal epithelium and stroma are 
labelled. 
 
Figure 4.19 Normal colorectal tissue stained for SIRT4. Colorectal epithelium and stroma are 
labelled. 
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Figure 4.20 Colorectal tumour tissue stained for SIRT4. Arrows show weak nuclear and 
cytoplasmic staining. 
 
Figure 4.21 Colorectal tumour tissue stained for SIRT4. This section shows generally 
moderate cytoplasmic staining, highlighted by the circle. Nuclear staining did not reach 
moderate levels in tumour tissue. 
Basic descriptive statistics for SIRT4 staining are given below. 
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SIRT4 
Nuclear 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
12.25 16.88 0.00 80.00 5.00 20.00
Tumour 
tissue 0.00 1.25 0.00 16.25 0.00 1.25
SIRT4 
Cytoplasmic 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
65.00 46.25 0.00 125.00 40.00 80.00
Tumour 
tissue 50.00 42.81 1.25 122.50 27.19 70.00
 
Table 4.3 Descriptive statistics for SIRT4 Histoscores in nuclei and cytoplasm, in normal 
colorectal epithelium and tumour tissue. 
As one of the ‘mitochondrial sirtuins’, nuclear staining was unexpected for SIRT4 
and there are no previous reports of this, but the intensity of staining for SIRT4 
in the nucleus was higher than staining for SIRT3, for which there is a reported 
precedent. Staining intensity was lower in nuclei than in cytoplasm. 
4.4.1 SIRT4 protein expression levels in the nucleus in normal 
and tumour tissue. 
Distribution of SIRT4 Histoscores in nuclei is represented graphically below for 
both normal and tumour tissue. 
 
Figure 4.22 Two histograms showing the frequency distribution of SIRT4 Histoscores in 
nuclei, in normal and tumour tissue samples 
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Staining intensity was generally less in tumour than normal tissue and this was 
confirmed on related samples Wilcoxon Signed Rank test (p=0.00016). Thus 
matched levels of SIRT4 protein in nuclei were significantly lower in colorectal 
tumour cells than in normal colorectal cells. 
 
Figure 4.23 Scatterplot shows SIRT4 nuclear Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the line of 
equivalence. Most points showed higher Histoscore in normal than in tumour tissue. The 
boxplots of SIRT4 nuclear Histoscores from matched samples of colorectal tumour and 
normal tissue showed lower Histoscores in tumour tissue (Wilcoxon Signed Rank test, 
p=0.00016). 
4.4.2 SIRT4 protein expression levels in the cytoplasm in normal 
and tumour tissue. 
Distribution of SIRT4 Histoscores in cytoplasm is represented graphically below 
for both normal and tumour tissue. 
 
Figure 4.24 Two histograms show the frequency distribution of SIRT4 Histoscores in 
cytoplasm, in normal and tumour tissue samples. 
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There was a significant correlation between cytoplasmic Histoscores for both 
normal and tumour tissue (Spearman correlation coefficient 0.549, p=0.008) with 
lower Histoscores in tumour tissue (Wilcoxon Signed Rank test, p=0.041). 
 
Figure 4.25 Scatterplot shows cytoplasmic Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue stained for SIRT4. The solid 
line is the line of equivalence, the dashed line is the line of best fit (Spearman correlation 
coefficient 0.549, p=0.008). Most points showed lower Histoscore in tumour than in normal 
tissue. The boxplots of SIRT4 cytoplasmic Histoscores from matched samples of colorectal 
tumour and normal tissue showed lower Histoscores in tumour tissue (Wilcoxon Signed 
Rank test, p=0.041). 
SIRT4 protein levels in the cytoplasmic compartment were significantly lower in 
colorectal tumour tissue than in adjacent normal tissue. 
4.5 SIRT5 Immunohistochemistry 
Representative pictures of sections stained for SIRT5 are shown. There was no 
staining for SIRT5 in nuclei of any of the normal tissue samples available (n=20). 
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Figure 4.26 Normal colorectal tissue stained for SIRT5. Colorectal epithelium and stroma are 
labelled. 
 
Figure 4.27 Colorectal tumour section stained for SIRT5. Arrows indicate few weakly stained 
nuclei. Cytoplasmic staining is patchy and of variable intensity within individual cells 
(arrows indicate areas of weak and moderate staining). There appears to be significant 
membrane-bound staining. Specific Histoscore was not calculated for cell membrane 
staining. 
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Figure 4.28 Heavy SIRT5 cytoplasmic staining is widespread in this section of colorectal 
tumour and is specifically indicated by the arrow. 
Basic descriptive statistics for SIRT5 staining are given below. 
SIRT5 
Nuclear 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
* * * * * *
Tumour 
tissue 0.00 0.00 0.00 10.00 0.00 0.00
SIRT5 
Cytoplasmic 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
152.50 52.50 85.00 220.00 137.50 187.50
Tumour 
tissue 88.54 52.19 2.50 230.00 67.50 119.69
 
Table 4.4 Descriptive statistics for SIRT5 Histoscores in nuclei and cytoplasm, in normal 
colorectal epithelium and tumour tissue. 
Staining intensity was overall very low, similar to SIRT3; staining was particularly 
low in the nucleus in tumour samples. 
4.5.1 SIRT5 protein expression levels in the nucleus in normal 
and tumour tissue. 
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There was no staining for SIRT5 in the nucleus in normal tissue, so no comparison 
was possible. 
 
Figure 4.29 Distribution of SIRT5 Histoscores in nuclei is represented graphically below for 
tumour tissue, using both linear and logarithmic frequency scale. 
As one of the ‘mitochondrial sirtuins’, nuclear staining was unexpected for SIRT5 
as for SIRT4, and there are no previous reports of this. Histoscores were very low 
in tumour tissue and a larger study of normal tissue samples would be required 
to confirm nuclear expression of SIRT5 in normal tissue. 
4.5.2 SIRT5 protein expression levels in the cytoplasm in normal 
and tumour tissue. 
Distribution of SIRT5 Histoscores in cytoplasm is represented graphically below 
for both normal and tumour tissue. Staining intensity was generally less in 
tumour than normal tissue and this was confirmed on related samples Wilcoxon 
Signed Rank test (p=0.00068). Thus matched levels of SIRT5 protein in the 
cytoplasm were significantly lower in colorectal tumour cells than in normal 
colorectal cells. 
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Figure 4.30 Two histograms show the frequency distribution of SIRT5 Histoscores in 
cytoplasm, in normal and tumour tissue samples. 
 
Figure 4.31 Scatterplot shows SIRT5 cytoplasmic Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the line of 
equivalence. Most points showed higher Histoscore in normal than in tumour tissue. The 
boxplots of SIRT5 cytoplasmic Histoscores from matched samples of colorectal tumour and 
normal tissue showed lower Histoscores in tumour tissue (Wilcoxon Signed Rank test, 
p=0.00068). 
4.6 SIRT6 Immunohistochemistry 
Representative pictures of sections stained for SIRT6 are shown. 
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Figure 4.32 Normal colorectal tissue stained for SIRT6. Colorectal epithelium and stroma are 
labelled. 
 
Figure 4.33 Colorectal tumour tissue stained for SIRT6. Cytoplasmic staining is generally 
weak (arrow highlights representative area). Nuclear staining is weak, where present (also 
indicated by arrows). 
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Figure 4.34 Colorectal tumour tissue stained for SIRT6. Cytoplasmic staining is variable 
within individual cells and appears stronger towards, but not close to the apical aspect. 
Arrows indicate contrasting areas of moderate and strong staining. Granular areas of strong 
staining may represent containment in intracellular organelles. 
 
Figure 4.35 Colorectal tumour tissue stained for SIRT6. Strongest staining here appears to 
be at the apical aspect of the cell. Conglomerations of strongly staining tissue may indicate 
SIRT6 contained in intracellular organelles or vacuoles, possibly for secretion. 
Basic descriptive statistics for SIRT6 staining are given below. 
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SIRT6 
Nuclear 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
0.75 1.50 0.00 6.00 0.00 1.50
Tumour 
tissue 2.00 5.17 0.00 50.00 0.50 5.67
SIRT6 
Cytoplasmic 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
69.50 35.63 34.00 140.00 55.00 88.75
Tumour 
tissue 90.00 57.25 0.00 210.00 62.50 119.75
 
Table 4.5 Descriptive statistics for SIRT6 Histoscores in nuclei and cytoplasm, in normal 
colorectal epithelium and tumour tissue. 
4.6.1 SIRT6 protein expression levels in the nucleus in normal 
and tumour tissue. 
Distribution of SIRT6 Histoscores in nuclei is represented graphically below for 
both normal and tumour tissue.  
 
Figure 4.36 Two histograms showing the frequency distribution of SIRT6 Histoscores in 
nuclei, in normal and tumour tissue samples. 
Wilcoxon Signed Rank test (p=0.011) comparing the distribution of Histoscores in 
both tissues, showed a significant difference in staining on exclusion of an 
outlier (sample 31). Comparison of the distribution of Histoscores in the full 
cohort of tumour samples showed the same pattern, with a more pronounced 
result (Mann-Whitney U test, p=0.0026). 
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Figure 4.37 Nuclear Histoscores for matched samples from colorectal tumour tissue and 
adjacent normal colorectal tissue stained for SIRT6 are displayed on the scatterplot. The 
solid line is the line of equivalence. There was a statistically significant difference between 
nuclear Histoscores in normal and tumour tissue when the sample with high nuclear 
Histoscore in normal tissue was excluded (Wilcoxon Signed Ranks test, p=0.011). The 
boxplots of nuclear Histoscores from the full cohort of colorectal tumour and normal tissue 
samples showed higher Histoscores in tumour tissue (Mann-Whitney U test, p=0.0026). 
Thus levels of SIRT6 protein in nuclei were significantly higher in colorectal 
tumour cells than in normal colorectal cells. 
4.6.2 SIRT6 protein expression levels in the cytoplasm in normal 
and tumour tissue. 
Distribution of SIRT6 Histoscores in cytoplasm is represented graphically below 
for both normal and tumour tissue. 
 
Figure 4.38 Two histograms show the frequency distribution of SIRT6 Histoscores in 
cytoplasm, in normal and tumour tissue samples. 
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Staining intensity was generally higher in tumour than normal tissue; this was 
not significantly different on related samples Wilcoxon Signed Rank test 
(p=0.211). Comparison of the distribution of Histoscores in the full cohort of 
tumour samples did show a significant difference (Mann-Whitney U test, 
p=0.0278). Thus levels of SIRT6 protein in the cytoplasm were higher in 
colorectal tumour cells than in normal colorectal cells. 
 
Figure 4.39 Scatterplot shows SIRT6 cytoplasmic Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the line of 
equivalence. Most points showed lower Histoscore in normal than in tumour tissue. The 
boxplots of SIRT6 cytoplasmic Histoscores from the full cohort of colorectal tumour and 
normal tissue samples showed higher Histoscores in tumour tissue (Mann-Whitney U test, 
p=0.0278). 
4.7 SIRT7 Immunohistochemistry 
Representative pictures of sections stained for SIRT7 are shown. 
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Figure 4.40 Normal colorectal tissue stained for SIRT7. Colorectal epithelium and stroma are 
labelled. 
 
Figure 4.41 Colorectal tumour tissue stained for SIRT7. In this example, cytoplasmic 
staining is weak (arrows) where present. Nuclear staining is also weak as indicated by 
arrows. 
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Figure 4.42 Colorectal tumour tissue stained for SIRT7; cytoplasmic staining is stronger in 
this section and nuclear staining is also more prominent (as indicated by arrows). 
 
Figure 4.43 Colorectal tissue stained for SIRT7. Cytoplasmic staining is once again 
moderate and shows patchy variation. Nuclear staining varies between weak and very 
strong. 
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Figure 4.44 Colorectal tumour tissue stained for SIRT7. Cytoplasmic staining is very strong 
and shows a granular pattern in some areas. Nuclear staining by contrast is quite weak. 
Basic descriptive statistics for SIRT7 staining are given below. 
SIRT7 
Nuclear 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
20.00 28.13 5.00 142.50 10.00 37.50
Tumour 
tissue 32.50 37.50 0.00 146.67 15.00 52.50
SIRT7 
Cytoplasmic 
Histoscore Median
Interquartile 
range Minimum Maximum
Lower 
quadrant
Upper 
quadrant
Normal 
tissue
125.00 36.88 100.00 175.00 115.00 150.00
Tumour 
tissue 112.50 31.25 41.25 265.00 98.75 130.00
 
Table 4.6 Descriptive statistics for SIRT7 Histoscores in nuclei and cytoplasm, in normal 
colorectal epithelium and tumour tissue. 
4.7.1 SIRT7 protein expression levels in the nucleus in normal 
and tumour tissue. 
Distribution of SIRT7 Histoscores in nuclei is represented graphically below for 
both normal and tumour tissue. 
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Figure 4.45 Two histograms showing the frequency distribution of SIRT7 Histoscores in 
nuclei, in normal and tumour tissue samples. 
Related samples Wilcoxon Signed Rank test (p=0.6377) and Mann-Whitney U test 
(p=0.151) comparing the distribution of Histoscores in matched and unmatched 
samples showed there was no significant difference in staining between normal 
colorectal and colorectal tumour tissue. 
 
Figure 4.46 Scatterplot shows SIRT7 nuclear Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the line of 
equivalence. Histoscores in matched tumour and normal tissue samples were similar 
Wilcoxon Signed Rank test (p=0.6377). The boxplots of SIRT7 nuclear Histoscores from the 
full cohort of colorectal tumour and normal tissue samples showed similar Histoscores in 
both tissues (Mann-Whitney U test, p=0.151). 
4.7.2 SIRT7 protein expression levels in the cytoplasm in normal 
and tumour tissue. 
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Distribution of SIRT7 Histoscores in cytoplasm is represented graphically below 
for both normal and tumour tissue. 
 
Figure 4.47 Two histograms show the frequency distribution of SIRT7 Histoscores in 
cytoplasm, in normal and tumour tissue samples. 
Staining intensity was generally lower in tumour than normal tissue; this was not 
significantly different on related samples Wilcoxon Signed Rank test (p=0.079). 
Comparison of the distribution of Histoscores in the full cohort of tumour 
samples did show a significant difference (Mann-Whitney U test, p=0.009). Thus 
levels of SIRT7 protein in the cytoplasm were lower in colorectal tumour cells 
than in normal colorectal cells. 
 
Figure 4.48 Scatterplot shows SIRT7 cytoplasmic Histoscores for matched samples from 
colorectal tumour tissue and adjacent normal colorectal tissue. The solid line is the line of 
equivalence. Most points showed higher Histoscore in normal than in tumour tissue. The 
boxplots of SIRT7 cytoplasmic Histoscores from the full cohort of colorectal tumour and 
normal tissue samples showed lower Histoscores in tumour tissue (Mann-Whitney U test, 
p=0.009). 
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These results will be discussed in the context of clinicopathological associations 
with sirtuin expression, outlined in Chapter 5. Each sirtuin is considered 
separately, with analysis of sirtuin interrelationships in Chapter 6. 
4.8 Effect of sirtuin expression in colorectal tumour 
tissue on cancer-specific survival. 
Survival data was collated by Mr James Park at December 2011, a period at least 
5 years from operation for all cases in the database. Cause of death was 
identified as colorectal cancer-related or due to other cause. Kaplan-Meier 
survival curves were produced for each combination of sirtuin (SIRT2-7) and 
location (nuclear or cytoplasmic), with cancer-related death as the outcome of 
interest. Histoscores were divided into quartiles and equality of survival 
distribution for each quartile was compared. 
4.8.1 Effect of SIRT2 expression in colorectal tumour tissue on 
survival. 
Kaplan-Meier analysis of survival was performed with SIRT2 nuclear Histoscore 
divided into quartiles. There was a significant difference between quartiles on 
log rank (Mantel-Cox) test (p=0.0202): from the Kaplan-Meier curves, lowest and 
highest quartiles of SIRT2 nuclear staining were associated with similarly worse 
outcomes than middle quartiles. 
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Figure 4.49 Kaplan-Meier survival curves for SIRT2 nuclear Histoscores split in quartiles. 
There was a significant difference between quartiles on log rank (Mantel-Cox) test 
(p=0.0202): from the Kaplan-Meier curves, lowest and highest quartile SIRT2 nuclear 
staining was associated with worse outcome. 
 
Table 4.7 Tests of equality of survival distributions for the different levels of SIRT2 nuclear 
Histoscore (split in quartiles). 
Lowest and highest quartile SIRT2 nuclear Histoscores were combined and 
survival analysis was performed on the ‘extreme quartiles’ versus the middle 
two quartiles. The difference between the two groups in terms of survival, on 
log rank (Mantel-Cox) test, was more statistically significant again (p=0.0018). 
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Figure 4.50 Kaplan-Meier survival curves for SIRT2 nuclear Histoscores, split lowest and 
highest quartiles versus middle quartiles. 
 
Table 4.8 Tests of equality of survival distributions for the different levels of SIRT2 nuclear 
Histoscore (split lowest and highest quartiles versus middle quartiles). 
Kaplan-Meier analysis of survival was performed with SIRT2 cytoplasmic 
Histoscore divided into quartiles. There was no significant difference in equality 
of survival distribution between quartiles. 
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Figure 4.51 Kaplan-Meier survival curves for SIRT2 cytoplasmic Histoscores split in 
quartiles. 
 
Table 4.9 Tests of equality of survival distributions for the different levels of SIRT2 
cytoplasmic Histoscores (split in quartiles). 
4.8.2 Effect of SIRT3 expression in colorectal tumour tissue on 
survival. 
Kaplan-Meier analysis of survival was performed with SIRT3 nuclear Histoscore 
divided into quartiles. SIRT3 nuclear staining was present in less than half the 
cases and weak, where present. There was therefore no way to divide cases into 
lowest quartile and second quartile and these were amalgamated into one 
group. There was a difference between groups on log rank (Mantel-Cox) test, 
although this did not reach significance. 
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Figure 4.52 Kaplan-Meier survival curves for SIRT3 nuclear Histoscores split in quartiles. 
 
Table 4.10 Tests of equality of survival distributions for the different levels of SIRT3 nuclear 
Histoscores (split in quartiles). 
Kaplan-Meier survival curves and tests to compare the equality of survival 
distributions are included above, but given the characteristics of the data, this 
analysis (applied to the other sirtuins) may not be most suitable for SIRT3 
nuclear Histoscore. Therefore, similar analysis was performed with SIRT3 nuclear 
Histoscore divided about the median. The difference in distribution of survival 
between the two groups was statistically significant on log rank (Mantel-Cox) 
test (p=0.0343). 
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Figure 4.53 Kaplan-Meier survival curves for SIRT3 nuclear Histoscores split about the 
median. 
 
Table 4.11 Tests of equality of survival distributions for the different levels of SIRT3 nuclear 
Histoscores (split above and below the median). 
Kaplan-Meier analysis of survival was performed with SIRT3 cytoplasmic 
Histoscore divided into quartiles. There was no significant difference in equality 
of survival distribution between quartiles. 
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Figure 4.54 Kaplan-Meier survival curves for SIRT3 cytoplasmic Histoscores split in 
quartiles. 
 
Table 4.12 Tests of equality of survival distributions for the different levels of SIRT3 
cytoplasmic Histoscores (split in quartiles). 
4.8.3 Effect of SIRT4 expression in colorectal tumour tissue on 
survival. 
SIRT4 nuclear staining was weak and infrequent, and there was no way to 
differentiate cases into the lower three quartiles. Kaplan-Meier analysis of 
survival was therefore performed with SIRT4 nuclear Histoscore divided into 
lowest three quartiles and highest quartile. There was no significant difference 
in equality of survival distribution between the two groups. 
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Figure 4.55 Kaplan-Meier survival curves for SIRT4 nuclear Histoscores divided into lowest 
three quartiles and highest quartile. 
 
Table 4.13 Tests of equality of survival distributions for the different levels of SIRT4 nuclear 
Histoscores (divided into lowest three quartiles and highest quartile). 
Kaplan-Meier analysis of survival was performed with SIRT4 cytoplasmic 
Histoscore divided into quartiles. There was no significant difference in equality 
of survival distribution between quartiles. 
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Figure 4.56 Kaplan-Meier survival curves for SIRT4 cytoplasmic Histoscores split in 
quartiles. 
 
Table 4.14 Tests of equality of survival distributions for the different levels of SIRT4 
cytoplasmic Histoscores (split in quartiles). 
4.8.4 Effect of SIRT5 expression in colorectal tumour tissue on 
survival. 
SIRT5 nuclear staining was present in only 32 cases, and was thus so infrequent 
that it was not possible to divide cases into quartiles for comparison of survival. 
Kaplan-Meier analysis of survival was performed with SIRT5 cytoplasmic 
Histoscore divided into quartiles. There was no significant difference in equality 
of survival distribution between quartiles. 
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Figure 4.57 Kaplan-Meier survival curves for SIRT5 cytoplasmic Histoscores split in 
quartiles. 
 
Table 4.15 Tests of equality of survival distributions for the different levels of SIRT5 
cytoplasmic Histoscores (split in quartiles). 
Figure 4.58 Tests of equality of survival distributions for the different levels of SIRT5 
cytoplasmic Histoscores (split in quartiles). 
4.8.5 Effect of SIRT6 expression in colorectal tumour tissue on 
survival. 
Kaplan-Meier analysis of survival was performed with SIRT6 nuclear Histoscore 
divided into quartiles. There was no significant difference in equality of survival 
distribution between quartiles. 
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Figure 4.59 Kaplan-Meier survival curves for SIRT6 nuclear Histoscores split in quartiles. 
 
Table 4.16 Tests of equality of survival distributions for the different levels of SIRT6 nuclear 
Histoscores (split in quartiles). 
Kaplan-Meier analysis of survival was performed with SIRT6 cytoplasmic 
Histoscore divided into quartiles. There was no significant difference in equality 
of survival distribution between quartiles. 
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Figure 4.60 Kaplan-Meier survival curves for SIRT6 cytoplasmic Histoscores split in 
quartiles. 
 
Table 4.17 Tests of equality of survival distributions for the different levels of SIRT6 
cytoplasmic Histoscores (split in quartiles). 
4.8.6 Effect of SIRT7 expression in colorectal tumour tissue on 
survival. 
Kaplan-Meier analysis of survival was performed with SIRT7 nuclear Histoscore 
divided into quartiles. There was no significant difference in equality of survival 
distribution between quartiles. 
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Figure 4.61 Kaplan-Meier survival curves for SIRT7 nuclear Histoscores split in quartiles. 
 
Table 4.18 Tests of equality of survival distributions for the different levels of SIRT7 nuclear 
Histoscores (split in quartiles). 
Kaplan-Meier analysis of survival was performed with SIRT7 cytoplasmic 
Histoscore divided into quartiles. There was a significant difference between 
quartiles on log rank (Mantel-Cox) test (p=0.0088). There was no incremental 
relationship between SIRT7 cytoplasmic Histoscore by quartile and survival. 
There was no relationship between extremes of expression and survival, unlike 
the relationship with SIRT2 nuclear Histoscore. 
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Figure 4.62 Kaplan-Meier survival curves for SIRT7 cytoplasmic Histoscores split in 
quartiles.  
 
Table 4.19 Tests of equality of survival distributions for the different levels of SIRT7 
cytoplasmic Histoscores (split in quartiles). 
4.9 Regression analysis of effect of sirtuin expression on 
survival 
Univariate survival analysis was performed using Cox’s proportional hazards 
model, for Histoscores for each sirtuin and subcellular combination where 
Kaplan-Meier analysis of Histoscore quartiles showed a significant effect on 
equality of survival distribution. Univariate survival analysis was also performed 
for variables with accepted association with outcome from colorectal cancer. 
Data was available for smoking status for only 80% of cases and platelet count 
for only half the cases, so these variables were excluded from the analysis. 
Included variables and the corresponding p-values are listed in the figure below.  
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Variables with significant effect according to univariate survival analysis were 
included in a multivariate survival analysis also using Cox’s proportional hazards 
model. Composite variables were not included. Including composite variables has 
the effect of amplifying the effect their component variables have on the 
statistical analysis. Thus, of the variables identified as having a significant effect 
on survival in univariate analysis, the following were excluded: mGPS, Dukes’ 
stage and peritoneal involvement. The first of these are composite measures 
whose components have an effect on colorectal cancer outcome in their own 
right. Peritoneal involvement is part of the defining criteria for T stage. T stage 
was included instead to allow for the other aspects of local invasion that it 
measures over and above peritoneal involvement.  
A threshold p-value of less than or equal to 0.1 was used as the criterion for 
inclusion in the multivariate model. A stepwise backward procedure was used to 
derive a model of variables with independent relationship with survival. 
Variables were removed if the corresponding p-value was greater than 0.05. 
Nodal status (reflected in N stage), higher CRP, and presence of venous invasion 
and tumour perforation were independently associated with lower survival in 
this multivariate model. These are accepted risk factors which support the 
assumption that this is a cohort of characteristic colorectal cancer patients. 
Highest and lowest quartiles of SIRT2 nuclear protein levels are a novel risk 
factor associated with lower survival. 
Peritumoural inflammation and higher SIRT3 nuclear protein levels show a trend 
towards an effect on survival.  
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VARIABLE p-value
Age 0.209
BMI category 0.459
WCC 0.167
CRP 0.0052
Albumin 0.0042
mGPS 0.000024
Haemoglobin 0.585
Presentation (Elective or emergency) 0.058
SIRT2 Nuclear Histoscore categorised 
by extreme and middle quartiles
0.0022
SIRT2 Nuclear Histoscore categorised 
by quartiles
0.793
SIRT3 Nuclear Histoscore categorised 
about median
0.036
SIRT3 Nuclear Histoscore categorised 
absent or present
0.078
SIRT7 Cytoplasmic Histoscore 
categorised by quartiles
0.633
Dukes’ 0.00004
T stage 0.0047
N stage 0.000018
M stage 0.275
Differentiation category 0.223
Margin Invasion 0.00079
Tumour Perforation 0.0083
Peritoneal Involvement 0.00036
Venous Invasion 0.000031
Petersen Index 0.0000000051
Peritumoural inflammation 0.014
 
Figure 4.63 Univariate survival analysis was performed for the variables listed above, and 
the corresponding p-values are included. 
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Figure 4.64 Variables with independent relationship with survival from colorectal cancer, 
with corresponding p-values and hazard ratios. 
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4.10 Discussion 
Cellular events determine the development of a macroscopically evident 
tumour, which in turn contains a huge variety of cellular phenotypes. The 
measurements made in these investigations average over many cellular histories 
and current phenotypes, but they have revealed widespread alteration in protein 
expression on development of malignancy in colorectal tissue, and in the case of 
SIRT2, a robust effect on survival. 
4.10.1 SIRT2 protein levels in normal and colorectal tumour 
tissue 
There are 3 isoforms of SIRT2 shown to produce physiologically active proteins in 
humans. Not all of these have been demonstrated in all tissues, and none have 
been specifically demonstrated in colorectal tissue. The antibody used in these 
experiments did not distinguish between isoforms of SIRT2 (LifespanBiosciences 
2010). Given the subsequent effect on survival it would be useful to know more 
about the relative distribution of each one.  
SIRT2 nuclear and cytoplasmic Histoscores are generally lower in colorectal 
cancer specimens. There are no previous reports of SIRT2 protein expression in 
colorectal cancer for comparison. A sample of 23 glioblastoma samples showed a 
similar relationship in terms of cytoplasmic staining, but an opposite correlation 
for nuclear staining which was higher than normal in the tumour tissue (Imaoka, 
Hiratsuka et al. 2012). Kim et al used a qualitative scale and found that SIRT2 
staining was lower in all of 36 samples of breast tumour compared with adjacent 
normal tissue, but did not specify the subcellular localisation of the staining 
(Kim, Vassilopoulos et al. 2011). They also reported on 264 cases of HCC, of 
which 229 samples showed reduced staining for SIRT2 with respect to a group of 
unmatched normal samples, 125 showed no change, and 10 cases showed 
increased staining. 
In a cohort of 374 cases of oesophageal adenocarcinoma, SIRT2 was identified as 
one of three dysregulated biomarkers which conferred poorer prognosis(Ong, 
Shapiro et al. 2013). SIRT2 staining was only measured in cytoplasm and the 
‘dysregulated’ result was defined as low-level staining with respect to normal 
tissue (<10% cells positive). 
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SIRT2 mRNA levels were reduced in a range of human cancers (anaplastic 
oligodendroglioma, glioblastoma, clear cell renal carcinoma, and prostate 
carcinoma). SIRT2 mRNA levels were increased in 11 myeloid leukaemia 
cases(Dan, Klimenkova et al. 2012). 
Given the small number of studies, the variability of tissue types and form of 
SIRT2 expression measured (mRNA or protein) and the dearth of precise 
subcellular localisation data contained in them, it is not possible to comment 
simply on whether these results are in keeping with other data. It is notable 
though that there is a tendency for reduced SIRT2 mRNA expression and protein 
levels across a wide range of cancers and the data presented here are broadly in 
keeping with this trend. 
4.10.2 SIRT2 tumour Histoscore and association with survival 
SIRT2 nuclear Histoscores in lowest and highest quartile are associated with 
worse survival in colorectal cancer in this cohort. While this pattern is common 
in many physiological measurements where homeostatic mechanisms are 
designed to keep parameters within a ‘normal’ range, it is slightly more difficult 
to interpret the significance of this observation against a background of 
generally reduced SIRT2 nuclear Histoscore with respect to normal tissue. The 
matched cohort on which this observation is based was very small. 
The only other study identified linking SIRT2 nuclear protein levels with survival 
is referred to above (Kim, Vassilopoulos et al. 2011) and used glioblastoma 
specimens. These investigators found an inverse relationship: high SIRT2 nuclear 
protein levels correlated with worse survival, and were higher than in normal 
tissue. This simpler relationship, with increasing SIRT2 nuclear protein 
expression associated with cancer, and a more marked increase associated with 
worse survival is easier to conceptualise. 
 SIRT2 function as a mitotic checkpoint sensor is an obvious focus for further 
research to understand the observed effects on survival described here. 
Overexpression mutants show prolonged mitotic phase(Nahhas, Dryden et al. 
2007). Overexpression also increases multinucleation, but so does the expression 
of a catalytically inactive form of SIRT2, reflecting the association with worse 
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survival in particularly high or low levels of SIRT2 expression reported here(North 
and Verdin 2007). SIRT2 deficiency in mice causes more mitotic abnormalities, 
aneuploidy and cell death(Kim, Vassilopoulos et al. 2011). 
There are several SIRT2 isoforms in existence, each of which may have several 
and different actions in the nucleus. The shorter isoform is associated with 
reduced cell survival(Nahhas, Dryden et al. 2007). Information linking isoforms 
with actions and substrates is needed. Understanding the balance of SIRT2 
isoforms in normal tissue, the variability among individuals and how the isoform 
levels change in the development of cancer would allow us to begin to fully 
understand the effect of SIRT2 on survival. However, the current results do 
highlight the significance of this protein as a useful focus for research and a 
possible therapeutic target in colorectal cancer and potentially in other 
malignancies as well. 
4.10.3 SIRT3 protein levels in normal and colorectal tumour 
tissue 
The antibody used in these experiments did not differentiate between the long 
and short isoforms of the SIRT3 protein. The datasheet notes that it was 
developed in response to a peptide corresponding to the human SIRT3 
sequence(CellSignalling 2010), but it is not clear if this identifies a specific part 
of the protein. This is relevant as there is evidence to suggest that both long and 
short forms are found in the nucleus(Scher, Vaquero et al. 2007), and an 
antibody recognising only the short form may give a falsely low reading of SIRT3 
nuclear protein expression. However this team did note very low endogenous 
protein levels for SIRT3, which is in keeping with the results found here. 
This is the first reported account of SIRT3 protein expression in normal 
colorectal and colorectal tumour tissue. Of note, in comparison with other 
sirtuins, absolute Histoscore (and by inference, absolute protein levels) are very 
low. SIRT3 levels in the nucleus in both normal and tumour tissue are much 
lower than cytoplasmic expression. This is not indicative of level of importance 
of interactions with other proteins and may rather indicate specificity and 
precision of effect. 
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SIRT3 staining in both nuclear and cytoplasmic compartments are higher in 
tumour tissue, although this difference is only statistically significant in regard 
to cytoplasmic SIRT3. Previous work in this laboratory has noted reduced levels 
of SIRT3 mRNA in colorectal tumour samples with respect to matched normal 
tissue(Maxwell 2013). The alteration in protein expression in the opposite 
direction suggests significant differences in post-translational processing in 
normal and tumour tissue, which would bear further examination. 
Depending on context, abundant SIRT3 could have a variety of different effects 
as indicated in a recent review on the place of SIRT3 in cancer cell 
function(Alhazzazi, Kamarajan et al. 2013). However, the presence of 
differential expression in tumour tissue highlights an anomaly worth 
investigation particularly in light of the worse survival associated with lower 
SIRT3 nuclear staining in tumour tissue. 
4.10.4 SIRT3 tumour Histoscore and association with survival 
SIRT3 cytoplasmic Histoscore was not associated with survival. Low SIRT3 nuclear 
Histoscore was associated with worse survival, although this effect did not reach 
significance on multivariable analysis. SIRT3 protein localisation to the nucleus is 
not entirely accepted in the field, but the weight of evidence for its presence 
and function there is growing(Scher, Vaquero et al. 2007; Iwahara, Bonasio et al. 
2012). Through this observed effect on survival in a relatively large study, this 
data indicates the likelihood that SIRT3 has relevant functions in histone 
deacetylation and genetic silencing. It is of interest that Iwahara’s team found 
that the long form of SIRT3 has a relatively short half-life in the nucleus, 
indicating that it can be controlled relatively tightly, possibly allowing for 
precise control of target gene expression. 
 A better understanding of the interactions which underlie the effect of SIRT3 on 
survival in univariate analysis, and the confounding factors which actually have 
the effect on survival, might open novel therapeutic avenues. 
4.10.5 SIRT4 protein levels in normal and colorectal tumour 
tissue 
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The most surprising finding in the Histoscore analysis of SIRT4-stained tissue is 
the nuclear staining observed in both normal and tumour tissue. The antibody 
used in these studies was polyclonal and directed to C-terminal amino acids of 
human SIRT4, ensuring that it did not interfere with mitochondrial 
localisation(Abcam 2010). 
Nuclear staining was not expected. This was weak and by no means ubiquitous. 
However, it was substantially higher than SIRT3 staining, and although the fact 
and relevance of SIRT3’s presence in the nucleus has been the subject of 
controversy, substrates and physiological relevance of SIRT3 action in the 
nucleus are coming to light. Therefore, it is possible that this report of SIRT4 
staining in the nucleus of colorectal cells may represent hitherto unsuspected 
activity in transcription regulation, as is seen in many of the other sirtuins. 
 
Figure 4.65 Comparison of SIRT3 and SIRT4 nuclear Histoscores in normal colorectal 
tissue. 
SIRT4 nuclear staining was significantly reduced in tumour tissue. It is difficult to 
interpret this finding given that there is no accepted substrate for SIRT4 in the 
nucleus. Given data suggesting that SIRT4 inhibits expression of SIRT3 and 
SIRT1(Nasrin, Wu et al. 2010) this finding opens the possibility of direct 
inhibitory action of SIRT4, with a concomitant release of inhibition of SIRT3 and 
SIRT1 in colorectal tumours. 
Comparison of cytoplasmic SIRT4 Histoscores showed a relatively strong 
correlation between matched normal and tumour samples, and tumours tend to 
show lower SIRT4 staining. Does some characteristic of malignant transformation 
affect SIRT4 cytoplasmic staining in a reliable manner? Given the lack of data on 
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SIRT4 action at all, and particularly in cancer, it is difficult to speculate. This 
result stands out because it is the one example of retained order in the 
comparison of normal and transformed colorectal epithelium. One possibility is 
that retained functions of SIRT4 in the cytoplasm contribute to the transformed 
phenotype. 
SIRT4 knockdown decreases calcium-mediated induction of mitochondrial 
permeability transition pore opening, and increases calcium-retaining capacity 
of mitochondria(Verma, Shulga et al. 2013). This may be a protective strategy 
for tumour cells which have lost the capacity to precisely regulate calcium flux, 
allowing them to manage intracellular calcium leaks, and contribute to the 
immortality characteristic of transformed cells. 
4.10.6 SIRT5 nuclear expression in normal and colorectal 
tumour tissue: association with age 
SIRT5 expression in the nucleus has only recently been suggested and where 
reported is confined to subsets of cells tested(Pfister, Ma et al. 2008; Park, Chen 
et al. 2013). Overexpression of SIRT3 and SIRT5 in COS7 cells has shown 
translocation of only SIRT3 to the nucleus(Nakamura, Ogura et al. 2008). Our 
data do not support SIRT5 expression in normal colorectal epithelial cell nuclei 
as no nuclear SIRT5 staining was observed in the 20 normal samples examined in 
this study, but this number is probably too small to draw definitive conclusions. 
It is interesting that it is expressed in tumour tissue nuclei and that there is a 
weak association with age (next chapter), so further corroboration and 
information on its function will be useful. 
The antibody used here recognises a peptide based on amino acids181-230 of the 
human SIRT5 protein, and will therefore recognise both of the isoforms 
transcribed from the SIRT5 gene(Abcam 2010 ) but will not distinguish between 
them. 
4.10.7 SIRT5 cytoplasmic expression: reduced but no 
association with survival 
The significant reduction in cytoplasmic expression of SIRT5 in tumour tissues 
with respect to normal epithelium could have widespread effects on protein 
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lysine succinylation on the basis of recently reported effects in mice(Park, Chen 
et al. 2013). They showed that 779 proteins were subject to succinylation and 
that a sizeable proportion of Sirt5 was located outside the mitochondria. 
Confirmation of similar findings in humans and in colorectal tissue rather than 
fibroblasts is probably the first step before extrapolating to expect a survival 
effect from reduction in SIRT5 levels. Equally many of the protein targets have 
multiple lysine succinlylation sites, so that they could integrate regulation from 
several different sources. This may also be why there is no significant effect on 
survival in this study despite the notable variation from normal. 
4.10.8 SIRT6 protein levels in normal and colorectal tumour 
tissue 
Reports on function and localisation thus far have placed SIRT6 firmly in the 
nucleus, with variable nucleolar access. The most recent paper, on breast 
cancer, has commented on SIRT6 cytoplasmic staining, which tended to 
associate with better prognosis (Khongkow, Olmos et al. 2013). SIRT6 staining in 
colorectal tissue has been reported previously although localisation of staining 
was not specifically mentioned (Sebastian, Zwaans et al. 2012). 
In contrast to this trend in the literature, SIRT6 cytoplasmic Histoscores were 
generally higher (by a factor of ten) than nuclear scores in this cohort, indicating 
significant protein levels in cytoplasm in both normal and tumour cases relative 
to the nucleus. Cytoplasmic staining patterns in some cases showed specific 
intracytoplasmic conglomerations, although it was not possible to tell whether 
these were associated with intracellular organelles or possibly with containment 
in vesicles. 
Nuclear Histoscores in tumour tissue were higher than in normal tissue. There 
was a similar less marked effect on comparison of matched cytoplasmic scores, 
which did not reach statistical significance. The unmatched comparison between 
the full cohorts of tumour and normal samples did show a significant difference, 
and although tumour cytoplasmic SIRT6 staining shows great variability, it 
appears to be stronger. This is in contrast to previous work on mRNA levels of 
SIRT6 in colorectal and breast cancer(Ashraf, Zino et al. 2006; Maxwell 2013). 
Differences in post-translational processing may underlie the variation in results. 
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Future research is likely to shed interesting light on the function and tissue 
distribution of SIRT6 cytoplasmic expression. 
4.10.9 SIRT6 tumour Histoscore and association with survival 
There was no difference in survival distribution when SIRT6 Histoscores in either 
the nuclear or cytoplasmic compartments were divided by quartile. Published 
observations on SIRT6 expression in colorectal cancer reported reduced staining 
in cancer specimens, with no effect on survival in node-negative patients with 
high SIRT6 Histoscores, but improved survival in node-positive patients 
(Sebastian, Zwaans et al. 2012). Similar subgroup analysis was not performed on 
this cohort. 
In breast cancer(Khongkow, Olmos et al. 2013), high nuclear SIRT6 was 
associated with poorer survival. Although SIRT6 cytoplasmic staining was noted 
in the tumour samples stained, it was not clear how staining patterns compare 
to those in normal tissue. 
4.10.10 SIRT7 levels in normal and colorectal tumour tissue 
The antibody used in these experiments was raised against amino acids 35-51 
and 361-377 of the 400 amino acid SIRT7 protein and therefore recognises both 
N- and C-terminal sequences (Abcam 2010). The C-terminus contains the 
nucleolar localisation sequence while the nuclear localisation sequence is 
positioned near the N-terminus. This antibody does not distinguish between the 
47.5 kDa and 45kDa forms of SIRT7. Since these differ due to post-translational 
processing, it is not known whether it identifies both forms at all or with the 
same affinity. 
The only previous publication to mention SIRT7 staining in human colorectal 
tissue reported heavy cytoplasmic staining in normal colorectal tissue, but no 
nuclear staining (Kiran, Chatterjee et al. 2013). In contrast, nuclear staining was 
noted in both normal and tumour tissue in the TMA examined here, and was 
comparable in both tissue groups. 
Cytoplasmic staining measured by Histoscore was much higher than nuclear 
staining, in both normal and tumour tissue, in this dataset. The unmatched 
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comparison showed significantly lower cytoplasmic Histoscore in tumour tissue 
with respect to normal tissue. This is in keeping with mRNA studies which 
showed lower levels of SIRT7 mRNA in colorectal tumour tissue in comparison to 
matched normal samples, and with the previous study on colorectal tissue 
alluded to above. Further information on the function of this highly prevalent 
protein in the cytoplasm will be enlightening. 
4.10.11 SIRT7 tumour Histoscore and association with survival 
There is no difference between survival distributions for SIRT7 nuclear 
Histoscores divided in quartiles on Kaplan-Meier analysis. On Kaplan-Meier 
analysis of SIRT7 cytoplasmic Histoscore divided in quartiles, there was a 
significant difference in survival distributions on log-rank test, but reduced 
survival was associated with second quartile and highest quartile SIRT7 
cytoplasmic Histoscore. There was no incremental association with SIRT7 
Histoscore quartiles, or association with highest and lowest quartiles of SIRT7 
Histoscore as seen with SIRT2 nuclear Histoscores. On univariate survival 
analysis, SIRT7 Histoscore divided in quartiles had no significant effect on 
survival. It was not therefore included in multivariate regression analysis. It is 
unlikely that the significant difference in survival distributions noted in Kaplan-
Meier analysis translates into a true effect on survival from colorectal cancer. 
There has only been one previous report on a survival effect of SIRT7 protein 
expression in cancer: in 39 cases of head and neck cancer, protein expression 
was nuclear rather than cytoplasmic and lower than in normal tissue (Lai, Lin et 
al. 2013). Lai et al reported no association with survival. These results are in 
keeping with the findings here in colorectal cancer. 
 5 Sirtuin Expression in Colorectal Tumours and 
Relation with Clinicopathological Factors 
Associations between clinicopathological factors and Histoscores for each 
combination of sirtuin and subcellular location in tumour samples were 
examined; the rationale for these analyses was explained in the Experimental 
Methods chapter. There were insufficient numbers of normal samples in the TMA 
used for meaningful analysis of associations with clinicopathological factors. 
Data on associations between 23 clinicopathological variables and sirtuin 
Histoscores in nucleus and cytoplasm in colorectal tumour tissue are presented 
below. p<0.01 was accepted as the level of statistical significance; associations 
with p-value >0.01 are lowlighted in grey text in summary results tables.  
5.1 Clinical and Pathological Characteristics of the 
Patient Cohort 
Clinical and pathological characteristics of this patient cohort (n=272) are 
summarised in the table overleaf. 
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Sex M 147 Dukes' stage A 20 
 F 125  B 132 
 Total 272  C 119 
Age  <65 97  D 1 
 65<X<75 89  Total 272 
 >75 86 T stage 1 9 
 Total 272  2 20 
BMI  <20 15  3 162 
 20-25 81  4 81 
 25.1-30 71  Total 272 
 >30 25 N stage 0 152 
 Total 192  1 91 
Albumin   <35 230  2 29 
 >35 42  Total 272 
 Total 272 Differentiation Poor 33 
CRP  >10 123  Well/Mod 239 
 <10 149  Total 272 
 Total 272 Peritoneum involved Y 80 
mGPS 0 149  N 192 
 1 91  Total 272 
 2 32 Margin involved Y 21 
 Total 272  N 251 
Anaemia None 116  Total 272 
 Mild 65 Venous invasion Y 99 
 Severe 55  N 173 
 Total 236  Total 272 
Smoker N 98 Tumour perforation Y 10 
 Y 27  N 262 
 Total 125  Total 272 
Elective 
presentation 
Y 254 High risk Petersen 
Index 
Y 52 
 N 18  N 220 
 Total 272  Total 272 
Tumour 
location 
Colon 183 PTI Y 53 
 Rectum 89  N 195 
 Total 272  Total 248 
Table 5.1 Clinicopathological characteristics of the patient cohort who contributed tissue to 
the TMA used for sirtuin Histoscore analysis. 
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5.2 SIRT2 Expression in Colorectal Tumours and 
Relation with Clinicopathological Factors 
Associations between SIRT2 nuclear and cytoplasmic Histoscores and 
clinicopathological factors are summarised in the following tables and significant 
associations are subsequently discussed in more detail. Associations with 
extreme quartiles of SIRT2 nuclear Histoscores were assessed in view of the 
relationship between extreme quartiles of SIRT2 nuclear Histoscore and survival 
described in the previous chapter.
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Nucleus Nucleus:(extreme(quartiles Cytoplasm
Age Pearson(Chi(square,(p=0.606
Extreme(quartile(Histoscores(
were(associated(with(extremes(
of(age.(Pearson(Chi(square,(
p=0.045,(LinearBbyBlinear,(
p=0.940 Pearson(Chi(square,(p=0.513
Sex Pearson(Chi(square,(p=0.806 Pearson(Chi(square,(p=0.623 Pearson(Chi(square,(p=0.049
BMI Pearson(Chi(square,(p=0.654 Pearson(Chi(square,(p=0.518
Low(Histoscores(associated(with(
increased(BMI.(Pearson(Chi(
square,(p=0.047,(linearBbyBlinear,(
p=0.031
WCC
High(Histoscores(were(associated(
with(high(WCC.(KruskalBWallis(test,(
p=0.0225 Pearson(Chi(square,(p=0.069 Pearson(Chi(square,(p=0.918
CRP
Highest(quartile(Histoscores(were(
associated(with(high(CRP.(KruskalB
Wallis(test,(p=0.0038
Extreme(quartile(Histoscores(
were(associated(with(high(CRP.(
MannBWhitney(U(test,(p=0.001 Pearson(Chi(square,(p=0.622
Albumin
Lowest(quartile(Histoscores(were(
associated(with(low(albumin.((
Pearson(Chi(square,(p=0.027
Extreme(quartile(Histoscores(
were(associated(with(high(
albumin.(Pearson(Chi(square,(
p=0.009
Lower(albumin(was(associated(
with(lowest(quartile(SIRT2(
cytoplasmic(staining((MannB
Whitney(U(test,(p=0.0068).
mGPS
Highest(quartile(Histoscore(was(
associated(with(high(mGPS.(
Pearson(Chi(square,(p=0.028,(
linearBbyBlinear,(p=0.010
Extreme(quartile(Histoscores(
were(associated(with(high(
mGPS.(Pearson(Chi(square,(
p=0.001,(linearBbyBlinear,(
p=0.0018 Pearson(Chi(square,(p=0.866
SIRT2
Demographic(
variables
Inflammatory(
markers
 
Table 5.2 Associations between SIRT2 nuclear and cytoplasmic Histoscores and demographic variables, and classical markers of inflammation. 
Relationships with extreme quartiles of nuclear Histoscores were assessed in view of the relationship between extreme quartiles of SIRT2 nuclear 
Histoscore and survival described in the previous chapter. Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise 
indicated. 
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Table 5.3 Associations between SIRT2 nuclear and cytoplasmic Histoscores and atypical markers of inflammation, mode of presentation, tumour location, 
measures of cancer stage and Charlson Comorbidity Index. Relationships with extreme quartiles of nuclear Histoscores were assessed in view of the 
relationship between extreme quartiles of SIRT2 nuclear Histoscore and survival described in the relevant chapter. Pearson Chi square p-values are for 
sirtuin Histoscores split about the median unless otherwise indicated. 
Nucleus Nucleus:(extreme(quartiles Cytoplasm
Hb
Highest(quartile(was(associated(
with(severe(anaemia.(Pearson(Chi(
square,(p=0.027,(linear>by>linear,(
p=0.096 Pearson(Chi(square,(p=0.380 Pearson(Chi(square,(p=0.829
Smoking(status Pearson(Chi(square,(p=0.503 Pearson(Chi(square,(p=0.104 Pearson(Chi(square,(p=0.233
Lower(Histoscore(was(associated(
with(elective(presentation,(
Pearson(Chi(square,(p=0.014
Extreme(quartile(Histoscores(
were(associated(with(elective(
presentation,(Pearson(Chi(
square,(p=0.015 Pearson(Chi(square,(p=0.625
Pearson(Chi(square,(p=0.092 Pearson(Chi(square,(p=0.310 Pearson(Chi(square,(p=0.154
Pearson(Chi(square,(p=0.793 Pearson(Chi(square,(p=0.600 Pearson(Chi(square,(p=0.793
Dukes'(stage
Low(Histoscore(was(associated(
with(lower(Dukes'(stage.(Pearson(
Chi(square,(p=0.058,(Linear>by>
linear,(p=0.040 Pearson(Chi(square,(p=0.259 Pearson(Chi(square,(p=0.638
T(stage
Higher(Histoscore(was(associated(
with(higher(T(stage.(Pearson(Chi(
square,(p=0.045,(linear>by>linear,(
p=0.018
Extreme(Histoscore(was(
associated(with(higher(T(stage.(
Pearson(Chi(square,(p=0.150,(
linear>by>linear(association,(
p=0.0430 Pearson(Chi(square,(p=0.470
N(stage
Highest(quartile(Histoscore(was(
associated(with(higher(N(stage.(
Pearson(Chi(square,(p=0.032,(
linear>by>linear,(p=0.013 Pearson(Chi(square,(p=0.159 Pearson(Chi(square,(p=0.798
M(stage Pearson(Chi(square,(p=0.316 Pearson(Chi(square,(p=0.316 Pearson(Chi(square,(p=0.316
Presentation
Charlson(Comorbidity(Index
Tumour(location
Atypical(markers(of(
inflammation
Measures(of(cancer(
staging
SIRT2
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Nucleus Nucleus:(extreme(quartiles Cytoplasm
Differentiation
Higher'Histoscores'were'
associated'with'poor'
differentiation.'Mann4Whitney'U'
test,'p=0.0007 Pearson'Chi'square,'p=0.132 Pearson'Chi'square,'p=0.706
Margin(
involvement Pearson'Chi'square,'p=0.642 Pearson'Chi'square,'p=0.163
Highest'quartile'was'associated'
with'margin'involvement.'
Pearson'Chi'square,'p=0.043
Peritoneal(
involvement Pearson'Chi'square,'p=0.178 Pearson'Chi'square,'p=0.059
Lowest'quartile'Histosore'was'
associated'with'peritoneal'
involvement.'Pearson'Chi'square,'
p=0.017
Tumour(
perforation Pearson'Chi'square,'p=0.197 Pearson'Chi'square,'p=0.197 Pearson'Chi'square,'p=1.000
Venous(invasion
Highest'quartile'Histoscore'was'
associated'with'venous'invasion.'
Pearson'Chi'square,'p=0.0091
Extreme'quartile'Histoscores'
were'associated'with'venous'
invasion.'Pearson'Chi'square,'
p=0.022 Pearson'Chi'square,'p=0.309
High(risk(Petersen(
index
Highest'quartile'Histoscore'was'
associated'with'high'risk'PI.'Mann4
Whitney'U'test,'p=0.0378
Extreme'quartile'Histoscores'
were'associated'with'high'risk'
PI.'Pearson'Chi'square,'p=0.003 Pearson'Chi'square,'p=0.640
High'Histoscore'was'associated'
with'absence'of'PTI.'Mann4
Whitney'U'test,'p=0.0483 Pearson'Chi'square,'p=0.696 Pearson'Chi'square,'p=0.377
Pathological(
prognostic(markers
Peritumoural(Inflammation
SIRT2
 
Table 5.4 Associations between SIRT2 nuclear and cytoplasmic Histoscores and histopathological markers of prognostic significance in colorectal cancer. 
Relationships with extreme quartiles of nuclear Histoscores were assessed in view of the relationship between extreme quartiles of SIRT2 nuclear 
Histoscore and survival described in the relevant chapter. Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise 
indicated. 
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5.2.1 Association with inflammatory markers 
5.2.1.1 Association with serum C-reactive protein 
Extremes of SIRT2 staining in the nucleus (highest and lowest quartiles) were 
associated with higher serum CRP. Kruskal-Wallis test indicated this pattern as 
shown in the boxplots below (p=0.0038), and the relationship was stronger when 
SIRT2 nuclear Histoscores were categorised into ‘extreme’ (lowest and highest 
quartile) and middle quartiles (Mann-Whitney U test, p=0.001). 
 
Figure 5.1 Boxplots showing distribution of preoperative serum CRP categorised according 
to quartiles of SIRT2 nuclear Histoscores. Highest and lowest quartile SIRT2 nuclear 
Histoscores were associated with higher CRP (Mann-Whitney U test, p=0.001). 
5.2.1.2 Association with serum albumin 
Low albumin was associated with extremes of SIRT2 nuclear staining (Chi square 
test, p=0.009). 
Highest or 
lowest quartile
Middle 2 
quartiles
>35 106 121 227
<35 27 12 39
133 133 266Total
SIRT2 Nuclear Histoscore
Total
Albumin
 
Table 5.5 Crosstabulation of high and low albumin (split about 35, the dividing point used in 
the modified Glasgow Prognostic Score) and SIRT2 nuclear Histoscores, divided into 
‘extremes’ (highest and lowest quartiles, and middle two quartiles). Chi square analysis 
showed significant association between extreme values of SIRT2 nuclear Histoscores and 
low albumin (p=0.009). 
Lower albumin was associated with lowest quartile SIRT2 cytoplasmic staining 
(Mann-Whitney U test, p=0.0068). 
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Figure 5.2 Boxplots showing preoperative albumin categorised by SIRT2 nuclear Histoscore 
split in quartiles (Kruskal-Wallis test, p=0.0275). Mann-Whitney U test showed that low 
albumin is associated with lowest quartile SIRT2 nuclear Histoscore (p=0.0068). 
5.2.1.3 Association with modified Glasgow Prognostic Score 
High modified Glasgow Prognostic Score (mGPS) was associated with highest 
quartile SIRT2 nuclear staining, (Pearson Chi square, p=0.028, linear-by-linear, 
p=0.010). 
Highest 
quartile
3 lowest 
quartiles
0 118 28 146
1 61 29 90
2 19 11 30
198 68 266Total
SIRT2 Nuclear Histoscore
Total
mGPS
 
Table 5.6 Crosstabulation of mGPS with SIRT2 nuclear Histoscores by highest quartile and 
lower 3 quartiles. Highest quartile Histoscore is associated with high mGPS. Pearson Chi 
square, p=0.028, linear-by-linear, p=0.010. 
High mGPS (more inflammation) was more strongly associated with extremes of 
SIRT2 nuclear staining (Pearson Chi square, p=0.001, linear-by-linear association, 
p=0.00018). 
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Extreme 
quartiles
Middle 2 
quartiles
0 60 86 146
1 50 40 90
2 23 7 30
133 133 266Total
SIRT2 Nuclear Histoscore
Total
mGPS
 
Table 5.7 Crosstabulation of mGPS with SIRT2 nuclear Histoscores categorised in extreme 
quartiles, and middle quartiles showed a stronger relationship than simply with SIRT2 
nuclear Histoscores categorised in quartiles (Pearson Chi square, p=0.001, linear-by-linear 
association, p=0.00018. 
5.2.2 Association with histological markers of prognostic 
significance 
5.2.2.1 Associations with histological factors of prognostic 
significance 
Higher SIRT2 nuclear staining was associated with poorly differentiated tumours 
(Mann-Whitney U test, p=0.0007).  
Highest quartile SIRT2 nuclear staining was associated with venous invasion (Chi 
square test, p=0.0091). 
3 lower 
quartiles
Highest 
quartile
N 134 34 168
Y 64 34 98
198 68 266Total
SIRT2 Nuclear Histoscore
Total
Venous 
invasion
 
Table 5.8 Crosstabulation of venous invasion and SIRT2 nuclear Histoscore showed 
significant association between lowest quartile SIRT2 nuclear Histoscore and venous 
invasion (Chi square analysis, p=0.0091). 
5.3 SIRT3 Expression in Colorectal Tumours and 
Relation with Clinicopathological Factors 
Associations between SIRT3 nuclear and cytoplasmic Histoscores and 
clinicopathological factors are summarised in the following tables and significant 
associations are subsequently discussed in more detail.
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Nucleus Cytoplasm
Age Pearson(Chi(square,(p=0.307
Higher(Histoscore(was(associated(with(older(age.(
Mann=Whitney(U(test,(p=0.0185
Sex Pearson(Chi(square,(p=0.553 Pearson(Chi(square,(p=0.109
BMI Pearson(Chi(square,(p=0.815 Pearson(Chi(square,(p=0.932
WCC
Higher(Histoscores(were(associated(with(high(
WCC.(Pearson(Chi(square,(p=0.092,(linear=by=
linear,(p=0.029
Lower(Histoscores(were(associated(with(high(
WCC.(Mann=Whitney(U(test,(p=0.0059
CRP Pearson(Chi(square,(p=0.692
Low(Histoscore(was(associated(with(high(CRP.(
Mann=Whitney(U(test,(p=0.0009
Albumin
Highest(quartile(SIRT3(nuclear(Histoscores(were(
associated(with(higher(preoperative(serum(
albumin,(Mann=Whitney(U(test,(p=0.012.
Lowest(quartile(Histoscore(was(associated(with(
lower(albumin.(Mann=Whitney(U(test,(p=0.0438
mGPS Pearson(Chi(square,(p=0.499
Higher(Histoscores(were(associated(with(low(
mGPS.(Pearson(Chi(square,(p=0.062,(linear=by=
linear,(p=0.026
Hb Pearson(Chi(square,(p=0.989
Lower(Histoscores(were(associated(with((
anaemia.(Mann=Whitney(U(test,(p=0.00029
Smoking>status
High(Histoscore(was(associated(with(smoking(
status.(Pearson(Chi(square,(p=0.036 Pearson(Chi(square,(p=0.418
Presence(of(nuclear(staining(was(associated(with(
emergency(presentation.(Mann=Whitney(U(test,(
p=0.038 Pearson(Chi(square,(p=0.452
Pearson(Chi(square,(p=0.747 Pearson(Chi(square,(p=0.206
Pearson(Chi(square,(p=0.825 Pearson(Chi(square,(p=0.151
SIRT3
Demographic>
variables
Inflammatory>
markers
Atypical>
markers>of>
inflammation
Charlson>Comorbidity>Index
Tumour>location
Presentation
 
Table 5.9 Associations between SIRT3 nuclear and cytoplasmic Histoscores and demographic variables, classical and atypical markers of inflammation, 
comorbidity, presentation and tumour location. Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise indicated. 
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Nucleus Cytoplasm
Dukes'1stage Pearson(Chi(square,(p=0.488 Pearson(Chi(square,(p=0.743
T1stage Pearson(Chi(square,(p=0.704
Low(Histoscore(was(associated(with(higher(T(
stage.(Pearson(Chi(square,(p=0.064,(linearAbyA
linear,(p=0.034
N1stage Pearson(Chi(square,(p=0.614 Pearson(Chi(square,(p=0.806
M1stage Pearson(Chi(square,(p=0.309 Pearson(Chi(square,(p=0.316
Differentiation
Nuclear(staining(was(associated(with(poor(
differentiation.(Pearson(Chi(square,(p=0.013
Poor(differentiation(was(associated(with(lower(
Histoscore.(MannAWhitney(U(test,(p=0.0055
Margin1
involvement Pearson(Chi(square,(p=0.593 Pearson(Chi(square,(p=0.163
Peritoneal1
involvement Pearson(Chi(square,(p=0.703 Pearson(Chi(square,(p=0.106
Tumour1
perforation Pearson(Chi(square,(p=0.099 Pearson(Chi(square,(p=0.309
Venous1invasion
Nuclear(staining(was(associated(with(venous(
invasion,(Pearson(Chi(square,(p=0.005 Pearson(Chi(square,(p=0.446
High1risk1
Petersen1index Pearson(Chi(square,(p=0.410 Pearson(Chi(square,(p=0.117
Pearson(Chi(square,(p=0.525
Lowest(quartile(Histoscore(was(associated(with(
PTI.(Pearson(Chi(square,(p=0.033Peritumoural1Inflammation
Measures1of1
cancer1staging
Pathological1
prognostic1
markers
SIRT3
 
Table 5.10 Associations between SIRT3 nuclear and cytoplasmic Histoscores and accepted factors of prognostic significance in colorectal cancer (cancer 
staging systems and histopathological markers). Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise 
indicated.
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5.3.1 Association with inflammatory markers 
5.3.1.1 Association with white cell count 
SIRT3 cytoplasmic staining above the median was associated with lower white 
cell count (Mann-Whitney U test, p=0.0059). 
5.3.1.2 Association with serum C-reactive protein (CRP) 
SIRT3 cytoplasmic Histoscores above the median were associated with lower 
preoperative serum CRP (Mann-Whitney U test, p=0.0009). There is a parallel 
between this association and the relationship with white cell count.  
5.3.2 Association with atypical inflammatory markers 
5.3.2.1 Association with haemoglobin 
Higher haemoglobin was associated with SIRT3 cytoplasmic Histoscores above 
the median (Mann-Whitney U test, p=0.00029). 
5.3.3 Associations with histological factors of prognostic 
significance in colorectal cancer 
Poorly differentiated tumours were more likely to have low cytoplasmic SIRT3 
staining (Mann-Whitney U test, p=0.0055).  
Presence of SIRT3 nuclear staining was associated with peritumoural venous 
invasion (a positive prognostic factor) (Pearson Chi square, p=0.005). 
Absent Present
70 98 168
24 74 98
94 172 266Total
Venous 
invasion
SIRT3 Nuclear Histoscore
Total
N
Y
 
Table 5.11 Crosstabulation of venous invasion and presence of SIRT3 nuclear staining. 
There was an association between presence of nuclear staining and venous invasion 
(Pearson Chi square, p=0.005). 
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5.4 SIRT4 Expression in Colorectal Tumours and 
Relation with Clinicopathological Factors 
Associations between SIRT4 nuclear and cytoplasmic Histoscores and 
clinicopathological factors are summarised in the table above and significant 
associations are then discussed in more detail. 
Table 5.12 (following page) Associations between SIRT4 nuclear and cytoplasmic 
Histoscores and demographic variables, markers of inflammation and accepted factors of 
prognostic significance in colorectal cancer. Pearson Chi square p-values are for sirtuin 
Histoscores split about the median unless otherwise indicated. 
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SIRT4& !Nucleus& Cytoplasm&
Demographic&
variables&
Age& Pearson!Chi!square,!p=0.879! Pearson!Chi!square,!p=0.568!
Sex& Pearson!Chi!square,!p=0.275! Pearson!Chi!square,!p=0.781!
BMI& Pearson!Chi!square,!p=0.294! Pearson!Chi!square,!p=0.936!
Inflammatory&
markers&
WCC& Pearson!Chi!square,!p=0.203! Lowest!quartile!Histoscore!was!
associated!with!normal!range!
WCC.!KruskalHWallis!test,!
p=0.0280!
CRP& Pearson!Chi!square,!p=0.342! Lower!quartile!Histoscores!
were!associated!with!higher!
CRP.!KruskalHWallis!test,!
p=0.00015!
Albumin& Pearson!Chi!square,!p=0.341! Pearson!Chi!square,!p=0.838!
mGPS& Pearson!Chi!square,!p=0.635! Higher!Histoscores!were!
associated!with!low!mGPS.!
KruskalHWallis!test,!p=0.0190!
Atypical&
markers&of&
inflammation&
Hb& Pearson!Chi!square,!p=0.333! Pearson!Chi!square,!p=0.675!
Smoking&status& Pearson!Chi!square,!p=0.167! Pearson!Chi!square,!p=0.253!
Presentation! Pearson!Chi!square,!p=0.135! Higher!Histoscore!was!
associated!with!elective!
presentation,!Pearson!Chi!
square,!p=0.020!
Charlson&Comorbidity&Index& Pearson!Chi!square,!p=0.300! Higher!Histoscore!was!
associated!with!lower!CCI.!
Pearson!Chi!square,!p=0.009,!
linearHbyHlinear,!p=0.261!
Tumour&location! Pearson!Chi!square,!p=0.906! Pearson!Chi!square,!p=0.832!
Measures&of&
cancer&staging&
Dukes'&stage& Pearson!Chi!square,!p=0.537! Pearson!Chi!square,!p=0.698!
T&stage& Pearson!Chi!square,!p=0.450! Pearson!Chi!square,!p=0.721!
N&stage& Pearson!Chi!square,!p=0.259! Pearson!Chi!square,!p=0.784!
M&stage& Pearson!Chi!square,!p=0.343! Pearson!Chi!square,!p=0.307!
Pathological&
prognostic&
markers&
Differentiation& Pearson!Chi!square,!p=0.968! Pearson!Chi!square,!p=0.214!
Margin&
involvement&
Pearson!Chi!square,!p=0.256! Pearson!Chi!square,!p=0.705!
Peritoneal&
involvement&
Pearson!Chi!square,!p=0.207! Pearson!Chi!square,!p=0.386!
Tumour&
perforation&
Pearson!Chi!square,!p=0.610! Pearson!Chi!square,!p=0.080!
Venous&invasion&Nuclear!staining!was!associated!
with!venous!invasion.!MannH
Whitney!U!test,!p=0.0181!
Highest!quartile!Histoscore!
was!associated!with!venous!
invasion.!Pearson!Chi!square,!
p=0.030!
High&risk&
Petersen&index&
Pearson!Chi!square,!p=0.168! Pearson!Chi!square,!p=0.646!
Peritumoural&Inflammation& Pearson!Chi!square,!p=0.110! Highest!quartile!Histoscore!
was!associated!with!absence!of!
PTI.!Pearson!Chi!square,!
p=0.029!
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5.4.1 Association with inflammatory markers 
5.4.1.1 Association with serum C-reactive protein (CRP) 
Higher CRP was associated with SIRT4 cytoplasmic Histoscore in the lower 
quartiles (Kruskal-Wallis test, p=0.00015). 
 
Figure 5.3 Boxplots of CRP categorised according to SIRT4 cytoplasmic Histoscore 
quartiles. There was a significant difference in the distribution of CRP grouped according to 
SIRT4 cytoplasmic Histoscore in quartiles. Higher CRP was associated with lower 
cytoplasmic SIRT4 Histoscores (Kruskal-Wallis test, p=0.00015). 
5.5 SIRT5 Expression in Colorectal Tumours and 
Relation with Clinicopathological Factors 
SIRT5 nuclear staining was infrequent and very weak and was therefore 
categorised as absent or present rather than in quartiles or about the median, as 
was the categorisation used for the other sirtuins and SIRT5 cytoplasmic staining. 
Associations between SIRT5 nuclear and cytoplasmic Histoscores and 
clinicopathological factors are summarised in the following tables and 
statistically significant associations are subsequently discussed in more detail. 
Table 5.13 (following page) Associations between SIRT5 nuclear and cytoplasmic 
Histoscores and demographic variables, markers of inflammation and accepted factors of 
prognostic significance in colorectal cancer. Pearson Chi square p-values are for sirtuin 
Histoscores split about the median unless otherwise indicated. 
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SIRT5& !Nucleus& Cytoplasm&
Demographic&
variables&
Age& Nuclear!staining!was!
associated!with!younger!age.!
KruskalHWallis!test,!p=0.044.!
Pearson!Chi!square,!p=0.133!
Sex& Pearson!Chi!square,!p=0.510! Pearson!Chi!square,!p=0.858!
BMI& Pearson!Chi!square,!p=0.407! Pearson!Chi!square,!p=0.287!
Inflammatory&
markers&
WCC& Pearson!Chi!square,!p=0.617! Lowest!quartile!Histoscore!was!
associated!with!higher!WCC.!
MannHWhitney!U!test,!p=0.0061!
CRP& Pearson!Chi!square,!p=0.201! Lowest!quartile!was!associated!
with!high!CRP.!MannHWhitney!U!
test,!p=0.0095!
Albumin& Nuclear!staining!was!
associated!with!higher!
albumin.!MannHWhitney!U!
test,!p=0.0234!
Lowest!quartile!Histoscore!was!
associated!with!lower!serum!
albumin.!MannHWhitney!U!test,!
p=0.017!
mGPS& Pearson!Chi!square,!p=0.435! Highest!quartile!was!associated!
with!low!mGPS.!Pearson!Chi!
square,!p=0.011,!linearHbyHlinear,!
p=0.006!
Atypical&
markers&of&
inflammation&
Hb& Pearson!Chi!square,!p=0.623! Pearson!Chi!square,!p=0.968!
Smoking&status& Pearson!Chi!square,!p=0.708! Pearson!Chi!square,!p=0.703!
Presentation! Pearson!Chi!square,!p=0.116! Pearson!Chi!square,!p=0.443!
Charlson&Comorbidity&Index& Pearson!Chi!square,!p=0.756! Pearson!Chi!square,!p=0.114!
Tumour&location! Pearson!Chi!square,!p=0.325! Pearson!Chi!square,!p=0.762!
Measures&of&
cancer&staging&
Dukes'&stage& Pearson!Chi!square,!p=0.604! Pearson!Chi!square,!p=0.410!
T&stage& Pearson!Chi!square,!p=0.640! Pearson!Chi!square,!p=0.775!
N&stage& Pearson!Chi!square,!p=0.498! Pearson!Chi!square,!p=0.201!
M&stage& Pearson!Chi!square,!p=0.712! Pearson!Chi!square,!p=0.318!
Pathological&
prognostic&
markers&
Differentiation& Pearson!Chi!square,!p=0.550! Poor!differentiation!was!
associated!with!lowest!quartile!
Histoscore.!Pearson!Chi!square,!
p=0.017!
Margin&
involvement&
Pearson!Chi!square,!p=0.718! Higher!Histoscore!was!associated!
with!margin!involvement.!MannH
Whitney!U!test,!p=0.0196!
Peritoneal&
involvement&
Pearson!Chi!square,!p=0.865! Pearson!Chi!square,!p=0.446!
Tumour&
perforation&
Pearson!Chi!square,!p=0.336! Tumour!perforation!was!
associated!with!lower!Histoscore.!
MannHWhitney!U!test,!p=0.0372!
Venous&invasion&Pearson!Chi!square,!p=0.221! Pearson!Chi!square,!p=0.401!
High&risk&
Petersen&index&
Pearson!Chi!square,!p=0.670! Pearson!Chi!square,!p=0.454!
Peritumoural&Inflammation& Pearson!Chi!square,!p=0.311! Pearson!Chi!square,!p=0.930!
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5.5.1 Association with inflammatory markers 
5.5.1.1 Association with white cell count 
Lowest quartile SIRT5 cytoplasmic Histoscore was associated with higher white 
cell count (Mann-Whitney U test, p=0.0061). 
 
Figure 5.4 Boxplots showing distribution of white cell count categorised by SIRT5 
cytoplasmic Histoscore in quartiles. Lowest quartile SIRT5 cytoplasmic Histoscore was 
associated with higher white cell count (Mann-Whitney U test, p=0.0061). 
5.5.1.2 Association with serum C-reactive protein (CRP) 
Lowest quartile SIRT5 cytoplasmic staining was associated with higher serum CRP 
(Mann-Whitney U test, p=0.0095). 
 
Figure 5.5 Boxplots showing preoperative serum CRP categorised by SIRT5 cytoplasmic 
Histoscore in quartiles. Lowest quartile SIRT5 cytoplasmic Histoscore was associated with 
higher CRP (Mann-Whitney U test, p=0.0095). 
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5.5.1.3 Association with modified Glasgow Prognostic Score (mGPS) 
Highest quartile SIRT5 cytoplasmic staining is associated with mGPS (Chi square 
test, linear by linear association, p=0.0248). 
Lower 3 
quartiles Highest quartile
0 101 44 145
1 70 20 90
2 29 3 32
200 67 267
SIRT5 Cytoplasmic Histoscore
Total
mGPS
Total
 
Table 5.14 Crosstabulation of mGPS with SIRT5 cytoplasmic Histoscores categorised 
highest and lower three quartiles. Low mGPS was associated with highest quartile 
cytoplasmic Histoscore (Pearson Chi square, p=0.011, linear-by-linear, p=0.006). 
5.6 SIRT6 Expression in Colorectal Tumours and 
Relation with Clinicopathological Factors 
Associations between SIRT6 nuclear and cytoplasmic Histoscores and 
clinicopathological factors are summarised in the following tables and significant 
associations are subsequently discussed in more detail.
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Nucleus Cytoplasm
Age Pearson(Chi(square,(p=0.929
Lowest(quartile(was(associated(with(lower(age.(
Pearson(Chi(square,(p=0.027,(linear=by=linear,(
p=0.096
Sex Pearson(Chi(square,(p=0.027
Female(sex(was(associated(with(lower(
Histoscore.(Mann=Whitney(U(test,(p=0.0357
BMI
Highest(quartile(Histoscore(was(associated(with(
higher(BMI.(Mann=Whitney(U(test,(p=0.0005 Pearson(Chi(square,(p=0.287
WCC
Lowest(quartile(Histoscore(was(associated(with(
lower(WCC.(Mann=Whitney(U(test,(p=0.0331
Histoscores(above(the(median(were(associated(
with(lower(WCC.(Mann=Whitney(U(test,(p=0.0009
CRP
Histoscores(above(the(median(were((associated(
with(low(CRP.(Mann=Whitney(U(test,(p=0.00013
Highest(quartile(Histoscore(was(associated(with(
low(CRP.(Mann=Whitney(U(test,(p=0.00003
Albumin Pearson(Chi(square,(p=0.431
Highest(quartile(SIRT6(cytoplasmic(Histoscore(
was(associated(with(higher(serum(albumin.(
Mann=Whitney(U(test,(p=0.0051
mGPS
Higher(Histoscore(was(associated(with(high(
mGPS.(Kruskal=Wallis(test,(p=0.0008
Lower(Histoscore(was(associated(with(high(
mGPS.(Kruskal=Wallis(test,(p=0.0054
Hb Pearson(Chi(square,(p=0.534
Highest(quartile(Histoscore(was(associated(with(
higher((haemoglobin.(Mann=Whitney(U(test,(
p=0.0036
Smoking>status Pearson(Chi(square,(p=0.644 Pearson(Chi(square,(p=0.369
Pearson(Chi(square,(p=0.492 Pearson(Chi(square,(p=0.452
Pearson(Chi(square,(p=0.119 Pearson(Chi(square,(p=0.630
Pearson(Chi(square,(p=0.762 Pearson(Chi(square,(p=0.509
SIRT6
Demographic>
variables
Inflammatory>
markers
Atypical>
markers>of>
inflammation
Presentation
Charlson>Comorbidity>Index
Tumour>location
 
Table 5.15 Associations between SIRT6 nuclear and cytoplasmic Histoscores and demographic variables, classical and atypical markers of inflammation, 
presentation, comorbidity and tumour location. Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise indicated. 
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Nucleus Cytoplasm
Dukes'1stage
Lowest'quartile'Histoscore'was'associated'with'
lower'Dukes''stage.'Pearson'Chi'square,'p=0.025,'
linear@by@linear,'p=0.049 Pearson'Chi'square,'p=0.582
T1stage Pearson'Chi'square,'p=0.679 Pearson'Chi'square,'p=0.766
N1stage
Lowest'quartile'Histoscore'was'associated'with'
lower'N'stage.'Pearson'Chi'square,'p=0.061,'
linear@by@linear,'p=0.036 Pearson'Chi'square,'p=0.641
M1stage Pearson'Chi'square,'p=0.309 Pearson'Chi'square,'p=0.316
Differentiation Pearson'Chi'square,'p=0.114
Poor'differentiation'was'associated'with'lower'
Histoscore.'Mann@Whitney'U'test,'p=0.0008
Margin1
involvement Pearson'Chi'square,'p=0.287
Low'Histoscore'was'associated'with'margin'
involvement.'Mann@Whitney'U'test,'p=0.0268
Peritoneal1
involvement Pearson'Chi'square,'p=0.571 Pearson'Chi'square,'p=0.346
Tumour1
perforation Pearson'Chi'square,'p=0.331 Pearson'Chi'square,'p=0.090
Venous1invasion
Highest'quartile'Histoscore'was'associated'with'
venous'invasion.'Pearson'Chi'square,'p=0.010 Pearson'Chi'square,'p=0.307
High1risk1
Petersen1index Pearson'Chi'square,'p=0.972
Lowest'quartile'Histoscore'was'associated'with'
high'risk'PI.'Pearson'Chi'square,'p=0.008
Pearson'Chi'square,'p=0.616 Pearson'Chi'square,'p=0.478
Measures1of1
cancer1staging
Peritumoural1Inflammation
Pathological1
prognostic1
markers
SIRT6
 
Table 5.16 Associations between SIRT6 nuclear and cytoplasmic Histoscores and accepted factors of prognostic significance in colorectal cancer (cancer 
staging systems and histopathological markers). Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise 
indicated.
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5.6.1 Association with demographic factors.  
5.6.1.1 Associations with BMI 
Highest quartile SIRT6 nuclear Histoscore was associated with higher BMI (Mann-
Whitney U test, p=0.0005). 
 
Figure 5.6 Boxplots showing distribution of BMI categorised by quartile of SIRT6 nuclear 
Histoscore. Highest quartile SIRT6 nuclear Histoscore was associated with higher BMI 
(Mann-Whitney U test, p=0.0005). 
5.6.2 Association with inflammatory markers 
5.6.2.1 Association with white cell count 
Lower white cell counts were associated with SIRT6 cytoplasmic Histoscore 
above the median (Mann-Whitney U test, p=0.0009). 
 
Figure 5.7 Boxplots showing distribution of white cell count by quartiles of SIRT6 
cytoplasmic Histoscore. SIRT6 cytoplasmic Histoscore above the median was associated 
with lower white cell count (Mann-Whitney U test, p=0.0009). 
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5.6.2.2 Association with serum C-reactive protein (CRP) 
SIRT6 nuclear Histoscores above the median were associated with higher CRP 
(Mann-Whitney U test, p=0.00013). 
 
Figure 5.8 Boxplots showing distribution of CRP by quartiles of SIRT6 nuclear Histoscore. 
SIRT6 nuclear Histoscore above the median was associated with higher CRP (Mann-Whitney 
U test, p=0.00013). 
Highest quartile SIRT6 cytoplasmic Histoscore was associated with low CRP 
(Mann-Whitney U test, p=0.00003). 
 
Figure 5.9 Boxplots showing distribution of CRP by quartiles of SIRT6 cytoplasmic 
Histoscore. Highest quartile SIRT6 cytoplasmic Histoscore was associated with lower CRP 
(Mann-Whitney U test, p=0.00003). 
5.6.2.3 Association with serum albumin 
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Highest quartile SIRT6 cytoplasmic Histoscore was associated with higher serum 
albumin (Mann-Whitney U test, p=0.0051). 
 
Figure 5.10 Boxplots showing distribution of preoperative albumin by quartiles of SIRT6 
cytoplasmic Histoscore. Highest quartile SIRT6 cytoplasmic Histoscore was associated with 
higher albumin (Mann-Whitney U test, p=0.0051). 
5.6.2.4 Association with modified Glasgow Prognostic Score (mGPS) 
High mGPS (more inflammation) was associated with higher SIRT6 nuclear 
staining (Kruskal-Wallis test, p=0.0008). 
 
Figure 5.11 Boxplots showing distribution of SIRT6 nuclear Histoscore categorised by 
mGPS. Higher SIRT6 nuclear Histoscore was associated with higher mGPS score (Kruskal-
Wallis test, p=0.0008). 
Increasing mGPS was associated with lower SIRT6 cytoplasmic staining, (Kruskal-
Wallis test, p=0.0054). 
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Figure 5.12 Boxplots showing distribution of SIRT6 cytoplasmic Histoscore categorised by 
mGPS. Lower SIRT6 cytoplasmic Histoscore was associated with higher mGPS score 
(Kruskal-Wallis test, p=0.0054). 
5.6.3 Association with atypical inflammatory markers 
5.6.3.1 Association with haemoglobin 
Highest quartile SIRT6 cytoplasmic Histoscore was associated with higher 
haemoglobin (Mann-Whitney U test, p=0.0036). 
 
Figure 5.13 Boxplots showing distribution of preoperative haemoglobin by quartiles of 
SIRT6 cytoplasmic Histoscore. Highest quartile SIRT6 cytoplasmic Histoscore was 
associated with higher haemoglobin (Mann-Whitney U test, p=0.0036). 
5.6.4 Associations with histological factors of prognostic 
significance in colorectal cancer 
 
Chapter 5: Sirtuin Protein Expression and Clinicopathological Factors   242 
Low SIRT6 cytoplasmic staining was associated with poorly differentiated 
tumours (Mann-Whitney U test, p=0.0008). 
Highest quartile SIRT6 nuclear staining was associated with venous invasion 
(Pearson Chi square, p=0.010). 
3 lower 
quartiles
Highest 
quartlle
N 132 32 164
Y 65 33 98
197 65 262Total
SIRT6 Nuclear Histoscore 
Total
Venous 
invasion
 
Table 5.17 Crosstabulation of venous invasion and SIRT6 nuclear Histoscore categorised by 
highest quartile and lower quartiles. Highest quartile SIRT6 nuclear Histoscore was 
associated with venous invasion (Pearson Chi square, p=0.010). 
Lowest quartile SIRT6 cytoplasmic staining is associated with high risk Petersen 
index (Pearson Chi square, p=0.008). This is interesting given that there is no 
relationship with any of the Petersen Index component measures and may 
reflect the incremental effects of small changes in each component. There was 
no similar association between high risk Petersen index and nuclear staining. 
Lowest 
quartile Higher 3 quartiles
N 45 166 211
Y 20 31 51
65 197 262
SIRT6 Cytoplasmic Histoscore
Total
Total
High risk 
Petersen Index
 
Table 5.18 Crosstabulation of high risk Petersen Index and SIRT6 cytoplasmic Histoscore 
categorised by lowest quartile and higher quartiles. Lowest quartile SIRT6 cytoplasmic 
Histoscore was associated with high risk Petersen Index (Pearson Chi square, p=0.008). 
5.7 SIRT7 Expression in Colorectal Tumours and 
Relation with Clinicopathological Factors 
Associations between SIRT7 nuclear and cytoplasmic Histoscores and 
clinicopathological factors are summarised in the following tables and 
statistically significant associations are subsequently discussed in more detail.
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Nucleus Cytoplasm
Age Pearson(Chi(square,(p=0.204 Pearson(Chi(square,(p=0.323
Sex Pearson(Chi(square,(p=0.061 Pearson(Chi(square,(p=0.780
BMI
Highest(quartile(Histoscore(associated(with(
higher(BMI.(MannDWhitney(U(test,(p=0.012 Pearson(Chi(square,(p=0.293
WCC
Lowest(quartile(Histoscore(was(associated(with(
low(WCC.(MannDWhitney(U(test,(p=0.0487
Lowest(quartile(Histoscore(was(associated(with(
higher(WCC.(MannDWhitney(U(test,(p=0.0264
CRP
Higher(Histoscore(was(associated(with(higher(
CRP.(MannDWhitney(U(test,(p=0.0224
Lower(Histoscore(was(associated(with(high(CRP.(
MannDWhitney(U(test,(p=0.0015
Albumin Pearson(Chi(square,(p=0.996
Higher(serum(albumin(was(associated(with(
higher(quartile(Histoscores.(KruskalDWallis(test,(
p=0.00004
mGPS
Lowest(quartile(Histoscore(was(associated(with(
low(mGPS.(Pearson(Chi(square,(p=0.011,(linearD
byDlinear,(p=0.004
High(Histoscore(was(associated(with(low(mGPS.(
Pearson(Chi(square,(p=0.001,(linearDbyDlinear,(
p=0.00012
Hb Pearson(Chi(square,(p=0.111 Pearson(Chi(square,(p=0.916
Smoking>status Pearson(Chi(square,(p=0.610 Pearson(Chi(square,(p=0.254
Pearson(Chi(square,(p=0.522 Pearson(Chi(square,(p=0.405
Pearson(Chi(square,(p=0.560 Pearson(Chi(square,(p=0.533
Pearson(Chi(square,(p=0.927 Pearson(Chi(square,(p=0.483
SIRT7
Demographic>
variables
Inflammatory>
markers
Atypical>
markers>of>
Presentation
Charlson>Comorbidity>Index
Tumour>location
 
Table 5.19 Associations between SIRT7 nuclear and cytoplasmic Histoscores and demographic variables, classical and atypical markers of inflammation, 
presentation, comorbidity and tumour location. Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise indicated.  
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Nucleus Cytoplasm
Dukes'1stage
Higher'Histoscore'was'associated'with'higher'
Dukes''stage.'Kruskal6Wallis'test,'p=0.0264 Pearson'Chi'square,'p=0.621
T1stage
Higher'quartile'Histoscores'were'associated'with'
higher'T'stage.'Kruskal6Wallis'tesst,'p=0.049 Pearson'Chi'square,'p=0.961
N1stage
Lowest'quartile'Histoscore'was'associated'with'
low'N'stage.'Pearson'Chi'square,'p=0.006,'linear6
by6linear,'p=0.001 Pearson'Chi'square,'p=0.189
M1stage Pearson'Chi'square,'p=0.329 Pearson'Chi'square,'p=0.326
Differentiation Pearson'Chi'square,'p=0.084 Pearson'Chi'square,'p=0.213
Margin1
involvement Pearson'Chi'square,'p=0.419 Pearson'Chi'square,'p=0.706
Peritoneal1
involvement
Higher'Histoscore'was'associated'with'peritoneal'
involvement.'Mann6Whitney'U'test,'p=0.0033 Pearson'Chi'square,'p=0.740
Tumour1
perforation Pearson'Chi'square,'p=0.932 Pearson'Chi'square,'p=0.480
Venous1invasion
Higher'quartile'Histoscores'were'associated'with'
venous'invasion.'Mann6Whitney'U'test,'p=0.0291
Higher'Histoscores'were'associated'with'venous'
invasion.'Mann6Whitney'U'test,'p=0.0034
High1risk1
Petersen1index
Lowest'quartile'Histoscore'was'associated'with'
low'risk'PI.'Mann6Whitney'U'test','p=0.0003 Pearson'Chi'square,'p=0.347
Pearson'Chi'square,'p=0.308 Pearson'Chi'square,'p=0.793
Measures1of1
cancer1staging
Peritumoural1Inflammation
Pathological1
prognostic1
markers
SIRT7
 
Table 5.20 Associations between SIRT7 nuclear and cytoplasmic Histoscores and accepted factors of prognostic significance in colorectal cancer (cancer 
staging systems and histopathological markers). Pearson Chi square p-values are for sirtuin Histoscores split about the median unless otherwise 
indicated.
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5.7.1 Association with inflammatory markers 
5.7.1.1 Association with white cell count 
Lowest quartile SIRT7 cytoplasmic staining was associated with higher WCC 
(Mann-Whitney U test, p=0.0264). 
5.7.1.2 Association with serum C-reactive protein (CRP) 
Higher SIRT7 nuclear Histoscores were associated with CRP above 10 (Mann-
Whitney U test, p=0.0224). Lower SIRT7 cytoplasmic Histoscores were associated 
with high CRP (Mann-Whitney U test, p=0.0015). 
5.7.1.3 Association with serum albumin 
Serum albumin increased with increasing quartiles of SIRT7 cytoplasmic 
Histoscores (Kruskal-Wallis test, p=0.00004). 
 
Figure 5.14 Boxplots of serum albumin categorised by SIRT7 nuclear Histoscore quartiles. 
Albumin increased with increasing quartiles of SIRT7 cytoplasmic Histoscores (Kruskal-
Wallis test, p=0.00004). 
5.7.1.4 Association with modified Glasgow Prognostic Score (mGPS) 
Lowest quartile SIRT7 nuclear staining was associated with lower mGPS (Pearson 
Chi square, p=0.011, linear-by-linear, p=0.004). 
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Lowest 
quartile
Higher 3 
quartiles
0 43 103 146
1 14 76 90
2 3 26 29
60 205 265Total
SIRT7 Nuclear Histoscore 
Total
mGPS
 
Table 5.21 Crosstabulation of modified Glasgow Prognostic Score (mGPS) with SIRT7 
nuclear Histoscore, categorised by lowest quartile and higher three quartiles. Lowest 
quartile SIRT7 nuclear staining was associated with lower mGPS (Pearson Chi square, 
p=0.011, linear-by-linear, p=0.004). 
SIRT7 cytoplasmic staining above the median was associated with low mGPS 
(Pearson Chi square, p=0.001, linear-by-linear, p=0.00012). 
Below median Above median
mGPS 0 57 89 146
1 52 38 90
2 21 8 29
130 135 265
SIRT7 Cytoplasmic Histoscore
Total
Total
 
Table 5.22 Crosstabulation of modified Glasgow Prognostic Score (mGPS) with SIRT7 
cytoplasmic Histoscore, categorised by quartiles. Lower mGPS was associated with higher 
quartile SIRT7 cytoplasmic Histoscore (Pearson Chi square, p=0.001, linear-by-linear, 
p=0.00012. 
5.7.2 Associations with accepted factors of prognostic 
significance in colorectal cancer 
5.7.2.1 Associations with cancer stage 
Lowest quartile SIRT7 nuclear Histoscore was associated with less advanced N 
stage (Pearson Chi square, p=0.006, linear-by-linear, p=0.001). 
Lowest 
quartile
Higher three 
quartiles
0 44 104 148
1 14 76 90
2 2 25 27
60 205 265
SIRT7 Nuclear Histoscore 
Total
Total
N stage
 
Table 5.23 Crosstabulation of nodal (N) stage with SIRT7 nuclear Histoscore, categorised by 
lowest and higher three quartiles. Lowest quartile Histoscore was associated with lower N 
stage (Pearson Chi square, p=0.006, linear-by-linear, p=0.001). 
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5.7.2.2 Associations with histological factors of prognostic 
significance 
Venous invasion was associated with heavier SIRT7 cytoplasmic staining (Mann-
Whitney U test, p=0.0034). 
Peritoneal involvement was associated with higher SIRT7 nuclear Histoscore 
(Mann-Whitney U test, p=0.0033). Higher SIRT7 nuclear Histoscore was also 
associated with high-risk Petersen index (Mann-Whitney U test, p=0.0003). 
5.8 Discussion 
5.8.1 SIRT2 tumour Histoscore and associations with 
inflammatory markers 
Higher CRP and low albumin and the corresponding composite measure of high 
mGPS are markers of a systemic inflammatory response. All three were 
associated with extreme quartiles of SIRT2 nuclear Histoscore. Systemic 
inflammation has been linked with poorer outcome in colorectal cancer. The 
observed relationships between extreme quartiles of SIRT2 nuclear Histoscore, 
increased systemic inflammation and survival point to the involvement of SIRT2 
in a nuclear role in this interaction.  
There was no significant association between SIRT2 nuclear Histoscore and white 
cell count. The inflammatory response is a complex process involving many ways 
of responding to different threats to the organism. These parameters may 
measure different aspects of the inflammatory process. What determines 
whether SIRT2 levels in the nucleus rise rather than fall, and what downstream 
effects do these two outcomes have? SIRT2 deacetylates a component of NFκB 
and carries NFκB binding sites in its 5’UTR (Rothgiesser, Erener et al. 2010). 
NFκB controls many genes involved in inflammation, in cell division and in the 
immune response. Further investigation into the place of SIRT2 in inflammatory 
responses is likely to be fruitful. 
5.8.2 SIRT2 tumour Histoscore and associations with accepted 
factors of prognostic significance in colorectal cancer 
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T stage provides a more detailed summary of local progression of the tumour and 
increasing T stage was associated with extremes of SIRT2 nuclear Histoscore. 
There was no significant relationship with overall Dukes’ stage or with nodal 
involvement, which might have been expected to have more bearing on survival 
and thus a stronger relationship with SIRT2. 
Two cellular measures of poor prognosis were associated with SIRT2 nuclear 
Histoscore and these may indicate useful lines of investigation to understand 
instead how the survival effect is manifest and how this may be modulated with 
therapeutic intent. Associations with poorly differentiated tumours could be 
linked to SIRT2 influences on HOXA10. HOXA10 is a DNA-binding transcription 
factor and one of the homeobox genes that govern morphogenesis in 
embryological development and are necessary in adult life for functional 
differentiation(Daftary and Taylor 2006). Aberrant regulation of such a gene 
could potentially contribute to the poorly differentiated phenotype of some 
cancer cells.  
Venous invasion requires that a malignant cell has altered interaction with 
neighbouring cells and increased mobility, part of the epidermal-to-
mesenchymal transition that underlies metastatic potential. SIRT2 is 
phosphorylated by cyclin-dependent kinases with measured reduction in 
adherence to the substratum and increased cell mobility(Pandithage, Lilischkis 
et al. 2008). There is associated reduction in acetylated α-tubulin. SIRT2 
interaction with tubulin is likely largely the preserve of the cytoplasmic fraction, 
but it could relate to SIRT2 nuclear Histoscores, if subcellular distribution of 
SIRT2 is conjointly controlled. 
SIRT2 has several other targets in the nucleus, which in turn have widespread 
effects on translation of genes from pathways governing a range of processes 
including apoptosis and cell division. H3K56Ac levels are increased in many types 
of cancer(Vempati, Jayani et al. 2010) and the reduced levels of SIRT2 in 
colorectal cancer would facilitate this, by reducing the deacetylation of this 
substrate. H3K56Ac localises to areas of DNA damage along with p53, also 
subject to regulation by deacetylation by SIRT2(Jin, Kim et al. 2008). The details 
of the effects of the interactions between H3K56Ac and p53 are not known but 
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they certainly have the capacity to significantly influence gene transcription to 
produce the widespread changes involved in acquisition of metastatic potential. 
Taken together these results support a detrimental effect of extreme SIRT2 
nuclear Histoscores on survival. Highest quartile SIRT2 nuclear Histoscore may be 
the worst of the two abnormalities as it is also associated with markers of 
inflammation and of histopathologically defined poor prognosis.  
It must be noted that these associations do not imply causality. Further 
investigation is needed to clarify the mechanisms by which SIRT2 nuclear 
expression impacts on survival from colorectal cancer. The recently published 
interaction between SIRT2 and K-RAS is an exciting extension to this(Yang, 
Laurent et al. 2013). SIRT2 deacetylates K-RAS which has been known for some 
time to affect survival from colorectal cancer, and deacetylation enhances K-
RAS transforming activity. 
5.8.3 SIRT3 tumour Histoscore and associations with 
demographic variables 
5.8.3.1 Age 
Previous reports that SIRT3 is the only sirtuin associated with age in 
humans(Rose, Dato et al. 2003; Bellizzi, Rose et al. 2005) were not borne out by 
this dataset, as the trend to older age with higher cytoplasmic expression of 
SIRT3 did not reach statistical significance. Interestingly, the work by Rose et al 
noted the association between SIRT3 polymorphisms and age in males only. The 
cohort examined here was equally mixed in terms of sex. There was no 
association with nuclear SIRT3. It is possible that the association with 
chronological age might be mediated through SIRT3 functions in the 
mitochondria, by modulating redox homeostasis. The protective effect of 
oestrogen on redox homeostasis may reduce the magnitude of this interaction in 
females. 
5.8.4 SIRT3 tumour Histoscore and associations with 
inflammatory markers 
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Higher SIRT3 cytoplasmic Histoscores were associated with lower white cell 
count and CRP. The inverse relationship between SIRT3 cytoplasmic Histoscores 
and white cell count may relate to the nuclear targeting of SIRT3 in some 
conditions, such as inflammation when there may be a link with NFκB signalling 
and increased oxidative stress. The relationship between SIRT3 nuclear 
Histoscores and white cell count did not reach statistical significance. This may 
relate to the relatively low overall nuclear staining for SIRT3 in that the 
Histoscore measurement may not have been precise enough to detect relevant 
staining, or to differentiate at this level. 
Higher haemoglobin associates with higher SIRT3 cytoplasmic expression and 
overall, higher SIRT3 cytoplasmic expression is associated with more favourable 
physiological parameters. 
5.8.5 SIRT3 tumour Histoscore and associations with accepted 
factors of prognostic significance in colorectal cancer 
Lower cytoplasmic staining for SIRT3 was associated with poorly differentiated 
tumours, while higher nuclear staining was associated with venous invasion. In 
keeping with the associations with inflammatory markers, lower cytoplasmic 
staining (and in this context, higher nuclear staining) seem to be correlated with 
less favourable pathological features. 
Of note, this model does not accord with the association between lower nuclear 
protein expression and worse survival. The significance of the associations with 
serum and pathological markers for the patient may be questioned, but it must 
be remembered that the association between low nuclear SIRT3 staining and 
worse survival was not maintained on multivariate analysis, whereas the 
association between survival and systemic inflammation (CRP) was robust. 
Notwithstanding, lower SIRT3 expression in the cytoplasm is in keeping with 
preferential glycolytic metabolism in cancer cells. SIRT3 tends to shift the 
balance towards other substrates(Finley, Carracedo et al. 2011), a useful trait in 
times of glucose scarcity but one that may be suppressed in cancer cells. The 
shift towards glycolysis may be a prerequisite for increased cell division and 
local invasion. 
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Nuclear targets of SIRT3 include histone 3 and 4: increased deacetylation of 
these histones will modulate expression of a range of genes. Specific targets 
include a sulphotransferase (GAL3ST1) known to be upregulated in renal cell 
carcinoma, although there is little information on its downstream 
effects(Iwahara, Bonasio et al. 2012). Another target is focal adhesion kinase, 
central to cell adhesion and spreading processes including fast turnover of focal 
adhesions. Depletion of this protein in breast cancer cells reduced invasive cell 
migration(Chan, Cortesio et al. 2009) and it is possible that increased expression 
as a result of SIRT3 activity in the nucleus could be instrumental in aiding local 
invasion and underlie the association with increased T stage and possibly the link 
with venous invasion.  
A mechanistic link between poor differentiation and low cytoplasmic staining is 
less easy to see. It is difficult to define poor differentiation in molecular 
biological terms but this may change as more molecular markers come into 
regular use. 
5.8.6 SIRT4 tumour Histoscore and associations with 
inflammatory markers 
Cytoplasmic localisation of SIRT4 in colorectal tumour cells appears to 
accompany a reduced systemic inflammatory response. Systemic inflammation is 
associated with worse outcome in colorectal cancer but there are no data at 
present to link SIRT4 mechanistically to this effect. This was the only association 
identified with SIRT4. Data in the following chapter on sirtuin interrelationships 
might indicate that SIRT4 has a regulatory effect on other sirtuins, rather than 
any demonstrable impression on other cellular pathways investigated here. 
SIRT4 decreases mitochondrial capacity to store calcium: higher levels of SIRT4 
in the cytoplasm may aid cancer cell survival when calcium regulation is 
perturbed. This is normally a late stage in cancer however, and was not a 
common feature in the cohort of patients with operable tumours under 
investigation. Further research on the functions and interactions of SIRT4 may 
enable more useful interpretation of its role in systemic inflammation in 
colorectal cancer. 
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5.8.7 SIRT5 tumour Histoscore and associations with 
inflammatory markers 
Lowest quartile SIRT5 cytoplasmic staining was associated with higher white cell 
count and CRP, both markers of a systemic inflammatory response, carrying a 
poorer prognosis. SIRT5 activity is important in regulating the use of alternative 
sources of energy, while mitigating the build-up of toxic by-products such as 
ammonia. The general reduction of SIRT5 expression in the cytoplasm may limit 
the tumour cell’s ability to deal with periods of nutrient restriction, or high 
usage in inflammation.  
This could incline to reliance on the simpler process of glycolysis as is seen in 
tumour cells. The Warburg effect describes the dependence on glycolysis even in 
the presence of preferable substrates(Warburg 1956), but that dependence is 
equally useful in the absence of such substrates. Tumour cells are uncoupled 
from the regulation essential to mediate the interdependence of cells forming 
part of a whole body, and thus may not avail of the signalling systems which 
mobilise stored nutrients to provide for excess requirements. Escape from this 
regulation is one of the characteristics of malignantly transformed cells(Hanahan 
and Weinberg 2011). 
5.8.8 SIRT6 tumour Histoscore and associations with 
demographic variables 
5.8.8.1 Age, sex, BMI 
Although SIRT6 levels decline in human fibroblasts in line with the development 
of replicative senescence (Mao, Tian et al. 2012) there was no association 
between staining in colorectal tumour cells and chronological age. 
Higher quartile SIRT6 nuclear staining associates with higher BMI. SIRT6 and 
SIRT1 have a role in lipid metabolism and it may be that background higher 
levels of SIRT6 allow organisms to grow larger, through efficient use of lipids. It 
may be more simply that such organisms store more lipid. Given that the 
interaction with SIRT1 is central to these lipid regulatory networks, it is a pity 
that no SIRT1 staining could be completed for this cohort. 
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5.8.9 SIRT6 tumour Histoscore and associations with 
inflammatory markers 
Higher nuclear SIRT6 Histoscore was associated with lower CRP and lower mGPS. 
Higher cytoplasmic SIRT6 Histoscore was associated with lower white cell count, 
CRP below 10, higher albumin and lower mGPS. Higher cytoplasmic SIRT6 
Histoscore also associated with higher haemoglobin. Thus it appears that 
markers of increased systemic inflammation were reflected in lower nuclear 
SIRT6 staining and lower cytoplasmic staining. 
SIRT6 is known to have an inhibitory effect on expression of NFκB genes and 
TNFα, in endothelial cells and cells of the amnion(Lappas 2012; Lim, Barker et 
al. 2013). In idiopathic pulmonary fibrosis, diseased lung tissue increases 
expression of SIRT6, which can inhibit senescence and influence production of 
secreted cytokines(Minagawa, Araya et al. 2011). Higher SIRT6 in colorectal 
cancer may be acting in a similar way, dampening an inflammatory response.  
Either way, the effect of SIRT6 cytoplasmic and nuclear protein levels may 
reflect changes with prognostic effects, as systemic inflammatory response is 
associated with poorer tumour outcomes. The relationship between haemoglobin 
and cytoplasmic SIRT6 Histoscore may indicate an alteration in tissue function at 
a more constitutive level. More data on the significance of SIRT6 protein in the 
cytoplasm is necessary before further extrapolation. 
5.8.10 SIRT6 tumour Histoscore and associations with 
accepted factors of prognostic significance in colorectal 
cancer 
Highest quartile nuclear SIRT6 Histoscores were associated with venous invasion. 
Lower cytoplasmic SIRT6 staining was associated with poorly differentiated 
tumours. Although there is no statistically significant effect on survival, it 
appears that higher nuclear SIRT6 staining is associated with a range of poor 
prognostic indicators, at both local and systemic levels. Conversely, higher 
cytoplasmic staining is associated with factors usually linked to better outcomes 
at systemic level but with local histopathological markers of poor prognosis. 
Immunohistochemistry analysis in a very similar cohort of 253 colorectal cancer 
cases reported reduced staining for SIRT6 overall, but improved outcome for 
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node-positive patients with higher SIRT6 levels (Sebastian, Zwaans et al. 2012). 
The localisation of the staining was not further characterised so it is difficult to 
say whether these results correspond to the data presented here. 
SIRT6 has several known nuclear functions in maintenance of DNA and telomere 
length. The specific role played by SIRT6 in maintenance of telomere length is 
not understood but involves stabilisation and prevention of replicative 
senescence which must be a priority for tumour cells. In rapidly dividing cells, 
there is likely to be an increased requirement for DNA repair and increased 
SIRT6 staining in the nucleus could reflect more mobilisation to compensate for 
this. Homologous recombination, the more precise form of DNA repair decreases 
with onset of replicative senescence. SIRT6 thus has a twofold effect on DNA 
integrity, since it is central to the recruitment of the DSB repair machinery. 
SIRT6 also has a key although undefined part to play in base excision repair.  
Although none of this information provides a direct link to the association 
between venous invasion and SIRT6 nuclear expression, increased tumour cell 
survival and division is necessary to facilitate tumour spread. Research into the 
dynamics of SIRT6 movement at a subcellular level and to clarify its roles in the 
nucleus are likely to prove fruitful in determining how to influence its regulatory 
actions within tumour cells. 
5.8.11 SIRT7 tumour Histoscore and associations with 
demographic variables 
5.8.11.1 Age 
SIRT7 staining in colorectal epithelium appears to be similar in distribution to 
that reported in fibroblasts (Kiran, Chatterjee et al. 2013). However, the 
reduced nucleolar staining associated with replicative senescence in fibroblasts 
is not reflected in substantially reduced nuclear Histoscores in colorectal tumour 
tissue. There was no association between nuclear or cytoplasmic SIRT7 
Histoscores and age in this cohort of tissue samples. Although cancer cells are 
thought to represent aged tissue, this may not simply be ageing through 
repeated cell divisions. Of note, premature ageing does not produce the same 
reduction in nucleolar staining as replicative senescence, and it may be a better 
model of the aged nature of cancer cells.  
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5.8.12 SIRT7 tumour Histoscore and associations with 
inflammatory markers 
Lower SIRT7 nuclear Histoscores were associated with lower mGPS. Lower SIRT7 
cytoplasmic Histoscores were associated with high CRP, low albumin and higher 
mGPS. Taken together these results suggest a reciprocal relationship between 
SIRT7 subcellular localisation and systemic inflammatory status. Thus high 
nuclear SIRT7 Histoscore is associated with higher systemic inflammation and by 
inference, poorer prognosis, given reported relationships between outcome and 
systemic inflammatory response in colorectal cancer (Roxburgh, Salmond et al. 
2009). 
The reciprocal variation in nuclear and cytoplasmic SIRT7 Histoscores is 
reminiscent of the reciprocal change in nuclear and cytoplasmic forms of SIRT7 
reported by Kiran et al in fibroblasts, in association with replicative 
senescence(Kiran, Chatterjee et al. 2013). The change seen in these colorectal 
cancer specimens is in the opposite direction, with increasing SIRT7 nuclear 
Histoscore associated with increasing systemic inflammatory features. However, 
the motif worth further investigation is of 2 pools of SIRT7 whose cellular 
localisation changes in association with cellular responses. Whether this change 
in localisation is causative or reactive is not clear. Indeed, it is not known 
whether the cytoplasmic fraction of SIRT7 is an inert sequestered pool or an 
enzymatically active agent regulating as yet unidentified processes. The former 
might be possible given the lack of antibody reactivity of cytoplasmic SIRT7 in 
epithelial cells, although this fraction was detectable on immunoblotting. 
5.8.13 SIRT7 tumour Histoscore and associations with 
accepted factors of prognostic significance in colorectal 
cancer 
Increasing SIRT7 nuclear Histoscores were associated with increasing N stage, 
peritoneal invasion and high-risk Petersen Index. There was also an association 
between increased SIRT7 cytoplasmic Histoscore and venous invasion. Given the 
several associations between histopathological features of worse prognosis and 
SIRT7 nuclear staining, it is surprising that there is not a survival disadvantage 
for patients with higher SIRT7 nuclear Histoscores. However, as indicated by 
Barber et al, it is possible that SIRT7 also has a role in maintaining the 
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transformed phenotype through deacetylation of acetylated lysine 18 of histone 
H3 at a specific set of gene targets (Barber, Michishita-Kioi et al. 2012). They did 
not find any evidence of a role for SIRT7 in initiating transformation of cells.  
Tumour cells have an active TCA cycle and appear to depend heavily on 
glutamine metabolism for production of NADH. Although there are significant 
biosynthetic requirements for expansion of cell numbers, the rate of these 
reactions exceeds that requirement. Handling this increased throughput of 
substrate and the increased synthetic requirements of malignant transformation 
must require some increase in ribosomal protein synthesis. This may explain at 
least part of the increased nuclear staining for SIRT7. 
The genes targeted by SIRT7 comprise a set of ribosomal proteins whose 
expression is repressed by its action. While this is unexpected, there are also 
reports of links between ribosomal proteins and cancer progression possibly 
through imbalances in regulation of translation. 
Further research into the function of the SIRT7 nuclear and cytoplasmic 
fractions, and the mobilisation or exchange between these two pools in response 
to cellular conditions is likely to prove and exciting and fruitful area of research. 
 6 Sirtuin Interrelationships  
6.1 Integrated control of protein interactions 
Proteins that act in same pathways may be expected to have correlated 
expression levels (Clarke, Ressom et al. 2008). However, reverse causation does 
not mean that proteins that are correlated will interact. Bearing in mind also 
that proteins that are correlated may act in the same pathways, but do not 
necessarily interact directly with each other, correlations between protein levels 
may be a useful starting point to look for pathways of interaction. 
Some documented interactions have already been reported between sirtuins; 
these are summarised here.  
6.1.1 Direct regulation within the sirtuin family 
There is evidence of direct negative regulation of SIRT1 and SIRT3 by SIRT4 in 
mouse hepatocytes (Chen, Fang et al. 2010). SIRT1 has positive regulatory effect 
on SIRT6 in TLR4 activation in a human model of inflammation (using THP1 
human promonocytes) (Liu, Vachharajani et al. 2012). SIRT1 also has positive 
regulatory effect on SIRT6 via complex formation with FOXO3a and NRF1(Kim, 
Xiao et al. 2010). 
Coexpression of SIRT3 and SIRT5 results in translocation of SIRT3 to the nucleus 
in mice (Nakamura, Ogura et al. 2008). While this interaction does not impact on 
SIRT3 expression levels, it may regulate function within the cell by modulating 
subcellular localisation. 
6.1.2 Common substrates within the sirtuin family 
There are several reports of sirtuins that have opposing effects on one substrate, 
glutamate dehydrogenase (GDH) was first identified as a target for inhibition by 
SIRT4 (Haigis, Mostoslavsky et al. 2006). SIRT3 has since been shown to activate 
GDH(Lombard, Alt et al. 2007). SIRT1 and SIRT7 interact with RNAPol1 to inhibit 
and activate it respectively (Muth, Nadaud et al. 2001; Ford, Voit et al. 2006). 
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There are several lines of evidence that more than one sirtuin targets the same 
substrate with similar effect. This may reflect a degree of redundancy in crucial 
pathways. Different subcellular localisations of sirtuins may also require this 
arrangement to regulate separate pools of substrate, and this has been 
suggested as the underlying evolutionary rationale for the existence of a number 
of similar or identical substrates for SIRT1 and SIRT3. For example, SIRT1 and 
SIRT3 both deacetylate acetyl CoA synthase 1 (AceCS1) in vitro (Hirschey, 
Shimazu et al. 2011). In vivo SIRT3 appears not to show this activity, possibly 
because of its largely mitochondrial location; instead, SIRT3 deacetylates 
AceCS2 in mitochondria. These authors also reported on HMGCS as a target for 
both SIRT1 and SIRT3. Other substrates common to both SIRT1 and SIRT3 include 
FOXO3a, chaperonin, heat shock protein 70 (Hsp70) and uridine 
diphosphoglucose dehydrogenase (Jacobs, Pennington et al. 2008; Law, Liu et al. 
2009). 
SIRT1, SIRT6, SIRT2 all deacetylate H3K56 (Das, Lucia et al. 2009; Michishita, 
McCord et al. 2009; Vempati, Jayani et al. 2010). PGC1α is an important 
transcription regulator and a common target of SIRT1 and SIRT6. Interestingly 
however, it is directly deacetylated by SIRT1 to produce activation, but the 
opposite negative regulatory effect is achieved by SIRT6 deacetylation of GCN5, 
which acetylates PGC1α(Rodgers and Puigserver 2007; Dominy, Lee et al. 2012). 
The specific interaction of a sirtuin with a particular substrate may not be 
limited to deacetylation with the discovery that SIRT5, a weak deacetylase in 
general and in comparison to other sirtuins, is an efficient desuccinylase and 
demalonylase(Park, Chen et al. 2013). This widens the scope of multiple 
interactions with a single target. 
6.1.3 Common regulators of sirtuins 
The ubiquitous control of sirtuin activity by ambient NAD levels must be taken 
into account. Reports of common regulators of multiple sirtuins are more sparse. 
SIRT2 and SIRT7 are both phosphorylated by the CDK1-cyclin B pathway (Grob, 
Roussel et al. 2009). 
6.1.4 Current evidence of sirtuin interrelationships 
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Previous research has shown evidence of strong and significant correlations 
between sirtuins at the gene transcription level, i.e. between levels of sirtuin 
mRNA (Maxwell 2013).  
Posttranscriptional processing adds a level of precise regulation after 
transcription, and subcellular localisation of proteins, yet another layer. It 
seemed reasonable to investigate whether the correlations reported at mRNA 
level persisted to protein level, and how they may be manifest through the filter 
of subcellular localisation. 
6.2 Analysis of sirtuin interrelationships in RNA and 
protein 
Histoscore data did show significant correlations between protein expression of 
several sirtuins in both normal and tumour tissue. Correlations between sirtuin 
mRNA expression previously published (Maxwell 2013) were represented as a 
network. Networks were constructed for normal and tumour mRNA. Similar 
networks were constructed using Histoscores for each combination of sirtuin and 
subcellular localisation to build a picture of sirtuin protein expression. At this 
level, a second dimension – that of subcellular localisation - was incorporated, 
such that SIRT2C represents SIRT2 expression in the cytoplasm, and SIRT2N 
represents SIRT2 expression in the nucleus. 
A comparison was performed of sirtuin interrelationships in RNA and protein 
expression in normal tissue, and of sirtuin interrelationships in RNA and protein 
expression in tumour tissue, using these networks. Finally, sirtuin protein 
interrelationships in normal and tumour tissue were compared. 
mRNA data was available for all 7 sirtuins, and protein data for sirtuins 2-7. Thus 
multiple correlations were required to construct each network. The statistical 
analysis used to interpret the results is discussed in the Methods. 
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6.3 Comparison of Sirtuin RNA Interrelationships and 
Sirtuin Protein Interrelationships in Normal Colorectal 
Tissue  
Strong and statistically significant correlations between mRNA expression of 
different sirtuins in normal colorectal tissue were represented as a network. 
Strong and statistically significant correlations between protein expression of 
different sirtuins in normal colorectal tissue were represented similarly. 
Note that there was no data for SIRT1 protein expression. Some correlations 
seem to be maintained from mRNA to protein expression, but in some cases 
there was no evidence of correlation at the protein level. There were also some 
correlations at protein level, not seen between sirtuin mRNA levels. Protein 
expression may give a better indication of the functional effect of the sirtuins 
within the cell. Differential protein expression levels in colorectal cancer 
compared to normal colorectal tissue suggest altered posttranslational 
processing in colorectal cancer cells. Posttranslational processing alterations in 
colorectal cancer cells may be a useful avenue for therapeutic research involving 
sirtuins, if the altered protein levels proved to be of functional relevance. 
The correlations between sirtuins at mRNA and protein levels are tabulated for 
easier recognition of conserved and differing associations. 
Correlation Correlation
SIRT2 and SIRT3 .
SIRT2 and SIRT4 .
SIRT3 and SIRT4 .
SIRT3 and SIRT5 SIRT3N and SIRT5C
SIRT3 and SIRT7 SIRT3C and SIRT7C
SIRT5 and SIRT7 .
SIRT6 and SIRT7 .
. SIRT2N with SIRT7C
. SIRT4N with SIRT4C
Protein
Novel protein-
only correlations
mRNA
 
Table 6.1 Comparison of correlations observed at mRNA and protein level between different 
sirtuins in normal colorectal tissue, listing the correlations represented in the networks 
above. The correlations seen at mRNA level but not at protein level or vice versa are marked 
with a dot. 
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Figure 6.1 Two networks showing strong and significant correlations between mRNA levels 
(upper) and protein levels (lower) for the sirtuins in normal colorectal tissue. The N and C 
suffixes in the protein designators indicate whether the Histoscores refer to nuclear or 
cytoplasmic expression. 
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6.4 Comparison of Sirtuin RNA Interrelationships and 
Sirtuin Protein Interrelationships in Colorectal 
Tumour Tissue 
The correlations between sirtuins at mRNA and protein levels are tabulated for 
easier recognition of the few conserved and differing associations. Correlations 
at the protein level with moderate/strong correlation coefficients are 
highlighted. 
Strong and statistically significant correlations between mRNA expression of 
different sirtuins in colorectal tumour tissue were represented as a network. 
Strong and statistically significant correlations between protein expression of 
different sirtuins in colorectal tumour tissue were represented similarly. 
In comparison with the mRNA network in normal tissue there appears to be a 
gain in complexity of the mRNA network in tumour tissue. However, this 
decidedly does not translate into a more complex network of correlations at the 
protein level. 
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Correlation Correlation
SIRT2C and SIRT3N
SIRT2C and SIRT3C
SIRT2N and SIRT4N
SIRT2C and SIRT4C
SIRT2 and SIRT5 SIRT2C and SIRT5C
SIRT2C and SIRT6C
SIRT2N and SIRT7N 
SIRT2C and SIRT7C
SIRT3N and SIRT4N 
SIRT3N and SIRT4C 
SIRT3C and SIRT4C
SIRT3N and SIRT5N 
SIRT3N and SIRT6N
SIRT3N and SIRT6C
SIRT3C and SIRT6C
SIRT3N and SIRT7N 
SIRT3C and SIRT7C
SIRT4N and SIRT6N
SIRT4C and SIRT6C
SIRT5N and SIRT6N
SIRT5C and SIRT6C
SIRT5 and SIRT7 SIRT5C and SIRT7C
SIRT6N and SIRT7N
SIRT6C and SIRT7N
SIRT6C and SIRT7C
. SIRT2N with SIRT2C
. SIRT3N with SIRT3C
. SIRT6N with SIRT6C
. SIRT7N with SIRT7C
SIRT4C and SIRT5C
SIRT4C and SIRT7N
SIRT4C and SIRT7C
.
SIRT2 and SIRT4
Novel protein-
only correlations
RNA ProteinSIRT2 and SIRT3
SIRT2 and SIRT6
SIRT2 and SIRT7
SIRT3 and SIRT4
SIRT3 and SIRT5
SIRT3 and SIRT6
SIRT3 and SIRT7
SIRT4 and SIRT6
SIRT5 and SIRT6
SIRT6 and SIRT7
 
Table 6.2 Comparison of correlations observed at mRNA and protein level between different 
sirtuins in colorectal tumour tissue. The correlations seen at mRNA level but not at protein 
level or vice versa are marked with a dot. Statistically significant correlations between 
sirtuin protein levels with correlation coefficients <0.35 are suppressed. 
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Figure 6.2 Two networks showing strong and significant correlations between mRNA levels 
(upper) and protein levels (lower) for the sirtuins in colorectal tumour tissue. The N and C 
suffixes in the protein designators indicate whether the Histoscores refer to nuclear or 
cytoplasmic expression. There were many fewer strong correlations in the protein network. 
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6.5 Comparison of Sirtuin Protein Interrelationships in 
Normal Colorectal Tissue and Colorectal Tumour 
Tissue 
The significant correlations, correlation coefficients and p-values for normal and 
tumour tissue are tabulated with strong correlations highlighted. Strong and 
statistically significant correlations between protein expression of different 
sirtuins in colorectal normal and tumour tissue were represented as networks as 
in previous sections, and were compared. It is important to note that there is no 
data for SIRT1 protein expression. 
On comparison with the sirtuin network in normal tissue, it is worth noting that 
there is no commonality in strong correlations between normal and tumour 
tissue. In other words, all the sirtuin interrelationships seen in normal tissue are 
lost in tumour tissue, and some new interrelationships are gained. 
The functional significance of these changes, the molecular interactions 
underlying and explaining them and the position of SIRT1 in the network are 
necessary for accurate interpretation of these results. Although weaker 
correlations are generally not felt to have functional relevance, the presence of 
so many more marginal relationships between proteins in colorectal tumour cells 
(not represented in these networks) may provide a useful picture of the 
breakdown of clear and precise signalling into noise in tumour cells. 
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Rho p value Rho p value
SIRT2N SIRT2N SIRT2C .253** 0.00002813
SIRT2N SIRT2N SIRT4N .241** 0.00007120
SIRT2N SIRT2N SIRT7N .234** 0.00012232
SIRT2N SIRT7C .683** 0.00065208 SIRT2N
SIRT2C SIRT2C SIRT3N -.206** 0.00072281
SIRT2C SIRT2C SIRT3C .339** 0.00000001
SIRT2C SIRT2C SIRT4C .470** 0.00000000
SIRT2C SIRT2C SIRT5C .181** 0.00317293
SIRT2C SIRT2C SIRT6C .351** 0.00000001
SIRT2C SIRT2C SIRT7C .205** 0.00079613
SIRT3N SIRT3N SIRT3C -.235** 0.00010933
SIRT3N SIRT3N SIRT4N .256** 0.00002332
SIRT3N SIRT3N SIRT4C -.248** 0.00004163
SIRT3N SIRT3N SIRT5N .210** 0.00058052
SIRT3N SIRT5C .563** 0.00974608 SIRT3N
SIRT3N SIRT3N SIRT6N .466** 0.00000000
SIRT3N SIRT3N SIRT6C -.301** 0.00000069
SIRT3N SIRT3N SIRT7N .265** 0.00001231
SIRT3C SIRT3C SIRT4C .563** 0.00000000
SIRT3C SIRT3C SIRT6C .460** 0.00000000
SIRT3C SIRT7C .581** 0.00461773 SIRT3C SIRT7C .321** 0.00000009
SIRT4N SIRT4C .576** 0.00501604 SIRT4N
SIRT4N SIRT4N SIRT6N .279** 0.00000439
SIRT4C SIRT4C SIRT5C .274** 0.00000535
SIRT4C SIRT4C SIRT6C .438** 0.00000000
SIRT4C SIRT4C SIRT7N -.160** 0.00886534
SIRT4C SIRT4C SIRT7C .284** 0.00000258
SIRT5N SIRT5N SIRT6N .231** 0.00015750
SIRT5C SIRT5C SIRT6C .189** 0.00204316
SIRT5C SIRT5C SIRT7C .218** 0.00036046
SIRT6N SIRT6N SIRT6C -.274** 0.00000657
SIRT6N SIRT6N SIRT7N .305** 0.00000054
SIRT6C SIRT6C SIRT7N -.220** 0.00034230
SIRT6C SIRT6C SIRT7C .335** 0.00000003
SIRT7N SIRT7N SIRT7C .197** 0.00125036
CorrelationsCorrelations
Tumour tissueNormal tissue
 
Table 6.3 Statistically significant correlations (p<0.01), Spearman correlation coefficients 
(rho) and p-values for sirtuin Histoscores in the nucleus and cytoplasm for normal and 
tumour tissue. The N and C suffixes in the protein designators indicate whether the 
Histoscores refer to nuclear or cytoplasmic expression. Strong correlations are highlighted. 
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Figure 6.3 Strong and significant correlations between sirtuin Histoscores in normal 
colorectal tissue (upper) and colorectal tumour tissue (lower) are represented as sirtuin 
protein networks. The N and C suffixes in the protein designators indicate whether the 
Histoscores refer to nuclear or cytoplasmic expression. 
Chapter 6: Sirtuin Interrelationships   268 
6.6 Discussion 
6.6.1 Functional significance of mRNA and protein networks 
The correlations between level of expression of different sirtuins identified here 
cannot be taken as proof of any real mechanism of interaction but they do 
indicate a direction for further research. Correlations which persist at both 
mRNA and protein level are most likely to reflect a relationship of functional 
significance, and a particularly fruitful subject for investigation. 
Evidence in support of some interactions between sirtuins has been summarised 
earlier. Several of these interactions involve SIRT1, and the lack of protein data 
for SIRT1 limits the degree to which that evidence can be applied to these 
results. However, in terms of correlations between sirtuin mRNA levels, this is 
not a factor. 
6.6.1.1 Direct interactions between sirtuins 
There is a correlation between mRNA levels of SIRT4 and SIRT1, and between 
SIRT4 and SIRT3, in line with the reports of regulation of SIRT1 and SIRT3 levels 
by SIRT4 in mouse hepatocytes(Chen, Fang et al. 2010). There is however no 
correlation to match with the relationship between SIRT1 and SIRT6 reported in 
human promonocytes in response to TLR4 activation (Liu, Vachharajani et al. 
2012). This may be explained by a lack of inflammation, or (given the baseline 
level of inflammation associated with cancer) to a tissue-specific response. The 
relationship between SIRT1 and SIRT6 reported in human promonocytes may not 
be seen in colorectal epithelial cells. 
There is a correlation between SIRT3 and SIRT5 mRNA levels. This may be 
relevant to reports that coexpression of these two sirtuins results in localisation 
of SIRT3 in the nucleus(Nakamura, Ogura et al. 2008). Given that this correlation 
is evident at the mRNA level, there may be an element of transcriptional 
regulation of both sirtuins involved. At the protein level however, it is notable 
that it is the nuclear expression of SIRT3 that correlates with the cytoplasmic 
expression of SIRT5, as predicted by Nakamura et al. 
6.6.1.2 Indirect interactions between sirtuins 
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Control of common substrates by different sirtuins, and common regulators of 
two or more sirtuins could result in correlations between the mRNA or protein 
levels of those sirtuins but the relationships are likely to be weaker. 
SIRT3 and SIRT1 share several substrates, and appear to have comparable effects 
on them, and it has already been speculated that this redundancy may offer 
access to and control of pools of the substrate which are required to remain 
separate for other reasons of cellular organisation. The correlation of mRNA 
levels of SIRT1 and SIRT3 may reflect linked control of these pools. The protein 
level data for this pairing is unfortunately not available. 
SIRT3 and SIRT4 have common substrates and opposite effects on at least one of 
these (GDH) (Lombard, Alt et al. 2007), and a previously described and stronger 
mechanistic link to explain the correlation observed at the mRNA level. Of note, 
there is also a correlation in protein expression, but only between cytoplasmic 
levels of SIRT3 and SIRT4, consistent with activity in a common mitochondrial 
pathway. 
SIRT1 and SIRT7 have opposing actions on RNAPol1, and SIRT1 and SIRT6 likewise 
have opposing effects on PGC1α expression. There is no correlation between 
either of these pairs at mRNA level, unlike the case for SIRT3 and SIRT4. 
The only common regulator reported for sirtuins is the CDK1-cyclin B 
pathway(Grob, Roussel et al. 2009), by which SIRT2 and SIRT7 are 
phosphorylated. There is no observed correlation between these sirtuins at 
mRNA level, but there is a correlation between protein levels. 
6.6.2 Sirtuin RNA Interrelationships and Sirtuin Protein 
Interrelationships in Normal Colorectal and Colorectal 
Tumour Tissue 
The most striking difference between the mRNA and protein networks seen in 
normal and tumour tissue is the gain in complexity of the network at mRNA 
level, which is not translated to the protein expression level, and thus is not 
translated into enzymatic activity within the cell. mRNA levels are universally 
reduced in tumour tissue (Maxwell 2013), but it is intriguing that they show such 
extensive degree of inter-sirtuin correlation. An overarching control mechanism 
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for sirtuin transcription could be postulated, which could lose specificity in 
tumour tissue and act indiscriminately bringing expression of all sirtuins into 
line. The nature and likelihood of this mechanism is speculative. 
6.6.3 Sirtuin Protein Interrelationships in Normal Colorectal 
Tissue and Colorectal Tumour Tissue 
There is no commonality in strong correlations between normal and tumour 
tissue. In other words, all the sirtuin interrelationships seen in normal tissue are 
lost in tumour tissue, and some new interrelationships are gained. 
The functional significance of these changes, the molecular interactions 
underlying and explaining them and the position of SIRT1 in the network are 
necessary for accurate interpretation of these results. However, further research 
into the few protein correlations which persist in this cohort of tumour tissues 
may help in understanding the action of sirtuins in maintaining the hallmarks of 
transformed cells. 
Weaker correlations are generally not felt to have functional relevance. 
However, the presence of so many more marginal relationships between proteins 
in tumour cells may offer a useful picture of the breakdown of clear and precise 
physiological signalling into background noise. 
 7 Is Telomere Length in Colorectal Cancer Tissue-
Specific? 
Short telomeres are thought to indicate biologically aged tissue. How do we use 
telomere length to identify a biologically aged individual? Which telomeres 
should we measure? There is evidence to support the proposal that cancer occurs 
in more biologically aged individuals: previous work from this laboratory showed 
that leukocyte telomere length is shorter in individuals with cancer than in age-
matched controls(Maxwell 2013).  
There is evidence and mechanism to support the development of cancer in 
biologically aged tissue. It has also been shown that telomere length in gut 
tumour tissue is shorter than in adjacent non-cancerous gut mucosa(Feng, Cai et 
al. 2012). It is not known how telomere length in non-cancerous gut mucosa in 
patients with colorectal cancer relates to telomere length in gut mucosa in 
patients with no identified disease.  
How does a biologically aged individual respond to the development of cancer? Is 
telomere length affected in a systemic, organism-wide manner? Is leukocyte 
telomere length affected specifically by the development of cancer in other 
tissues? The answers to these questions are not clear from published literature. 
In the first instance, it has not been shown whether there is a relationship 
between telomere length in leukocytes and telomere length in colorectal tissue 
in patients whether or not they have colorectal cancer. 
7.1 Telomere Length in Different Tissues 
Currently there is an assumption in the literature that peripheral blood 
leukocyte (PBL) telomere length provides an accurate surrogate measure for 
telomere length in other tissues. This is typified by the reference in the last 
paragraphs of Weischer et al’s impressive study of PBL telomere length in 
relation to cancer risk and outcomes (Weischer, Nordestgaard et al. 2013). This 
is a plausible theory, as leukocytes access most parts of the body and so might 
be exposed to stressors throughout the body that could impact on telomere 
length. They might form a “lowest common denominator” for biological ageing 
within the body. 
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This would be useful in clinical terms, as leukocytes are so easily accessible and 
could be assessed regularly, potentially forming a valuable screening tool for 
age-associated disease. However to use them to screen for disease in other 
organs, it would be necessary to know how leukocyte telomere length related to 
telomere length in the tissue of interest. 
7.1.1 Variation in cell turnover in different tissues 
Cell turnover rates in different human tissues vary widely (from 3-7 days in GI 
epithelial tissues to years in neural and muscle tissues – which were initially 
thought to be postmitotic and virtually incapable of regeneration). Most tissues 
are thought to have populations of stem cells, partly differentiated cells with 
greater capability for replication, and capacity for unequal replication, such that 
they divide to form one stem cell and one cell that will not retain the higher 
replicative potential but merely form part of the tissue of origin, and carry out 
the functions of a fully differentiated cell of that tissue. The proportion of stem 
cells present within a tissue may reflect the replication rate, or absolute range 
of divisions required during the organism’s usual lifespan.  
7.1.2 Implications for telomere length 
It is possible therefore that cell types which maintain a constant or higher rate 
of cell division may show more signs of ageing. This might be manifest as shorter 
telomeres, but this is often not the case. Faster-cycling cell compartments are 
postulated to maintain telomere length in stem cells in these compartments 
through activation of telomerase activity at the appropriate level(Chiu, 
Dragowska et al. 1996). It is not known whether the control of telomerase 
activity and telomere length is coordinated on a tissue or organism level. It is 
also not clear what degree of stem cell telomere length is passed on to daughter 
cells on asymmetric division. 
7.1.3 Methodological considerations 
TRFL and qPCR methods measure the average telomere length in the tissue 
sample. Unless specific purification steps are undertaken, samples consist of 
several different cell types. Within one cell type e.g. colonic mucosal cells, 
telomere length may vary depending on the expression of telomerase in stem 
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cells and partly differentiated cells. These are two potential sources of error in 
the measurement; they are likely to depend in part on the relevant abundance 
of cell types within the sample. There is limited evidence on the magnitude of 
the effect this has on measurements of telomere length, or of any functional 
effect of this degree of error. 
One paper which attempted to address this problem showed robust correlations 
between granulocyte telomere length and mean leukocyte telomere length in 24 
cases using the TRFL method and 400 cases using the FlowFISH method(Kimura, 
Gazitt et al. 2010). They suggested that average leukocyte telomere length is 
therefore a useful substitute for granulocyte telomere length without further 
purification measures.  
An analysis of telomere length in tumour and adjacent normal tissue used 
colorectal tumour and sarcoma tissue (Engelhardt, Albanell et al. 1997). Light 
microscopy suggested assess tumour cell infiltration comprised 30% of cells 
viewed in colorectal tumour samples and 65% in sarcoma. TRFL analysis of the 
samples showed 2 distinct peaks in 17 of 51 samples and the higher peak 
corresponded to TRFL in the adjacent normal tissue. These peaks were 
hypothesized to represent populations of tumour and normal cells within the 
tumour specimens. Computer modelling suggested that tumour cell telomere 
shortening is underestimated. 
Comparison of telomere lengths in selected cell populations may be possible 
using a combination of immunological labelling of separated cells and TRFL but 
this data is not available at present.  
Measurement of individual telomere lengths in a cell by Q-FISH has shown that 
different telomeres are of different lengths even in one cell. The trigger for 
cellular senescence is the inability to maintain higher order telomere structure, 
rather than a critical number of short telomeres or a single shortest telomere 
length (Chin, Artandi et al. 1999; Griffith, Comeau et al. 1999; Blackburn 2000). 
The average telomere length in a sample is unlikely to provide a useful 
measurement of the likelihood of invocation of cellular senescence, but may 
provide an assessment of frequency of cellular senescence as it affects the 
whole organ.  
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For the purposes of this literature review, studies using FISH to measure 
telomere length may provide data showing correlation between telomere lengths 
in different tissues but the resolution of the information provided is an order of 
magnitude beyond that provided by mean TRFL measurements. Only 3 of the 
papers included in the final review used FISH methodology. They compared 
subsets of lingual epithelial cells, PBL and lung cells and the combination of 
lymphocyte, epidermal, endothelial and vascular smooth muscle cell telomere 
lengths. 
7.1.4 Systematic review of the literature 
A review of the published literature was conducted using the PRISMA 
methodology (Liberati, Altman et al. 2009) (see flowchart in Appendix 4) to 
define available information on the relationship between telomere lengths in 
different tissues, with especial focus on the relationship between telomere 
length in colorectal tissue and PBLs. 
 Two searches were conducted of the Pubmed database. The first used the 
following criteria: "Tissues"[Mesh]) AND "Telomere"[Mesh] and yielded 417 
records. These were limited by the filters “English” and “Human” to 306 
records. A further Pubmed search used the following criteria: "Telomere"[Mesh] 
AND "Cells/classification"[Mesh] and yielded 15 records. Pertinent references 
from bibliographies were also examined and contributed a further 30 records.  
With the removal of duplicates, a total of 345 abstracts were screened. 
Abstracts which did not indicate or imply comparison of telomere lengths in 2 or 
more tissues were excluded.  
84 references were collected by this means and the full text of these papers 
examined. The definition of ‘tissue’ was specified to include studies that 
measured telomere length in defined populations of cells, as demonstrable 
differences within subpopulations of cells would make it less reasonable to 
assume a link between such diverse tissues as leukocytes and gut epithelial cells. 
Likewise, variation within such a category as ‘leukocytes’ underlines the fact 
that when ‘leukocyte telomere length’ is reported, this is an average value over 
included subclasses of cells.  
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A further 49 records were excluded as they investigated telomere length in only 
one tissue from the same individual. Six papers were excluded because only 
mean telomere length for cell groups were compared statistically, rather than 
telomere length for cell types from one individual (Monteiro, Batliwalla et al. 
1996; Kinouchi, Hiwatashi et al. 1998; Rufer, Dragowska et al. 1998; Richardson, 
Sverstiuk et al. 2000; Aida, Izumiyama-Shimomura et al. 2007; Romagnani, 
Juelke et al. 2007). These included one paper which compared rectal and caecal 
mucosal telomere length in 17 patients with ulcerative colitis and 17 controls 
with colorectal cancer(Kinouchi, Hiwatashi et al. 1998). One paper using FISH 
showed that telomere length profile in lymphocytes correlated with that in 
fibroblasts but did not address telomere length per se, and analysed only 3 cases 
(Graakjaer, Bischoff et al. 2003). 
A total of 27 records remained which compared telomere length in 1 or more 
individuals, in 2 or more cell types or tissues. 
7.1.4.1 Comparison articles excluded from final qualitative review 
In many cases, comparison of telomere length in different tissues was not the 
main focus of the study and small numbers and variable statistical analysis led to 
the exclusion of several more papers. One study examined telomere length in 
ten tissues of one 72-year-old male, including blood and large intestine, and in 
eight tissues of a 20-week foetus, including blood but not large intestine(Butler, 
Tilburt et al. 1998). Although a wide range of tissues were examined, the study 
concentrated on only 2 individuals, and did not examine the full range of tissues 
in each. It concluded that there was more variation in telomere size among 
tissues in the adult than in the foetus, but that there was no significant 
difference in average telomere length of each tissue for the adult male or the 
foetus. Further it reported that when comparing the foetal with adult TL 
measurements for tissues which were available for both (blood, skin, skeletal 
muscle, heart, liver, pancreas, lung, brain and fat), the greatest difference 
between the two was seen in blood telomeric DNA. 
Another study examined a range of 14 foetal tissues, not including 
blood(Youngren, Jeanclos et al. 1998). This study found similar telomere lengths 
in all tissues from the 11 individuals, but also reported significant inter-
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individual variation in telomere length, and no link with gestational age. Small 
bowel tissue was included in the range of tissues examined from 3 cases, and 
colonic tissue likewise from 3 cases; 2 had both intestinal tissues available.  
Analysis of endothelial cell telomere length in internal thoracic and iliac artery 
showed an increasing difference in mean TRFL between these two tissues with 
increasing age; this difference was of increasing statistical significance but 
considered only 4 individuals(Chang and Harley 1995). 
Two studies on subclasses of leukocytes, which each reported on only 5 cases, 
(Yamada, Oshimi et al. 1995; Batliwalla, Damle et al. 2001), a larger study with 
30 cases(Weng, Levine et al. 1995), a study of thyroid and parathyroid tissue 
telomere length, (Kammori, Nakamura et al. 2002) and a comparison of PBMC 
and fibroblasts in 3 centenarians(Mondello, Petropoulou et al. 1999) omitted 
formal statistical analysis. Telomere length was similar between epidermal 
layers in 14 individuals but the relationship was not formally analysed (Krunic, 
Moshir et al. 2009). Telomere lengths in 6 terminal duct lobular units in breast 
tissue were shorter in luminal cells than in myoepithelial cells(Meeker, Hicks et 
al. 2004). This pattern was not seen in the less hormonally responsive lactiferous 
ducts. This may reflect telomere shortening in terminal duct lobular cells due to 
increased number of cycles of proliferation in response to hormonal stimulation 
but no statistical analysis was performed. 
7.1.5 Results of systematic review 
The tables in Appendix 5 display data on method of telomere length 
measurement, tissues examined, number of cases, and age of subjects for 18 
papers included in the final review. There was notable heterogeneity of study 
populations in terms of age, number of cases and tissues studied, and method of 
telomere length measurement. Two studies examined cell types purely of 
haematopoietic lineage, and 15 examined tissues not including those of 
gastrointestinal origin, leaving only 1 study which included some tissue of 
gastrointestinal origin. 
7.1.5.1 Telomere length in haematopoietic tissues 
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Two studies looked at TL in subclasses of cells of haematopoietic lineage. 
Correlation between telomere lengths in T cell subsets was confirmed in 8 
newborns, and a correlation between granulocyte and general leukocyte 
telomere length noted in the newborns and 2 further cohorts of 24 adults (TRFL 
measurement) and 400 adults (FlowFISH measurement) (Kimura, Gazitt et al. 
2010). These authors also commented: "No doubt, leukocyte subsets have central 
and diverse roles in health and disease, but seeking to understand telomere 
dynamics in one type of cell vs. another is insightful only in the context of the 
specific hypothesis that is being tested.” 
In a comparison of polymorphonuclear (PMN) cells and CD34+ lymphocytes in 
patients with ischemic heart failure (IHF) (n=27) and controls (n=24), and their 
offspring (n=29 and n=25 respectively), there was a correlation between 
telomere length in CD34+ cells and PMN cells in controls and their offspring but 
not in patients with ischemic heart failure – or in their offspring(Wong, Huzen et 
al. 2011). 
Kimura et al also provide some evidence that average leukocyte telomere length 
approximates granulocyte telomere length. However, in the absence of detailed 
information on associations with lymphocyte telomere length, there is no 
complete answer to the question of how (average) leukocyte telomere length 
might be used as a common denominator or biomarker of ageing at a wider 
level, particularly at the organism (or patient) level. 
7.1.5.2 Telomere length in non-gastrointestinal tissues 
There were 15 studies which examined telomere length in tissues including blood 
but excluding gastrointestinal tissues. The findings of each study are summarised 
in the second table in Appendix 5 and discussed here. Six studies reported on 
large cohorts of over 50 patients. In newborns, there was significant intra-
individual correlation between each pair of mean TRF length in skin, leukocytes 
and umbilical artery tissue (22 skin samples - all male, 155 blood and umbilical 
artery samples), but a similar degree of inter-individual variability (Okuda, 
Bardeguez et al. 2002). Mean TRF length for skin cells was longer than for white 
blood cells. 
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A study of 62 cases showed significant correlation between telomere length in 
epidermis and lingual mucosa, with shorter telomeres in epidermis (Nakamura, 
Izumiyama-Shimomura et al. 2002). 
A study of telomere length in 4 organs (heart, cerebral cortex, liver and kidney) 
from 100 autopsy cases (age at death 0-101 years) found significant correlations 
between telomere length in each tissue pair(Takubo, Izumiyama-Shimomura et 
al. 2002). Telomere length was longer in cerebral cortex and myocardium than 
in liver or kidney, and there was significant inter-individual variability as well as 
heterogeneity of telomere length within individual samples. There was more 
internal coherence in telomere length within individuals than correlation with 
tissue renewal rates. This was interpreted to suggest that correlations between 
tissue types are present and may be maintained despite different cell division 
rates. This is the largest study to date to examine solid organ telomere lengths 
but no association with blood cells was investigated. 
In a study combining diabetic patients from 2 previous cohorts, 58 patients were 
included(Ahmad, Heraclides et al. 2012). Adjusting for age, sex and family 
history of diabetes, a modest correlation between relative telomere length in 
leukocyte and skeletal muscle was found. Given the contrasting fast and slow 
cycling characteristics of these cell types, this may provide evidence of an 
organism-wide regulation of telomere length, although the method used (like 
the method used in the experiments describe in this thesis) does not measure 
absolute telomere length. 
"It is well established that TL is synchronized (positively correlated) among 
somatic tissues of the individual”(Aston, Hunt et al. 2012). This paper offers 3 
studies in support of this claim, one of which deals with dogs, one with rhesus 
monkeys and one further described below, which compares telomere length in 
skin, blood and fat in humans. They add their own data which indicate that for 
135 cases, telomere length in human sperm cells (within a protected 
compartment) show a moderate correlation (r=0.33, p=0.0001) with leukocyte 
telomere length.  
In one of the most recent studies of telomere length in human tissues, 87 cases 
were examined (Daniali, Benetos et al. 2013). Telomere lengths in leukocytes, 
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skeletal muscle, skin and subcutaneous fat were measured and they reported 
that: "Individuals showed strong correlations of TL between tissues, such that 
those with long (or short) TL in one tissue typically displayed long (or short) TL 
in other tissues (r = 0.72–0.84,P<0.0001; Pearson’s correlation) for each possible 
pairing of tissue types …. The association of leukocyte TL with the other three 
tissues was also consistently high (r = 0.83–0.84, P<0.0001; Pearson’s correlation) 
for each pairing irrespective of the proliferative nature of the tissue.” 
Seven studies were of more moderate size. Von Zglinicki et al also found shorter 
telomeres in leukocytes than in fibroblasts, in a cohort of 24 patients, with a 
significant correlation between telomere length residuals (difference from 
average for that age) in PBLs and fibroblasts (von Zglinicki, Serra et al. 2000).  
In a study of macaques and humans, postmitotic skeletal muscle had longer TRFL 
than lung or skin in both species (11 humans) (Gardner, Kimura et al. 2007). The 
authors noted a remarkable synchrony of different tissue telomere lengths 
within individuals, such that “the effect of the individual monkey or human on 
mean TRFL is greater than the effect of organ differences”, but in humans the 
correlation coefficients for organ versus individual were 0.43 and 0.50 
respectively. An enlarged cohort augmented with 12 autopsy cases showed 
‘partial synchrony’ between telomere lengths in lung and skin, but this was not 
further analysed.  
In 21 autopsy specimens, normalised telomere:centromere ratio in 3 types of 
lingual epithelial cells were correlated but there was no similar correlation with 
fibroblasts (Aida, Izumiyama-Shimomura et al. 2008). Telomere length in 
leukocytes correlated with telomere length in aortic wall tissue in both normal 
(n-12) and aneurysmal (n=20) aortas(Wilson, Herbert et al. 2008).  
In 21 patients with inherited bone marrow failure disorders, blood telomere 
length was shorter than that measured in buccal cells or fibroblasts, and a 
significant correlation was observed between all pairs of tissue types (Gadalla, 
Cawthon et al. 2010). Each pairing of skin, blood and fat showed strong and 
significant correlations between telomere lengths for cohorts of 9, 9 and 15 
individuals, with fat cells tending to have longest telomere length(Granick, 
Kimura et al. 2011). 
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In a cohort of 23 patients with abdominal aortic aneurysms, blood samples were 
available for all 23, endothelial cells and vascular smooth muscle cells for 22, 
and samples of epidermal cells were available for only 11 cases. Telomere length 
as measured by arbitrary telomere fluorescence units in each pairing of 
lymphocytes, epidermal cells, endothelial cells and vascular smooth muscle cells 
all showed strong correlations(Cafueri, Parodi et al. 2012).  
Two smaller studies are included. In 9 elderly patients, significantly shorter 
telomere length was observed in leukocytes than in skin or synovial tissue, 
neither of which was significantly different from each other (Friedrich, Griese et 
al. 2000). There was a significant linear correlation between all pairs of tissue in 
this study, and it was stronger than the inverse correlation with age observed 
with each tissue. This was one of the first papers to propose that PBL leukocyte 
telomere length may provide an accessible surrogate marker for telomere length 
in other tissues. These data also support the theory that correlations between TL 
in different tissues are maintained through life, but the number of cases is 
small. 
9 patients with interstitial pulmonary fibrosis showed a strong and significant 
correlation between telomere lengths measured by FISH in alveolar cells and 
lymphocytes(Alder, Chen et al. 2008). 
7.1.5.3 Telomere length in gastrointestinal tissues 
Only one study compared telomere length in large intestine with other tissues, 
in this case leukocytes(Craig, McKinlay et al. 2003). Telomere length was 
measured in samples of gastric, duodenal, colonic (from sigmoid colon) mucosa 
and blood by the dot blot hybridisation method. Samples from 93 upper GI 
tracts, and 45 colons were collected. A strong correlation was noted between 
the gastric and duodenal tissue telomere length, but the correlation between 
blood and colon was not strong (rs = 0.25 (95% confidence interval = -0.09 to 
0.54), n = 34, P = 0.1491). The correlation between blood and gastric tissue was 
more significant but there was no significant correlation between blood and 
duodenal telomere length. 
Chapter 7: Telomere Length in Matched Tissues   281 
7.1.6 Variable evidence of correlation between telomere length in 
leukocytes and somatic cells. 
There was significant variation in study populations in terms of age, number of 
cases and tissues studied, and method of telomere length measurement. Given 
the heterogeneity of the studies, it is difficult to come to any conclusion 
regarding the usefulness or accuracy of leukocyte telomere length as a reflection 
of telomere length in any other tissue, and particularly colonic tissue. Most 
papers do not make correlation of telomeres in different tissues their main 
focus, but often examine this in a subset of cases and extrapolate the 
assumption.  
The available evidence suggests that telomere length in newborns is comparable 
in different tissues. In adults, studies comparing subclasses of haematopoietic 
cells and 2 moderate sized studies comparing subtypes of epithelial and vascular 
cells suggested significant correlations. One of these did not show any 
correlation between epithelium and fibroblasts. Five large studies, five 
moderate sized studies and 2 smaller ones comparing relatively unrelated cell 
types also showed moderate and strong correlations. Ten of these included 
leukocytes. 
Correlation of telomere lengths within tissue subtypes, or in tissues which are in 
anatomically close proximity is not surprising and it also appears leukocyte 
telomere length, in “close proximity” to all other tissues as blood cells flow 
throughout the body, may in fact mirror some of them. However, as Graakjaer 
et al comment: “Telomeres in different cell types may be subjected to different 
regulatory and stochastic processes both with regards to erosion and elongation. 
Therefore, the telomere profile found in lymphocytes may not be similar, or 
even present, in other cell types(Graakjaer, Bischoff et al. 2003).”  
Expected variation in telomere length between tissues with a high rate of cell 
turnover and those with a low rate of cell turnover is also inconsistent. Telomere 
length varies according to a multitude of factors, which may reflect variables 
specific to tissue, environment and organism. Thus any effect that is 
demonstrable is likely to be particularly strong, but requiring such a high 
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threshold for activation may make telomere length a specific but not 
particularly sensitive test. 
In the case of colorectal tissue specifically, the results obtained in the only 
relevant study do not support the use of leukocyte telomere length to reflect 
telomere length in colorectal mucosa at present.  
The magnitude of inter-individual variation in telomere length is commented on 
in several studies and because of this, establishing normal reference ranges for 
telomere length would be difficult. The longitudinal studies necessary to 
establish the effect of individual telomere length on health outcomes directly 
would take a lifetime – an unfeasibly long time so far.  
It has been assumed that PBL telomere length reflects telomere length in other 
somatic tissues; as a review of the literature has shown, there is limited 
evidence to prove this. A relationship has not been proven specifically between 
PBLs and colorectal tissue. Does PBL TL reflect colorectal tissue TL and is it 
shorter than in age-matched normal controls? This experiment was designed to 
examine the relationship between telomere lengths in three tissues from 
patients diagnosed with colorectal cancer.  
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7.2 Clinicopathological Characteristics of the Patient 
Cohort for Matched Samples 
Sex M 17 Dukes' code NTF 1 
F 11 A 2 
Age  <40 0 B 9 
40-49 2 C 11 
50-59 2 D 2 
60-69 14 Not recorded 0 
70-79 8 Total 28 
>80 2 T stage NTF 0 
Total 28 1 0 
BMI  <20 0 2 3 
20-25 8 3 19 
25.1-30 8 4 6 
30.1-35 4 Not recorded 0 
>35 6 Total 28 
Not recorded 2 N stage 0 11 
Total 28 1 9 
Albumin   <35 4 2 8 
>35 24 Not recorded 0 
Not recorded 0 Total 28 
Total 28 AJCC stage NTF 0 
CRP  >10 5 1 2 
<10 23 2 9 
Not recorded 0 3 14 
Total 28 4 3 
mGPS 0 24 Not recorded 0 
1 3 Total 28 
2 1 Peritoneum 
involved 
Y 5 
Not recorded 0 N 22 
Total 28 Total 27 
Smoker N 17 Margin involved Y 2 
Y 3 N 26 
Ex 8 Total 28 
Total 28 Venous invasion Y 16 
Tumour 
location 
Colon 19 N 12 
Rectum 9 Total 28 
Total 28 Tumour 
perforation 
Y 0 
Differentiation Poor 1 N 28 
Well/Mod 26 Total 28 
NTF 0 High risk Petersen 
Index 
Y 4 
Not recorded 1 N 24 
Total 28 Total 28 
Table 7.1 Clinicopathological characteristics of the patient cohort for measurement of 
telomere lengths in matched tissue samples. 
Samples of tumour tissue, of adjacent non-malignant gut mucosa and of 
peripheral blood leukocytes were obtained from patients as described in the 
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Methods. All were analysed for relative telomere length. Clinical and 
pathological characteristics of this matched patient cohort (n=28) are 
summarised in the table above. 
7.3 Comparison of Telomere Length in Peripheral Blood 
Leukocytes, Colorectal Mucosa and Tumour Tissue 
The subset of samples of T/S in PBLs matched to tumour and normal gut samples 
was normally distributed, as was T/S in the sets of normal and tumour tissue 
samples. 
Telomere length in PBLs, colorectal mucosa and colorectal tumour tissue was 
compared. There was no statistically significant correlation in relative telomere 
length between any paired combination of PBLs, normal gut tissue or gut tumour 
tissue. 
T/S normal gut 
tissue
T/S gut 
tumour tissue
Correlation Coefficient .078 .181
Sig. (2-tailed) .698 .365
N 27 27
Correlation Coefficient .286
Sig. (2-tailed) .156
N 26
T/S PBL
T/S normal gut 
tissue
 
Table 7.2 Results of Spearman correlations between each tissue pair. There is no significant 
correlation between any pair of tissue telomere lengths. 
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Figure 7-1 Scatterplots of tissue telomere length pairs. No significant correlations were 
identified. 
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The distribution of telomere lengths in each tissue group was examined by 
analysis of variance by ranks and this showed a significant difference between 
groups (related-samples Friedman’s two-way analysis of variance by ranks, 
p=0.00000345). To determine the nature of the difference, this analysis was 
followed by related-samples Wilcoxon signed ranks tests on each tissue pair. 
Comparison of telomere lengths in all tissue pairs showed a significant difference 
in each case as tabulated below. 
p"value
PBL+Telomeres Normal+Gut+Telomeres 0.0009149575
PBL+Telomeres Tumour+Telomeres 0.001517584
Normal+Gut+Telomeres Tumour+Telomeres 0.0000704433
Tissue+pair
 
Table 7.3 Significance of related-samples Wilcoxon signed ranks tests for telomere lengths 
in each tissue pair. 
Normal gut tissue telomere length was longer than PBL telomere length and both 
were longer than tumour tissue telomere length: both differences are 
significant. These data suggest that telomere length measured from blood 
samples cannot provide a surrogate marker for telomere length, nor by 
extrapolation, an estimate of the biological age of the colorectal mucosal 
compartment. They suggest that PBL telomere length cannot be used to screen 
for biological ageing in the colorectal mucosal compartment. This contrasts with 
previous reports of PBL telomere length correlation with other body tissues, but 
is in keeping with the conclusion from the previous study comparing telomere 
length in blood and colonic mucosa(Craig, McKinlay et al. 2003). It is in keeping 
with PBL telomere length as a comparatively weak biomarker of ageing (Shiels 
2010; Gingell-Littlejohn, McGuinness et al. 2013). 
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Figure 7-2 Scatterplot showing matched telomere lengths from PBL (red), normal gut 
(green) and colorectal tumour (blue). 
 
Figure 7-3 Boxplots showing distribution of relative telomere length (T/S) for each of PBLs, 
colorectal mucosa and colorectal tumour tissue. 
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7.4 Discussion 
One of the aims of this project was to investigate telomere length as a useful 
biomarker of ageing in colorectal cancer. Cancer is an age-associated disease 
and so patients with cancer might be expected to show other measures of 
biological ageing. According to Baker and Sprott, “A biomarker of aging is a 
biological parameter of an organism that either alone or in some multivariate 
composite will, in the absence of disease, better predict functional capability at 
some late age than will chronological age”.(Baker and Sprott 1988) 
Strictly speaking, the level of function is not defined. Thus a biomarker of ageing 
at the level of cellular function would fulfil this definition as well as a biomarker 
of ageing of the whole organism. This distinction is not always made explicit in 
the literature, but is of crucial importance in clinical practice. The ‘one 
measurement’ that could meaningfully integrate the numerous and complex 
facets of ageing in one cell is a different proposition to the measurement that 
would encapsulate the functional frailty of an entire organism. Baker and Sprott 
allowed for this in the original paper, anticipating that a composite measure 
might be more likely. The idea of the single item biomarker was admitted to be 
optimistic but possible, in a review of telomere length as a biomarker for ageing 
and age-related disease, which focused on PBL telomere length as the ‘single 
measurement’ (von Zglinicki and Martin-Ruiz 2005). This paper quoted two of 
the studies outlined in the earlier literature review to support PBL telomere 
length as a measure of other tissues telomere length. The authors did note that 
much of the data is ‘correlative, [and] that much of it comes from 
underpowered studies’. 
Another review on the subject (Bekaert, De Meyer et al. 2005) acknowledged 
that most of available information relating telomere length to ageing was based 
on PBL telomere lengths as the most accessible tissue for research. There are 
obvious clinical advantages over sampling more inaccessible tissues which may 
be the actual focus of interest, but the link between PBL telomere length and 
telomere length in other tissues should be clarified before inference is made. 
Mather et al noted that the necessary prerequisite data for this assumption are 
not yet available.(Mather, Jorm et al. 2011) 
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More recently, assessment of PBL telomere length as a biomarker of ageing (BoA) 
at the whole organism level was examined with regard to the West of Scotland 
Twenty-07 Study. This study did not consider the validity of PBL telomere length 
as a marker of ageing in less accessible tissues. As a single item BoA, it did add 
predictive power over and above chronological age, but it did not account for a 
large proportion of the effect of chronological age, and therefore did not satisfy 
the Baker and Sprott defintion. Assessed as a part of a multivariate model, 
telomere length did add predictive power again, athough its contribution was 
not overwhelming.(Der, Batty et al. 2012) 
The important point made by these authors is that careful thought needs to be 
given to the purpose of the biomarker we try to define. Do we want to predict 
incidence or progression of disease? Do we focus on outcome for the organism as 
a whole, or on the affected tissue? In the case of colorectal cancer patients, 
data presented here has not indicated a correlation between telomere length in 
blood, gut mucosa or tumour tissue. Telomere length in each compartment may 
be of use separately. The idea of telomere length as a biomarker of ageing might 
usefully be applied in several ways. 
7.4.1 Telomere length as Biomarker of Ageing in Whole Organism 
To accept a parameter as a biomarker of ageing of the organism, it should 
integrate the effects of forces which produce ageing (as an accumulation of 
frailty in physiological systems in an organism) in different parts of the body, 
eventually affecting the function of the organism as a whole. If a telomere 
length measurement fulfilled this criterion, it would likely be PBL telomere 
length. It is difficult to see how telomere length in any other tissue could 
integrate the effects of increasing bio-age as circulating leukocytes could. 
7.4.2 Telomere length as Biomarker of Ageing in Colorectal 
Cancer Patients 
With regard to cancer, there is evidence from this laboratory that patients with 
colorectal cancer have shorter PBL telomere length than age-matched 
controls(Maxwell 2013). In 4 case-control studies, patients with head and neck, 
lung, renal cell and bladder cancer had shorter lymphocyte telomere lengths 
than controls(Wu, Amos et al. 2003). However, the evidence of increased risk of 
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cancer with shorter PBL telomere length is not completely consistent. Weischer 
et al showed an association between PBL telomere length and cancer survival 
but not cancer risk in 47,102 patients with a wide range of cancers (Weischer, 
Nordestgaard et al. 2013). Assuming PBL telomere length in cancer patients is 
shorter than in age-matched controls, what does this tell us? One possibility is 
that these patients are more likely to develop cancer because they are more 
biologically aged, and PBL telomere length is a valid marker of organism bio-age. 
Alternatively, these patients have short PBL telomeres because they have 
developed cancer. Correlative studies such as we have available at present do 
not offer information on causality. If we accept this second possibility, then how 
does cancer in the gut shorten PBL telomeres? Bekaert et al suggest a link with 
immunosenescence or inflamm-ageing, and there is certainly a wealth of 
information linking outcome with inflammatory and immune responses to the 
tumour (Bekaert, De Meyer et al. 2005). 
The host-tumour interaction might be at the heart of the prognostic power of 
PBL telomeres. Rather than a direct integrative measure of agedness of different 
physiological systems and organs, PBL telomere length may reflect the 
robustness of the host systems of communication, embodied by the vascular 
system. Communication and integration of host defences against tumour may be 
the vulnerable link, as poor integration of defences may allow the tumour to 
gain a foothold. Defences which fail to prevent this are likely to be less 
competent to defend against a tumour which continues to gain in mass and 
genotypic advantage. 
PBL telomere length may also be a biomarker of the organism’s ability to cope 
with treatment. Where studies have shown correlation between telomere 
lengths in different tissues, there is some evidence that populations of cells in 
close physiological and anatomical proximity have more correlation in telomere 
length. Most of the major causes of death (non-cancer-specific, in the developed 
world, of aged people), are diseases of the aged vascular system (cardiovascular, 
cerebrovascular and chronic renal disease) or have major links with them. 
Respiratory disease affects the huge vascular endothelial surface area of the 
lungs, and type 2 diabetes is part of the metabolic syndrome, often co-existing 
with atherosclerosis. 
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Telomere length is a useful parameter. It integrates the effects of time with 
effects of oxidative stress, which is itself also a measure of the efficiency of 
cellular machinery, reflecting its functional resilience. Ageing as manifest by 
telomere length can indicate compartments with more ‘stress’, which are likely 
to decompensate and affect the overall body (other systems) more readily if 
current conditions prevail. This offers us predictive and potentially prognostic 
power but probably specific to the tissue of the telomere measurement. It is 
possible that PBL telomere length, for example, might function as a ‘lowest 
common denominator’ of biological age by reflecting non-telomere-related 
effects of bio-ageing in the tissues they integrate information from, but it seems 
reasonable to suppose that a factor that acts by affecting PBL telomere length 
would affect telomere length in the tissue of origin as well.  
7.4.3 Telomere length as Biomarker of Ageing in Normal 
Colorectal Tissue: predictive or prognostic marker. 
A search of the available literature has shown there is no robust evidence to 
support association between telomere length in PBLs and colorectal epithelial 
cells. No support for this assumption has been received from the results reported 
in this study. 
There is heterogeneity of cell types in normal colonic tissue which affects the 
telomere length measurement made as described above. There is heterogeneity 
of clonal phenotypes of telomere length within a tumour. There is also a 
significant degree of inter-individual variation.  Given these factors, one could 
predict that gut tissue telomere length, or tumour tissue telomere length would 
be difficult to use as a prognostic or predictive marker in colorectal cancer. 
More information is needed on change of telomere length in specific cell types 
over time, and with malignant transformation. With this information, in a 
specific individual, gut tissue telomere length may be prognostic for 
development of cancer. The rate of telomere change in an individual may be the 
critical factor for individual prognosis.  
Properly powered longitudinal studies to investigate the rate of change of 
telomere length in colorectal tissue (and in blood) would allow us to further 
assess the potential usefulness of telomere length in specific tissues in colorectal 
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cancer. The colorectal screening program is likely to be an effective means of 
gaining such data. It could be useful in establishing baseline for individuals, and 
could be the means of monitoring deviation from it, since blood tests cannot 
provide an accurate assessment. 
7.4.4 Telomere length in Colorectal Tumour Tissue: predictive or 
prognostic marker. 
Gastrointestinal epithelial cells, as distinct among other types of cells in the 
human body, achieve the regular renewal of the gut lining by continuous 
replacement. In the colorectum, replacement is from the stem cell population in 
the intestinal crypts. Clonal popoulations in adjacent crypts originate from stem 
cells deep in the crypt. Colonic stem cells have come under particular interest in 
recent years in research on the pathogenesis of colorectal cancer because the 
short lifespan of non-stem gut epithelial cells is too short to allow them to 
develop the sort of age-associated mutations necessary for malignant 
transformation. Thus colonic stem cells are thought to be the source of the 
cancer stem cells in colorectal adenocarcinoma.  
Telomere length analysis differentiates crypts which appear histologically 
identical,(Meeker, Hicks et al. 2004) some of which are malignant and some not. 
Different telomere lengths in adjacent crypts originating from stem cells which 
develop their own spectrum of mutations could explain the heterogeneity of 
telomere measurements in tumour specimens. Tumour telomere length may tell 
us about tumour behaviour. One paper has described an association between 
ratio of telomere length in colorectal tumour and adjacent normal mucosa, and 
survival in 147 patients(Valls, Pinol et al. 2011). This individualised result 
showing the effect of shorter tumour telomere length in a large study indicates 
the useful directions that specific tissue telomere length measurement could 
take. Experiments like this which associate longer telomere length with poorer 
prognosis suggest that individual telomere length measurements in tumour 
specimens could be of value in identifying tumours with increased risk of local 
invasion and metastasis. If these specimens were taken preoperatively, they 
could help tailor the use of neoadjuvant therapies. However, achieving sufficent 
sampling of the entire tumour to make a meaningful conclusion may be difficult. 
 8 Telomere length, Inflammation and Prognostic 
Markers in Colorectal Cancer 
8.1 Introduction 
Short telomeres are common in tissues which develop cancer and are postulated 
to reflect increased ageing and to make these tissues more susceptible to 
malignant transformation(Montalto, Phillips et al. 1999). The vast majority of 
cancer cells reactivate telomerase or show another process (alternative 
lengthening of telomeres - ALT) which allows them to maintain telomere 
length(Bechter, Zou et al. 2004). It is not clear how telomere length is 
controlled in transformed cells; it exhibits variation but appears to be above the 
critical level which normally results in cell death(Shay and Wright 2011). Cancer 
cells show a higher rate of joined chromosomes and break-fusion-bridge cycles 
of DNA damage with rearrangement of chromosomes, which are associated with 
dysfunctional telomeres and facilitate genomic reorganisation(Mathieu, Pirzio et 
al. 2004).  
Telomere length is reduced in PBLs in patients with colorectal cancer with 
respect to age-matched controls(Maxwell 2013). Data discussed in the previous 
chapter indicates that telomere length in colorectal tumour tissue is reduced 
relative to telomere length in adjacent normal colorectal tissue. Other 
clinicopathological factors associated with outcome in colorectal cancer may be 
associated with short telomeres and offer insight into mechanisms by which 
short telomeres encourage malignant potential, or ways to target the interaction 
between telomeres and changes leading to transformation. The rationale for 
selection of these factors was discussed in the earlier chapter on Experimental 
Methods.  
Data on associations between relevant clinicopathological variables and 
telomere length in PBLs, normal and colorectal tumour tissue are presented 
below. 
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8.2 Clinical and Pathological Characteristics of the 
Patient Cohort 
Clinical and pathological characteristics of this patient cohort (n=95) are 
summarised in Chapter 3. 
8.3 Overview of telomere length and clinicopathological 
factors 
Associations between telomere lengths and 29 clinicopathological factors were 
examined. p<0.01 was accepted as the level of statistical significance; 
associations with p-value >0.01 are lowlighted in grey text in summary results 
tables. 
Table 8.1 (Following page) Associations between telomere length in PBLs, normal colorectal 
tissue and colorectal tumour tissue and demographic variables and classical and atypical 
markers of inflammation.
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PBL Telomere length
Normal colorectal tissue 
telomere length
Colorectal tumour tissue 
telomere length
Age
Highest quartile TL is associated 
with higher age category, Pearson 
Chi square, p=0.048 Pearson Chi square, p=0.472 Pearson Chi square, p=0.616
Sex
Male sex is associated with shorter 
PBL telomere length, Mann-
Whitney U Test, p=0.018 Pearson Chi square, p=0.816 Pearson Chi square, p=0.345
Weight Pearson Chi square, p=0.573 Pearson Chi square, p=0.827 Pearson Chi square, p=0.639
BMI Pearson Chi square, p=0.691 Pearson Chi square, p=0.224 Pearson Chi square, p=0.691
WCC Pearson Chi square, p=0.755 Pearson Chi square, p=0.182 Pearson Chi square, p=0.863
CRP Pearson Chi square, p=0.131 Pearson Chi square, p=0.936
High CRP is associated with 
telomere length below the median, 
Pearson Chi square, p=0.025
Albumin Pearson Chi square, p=0.167 Pearson Chi square, p=0.936 Pearson Chi square, p=0.936
mGPS
PBL telomere length varies with 
mGPS, Kruskal-Wallis Test, 
p=0.018 Pearson Chi square, p=0.511
Telomere length below the median 
is associated with higher mGPS. 
Pearson Chi square, p=0.080, 
Linear-by-Linear Association, 
p=0.039
Hb Pearson Chi square, p=0.358
Telomere length in normal 
colorectal tissue is longer in cases 
with haemoglobin less than 10, 
Mann-Whitney U Test, p=0.034 Pearson Chi square, p=0.303
Plt Pearson Chi square, p=0.918
Shortest quartile telomere length is 
associated with platelet count 
above the median, Pearson Chi 
square, p=0.037
Shortest quartile telomere length is 
associated with platelet count 
above the median, Pearson Chi 
square, p=0.037
Smoking 
status Pearson Chi square, p=0.257 Pearson Chi square, p=0.177 Pearson Chi square, p=0.862
Demographic 
variables
Inflammatory 
markers
Atypical 
markers of 
inflammation
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PBL Telomere length
Normal colorectal tissue 
telomere length
Colorectal tumour tissue 
telomere length
Pearson Chi square, p=0.173 Pearson Chi square, p=1.000
Highest quartile telomere length is 
associated with highest quartile 
fetuin A, Pearson Chi square, 
p=0.029
Lutein
PBL telomere length below the 
median associates with high lutein 
levels, Pearson Chi square, 
p=0.025 Pearson Chi square, p=0.876 Pearson Chi square, p=1.000
Lycopene Pearson Chi square, p=0.642 Pearson Chi square, p=0.205 Pearson Chi square, p=0.302
alpha-
carotene Pearson Chi square, p=0.552 Pearson Chi square, p=0.447 Pearson Chi square, p=0.614
beta-carotene Pearson Chi square, p=1.000 Pearson Chi square, p=0.833 Pearson Chi square, p=0.302
VitA Pearson Chi square, p=0.642 Pearson Chi square, p=0.782 Pearson Chi square, p=1.000
VitE
Shortest quartile PBL telomere 
length is associated with lowest 
quartile Vitamin E, Pearson Chi 
square, p=0.040 Pearson Chi square, p=0.464 Pearson Chi square, p=1.000
Pearson Chi square, p=0.194 Pearson Chi square, p=0.420 Pearson Chi square, p=0.451Total comorbidities
Serum 
antioxidant 
levels
Fetuin A
 
Table 8.2 Associations between telomere length in PBLs, normal colorectal tissue and colorectal tumour tissue and fetuin A, serum antioxidant levels and 
comorbidities. 
Table 8.3 (Following page) Associations between telomere length in PBLs, normal colorectal tissue and colorectal tumour tissue and markers of tumour-
related prognostic significance. 
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PBL Telomere length
Normal colorectal tissue 
telomere length
Colorectal tumour tissue 
telomere length
Pearson Chi square, p=0.177 Pearson Chi square, p=0.883
Shortest quartile telomere length is 
associated with colonic tumours, 
Pearson Chi square, p=0.018
Dukes' stage Pearson Chi square, p=0.448 Pearson Chi square, p=0.271 Pearson Chi square, p=0.722
AJCC overall 
stage Pearson Chi square, p=0.411
Telomere length below the median 
is associated with early AJCC 
stage. Pearson Chi square, 
p=0.161, Linear-by-Linear 
Association, p=0.042 Pearson Chi square, p=0.557
T stage Pearson Chi square, p=0.352 Pearson Chi square, p=0.615 Pearson Chi square, p=0.145
N stage Pearson Chi square, p=0.426 Pearson Chi square, p=0.336 Pearson Chi square, p=0.549
M stage
Highest quartile TL is associated 
with distant metastases, Pearson 
Chi square, p=0.010 Pearson Chi square, p=0.315 Pearson Chi square, p=0.077
Differentiation Pearson Chi square, p=0.634 Pearson Chi square, p=0.308 Pearson Chi square, p=0.308
Margin 
involvement Pearson Chi square, p=0.448 Pearson Chi square, p=0.326 Pearson Chi square, p=0.127
Peritoneal 
involvement
Peritoneal involvement is 
associated with shorter PBL 
telomere length, Mann-Whitney U 
Test, p=0.043 Pearson Chi square, p=0.208
Peritoneal involvement is 
associated with shorter telomere 
length in colorectal tumours, Mann-
Whitney U Test, p=0.015
Tumour 
perforation
Tumour perforation is associated 
with lowest quartile PBL telomere 
length, Pearson Chi square, 
p=0.034 NO CASES NO CASES
Venous 
invasion Pearson Chi square, p=0.841 Pearson Chi square, p=0.343 Pearson Chi square, p=0.863
High risk 
Petersen 
index Pearson Chi square, p=0.544 Pearson Chi square, p=0.345 Pearson Chi square, p=0.516
Tumour location
Measures of 
cancer 
staging
Pathological 
prognostic 
markers
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8.3.1 PBL telomere length and associations with 
clinicopathological factors 
Peripheral blood leukocyte (PBL) telomere length was investigated in the full 
cohort of 95 colorectal cancer patients initially. The range of relative telomere 
length measurements was 0.605 (mean 0.615, min 0.383-max 0.988). 
8.3.1.1 Demographic variables 
8.3.1.1.1 Association with age 
Telomere length reduces with progressive divisions in all cells as a result of the 
end replication problem. It is also affected in the process of ageing, as cells are 
exposed to other factors which cause telomere erosion. The initial assessment of 
telomere length therefore was to examine the relationship with age. 
There was no correlation between PBL telomere length and age (see Appendix 7 
for scatterplot).  
8.3.1.1.2 Association with sex 
Female sex is generally associated with longer telomere length but this 
association did not reach statistical significance in this dataset (Mann-Whitney U 
test, p=0.018). 
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Figure 8.1 Boxplots showing telomere lengths in females and males (Mann-Whitney U test, 
p=0.018). 
8.3.1.2 Inflammatory status 
8.3.1.2.1 Associations with inflammatory markers: CRP, albumin, mGPS 
There was no association between PBL telomere length and serum albumin or 
CRP in this cohort.  
8.3.1.2.2 No association with serum fetuin A 
There was no association between serum fetuin A and telomere length in PBLs in 
this cohort. This is contrary to a previous report in a smaller sample (Maxwell, 
McGlynn et al. 2011). 
8.3.1.3 Measures of cancer staging 
8.3.1.3.1 Association with distant metastases 
In this dataset, there was no association between overall AJCC TNM stage, 
Dukes’ stage, T stage or N stage and PBL telomere length. 
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An association between presence of distant metastases and highest quartile PBL 
telomere length did not quite reach statistical significance (Pearson Chi square, 
p=0.010). One might expect that if telomere length in PBLs was a measure of 
biological ageing, and more advanced cancer corresponded to increased 
biological age, any association would be in the opposite direction.  
 PBL telomere length 
Total 
Lowest three 
quartiles 
Highest 
quartile 
No distant 
metastases 
63 17 80 
Distant metastases 
present 
3 5 8 
Total 66 22 88 
Table 8.4 Longest quartile PBL telomere length is associated with presence of distant 
metastases (Pearson Chi square, p=0.010). 
The number of cases with distant metastases was small (8/88) and an 
appropriately powered study would be necessary to answer this question more 
completely. A serological test to identify patients with distant metastases is an 
attractive prospect, but it is not conclusive from this data that PBL telomere 
length could fulfil this role.  
8.3.2 Normal colorectal tissue telomere length and associations 
with clinicopathological factors 
The range of relative telomere length measurements was 0.831 (mean 0.750, 
min 0.470 – max 1.301). There were no statistically significant associations with 
any of the clinicopathological markers examined in this cohort. 
8.3.3 Colorectal tumour telomere length and significant 
associations with clinicopathological factors 
The range of relative telomere length measurements was 0.631 (mean 0.456, 
min 0.231 – max 0.861). There were no statistically significant associations with 
any of the clinicopathological markers examined in this cohort. 
 
Chapter 8: Telomere Length and Clinicopathological Factors   301 
8.4 Discussion 
The relative telomere length to single copy gene ratio (relT/S) gives a measure 
of the average telomere length of cells in the sample of tissue from which the 
DNA was extracted. Cells were not selected for by type. Thus the average 
telomere length estimated is an average over all cell types present in the 
sample. In normal gut samples these include stromal cells and epithelial cells. In 
tumour samples this includes any normal cells that may remain after tumour cell 
infiltration and overgrowth, as well as the heterogeneous population of tumour 
cells. In blood, this includes all classes of leukocytes, and it is worth 
remembering that some inflammatory responses will disproportionately elevate 
different classes of leukocyte. 
The telomere length measurement used was therefore not a pure analysis of gut 
mucosal cell telomere length or leukocyte subtype.  
The number of patients for whom PBL telomere length was measured was quite 
small. An even smaller number of samples were available for telomere length 
measurement in gut mucosa and colorectal tumour tissue (n=27). The power to 
detect relationships with clinicopathological parameters is correspondingly 
affected and may be the main reason why several expected associations were 
not observed.  
8.4.1 Telomere length and cellular vs. organism ageing 
Control of telomere dynamics as a cell-specific, or cell-type specific process is 
readily understandable. Wider regulation of telomere length at a tissue level is 
possible as all cells respond to their environment and powerful homeostatic, 
endocrine and paracrine mechanisms operate ultimately at the molecular level 
on individual cells. Organism-level or system-wide effects on telomere length 
may be demonstrable through the competing noise of lower order level traffics 
described. An overarching system-wide process will also ultimately have tangible 
effects through events at the molecular level. Is telomere length one of the 
tangible effects of important processes modulating lifespan, or merely a 
measurable molecular-level characteristic? 
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Age, as such a ‘system-wide’ effect, does have an effect on telomere length 
variability in PBLs. The effect is relatively small as a proportion of total 
telomere length variability. Age accounts for 6-11% of total variability in 
telomere length in the larger studies reported, even though it is the archetypal 
parameter investigated(Weischer, Bojesen et al. 2012; Weischer, Nordestgaard 
et al. 2013). Leukocyte telomere length did not map to physical performance in 
a recent meta-analysis of studies (Gardner, Martin-Ruiz et al. 2013). These 
authors concluded that PBL telomere length may be a useful marker of cellular 
ageing but did not appear to offer much in assessment at a more macroscopic 
level. In diseases such as cancer, it may be however, that cellular ageing is the 
important parameter to measure as this may reflect the propensity for malignant 
transformation.  
In this dataset, although the age range of patients for whom PBL telomere 
length was measured was quite wide, the overall number of cases was small. In 
the colorectal tissue subgroups, the age range was correspondingly narrower so 
that the 6-11% variability would be harder to detect. 
8.4.1.1 PBL telomere length and sex. 
PBL telomere length was not significantly different between males and females, 
in this dataset. Sex is another system-wide variable like age and, manifest as it 
is at chromosomal level, does appear to have demonstrable effect on PBL 
telomere length. The molecular mechanism underlying this effect may involve 
modulation of other pathways, such as the ROS handling processes. 
Telomere length in different tissues is equal in males and females at birth 
(Youngren, Jeanclos et al. 1998; Okuda, Bardeguez et al. 2002), but in adult life, 
age-adjusted PBL telomere length was longer in women than in men(Jeanclos, 
Schork et al. 2000; Benetos, Okuda et al. 2001). These studies examined 49 twin 
pairs, and 193 unrelated individuals respectively, so that the cohort here may be 
too small to detect such differences in unmatched persons.  
Women differ in the production of hydrogen peroxide from age-matched men. 
They also differ in the activity of antioxidant enzymes, as females have higher 
superoxide dismutase and catalase activity but lower glutathione peroxidase 
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activity.(Bolzan, Bianchi et al. 1997) The hTERT promoter contains an oestrogen-
responsive element.(Kyo, Takakura et al. 1999) Telomere attrition is increased 
by ROS in fibroblasts (Richter and von Zglinicki 2007). Taken together these facts 
suggest that sex-dependent handling of reactive oxygen species may underlie the 
sex difference in PBL telomere length identified in the literature and replicated 
in this dataset. 
8.4.2 Telomere length and colorectal cancer stage 
To summarise, data analysis from this cohort showed longer PBL telomeres are 
associated with presence of metastases. Chi square analysis associated lower 
TNM stage with below-median telomere length in normal gut mucosa. 
8.4.2.1 Telomere length in colorectal tissue and cancer stage 
Several groups have investigated a relationship between cancer outcome and 
tumour and surrounding tissue telomere length in colorectal and other cancers. 
It has been proposed that critically short telomeres lead to telomere dysfunction 
and chromosomal instability with formation of anaphase bridges. Break-fusion-
bridge cycles can produce translocations and it is proposed that these critically 
short telomeres and chromosomal instability underlie the transition from benign 
to malignant neoplasm in colonic tissue. It is suggested that telomerase is 
reactivated after this by established malignant cells and explains their 
persistence. Very long telomeres (longer than seen in normal, non-aged cells) 
may represent cells in which dysfunctional telomerase reactivation has surpassed 
levels normally observed in the tissue (Rudolph, Millard et al. 2001). This may 
have been the underlying process at work in the one excluded case from this 
cohort with extremely long colorectal tumour tissue telomere length. 
In 50 human colorectal cancers and adjacent normal mucosa, longer telomeres 
were associated with higher levels of telomerase activity and higher Dukes’ 
stage in colorectal tumour samples (Engelhardt, Drullinsky et al. 1997). Patients 
with poor survival had short telomeres in tumour samples and high telomerase 
activity, and patients with better survival had low telomerase activity and long 
telomeres. Survival was affected distinct from the accepted effect of Dukes’ 
stage. In 57 cases of matched colorectal tumour and adjacent normal mucosa, 
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telomere lengths (measured using the TRFL method) between the normal and 
tumour tissue were correlated (Gertler, Rosenberg et al. 2004). These authors 
found, in keeping with the results reported in Chapter 7, that telomere length 
tended to be shorter in tumour tissue than normal tissue. This relationship is not 
absolute and although they reported a correlation between telomere length in 
normal and tumour tissue, tumour tissue telomere length was longer in 14% of 
cases.  
Gertler et al also found that telomere length in TNM Stage 1 cancer was shorter 
than in Stage 2-4 and telomere length was correlated with overall survival. Ratio 
of telomere length in normal and tumour tissue was correlated with survival (RR 
of death=3.3 for telomere ratio >0.90). However, the association between 
cancer stage and telomere length in colorectal cancer is not invariable. Another 
study of 20 cases found a greater rate of telomere shortening in Dukes’ C than in 
Dukes’ B tumours (Kim, Kim et al. 2002). In an analysis of telomere length and 
telomerase activity in T cells undergoing spontaneous immortalisation, telomere 
length shortened through crisis, until telomerase was activated, usually some 
time after immortalisation(Degerman, Siwicki et al. 2010). It is possible 
therefore that in colorectal cancer cells, shorter telomere length in the adjacent 
mucosa reflects a telomere field-effect around the malignant cells which in the 
early stages of transformation may exhibit exceptionally short telomeres. 
Telomerase activity is observed in primary CRC tumour cell lines but appears not 
to be constitutively maintained in invitro culture, resulting in short lifetime with 
limited passage; this is rescued by transfection with hTERT.(Dalerba, Guiducci et 
al. 2005) What maintains it in cancer cells? Is there a constant selection for 
telomerase-active cells? Do cells with super-active telomerase have a survival 
advantage, hence longer telomeres in more advanced stage cancers which have 
had more time to develop? In a study of 61 colorectal cancers and adjacent 
mucosa, there was no correlation between telomere length in tumours and 
telomerase activity, leading these investigators to conclude that telomerase 
activity may be an individual feature characteristic of a given tumour(Takagi, 
Kinouchi et al. 1999). Elongating telomeres whether identified by telomerase 
activity or elongated tumour telomeres (as compared to telomeres in 
background non-tumour gut epithelial cells, expressed as T/N ratio) may be the 
poor prognostic factor. In a group of 91 cases, there was no association between 
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Dukes’ stage and tumour telomere length, but cases with telomere length 
greater than 6.12 kbp and T/N >0.66 had reduced survival.(Garcia-Aranda, de 
Juan et al. 2006) 
It is possible that better survival in cancer reflects cells with longer telomeres 
ab initio in originating tissues and a cancer phenotype which does not ‘over-
reactivate’ telomerase. In this dataset, there was a trend to a relationship 
between telomere length in normal gut tissue and Dukes’ stage, but there was 
no observed relationship between stage and tumour tissue telomere length. 
Many of the studies summarised are of larger size than this dataset, but 
nevertheless there is neither a simple correlation between tumour telomere 
length and cancer stage, nor any conclusion as to the correspondence or 
otherwise of development of malignancy, and telomere shortening or elongation. 
It seems clear that telomere dysfunction is associated with development of 
malignancy, but neither the degree nor the direction of telomere length change 
is explained by a simple association.  
8.4.2.2 Telomere length in PBLs and cancer stage 
Evidence from this laboratory has shown that colorectal cancer develops in 
biologically aged individuals as measured by PBL telomere length which was 
shorter than PBL telomere length in age-matched controls. However there is no 
data on mean telomere length in non-malignant colorectal tissue in patients with 
cancer as compared to mean telomere length in colorectal tissue in patients 
without cancer. Is the gut more biologically aged, or is the organism more 
biologically aged? Do these two factors correlate? 
While there are many accounts of telomere length in tumour tissue from the 
colorectum and many other organs, describing a relationship or lack thereof 
between stage and telomere length in the tumour or adjacent normal tissue, 
there is no published detailed investigation of association between telomere 
length in PBLs and tumour stage for solid organ malignancy. In one large study of 
cancer risk, cancer prognosis and telomere length in PBLs, risk of death was 
measured in advanced (as opposed to localised) cancer as a function of telomere 
length(Weischer, Nordestgaard et al. 2013). They found increased risk of death 
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with decreasing telomere length quartiles. Previous investigation in this 
laboratory found no association between tumour stage and PBL telomere length 
in a cohort of 64 patients. This lack of information is not particularly surprising 
since the biological connection between the two seems tenuous. 
Interpreting the finding in this cohort, of an association between PBL telomere 
length and presence of distant metastasis, requires caution. Presence of distant 
metastasis is a component of Dukes’ and TNM staging, but also represents the 
first evidence of a cancer as a ‘systemic’, in the sense of ‘body-wide’ disease. Is 
that a significant difference from neoplasm as an invasive disease within the 
originating tissue, or from cancer which has achieved spread to nearby lymph 
nodes? These categorisations were developed on the basis of different clinical 
outcome, but may be reviewed in the era of molecular medicine. If it is a true 
finding, this association between PBL TL and presence of metastases implies that 
systemic spread of colorectal cancer manifests in systemic change in PBL 
telomere length. 
As discussed above in the context of sex and telomere length, the effect of a 
systemic variable on telomere length would likely modulate stronger local 
forces, and may be weak but still detectable. This finding could obviously be 
very useful if it predicted evidence of metastatic deposits on classical imaging 
but this result is merely a correlation. It is interesting to speculate by what 
processes metastatic cancer could modulate the telomere length of circulating 
blood leukocytes. An underlying causative process, if it existed might tell us 
much of interest about the metastatic cells. Of most use would be an indication 
of a telomere effect prior to observed metastatic deposits. However, this 
association needs to be established or refuted in a properly powered study first. 
It is also possible that this association is confounded. There may be a selection 
bias: patients with longer PBL telomeres (patients who are less biologically aged) 
may present with more advanced cancer. A genotype of longer telomeres in PBLs 
may be associated with the development of cancers that allow survival to 
metastasis with relatively good general health. 
8.4.3 Telomere length and inflammation 
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There is extensive literature suggesting that inflammatory conditions of many 
aetiologies are associated with shorter PBL telomeres. Cancer-associated 
inflammation has both systemic and local aspects(Colotta, Allavena et al. 2009). 
These may have differential effects on ‘systemic’ (PBL) and ‘local’ (gut/tumour) 
telomere length. Hypoalbuminaemia and high CRP reflect activation of the 
systemic inflammatory response. Evidence from ulcerative colitis and other 
inflammatory conditions indicates that shorter PBL telomeres are associated 
with systemic inflammation (a manifestation of increased biological ageing). In 
this dataset, however, there were no significant associations between any tissue 
telomere length and the parameters of systemic inflammation investigated. 
Tumour tissue telomere length may be deregulated as part of the transformed 
phenotype. It is likely that the small sample size acquired here precluded 
detection of any relevant associations. 
Weak local inflammatory response to tumour is associated with poorer survival in 
colorectal cancer.(Roxburgh, Richards et al. 2013) A lack of local inflammatory 
reaction to tumour cells could allow ongoing mutation and selection for tumour 
cell clones with increasingly active telomerase and longer telomeres. Longer 
tumour telomere lengths have been associated with poorer outcome. It is 
difficult to reconcile this association. Roxburgh et al reported that systemic and 
local inflammatory responses may be linked, with reduced local inflammatory 
response and high systemic response associated with poorer prognosis(Roxburgh, 
Salmond et al. 2009). In a recent review, Guthrie et al noted the association 
between tumour necrosis, decreased local inflammatory response and increased 
systemic inflammation, and suggest that IL-6 may be the underlying mediator 
(Guthrie, Roxburgh et al. 2013). IL-6 forms part of a positive feedback loop 
which maintains the senescence-associated secretory phenotype(Freund, Orjalo 
et al. 2010); a measure of local inflammation such as tumour IL-6 levels may 
offer further insight.
 9 Concluding Discussion 
The aim of this thesis was to evaluate 3 potential markers of biological ageing in 
the context of colorectal cancer. The data obtained is mainly descriptive but 
does suggest some avenues of research which are further discussed. 
Identification of markers of biological ageing has met with little success despite 
significant international investment. In part this is because it is difficult to 
define ageing as opposed to disease, and therefore difficult to define endpoints 
and deviations from what may be considered normal(Sprott 2010). For practical 
purposes however, markers of ‘ageing and disease’, where distinction between 
the two processes is not required may be most useful in clinical application. The 
subjects of study here (telomere length, fetuin A and the sirtuins) have come to 
the fore because of their striking effects across many disease processes which 
suggests a fundamental importance in the maintenance of healthy function. 
Cancer is an age-associated disease but differs from other age-associated 
diseases. It is noted for the intrinsic growth in cell mass; there are also 
important changes in interaction with the host organism and in interface with 
and subversion of important control and signalling pathways of the organism. 
Although they originally came to prominence in ageing research, the three 
candidates investigated here are intricately linked to the cancer disease process. 
Further unifying features are their interactions with the inflammatory response 
and metabolic regulatory pathways. This underlines the dependence of cancer 
cells on systems such as inflammation and metabolism, as well as control of cell 
division, and investigation is ongoing in these areas to unravel the molecular 
mechanisms underpinning both these processes and their subversion in malignant 
transformation. New avenues of research with therapeutic intent will rely on 
such a nanoscale understanding of systems in the incipient era of drug design. 
9.1 Telomere length in different tissues in colorectal 
cancer 
Telomere length is most widely accepted as a potential marker of biological 
ageing, because of its obvious link to cycles of cell division and to the cessation 
of cell division. Questions remain as to how it can be interpreted to give useful 
information at a cellular, tissue or whole organism level. Interindividual 
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variability in telomere length in one tissue is large, and has hindered efforts to 
make generalised conclusions across a population. Interindividual variability in 
telomere length in one tissue may be greater than inter-tissue variability in 
telomere length in one individual. 
One recent study measured telomere length in skin and blood and in fat and 
muscle and concluded that telomere length in the stem cell compartment in 
post-mitotic and continuously dividing tissues are equivalent(Daniali, Benetos et 
al. 2013). However, they did not include in this analysis the epithelial tissues 
which provide a large part of the human body’s interface with the external 
environment, but which are relatively hidden. These also include the tissues 
which are the source of the largest non-hormone-dependent cancer burden in 
adults, i.e. the respiratory and gastrointestinal epithelia. The data presented in 
this thesis showed that, in contrast to Daniali et al’s results, there was neither a 
correlation nor an equivalence between telomere length in two continuously 
dividing tissue compartments in the adult, blood and colorectal epithelium. 
Further large scale studies of telomere length in different tissues would be of 
benefit, to add a weight of evidence to one conclusion or the other. The specific 
tissues being compared will need to be considered as well.  
9.1.1 The ‘miles on the clock’ hypothesis and colorectal cancer 
Telomere length makes sense as marker of ageing in cells. The paracrine effect 
of senescent tissues, with dysregulation of handling of ROS, and the documented 
effect of ROS to shorten telomere length could exert a field effect in one tissue 
to integrate telomere length in that tissue. Telomere length could be useful as 
marker of ageing or of ‘miles on the clock’ in specific tissues. Data presented 
here could not determine if or how this might translate to report accurately on 
ageing at a higher level of organisation. 
PBL telomere length as generally reported may provide information about ageing 
of the haematopoietic system, averaging over several cell types. Because of 
close proximity to the endothelial layer, PBL telomere length may give us 
information about the ageing of the vascular system. PBLs are somewhat unique 
in that they are an easily accessible source of experimental tissue which is also 
in indirect contact with most other tissues of the body. PBLs may integrate 
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information on the ROS burden of other tissues they pass through, possibly by 
the effect of these ROS environments on PBL telomere length. It was hoped 
therefore that PBL telomere length might reflect telomere length in other 
tissues directly enough to provide a useful surrogate, and thus enable us to draw 
conclusions about the robustness of the whole organism. In particular, such a 
measure might provide a marker of the ability of the organism, or patient, to 
cope with treatments with systemic effect. A specific example might be 
chemotherapy, as many colorectal chemotherapy regimens impose significant 
stress on other systems, such as the cardiovascular system.  
The data reported here does not support PBL telomere length as a marker of 
biological ageing which can reflect the ageing of colorectal tissue presumed to 
be concomitant with the development of colorectal cancer, since it shows that 
telomere lengths in matched samples of PBLs and colorectal tissue do not 
correlate, and indeed appear to constitute separate populations. Telomere 
tissue of origin is important and it does not appear possible to use telomere 
lengths from different tissues as interchangeable or surrogate measures. 
However, telomere length in a certain tissue may still give us useful information 
about ageing in that tissue.  
9.1.2 Potential clinical applications of telomere length analysis in 
colorectal cancer 
In order for telomere length to function as a marker of ageing of the whole 
organism a unifying factor to link telomere length in all tissues would be 
necessary. ROS may be such a factor, but the link has not been conclusively 
described and may not be plausible. Nevertheless, PBL telomere length has been 
proposed as measure of biological ageing of the individual organism. PBL 
telomere length can perhaps indicate age in the vascular system; correlation 
with endothelial cell telomere length has already been demonstrated(Cafueri, 
Parodi et al. 2012). Ageing of the vascular system may have secondary effects 
increasing stress on other tissues through their dependence on the function of 
the vascular system, but one could question whether this is a directly translated 
relationship. However, ageing of the vascular system may have disproportionate 
effects on outcome from disease in any tissue, given the ubiquitous distribution 
of the vascular system and its secondary effects on other systems. In this sense 
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PBL telomere length could prove to be a reasonable single measure of ageing 
and outcome of disease or treatment. Although it may not be the panacea for 
measuring biological age of an individual, PBL telomere length may show utility 
in the assessment and treatment of colorectal cancer patients. Further research 
in telomere biology should more prominently define the tissue type under 
investigation than has been current practice in the past.  
PBL telomere length may link to survival and capacity to cope with systemic 
treatments which place particular demands on the cardiovascular system, for 
example. Further studies to investigate PBL telomere length and survival after 
surgery and chemotherapy may establish it as a viable prognostic marker of 
‘fitness for treatment’ in colorectal cancer.  In the future, PBL telomere length 
may provide useful information on vascular risk in preoperative assessment, or 
prior to chemotherapy. 
Telomere length in the tissue of origin of the disease studied may affect 
incidence and open the potential for targeted screening. Colorectal tissue 
telomere length has been related to progress along the neoplastic 
spectrum(Engelhardt, Drullinsky et al. 1997) (Nakamura, Furugori et al. 2000; 
Kim, Kim et al. 2002; Plentz, Wiemann et al. 2003; Feng, Cai et al. 2012) 
although some studies have not shown any change (Katayama, Shiota et al. 
1999). It may provide early warning of increasing biological age in this tissue 
compartment if used in conjunction with screening programs. Large-scale 
validation of colorectal tissue TL in this context would be necessary and the 
screening programs currently in operation in the UK and elsewhere could provide 
a source of tissue for this purpose.  
9.2 Fetuin A: Colorectal cancer and inflammation 
Currently we need much more information on function of fetuin A in colorectal 
tissues (and in humans in general). It is a complex multifunctional protein and as 
such will be vulnerable to the deterioration in integration and regulation that 
occurs with ageing. Its role as a negative acute phase protein constitutes 
another pathway in the complex networks linking inflammation and 
tumorigenesis. Specific roles may mean it is an important part of the disease 
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processes in certain tissues/systems: the vascular system seems to be a prime 
candidate.  
The evidence available demonstrated interaction with colorectal epithelial cells 
(Swallow, Partridge et al. 2004), with fetuin A probably functioning in the guise 
of TGF-β inhibitor. There is currently no data on the interaction between 
annexins, matrix metalloproteinases and fetuin A in colorectal cancer that is 
equivalent to interactions reported in breast cancer(Leite-Browning, McCawley 
et al. 2002; Ray, Lukyanov et al. 2003; Sakwe, Koumangoye et al. 2011; Watson, 
Koumangoye et al. 2012). Further work is necessary to investigate the 
relationship between serum levels of fetuin A and interaction with colorectal 
cells in normal and transformed epithelium.  
Of interest, a recent publication identified fetuin A precursor protein and β-
tubulin as potential diagnostic biomarkers from a case-control proteomic 
analysis of serum in colorectal cancer patients and healthy volunteers (Fan, Kang 
et al. 2014). Microtubules are formed of β-tubulin and α-tubulin heterodimers. 
α-tubulin is the originally identified substrate for SIRT2, which was associated 
with worse survival in subgroups of colorectal cancer patients in the data 
reported here. The interaction between SIRT2 and other members of the tubulin 
family will bear further investigation. 
9.3 Sirtuins in colorectal cancer 
The homogeneous reduction in sirtuin mRNA previously reported in colorectal 
cancer is not reflected in across-the-board reduction in protein expression and 
particularly not in protein expression in all subcellular locations(Maxwell 2013). 
Particularly, SIRT3 and SIRT6 protein expression in nucleus and cytoplasm are 
higher in tumour than in normal tissue. This indicates that there is a significant 
effect of post-transcriptional processing involved in sirtuin physiology. Once 
more were known about the most effective protein targets among the sirtuins, 
the corresponding post-transcriptional processing pathways could be useful 
therapeutic targets. It is interesting to note that SIRT3 and SIRT6 are the two 
members of this family shown to have an effect on longevity in mammals, but 
only in males (Rose, Dato et al. 2003; Kanfi, Naiman et al. 2012). It is possible 
that the mechanisms by which these sirtuins promote healthy chronological 
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ageing are also those subverted by tumour cells to maintain their own 
proliferative potential. Given the sex-differences in the effect of these sirtuins 
some interaction with oestrogen signalling is a logical assumption, and further 
research into this link may also impinge on the interaction between fetuin A and 
its differential effects on the sexes. 
9.3.1 Sirtuins and the MTR hypothesis 
This study supports the MTR hypothesis by confirming expected protein 
expression of the sirtuins with some caveats. Cytoplasmic staining cannot be 
directly assumed to be mitochondrial, and nuclear staining does not necessarily 
imply telomeric interaction. This study also adds complexity to the picture by 
widening the distribution of sirtuin localisation, particularly the pool of ‘nuclear’ 
sirtuins. A higher definition representation of the function of sirtuins to localise 
protein expression precisely within both nucleus and cytoplasm would be 
necessary to provide even stronger support for the MTR hypothesis. 
9.3.2 Sirtuins and inflammation 
Broadly speaking, data presented here indicated higher SIRT2 nuclear staining 
was associated with worse survival, higher levels of systemic inflammation and 
worse prognostic features on pathological assessment of the tumour. Lowest 
quartile levels of SIRT2 in the nucleus may also have a detrimental effect given 
the association with poor survival, but this appears to have less widespread 
ramifications among other relevant clinicopathological parameters. 
Higher nuclear staining for SIRT3 was associated with venous invasion. Lower 
cytoplasmic staining was linked to more systemic inflammation and poor 
differentiation, so that the balance between nuclear and cytoplasmic 
localisation seems important, and a higher cytoplasmic proportion may be 
favourable. 
Higher SIRT4 and SIRT5 cytoplasmic staining was associated with reduced 
systemic inflammation, and nuclear staining for both is a novel finding. Higher 
SIRT6 cytoplasmic and nuclear staining were associated with less systemic 
inflammation. Pathological markers of poor prognosis were associated with the 
opposite cytoplasmic staining.  
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High nuclear and low cytoplasmic expression of SIRT7 was associated with 
systemic inflammation. High nuclear staining was also associated with several 
pathological markers of poor prognosis. 
From the recap given above, higher nuclear staining associates with increased 
systemic inflammation and with poor pathological prognostic features, almost 
across the board, in keeping with the established interaction between cancer 
and inflammation. High cytoplasmic staining seems to be more specifically 
associated with systemic inflammation, and again this is true of all the sirtuins 
except SIRT2.  
Comprehensive comparison of sirtuin expression in other disease processes may 
help distinguish where sirtuins fit in the inflammatory response, and whether 
this is altered in cancer. Modulation of the inflammatory system and the immune 
response is emerging as a potent therapeutic option in cancer as in metabolic 
and vascular disease, but it will be important to fully understand the 
ramifications of such treatment in all these conditions in order to avoid 
significant unwanted effects(Stunkel and Campbell 2011). Understanding of the 
intricacies of the physiological responses is a fundamental prerequisite. 
9.3.3 The absent factor: SIRT1 
SIRT1 is the human sirtuin about which most is known, as it has been most 
widely studied and is most similar to the yeast sirtuin which sparked the initial 
interest in this diverse family of enzymes. Absence of data from this cohort on 
SIRT1 staining in colorectal cancer is a significant deficit. It also leaves a 
measureable gap in conclusions that may be drawn on sirtuin interrelationships. 
However, this deficit will hopefully be remedied in the near future as a suitable 
antibody to SIRT1 is optimised. 
In the meantime it is worth noting that in a tissue microarray containing normal 
colonic mucosa, adenomas and colorectal cancers of various stages stained for 
SIRT1 higher staining was found in the base of crypts where active cell division 
might be expected (Kabra, Li et al. 2009). Increased staining in all cells with 
adenomatous morphology was observed and staining in colorectal cancer cases 
was very variable but appeared to reduce in later stage cancers. This is in 
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keeping with a variable benefit of SIRT1 expression which changes with the 
developing genetic and intracellular milieu of a progressive cancer phenotype. 
9.4 Systems biology approach to colorectal cancer 
There is a sea-change under way in the scientific approach away from the 
reductionist dissection of molecular pathways, which has characterised the 
investigative focus for many decades. The reductionist approach is an essential 
starting point and is central in clarifying the detail of networks. More recently, 
however the limits of this approach have been appreciated and it is recognised 
that to fully understand how a network functions requires an appreciation of the 
spatiotemporal context as well as knowledge of the precise interactions of its 
physical components. 
Systems biology is the study of component parts within the environment where 
they function. Ageing has already been recognised as a good exemplar for the 
application of the principles of this discipline(Kriete, Sokhansanj et al. 2006). In 
order to achieve full understanding of a process which is initiated by repair 
events at a molecular level but whose effects are evident at a macroscopic 
level, it is necessary to integrate all the observations and all the theories about 
ageing into a coherent whole. Systems biology moves the emphasis from a 
‘competing models’ way of explaining observations to an integrative approach 
which starts simply and adds layers of complexity as the answers unfold. 
In taking advantage of all the tools and approaches available, it is recognised 
that these will span many fields and necessitate increasingly interdisciplinary 
modes of working. 
Systems biology theory proposes that the connectedness of a node within the 
network is more important than any single effect (or for example, the absolute 
concentration of a serum protein). Modulation of a well-connected node would 
be a more efficient and efficacious intervention, but it is necessary to 
understand all the ramifications - i.e. all about the network - to anticipate all 
effects, and particularly if therapies are designed to modulate it, to minimize 
unwanted effects.  
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Sirtuins and fetuin A both have connectivity in several diverse fields of research 
indicating that they might be promising “well-connected” players in the ageing 
process. The findings presented here support their importance and indicate that 
further study in these fields is likely to be useful. 
Many molecules have been identified as tumour suppressor or oncogene, or as 
protective or tumorigenic in the cancer literature. Although these are useful 
ideas, they can be limiting, particularly as the nature of many signals can change 
depending on time, location and milieu – the spatiotemporal context. The 
network view which maps interactions without loaded effect descriptions (‘value 
judgments’) may be more useful. 
Cells have evolved many defences against the proliferation of damaged 
genotypes, but cancer cells develop because they happen to undergo a 
combination of alterations and deteriorations which allow them to circumvent 
all of these defences. Only a few of the myriad combinations of random 
alterations produce cells with the potential to survive the breakdown of the 
machinery that normally integrates them into the whole organism. There may 
even be a required order to these changes, or required sequences or motifs 
within the random succession of changes to avoid cell death along the sequence. 
In studying the networks involved in cancer biology, the aim is to identify, from 
the myriad of changes in ageing cells, those alterations in cellular function that 
are key to development of the malignant phenotype – the ‘tipping points’ in 
development of cancer. Computer modelling of networks constructed from 
experimental data may help decipher the critical paths among a plethora of 
associations(August and Koeppl 2012; De Ambrosi, Barla et al. 2013). 
The ‘Swiss cheese model’ of error is one which may be relevant to cancer 
biology(Reason 2000). This is a construct applicable to many types of systems: 
inflight controls, hospital patient safety systems, molecular control of ROS 
sequestration and signalling. In any complex system, there are many layers of 
control designed to prevent calamity, none of which is perfect, but which 
together provide overlapping safety nets which usually compensate for the 
inevitable holes in each net. However, sometimes ‘the holes line up’, several 
safety nets fail, and the situation escalates from there. If the situation in 
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question is the development of a cancer cell, the Swiss cheese model maps very 
well to the multi-hit model of cancer development, and the adenoma-carcinoma 
sequence in colorectal cancer. 
Networks will be vulnerable where they lack redundancy and at the highest 
levels of control, where any malfunction has multiple downstream effects. These 
are likely to be the location of tipping points in cancer development. There is an 
extensive field of computational modelling and system analysis already reaching 
maturity which is being harnessed to attack the conundrums of cancer(Shen, 
Goonesekere et al. 2012; Yun, Johnson et al. 2012; Drier, Sheffer et al. 2013; 
Schweiger, Hussong et al. 2013). Some of the most forward thinking approaches 
involve experts in non-traditional disciplines and it will be exciting to see how 
their approach can shed new light on difficult problems(Fillon 2013). 
9.4.1 Sirtuin Interrelationships: network construction 
None of the sirtuins studied can be firmly identified as a biomarker of ageing, 
although all seem to be intricately involved in the cellular dynamics of 
colorectal cancer. One demonstration of this, and of the importance of networks 
in further understanding the molecular basis of malignant transformation and its 
defining characteristics, is in the change in the sirtuin interrelationships in 
normal and tumour tissue. Although the correlations between protein expression 
used to build the networks do not imply causation, or direct interaction, it is 
likely that correlated proteins act in the same pathways and so such correlations 
may be used as starting points to unravel the specific interacting components. 
9.5 Ageing and disease are not synonymous 
Ageing and disease are not synonymous. ‘Healthy ageing’ with retention of most 
faculties and functions is possible and indeed is the holy grail of medicine. 
Disease can occur in younger people, sometimes due to a relatively few defects 
which by their effect at a whole organism level highlight their importance within 
the system. Ageing meets disease when the cumulative effect of frailty 
(progressive minor deteriorations) happens to include a few defects which are of 
greater consequence. The outcome of disease in conjunction with ageing is more 
serious because the frailty (multiple minor deteriorations) of the individual 
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means that systems which normally prevent escalation of a problem lack the 
resilience to do so.  
Disease in young people highlights tipping points – important wayposts in the 
development of the disease where the outcome of an event (a genetic mutation, 
or a protein accumulation, for instance) drastically changes the downstream 
course. These events are identifiable because the negative outcome is of 
sufficient importance as to overcome the resilience of a younger system, with its 
inbuilt checks and balances more likely to be intact than in an older individual. 
9.6 Ageing is fundamentally a breakdown in integration 
All pathways interconnect, all processes are under integrated control, in the 
homeostatic regulation of the internal milieu of an organism. This is a basic 
tenet of life and the living organism. Ageing is a breakdown of integration, 
between cells, and between component pathways within a cell. Successful 
defence against threats to an organism presuppose an intact response pathway 
but with age, none of the ‘normal’ responses can be assured and as such the 
pathologies of age are those of an infinite permutation and perturbation of the 
evolutionarily designed order within cell biology. 
Ageing is a stochastic process but only a tiny minority of aged cells are able to 
escape integration in the organism and persist as cancer cells. What are the 
controllers of integration? These will be subject to ageing (deterioration) like 
any other system or components, but the deterioration in their function will 
have wider reaching consequences. Systems biology points to the most 
connected nodes in a network as being the most important, those with the most 
effects, the most control and influence. 
The systems biology approach is therefore an intrinsically sensible one for the 
study of ageing. It aims to examine, define and understand the multilevel, 
hierarchical structure of the networks that underlie and form the organism. It 
will also eventually allow us to model perturbations to the system and examine 
the outcomes on different levels as well. In the meantime however, it provides a 
useful focus on the importance of networks. 
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9.7 Limitations of this work, and future directions 
This study was designed to produce a multifaceted assessment of several 
potential markers of biological ageing in the specific context of colorectal 
cancer, and to describe any interactions between them. For this reason, ideally, 
all measurements would have been made on matched tissue, for more powerful 
direct comparisons. Thus integration of telomere length measurements, fetuin A 
and colorectal tissue sirtuin protein expression awaits further research.  
9.7.1 Telomere length 
The major limitation of the telomere analysis study was the small number of 
colorectal tissue samples available. Although this study did show a significant 
difference between telomere length in PBLs and colorectal tissue, with no 
correlation between the two, small numbers of tissue samples limited the 
investigation of relationships between colorectal tissue and tumour tissue 
telomere length and clinicopathological parameters. The small number of tissue 
samples obtainable was directly related to practical aspects of the study. 
Incidence of colorectal cancer during the study period was outwith experimental 
control although the catchment group of hospitals was widened to try to 
mitigate this effect. Tissue collection from patients who did develop colorectal 
cancer required a separate consent process that was not under the purview of 
this team, and took second place to the demands of clinical practice. These 
problems could be overcome for future research by extending the timescale of 
the study, and by dialogue to integrate the research process more closely with 
the function of the clinical team. 
As a proof of concept study, however, it has been shown that with good 
communication between clinical and laboratory teams, it would be reasonable to 
continue the collaboration and gain sufficient power to generate clinically 
relevant data. This could be used to determine the validity of colorectal tissue 
telomere length as a potential early marker of tissue ageing and increased risk of 
dysplasia and cancer. This may be of particular use in the context of colorectal 
screening for high-risk patients. 
9.7.2 Fetuin A 
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Fetuin A is a serum protein which interacts with tissues via cell surface 
receptors. Binding of fetuin A is reduced in tumour tissue compared to normal 
tissue (Swallow, Partridge et al. 2004). It would have been very informative to 
correlate fetuin A tissue binding with serum fetuin A levels, by construction of a 
TMA using samples from patients from whom serum had also been sampled in the 
preoperative period.  
Staining of the sirtuin TMA for fetuin A would be one relatively straightforward 
additional integrative study to assess any associations between fetuin A and 
sirtuins or any effect of fetuin A staining and survival. Such data would also be 
useful to corroborate the only existing data on fetuin A binding to colorectal 
tumour(Swallow, Partridge et al. 2004).(Condeelis and Pollard 2006)  
9.7.3 Sirtuin immunohistochemistry 
The obvious deficit in the immunohistochemical data available, namely the lack 
of data on expression of SIRT1 protein has been mentioned earlier. Although the 
immunohistochemical study of sirtuin expression in colorectal cancer which 
forms a large part of this thesis has been very informative, it would also be ideal 
to integrate it with analysis of telomere length and serum fetuin A levels, from 
one cohort.  
The advantage of using the TMA was obviously in the large number of cases to 
which it gave access, allowing relatively powerful analysis. However, the normal 
cohort for comparison numbered only 20 cases. Given that much of the data on 
sirtuin protein expression in normal colorectal tissue is lacking, it would have 
been useful to have a larger normal cohort for robust baseline comparison with 
the tumour tissue. No definitive conclusion could be drawn on possible alteration 
in expression of SIRT6 or SIRT7 in tumour tissue with respect to normal 
colorectal tissue because of this lack of power. Equally, information on baseline 
relations between sirtuin expression in normal tissue and clinicopathological 
factors such as serum inflammatory markers is lacking in the reported literature. 
It is always challenging to coordinate the collection of matched samples of 
different tissues from one patient as it necessitates liaison between clinical and 
laboratory-based teams, and must be streamlined to fit in with the patient’s 
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medical treatment which is the first priority. As the importance of gaining a 
complete snapshot of the biological system becomes established, integration of 
the laboratory and clinical teams may become more widespread, and will 
undoubtedly be easier as familiarity between them grows. 
9.8 Biomarker of ageing: a panel rather than a key factor. 
Although only a preliminary study of any biological networks is attempted in this 
thesis, it is clear that the processes involved are of a considerable degree of 
complexity. It is inherently unlikely that a single unifying Biomarker of Ageing 
could capture a summary of their state in a meaningful manner. Certainly, none 
of the candidates studied here has that power. CDKN2A is one biomarker which 
is showing promise and has prognostic value in colorectal cancer as well but 
further study is necessary to clarify its place (Shiels 2012; Xing, Cai et al. 2013). 
In the future, it is most likely that, once sufficient information was gathered and 
tailored to an individual, computer modelling techniques may be able to identify 
networks or parts thereof that were under particular strain. Analogous to the 
tissue-monitoring macrophages(Condeelis and Pollard 2006), they could direct 
treatment to tissues under stress, ideally before significant organ senescence 
and damage had occurred. 
9.8.1 Composite biomarkers of ageing and disease in colorectal 
cancer 
The key attribute of useful biomarkers is prognostic or predictive value. 
Although the data reported here comes from 2 separate cohorts, these cohorts 
are of similar populations i.e. both unselected patients with colorectal cancer 
from Glasgow hospitals separated by a short time interval. The same analysis 
was performed in respect of the accepted prognostic markers of colorectal 
cancer examined. Some of the experimental variables (like SIRT2 nuclear 
expression) appear to be clear candidates for further research and may have 
some therapeutic potential.  
As previously noted however, biomarkers of ageing and disease may be of use 
individually or in a composite panel. 
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9.8.2 Composite biomarkers of cancer stage 
TNM stage is the strongest prognostic indicator in colorectal cancer. The cohorts 
in this study are limited in that they had very few patients with metastatic 
cancer at the time of sampling. For this reason, no meaningful analysis of 
associations with M stage are made. Associations between T stage and N stage 
parallel and explain the associations with Dukes’ stage, which is therefore not 
discussed further. 
9.8.2.1 T stage 
Of the experimental variables assessed, lower serum fetuin A, was associated 
with higher T stage and there were trends towards associations with higher SIRT2 
and SIRT7 nuclear, and SIRT3 cytoplasmic staining. Individual underlying 
mechanisms have been discussed in earlier chapters and there does seem to be a 
biologically plausible explanation for most of these associations. It would be 
interesting to analyse this collection of markers further in a single cohort. This 
may identify confounding factors for instance between fetuin A and the sirtuins. 
Equally, however, they may each add predictive value. Of significant interest 
also would be an analysis of fetuin A in serum and in association with tumour 
tissue. This would require a large longitudinal study. Very small amounts of 
tissue are required, and it would be useful to establish baseline measurements in 
normal tissue. As mentioned in regard to future research on telomere length, 
the colorectal screening program could be a source of such tissue, with matched 
serum samples from appropriately consented patients at the time of screening 
colonoscopy. 
9.8.2.2 N stage 
Reduced nuclear expression of SIRT7 associated with N stage, with a trend to 
association with reduced nuclear expression of SIRT6 and enhanced nuclear 
expression of SIRT2. Large scale analysis of this panel as described above could 
guide adjuvant chemotherapy if this combination was proven to add predictive 
value to results obtained from pathological examination of an operative 
specimen. Analysis of diagnostic biopsies preoperatively might in the future 
identify a cohort of patient who could benefit from neoadjuvant chemotherapy 
to increase the chance of a curative resection. 
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9.8.2.3 Differentiation 
Differentiation parameters are somewhat subjective, although this may change 
as more molecular markers are identified, but is a well-recognised poor 
prognostic indicator. SIRT3 nuclear staining, in addition to the variables 
associated with high T stage completes the panel of markers which may offer 
useful information on the molecular mechanisms which produce poorly 
differentiated cells. Poorly differentiated cancers tend to be more locally 
invasive, and these markers may go some way to explaining this. 
9.8.2.4 Venous invasion 
Venous invasion as well as N stage is an indicator of systemic spread with a 
significant effect on prognosis. It is also even more difficult to detect on imaging 
and sometimes on superficial biopsies preoperatively so that predictive markers 
may be of great use. Increased nuclear staining (of SIRT3, SIRT4, SIRT6 and 
SIRT7) and SIRT4 cytoplasmic expression are prominent.  
While these combinations of sirtuins and sometimes fetuin A would be 
interesting to investigate further, it must be remembered that higher levels of 
tumour protein expression are associated with pathological markers of poor 
prognosis, this is against a background of reduced expression relative to normal. 
Establishment of normal baselines in a larger cohort may allow a proper 
assessment of the relevance of these observations. 
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Figure 9.1 Boxplots showing Histoscores for nuclear and cytoplasmic expression of SIRT2-
SIRT7 in normal and tumour tissue. The suffix N or T after SIRTX denotes normal or tumour 
tissue. 
9.9 Frailty not ageing or longevity? 
As translational science in many branches of medicine becomes more of an 
interdisciplinary routine, shared and standardised terminology will become more 
valued and familiar.  
9.9.1 Frailty 
Frailty is a clinical syndrome usefully applied to give an overview of the whole 
patient, which is gaining ground in the clinical arena(Chen, Mao et al. 2014). It 
encompasses several of the functional measures of bioageing such as gait, grip 
strength and physical exhaustion. The concept of frailty is readily applicable to 
the study of systems in many disciplines and as such offers a common readily 
understood language in which to communicate on this subject. It embodies the 
concept of agedness, without reference to chronology. It implies loss of 
resilience, loss of the capacity to effect adequate repair, and loss of the 
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integrity of systems and structures that are the consequence of ageing at any 
level. 
Hayflick has said with some truth that ‘The fundamental ageing process is not a 
disease but it increases vulnerability to disease’. Frailty may be the best way to 
describe this nexus of age and disease in a way that addresses the issues of 
importance to patients and clinicians, in terminology which can also be used by 
molecular biologists, genetic engineers and other involved professions. 
Assessment of frailty is already in use to predict postoperative morbidity in 
patients undergoing surgery for colorectal cancer(Tan, Kawamura et al. 2012). 
Resilience is the hallmark of youth; frailty may be the defining characteristic of 
ageing and the most valuable target for combating age-associated disease. 
9.9.2 Measurement of ageing: different levels 
The meaningful measurement of ageing, or measurement of frailty, depends on 
the level of organisation under consideration when we make the measurement. 
Thus, measurement of frailty of molecular systems involves specific assessment 
of the function of elements of molecular machinery, such as enzyme activity. In 
different circumstances, measurement of organ function may be more clinically 
useful. For some purposes, social functioning of a patient may be the relevant 
parameter to assess. All of these examples are used in the evaluation of a 
patient with cancer, and future research will need to develop assays tailored 
appropriately. 
 10 Appendices 
10.1 Appendix 1: Telomere and 36B4 primers for the 
QPCR reaction using the Roche LightCycler 480 
10.1.1 Telomere and 36B4 Primers 
Telo 1 Sequence (5’ to 3’): 
CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GTT 
Telo 2 Sequence (5’ to 3’): 
GGC TTG CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT 
36B4d Sequence (5’ to 3’): 
CCC ATT CTA TCA TCA ACG GGT ACA A  
36b4u  Sequence (5’ to 3’): 
CAG CAA GTG GGA AGG TGT AAT CC 
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10.2 Appendix 2: Telomere and 36B4 plate running 
conditions for the QPCR reaction using Roche 
LightCycler 480 
10.2.1 Telomere plate running conditions (Roche Light Cycler 
LC480) 
Program 
Name 
Heat Start (HS)    
Cycles 1 Analysis Mode None  
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
95 None 00:10:00 4.4  
Program 
Name 
Amplification (Amp)   
Cycles 30 Analysis Mode Quantification  
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
95 None 00:00:05 4.4  
59 None 00:00:10 2.2  
72 Single 00:02:00 4.4  
Program 
Name 
Melt    
Cycles 1 Analysis Mode Melting 
Curves 
 
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
95 None 00:00:30 4.4  
65 None 00:00:30 2.2  
95 Continuous 00:02:00 0.29 2 
Program 
Name 
Cool    
Cycles 1 Analysis Mode None  
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
40 None 00:00:10 2.2  
Table 10.1 Telomere plate running conditions 
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10.2.2 36B4 plate running conditions (Roche Light Cycler 
LC480) 
Program 
Name 
Heat Start (HS)    
Cycles 1 Analysis Mode None  
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
95 None 00:05:00 4.4  
Program 
Name 
Amplification (Amp)   
Cycles 30 Analysis Mode Quantification  
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
95 None 00:00:05 4.4  
58 None 00:00:15 2.2  
72 Single 00:00:15 4.4  
Program 
Name 
Melt    
Cycles 1 Analysis Mode Melting Curves 
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
95 None 00:00:30 4.4  
65 None 00:00:30 2.2  
95 Continuous 00:02:00 0.29 2 
Program 
Name 
Cool    
Cycles 1 Analysis Mode None  
Target 
(°C) 
Acquisition Mode Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
40 None 00:00:10 2.2  
Table 10.2 36B4 plate running conditions 
10.3 Appendix 3: Layout of slides for JP-CRC-TMA 1-5 
Layouts are shown on the following page.
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10.4 Appendix 4: PRISMA flowchart for systematic review 
of literature on telomere length in matched tissues 
!
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by review of abstract 
49 full-text articles 
excluded (single 
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Figure 10.1 PRISMA flowchart applied to systematic review of the literature on telomere 
length in matched tissues. 
10.5 Appendix 5: Literature comparing telomere lengths 
in different cell types  
Tables summarising the literature considered in the qualitative review are on 
following page. 
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Pub$
year$
Journal$ First$
author$
Pubmed$
number$
Telomere$length$
measurement$method$
Tissue$types$included$ Number$of$cases$ Age$range$$(yrs)$
2011$ PLoS$ONE$ Wong$ 21876736$ qPCR$ CD34+$lypmohcytes$and$
mononuclear$cells$
27$CHF$pts/$29$
controls$
62J76$
2010$ Experimental$
Hematology$
Kimura$ 20600576$ TRFL$Southern$blot$and$
flow$FISH$
Peripheral$blood$leukocytes$
and$subclasses$
8$$$$$$$$$$$24$$$$$$$400$ 0$$$$$22J34,$0J
100$
Table 10.8 Two papers comparing telomere length in classes of haematopoietic cells 
Table 10.9 (And following pages) Papers comparing telomere length in non-gastrointestinal tissues 
Pub$
year$
Journal$ First$
author$
Pubmed$
number$
Telomere$length$
measurement$method$
Tissue$types$ Number$of$cases$ Age$range$of$
cases$
2000$ Mechanisms$of$Ageing$
and$Development$
Friedrich$ 11080530$ TRFL$Southern$blot$ Leukocytes$
Skin$$
Synovial$tissue$
9$ 73J95$
2000$ Laboratory$
Investigation$
von$
Zglinicki$
11092534$ TRFL$Southern$blot$ Leukocytes$
Fibroblasts$
24$ 28J91$
2002$ Pediatric$Research$ Okuda$ 12193671$ TRFL$Southern$blot$ WBC$$
Umbilical$artery$
Foreskin$
165$
158$
23$
newborn$
2002$ J$Investigative$
Dermatology$
Nakamura$ 12445186$ TRFL$Southern$blot$ Epidermis$
Lingual$epithelium$
62$ 0J101$
2002$ Experimental$
Gerontology$
Takubo$ 11830355$ TRFL$Southern$blot$ Cerebral$cortex$
Myocardium$
Liver$
Kidney$
Spleen$
137$
168$
191$
137$
30$
0J104,$few$subj$
10J40$yrs$
2007$ J$Gerontology$Series$A$$ Gardner$ 17452729$ qPCR$ Lung$
Serratus$anterior$
Skin$
11+12$autopsy$
11$
11+12$autopsy$
$
50J76$
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Pub$
year$
Journal$ First$
author$
Pubmed$
number$
Telomere$length$
measurement$method$
Tissue$types$ Number$of$cases$ Age$range$of$
cases$
2008$ PNAS$ Alder$ 18753630$ FISH$ Leukocytes$$
Lung$alveolar$cells$
9$ Not$recorded$in$
paper$
2008$ European$Heart$
Journal$
Wilson$ 18762552$ qPCR$ Leukocytes$
Aortic$wall$
12$autopsy,$20$
AAA$patients$
56J78$
2008$ Experimental$
Gerontology$
Aida$ 18590810$ QFISH:$normalised$
telomere:$centromere$
ratio$
Lingual$cells:$basal$
Lingual$cells:$parabasal$
Lingual$cells:$prickle$cells$
Lingual$cells:$fibroblasts$
21$autopsy$
specimens$
0J101$
2010$ Aging$ Gadalla$ 21113082$ QPCR$ Leukocytes$
Buccal$
Fibroblast$
21$inherited$bone$
marrow$failure$
8J43$years$
2011$ Eplasty$ Granick$ 21436892$ TRFL$Southern$blot$ Leukocytes$
Fat$
Skin$
16$ 14J58$
2012$ Diabetic$Medicine$ Ahmad$ 22747879$ qPCR$ Leukocytes$
Muscle$
58$ 34J62$
2012$ Molecular$Human$
Reproduction$
Aston$ 22782639$ TRFL$Southern$blot$ Leukocytes$$$
Sperm$
135$ 18J68$
2012$ PLoS$ONE$ Cafueri$$ 22514726$ QFISH$ Lymphocytes$
Epidermal$cells$
Endothelial$cells$
Vascular$smooth$muscle$cells$
23$
11$
21$
21$
61J78$
2013$ Nature$
Communications$
Daniali$ 23511462$ TRFL$ Leukocytes$
Skeletal$muscle$
Skin$
Subcutaneous$fat$
87$ 19J77$
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Pub$
year$
Journal$ First$
author$
Pubmed$
number$
Telomere$length$
measurement$method$
Tissue$types$included$ Number$of$cases$ Age$range$$(yrs)$
2003$ European$J$
GastroenterJ$ology$&$
Hepatology$
Craig$ 14560153$ Dot$blot$hybridisation$
Telo/genomic$DNA$
Duodenal$cap$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Gastric$antrum$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Sigmoid$colon$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Blood$
90$$$$$$$$$$$86$$$$$$$$$$$
34$$$$$$$$$$$90$
20J90$
Table 10.10 Single paper comparing telomere length in gastrointestinal tissues and others. 
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10.6 Appendix 6: Inter-rater and intra-rater correlations 
for Histoscores 
 
 
Figure 10.2 Scatterplots and Bland-Altman plots for inter-rater nuclear and cytoplamic 
Histoscore correlations. ICCC for nuclear Histoscores was 0.851 and for cytoplasmic 
Histoscores was 0.913. 
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Figure 10.3 Scatterplots and Bland-Altman plots for intra-rater nuclear and cytoplamic 
Histoscore correlations. ICCC for nuclear Histoscores was 0.789 and for cytoplasmic 
Histoscores was 0.716. 
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10.7 Appendix 7: PBL telomere length and age 
 
Figure 10.4 Scatterplot of age vs PBL telomere length with line of best fit (Rsq =0.003). The 
correlation is weak and not statistically significant. 
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